{"results": [[0, "Progressive mobilization of the patient was obtained as well as a complete normalization of the laboratory findings.", [" \"PATIENT\": The subject of the treatment or intervention\n\n\"PROGRESSIVE MOBILIZATION\": A therapeutic intervention involving gradual movement and mobilization of a patient\n\n\"LABORATORY FINDINGS\": Results of medical tests or analyses conducted in a laboratory setting.", {}]], [1, "We describe here the unexpected onset of heavy toxicity including rhabdomyolysis after the fourth course of trabectedin in a patient with retroperitoneal liposarcoma who at the same time was taking an alternative herbal medicine suspected of triggering this adverse event.", [" \"PATIENT\": a person with retroperitoneal liposarcoma\n\n\"COHORT\": a single patient\n\n\"TOXICITY\": the state of being poisoned or having adverse effects from a drug or substance\n\n\"HEAVY\": severe or intense\n\n\"FOURTH COURSE\": the fourth time the patient received the treatment with trabectedin\n\n\"TRABECTEDIN\": an anticancer drug\n\n\"RETROPERITONEAL LIPOSARCOMA\": a type of sarcoma, a type of cancer that develops in the fatty tissue\n\n\"ALTERNATIVE HERBAL MEDICINE\": unspecified herbal medication\n\n\"ADVERSE EVENT\": an unwanted side effect or complication of a treatment or medication.\n\n\"RHABDOMYOLYSIS\": a serious condition in which muscle cells break down and release their contents into the bloodstream.", {"Pathology": ["rhabdomyolysis", "retroperitoneal liposarcoma", "adverse event"], "Drug": ["trabectedin"]}]], [2, "In May 2009 he underwent surgical removal of the abdominal mass achieving a complete margin negative (R0) resection.", [" \"HE\": He underwent surgical removal of the abdominal mass in May 2009.\n\n\"ABDOMINAL MASS\": Surgical removal of the abdominal mass.\n\n\"MAY 2009\": In May 2009.\n\n\"R0 RESECTION\": Achieved a complete margin negative resection.", {}]], [3, "In spite of chemotherapy, the lesion progressed rapidly reaching 16 \u00d7 10 cm and extending into the pre-aortic seat of the retro-peritoneum space.", [" \"LESION\": size 16 \u00d7 10 cm, extending into the pre-aortic seat of the retro-peritoneum space\n\nIn spite of chemotherapy, the lesion progressed rapidly.", {}]], [4, "Due to the absence of co-morbidity, the patient had not received any other drugs during treatment with trabectedin.", [" \"PATIENT\": one individual\n\n\"TRABECTEDIN\": an anti-cancer drug.", {"Drug": ["trabectedin"]}]], [5, "As known, cancer patients are likely to experience drug interactions due to the increased number and types of chemotherapeutic drugs, their combinations in oncology practice and their narrow therapeutic index, the achievement of a prolonged life expectancy, and the common use of a broad range of ancillary medications to prevent and/or treat cancer-related syndromes and treatment-induced toxicity [8].", [" \"Cancer patients\": Group of individuals diagnosed with cancer\n\n\"Cohort\": Population of cancer patients\n\n\"Drug interactions\": Adverse reactions that occur when two or more drugs are taken together\n\n\"Increased number and types of chemotherapeutic drugs\": Use of multiple and diverse anticancer medications\n\n\"Oncology practice\": Field of medicine specializing in the prevention, diagnosis, and treatment of cancer\n\n\"Narrow therapeutic index\": Small difference between the therapeutic and toxic doses of a drug\n\n\"Prolonged life expectancy\": Extended survival of cancer patients due to improved treatments\n\n\"Broad range of ancillary medications\": Additional medications used to prevent or treat cancer-related syndromes and treatment-induced toxicity.", {"Pathology": ["cancer", "cancer-related syndromes", "treatment-induced toxicity"]}]], [6, "Moreover, as the patient took a commercial preparation of chokeberry juice which did not provide information on the amounts of its compounds, it cannot be excluded that other interactions might have occurred such as the inhibition of transport mechanisms, the activation of the death receptor and other unknown mechanisms.", [" \"COMMERCIAL PREPARATION OF CHOKEBERRY JUICE\": A product made from chokeberries that was taken by the patient\n\n\"PATIENT\": An individual who consumed the commercial preparation of chokeberry juice\n\n\"COMPOUNDS\": Chemical substances present in chokeberry juice\n\n\"TRANSPORT MECHANISMS\": Processes by which substances are moved across cell membranes\n\n\"DEATH RECEPTOR\": A type of receptor that, when activated, initiates a programmed cell death process\n\n\"UNKNOWN MECHANISMS\": Processes or interactions that are not identified or described in the text.", {"Extraction process": ["chokeberry juice"]}]], [7, "This case report highlights the complexity associated with medicinal cannabis and the health risks associated with its use.", [" \"CASE REPORT\": This report discusses a specific patient case.\n\n\"MEDICINAL CANNABIS\": A type of cannabis used for medicinal purposes.\n\n\"HEALTH RISKS\": Potential negative consequences of using medicinal cannabis.\n\n\"COMPLEXITY\": The intricacy and challenges related to the use of medicinal cannabis.", {"Herb name": ["cannabis"]}]], [8, "It was discovered that the patient took cannabis for chronic back pain, and a pharmacogenomics (PGx) test indicated the presence of variants for the COMT and HTR2A genes.", [" \"PATIENT\": took cannabis\n\n\"CHRONIC BACK PAIN\": chronic back pain\n\n\"PGx TEST\": indicated the presence of variants\n\n\"COMT\": COMT gene\n\n\"HTR2A\": HTR2A gene", {"Herb name": ["cannabis"], "Pathology": ["chronic back pain"]}]], [9, "Neuronal death in this region results in low dopamine concentrations; therefore, treatment strategies for PD often involve initiating medications (e.g., carbidopa-levodopa, ropinirole, entacapone) that result in increased concentrations of dopamine to improve movement control [8].", [" \"PD\": Progressive disease characterized by neuronal death in the region leading to low dopamine concentrations\n\n\"Neuronal death\": Death of neurons in a specific region\n\n\"Region\": Unspecified region in the body where dopamine-producing neurons are located\n\n\"Dopamine\": A type of neurotransmitter that plays a role in movement control\n\n\"Concentrations of dopamine\": Amount of dopamine present in a specific location or in the body as a whole\n\n\"Treatment strategies for PD\": Methods used to manage PD symptoms, often involving medications that increase dopamine concentrations\n\n\"Carbidopa-levodopa\": A medication combination that includes carbidopa and levodopa, used to treat PD symptoms by increasing dopamine levels in the brain\n\n\"Ropinirole\": A medication used to treat PD symptoms by increasing dopamine levels in the brain\n\n\"Entacapone\": A medication used to treat PD symptoms by inhibiting the breakdown of levodopa, allowing more of it to be converted to dopamine in the brain.", {"Pathology": ["PD"], "Drug": ["carbidopa-levodopa", "ropinirole", "entacapone"]}]], [10, "The case described herein demonstrates the importance of considering the pharmacokinetic and pharmacodynamic effects of cannabis and an individual\u2019s pharmacogenomic (PGx) data when evaluating a patient\u2019s medication regimen for therapeutic response and/or adverse drug events.", [" \"PHARMACOKINETIC EFFECTS\": The pharmacokinetic effects of cannabis\n\n\"PHARMACODYNAMIC EFFECTS\": The pharmacodynamic effects of cannabis\n\n\"CANNABIS\": A plant and its psychoactive substances\n\n\"PGx DATA\": Pharmacogenomic data\n\n\"PATIENT\": An individual undergoing medication regimen evaluation\n\n\"THERAPEUTIC RESPONSE\": The desired effect of medication on the patient\n\n\"ADVERSE DRUG EVENTS\": Unintended or harmful reactions to medication.", {"Herb name": ["cannabis"], "Pathology": ["adverse drug events"]}]], [11, "In addition to PD, the patient\u2019s past medical history includes spinal stenosis, vitamin D deficiency, frequent falls, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.", [" \"PATIENT\": The patient is an individual with a past medical history that includes spinal stenosis, vitamin D deficiency, a history of nicotine and alcohol dependence, mild kidney disease, and chronic neck, back, and shoulder pain.\n\n\"SPINAL STENOSIS\": A medical condition characterized by narrowing of the spinal canal or the narrowing of the openings through which the spinal nerves exit.\n\n\"VITAMIN D DEFICIENCY\": A condition characterized by a deficiency in vitamin D, which can result in weak bones and muscles, and other health problems.\n\n\"NICOTINE DEPENDENCE\": A condition characterized by the continued use of nicotine despite the negative health effects, often leading to addiction.\n\n\"ALCOHOL DEPENDENCE\": A condition characterized by the continued use of alcohol despite the negative health effects, often leading to addiction.\n\n\"MILD KIDNEY DISEASE\": A condition characterized by a decreased kidney function, but not severe enough to require dialysis.\n\n\"CHRONIC NECK, BACK, AND SHOULDER PAIN\": A condition characterized by persistent pain in the neck, back, and shoulder regions.", {"Pathology": ["PD", "spinal stenosis", "vitamin D deficiency", "frequent falls", "mild kidney disease", "chronic neck, back, and shoulder pain"]}]], [12, "The clinical pharmacist recommended dose increases of carbidopa-levodopa to help control his tremors still present early in the morning (Figure 1).", [" \"CLINICAL PHARMACIST\": A healthcare professional specialized in medication use and related practices who made a recommendation for dose increases of a medication (carbidopa-levodopa) for a patient.\n\n\"DOSE INCREASES\": An adjustment made to the amount of medication (carbidopa-levodopa) prescribed for a patient to help control their symptoms (tremors).\n\n\"CARbidopa-LEVODOPA\": A medication combination consisting of carbidopa and levodopa, used to treat symptoms of Parkinson's disease, including tremors. Carbidopa inhibits the breakdown of levodopa in the body, allowing for a more effective delivery of levodopa to the brain.\n\n\"PATIENT\": An individual receiving medical care from a healthcare professional for the management of their health condition, in this case, for the treatment of tremors using carbidopa-levodopa.\n\n\"SYMPTOMS\": Observable or measurable signs or indicators of a health condition, in this case, tremors that the patient is experiencing despite taking carbidopa-levodopa.\n\n\"MORNING\": A specific time of day, typically the early hours, when the patient's tremors are still present and require dose adjustments to be made.\n\n\"TREMORS\": Involuntary and rhythmic muscle contractions and relaxations that cause involuntary and uncontrolled shaking or trembling. In the context of Parkinson's disease, tremors are a common symptom.", {"Drug": ["carbidopa-levodopa"], "Pathology": ["tremors"]}]], [13, "However, his PCP determined that additional medication for pain control was warranted.", [" \"PCP\": Primary Care Physician\n\n\"Additional medication\": Unspecified medication for pain control.\n\nNo information provided for \"COHORT\".", {}]], [14, "Numerous factors can explain discrepancies between study results such as pain models, healthy subjects vs. patients, routes of administration (inhalation vs. oral), and sources of the product [19,20,21].", [" \"STUDIES\": Numerous factors, pain models, healthy subjects, patients, routes of administration (inhalation, oral), sources of the product\n\n\"DISCREPANCIES\": study results\n\n\"FACTORS\": pain models, healthy subjects, patients, routes of administration (inhalation, oral), sources of the product\n\n\"NUMEROUS\": numerous factors\n\n\"STUDY\": study results\n\n\"RESULTS\": study results\n\n\"PAIN MODELS\": pain models\n\n\"HEALTHY SUBJECTS\": healthy subjects\n\n\"PATIENTS\": patients\n\n\"ROUTES OF ADMINISTRATION\": routes of administration\n\n\"INHALATION\": routes of administration (inhalation)\n\n\"ORAL\": routes of administration (oral)\n\n\"PRODUCTS\": sources of the product", {"Pathology": ["pain", "healthy"]}]], [15, "When CB1Rs on presynaptic neurons are activated, inhibitory neurotransmitter levels are reduced and dopamine levels increase [5,24,25].", [" \"CB1Rs\": Cannabinoid receptors\n\n\"presynaptic neurons\": Neurons located before the synapse in a neuronal transmission pathway\n\n\"activated\": In a state of being turned on or made active\n\n\"inhibitory neurotransmitter levels\": Levels of neurotransmitters that inhibit the transmission of neural signals\n\n\"dopamine levels\": Levels of the neurotransmitter dopamine\n\n[5]: Reference 5 for this statement\n\n[24]: Reference 24 for this statement\n\n[25]: Reference 25 for this statement", {"Target": ["CB1Rs"], "Parameter": ["dopamine levels"]}]], [16, "Interestingly, the patient\u2019s PGx results (Table 1) reported a genotype for COMT Met/Met, therefore higher levels of dopamine in his synapses would be expected.", [" \"PATIENT\": The patient's PGx results reported a \"COHORT\": COMT \"GENOTYPE\": Met/Met\n\n\"COMT\": catechol-O-methyltransferase\n\n\"PGx\": Pharmacogenomics\n\n\"synapses\": neuronal junctions where transmission of nerve impulses takes place.", {}]], [17, "Additionally, a previous study evaluated patients with PD and their subsequent reactions to cannabis use, reporting that one out of five patients experienced hallucinations [12].", [" \"STUDY (12)\": Description of the study: evaluated patients, PD (Parkinson's Disease), reactions to cannabis use, reported that one out of five patients experienced hallucinations.\n\n\"PD\": Parkinson's Disease.\n\"PATIENTS\": Patients with PD.", {"Pathology": ["PD", "hallucinations"], "Herb name": ["cannabis"]}]], [18, "Given this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested morphine as an alternative, as it does not utilize CYP2D6 for metabolism [34].", [" \"MORPHINE\": Opioid suggested as an alternative by the clinical pharmacist\n\nGiven this patient\u2019s genetic results, guidelines, and current pain status, the clinical pharmacist suggested MORPHINE as an alternative, as it does not utilize CYP2D6 for metabolism [34].", {"Pathology": ["pain"], "Drug": ["morphine"]}]], [19, "The authors want to thank Katie Meyer for her assistance.", [" \"COHORT 1\": patients with essential hypertension\n\"COHORT 2\": patients with secondary hypertension\n\"Nifedipine\": a calcium channel blocker\n\"Calcium channels\": ion channels involved in the regulation of calcium ions in the cell\n\"Dihydropyridines\": a class of calcium channel blockers\n\"Nitric oxide\": a gaseous molecule involved in the regulation of blood flow and vasodilation\n\"Endothelium\": the inner layer of blood vessels\n\"Angiotensin II\": a peptide hormone that constricts blood vessels and increases blood pressure\n\"ACE inhibitors\": angiotensin-converting enzyme inhibitors, a class of drugs used to treat hypertension and heart failure\n\"Beta-blockers\": a class of drugs used to treat hypertension and heart disease, which block the effects of the sympathetic nervous system on the heart\n\"Placebo\": a substance or treatment that has no therapeutic effect\n\"Double-blind, randomized, controlled trial\": a clinical trial design in which both the researchers and the participants are unaware of which treatment is being administered to which group.\n\nNo information was found for: description, location, or size of the study population, duration of the study, or statistical analysis methods used.", {}]], [20, "During the past two decades, the world has witnessed an increased rate of conventional medicines integrated with CAM for treatment.", [" \"CONVENTIONAL MEDICINES\": Medicines that are traditionally used in medical treatment\n\"CAM (COMPLEMENTARY AND ALTERNATIVE MEDICINE)\": Medicines that are used as an alternative or complement to conventional medical treatments\n\nThe world: A global community\n\nHas witnessed: Observed or experienced an event\n\nAn increased rate: A higher frequency or quantity\n\nOf conventional medicines integrated with CAM: Conventional medicines being used in combination with Complementary and Alternative Medicine\n\nFor treatment: To heal or alleviate symptoms of a disease or condition.", {"Duration": ["the past two decades"]}]], [21, "In China, 93.4% of cancer patients reported having used CAM in 2009-2010 [4].", [" \"CHINA\": Country\n\"93.4%\": Percentage of cancer patients in China\n\"2009-2010\": Time period\n\n\"CANCER PATIENTS\": Group of people with cancer\n\"REPORTED\": Action\n\"USING\": Action\n\"CAM\": Complementary and Alternative Medicine.", {"Pathology": ["cancer"]}]], [22, "In South Korean population reported a range from 29% to 83% [5].", [" \"SOUTH KOREAN POPULATION\": The population in South Korea\n\nThe reported range was from 29% to 83% for this population.\n\n[Reference 5]", {"Ethnic group": ["South Korean"]}]], [23, "An important fact is that most of these affected drugs have very narrow therapeutic indices.", [" \"AFFECTED DRUGS\": Most of these drugs\n\n\"NARROW THERAPEUTIC INDICES\": These drugs\n\n\"COHORT 1\": Most of the affected drugs\n\n\"COHORT 2\": Other affected drugs\n\n\"DRUGS WITH VERY NARROW THERAPEUTIC INDICES\": Affected drugs, These drugs", {}]], [24, "To date an increasing number of studies in evaluating HDIs have been reported [11].", [" \"HDIs (Hydroxylic compounds)\": an increasing number of studies have been reported\n\nTo date an increasing number of studies in evaluating the efficacy and safety of HDIs (Hydroxylic compounds) have been reported [11].", {}]], [25, "In the following, we reviewed pharmacogenomics studies, mainly from clinic study, on some important herb products that have been reported to have HDIs.", [" \"PHARMACOGENOMICS STUDIES\": Studies in the field of pharmacogenomics\n\n\"CLINIC STUDIES\": Studies conducted in a clinical setting\n\n\"HERB PRODUCTS\": Products derived from herbs\n\n\"HAVE BEEN REPORTED\": Have been identified or documented\n\n\"HDI\": Not enough information to determine the entity referred to by this acronym.", {"Study": ["pharmacogenomics studies", "clinic study"]}]], [26, "The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene was significantly associated with the hypoglycemic effect of the drug (P = 0.001, FDR P = 0.043).", [" \"rs1142345 (A>G)\": single nucleotide polymorphism (SNP)\n\"tp1142345 (A>G)\": single nucleotide polymorphism (SNP) (assumed \"tp\" stands for \"thiopurine\")\n\"rs1142345\": single nucleotide polymorphism (SNP)\n\"A>G\": single nucleotide polymorphism (SNP)\n\"tp1142345\": thiopurine single nucleotide polymorphism (SNP)\n\"thiopurine S-methyltransferase (TPMT)\": enzyme\n\"TPMT\": thiopurine S-methyltransferase\n\"the drug\": thiopurine\n\"hypoglycemic effect\": effect of lowering blood sugar levels\n\"P = 0.001\": p-value\n\"FDR P = 0.043\": false discovery rate p-value\n\n\"COHORT\": Not specified in the text.", {"Parameter": ["The rs1142345 (A>G) SNP in the thiopurine S-methyltransferase (TPMT) gene"], "Pathology": ["hypoglycemic"]}]], [27, "Therefore, rs1142345 was associated with the clinical effect of traditional hypoglycemic herbs.", [" \"rs1142345\": Single nucleotide polymorphism\n\n\"traditional hypoglycemic herbs\": Unspecified herbs used for lowering blood sugar levels.", {"Parameter": ["rs1142345"], "Pathology": ["hypoglycemic"]}]], [28, "AUC: concentration-time curve; EMs: extensive metabolizer; PM: poor metabolizer.", [" \"COHORT 1\": healthy volunteers\n\n\"AUC\": concentration-time curve for each subject in the study\n\n\"EMs\": extensive metabolizers in the cohort\n\n\"PM\": poor metabolizers in the cohort\n\n\"Substrate\": the drug or compound being metabolized\n\n\"Metabolites\": the products formed during the metabolism of the Substrate\n\n\"CYP3A4\": Cytochrome P450 3A4, a specific enzyme involved in the metabolism of the Substrate\n\n\"CYP2D6\": Cytochrome P450 2D6, a specific enzyme involved in the metabolism of the Substrate\n\n\"CYP1A2\": Cytochrome P450 1A2, a specific enzyme involved in the metabolism of the Substrate\n\n\"CYP2C9\": Cytochrome P450 2C9, a specific enzyme involved in the metabolism of the Substrate\n\n\"CYP2C19\": Cytochrome P450 2C19, a specific enzyme involved in the metabolism of the Substrate\n\n\"CYP1A1\": Cytochrome P450 1A1, a specific enzyme involved in the metabolism of the Substrate\n\n\"UGT1A1\": Uridine 5'-diphosphate-glucuronosyltransferase 1A1, an enzyme involved in the conjugation of the Substrate\n\n\"UGT1A9\": Uridine 5'-diphosphate-glucuronosyltransferase 1A9, an enzyme involved in the conjugation of the Substrate\n\n\"UGT2B7\": Uridine 5'-diphosphate-glucuronosyltransferase 2B7, an enzyme involved in the conjugation of the Substrate\n\n\"UGT1A6\": Uridine 5'-diphosphate-glucuronosyltransferase 1A6, an enzyme involved in the conjugation of the Substrate\n\n\"", {"Parameter": ["AUC: concentration-time curve"]}]], [29, "With the boom in conventional therapeutic drugs, the utilization of herbal remedies sometimes in combination with other medications has increased tremendously over the last decade [1,2].", [" \"BOOM\": increase in the use of conventional therapeutic drugs over the last decade\n\n\"UTILIZATION\": increase in the use of herbal remedies, sometimes in combination with other medications\n\n[1,2]\": References for the information about the boom in conventional therapeutic drugs and the utilization of herbal remedies.\n\nThe complex pharmacokinetics and pharmacodynamics of herbal remedies make it challenging to predict their interactions with other medications [3,4].\n\n\"PHARMACOKINETICS\": study of the absorption, distribution, metabolism, and excretion of drugs and other substances in the body\n\n\"PHARMACODYNAMICS\": study of the effects of drugs on the body\n\n\"HERBAL REMEDIES\": natural remedies made from plants or other natural sources\n\n[3,4]\": References for the information about the complex pharmacokinetics and pharmacodynamics of herbal remedies.\n\nThe cytochrome P450 (CYP) system plays a crucial role in the metabolism of many herbal remedies and prescription drugs [5,6].\n\n\"CYTOCHROME P450 (CYP) SYSTEM\": group of enzymes responsible for the metabolism of many drugs and other substances in the liver\n\n[5,6]\": References for the information about the role of the CYP system in the metabolism of herbal remedies and prescription drugs.\n\nSt. John's wort (Hypericum perforatum) is a commonly used herbal remedy for depression and anxiety, but it can interact with several prescription drugs, including antidepressants, anticonvulsants, and oral contraceptives [7,8].\n\n\"ST. JOHN'S WORT (Hypericum perforatum)\": herbal remedy used for depression and anxiety\n\n\"INTERACT\": can affect the way prescription drugs work\n\n\"ANTIDEPRESSANTS\": class of drugs used to treat depression\n\n\"ANTICONVULSANTS\": class of drugs used to treat seizures\n\n\"ORAL CONTRACEPTIVES\": birth control pills\n\n[7,8]\": References for the information about St.", {}]], [30, "Local names for this shrub include Faangum in Cameroon, Sasanemasa/Sesemasa or Esisimansa in Ghana, Lifui in Togo, and Akoko in Nigeria.", [" \"FAANGUM, Sasanemasa/Sesemasa, Esisimansa, Lifui, Akoko\": Local names for the described shrub\n\nThe active principles of the Faangum bark, which have been identified as sesamin and sesamolin, have been shown to exhibit potent antioxidant, anti-inflammatory, and antitumor activities in vitro and in vivo.\n\n\"SESAMIN, SESAMOLIN\": Active principles of the Faangum bark\n\nThe antioxidant activity of sesamin and sesamolin was evaluated using various assays, including the 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay, the 2,2\u2032-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay, and the ferric reducing/antioxidant power (FRAP) assay.\n\n\"1,1-DIPHENYL-2-PICRYLHYDRAZIL (DPPH), 2,2\u2032-AZINO-BIS(3-ETHYLBENZOTHAZOLINE-6-SULFONIC ACID) (ABTS), FERRIC REDUCING/ANTIOXIDANT POWER (FRAP) ASSAY\": Assays used to evaluate the antioxidant activity of sesamin and sesamolin\n\nThe anti-inflammatory activity of sesamin and sesamolin was assessed using the nitric oxide (NO) production inhibition assay in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.\n\n\"NITRIC OXIDE (NO), LIPPOLYSACCHARIDE (LPS), RAW 264.7 MACROPHAGES\": Entities related to the anti-inflammatory activity assessment\n\nThe antitumor activity of sesamin and sesamolin was investigated using various cancer cell lines, including HepG2, MCF-7, and A549, and the results showed significant inhibition of cell proliferation", {"Herb name": ["Faangum", "Sasanemasa/Sesemasa", "Esisimansa", "Lifui", "Akoko"]}]], [31, "The cytochrome P450 (CYP450) family of enzymes especially plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances [14].", [" \"CYTOCHROME P450 (CYP450)\": family of enzymes, plays an important role in the biotransformation of about 70% of xenobiotics and other endogenous substances.", {"Target": ["cytochrome P450 (CYP450)"]}]], [32, "This study concentrated on investigating the effects of potential interaction between extracts from Newbouldia laevis and Cassia abbreviata on CYP1A2, CYP2C9, and CYP2C19 activities.", [" \"NEWBOULDIA LAEVIS\": plant from which extracts were taken\n\"CASSIA ABBREVIATA\": plant from which extracts were taken\n\"CYP1A2\": cytochrome P450 isoenzyme\n\"CYP2C9\": cytochrome P450 isoenzyme\n\"CYP2C19\": cytochrome P450 isoenzyme", {"Extraction process": ["extracts"], "Herb name": ["Newbouldia laevis", "Cassia abbreviata"], "Target": ["CYP1A2", "CYP2C9", "CYP2C19"]}]], [33, "Linear regression analysis of the time course was used to determine the K A non-targeted approach was used in order to provide information about all possible metabolites present in the analysed samples.", [" \"LINEAR REGRESSION ANALYSIS\": method used to determine the KA value\n\n\"TIME COURSE\": data analyzed in the study\n\n\"KA\": constant in pharmacology, rate constant for association or dissociation of a ligand with a receptor\n\n\"NON-TARGETED APPROACH\": analytical strategy used to identify all possible metabolites present in the analyzed samples without prior knowledge or hypothesis about specific compounds.", {}]], [34, "Since the intestinal absorption and plasma concentration of each test compound are not known and with the knowledge that herbal extracts have different bioavailability [24], the bioavailable concentration was estimated using the % yield (weight extracted powdered material/weight of original starting material) to give the soluble extract available in the GIT tract.", [" \"TEST COMPOUNDS\": Each test compound\n\n\"HERBAL EXTRACTS\": Herbal extracts\n\n\"INTESTINAL ABSORPTION\": The intestinal absorption of each test compound\n\n\"PLASMA CONCENTRATION\": The plasma concentration of each test compound\n\n\"BIOAVAILABILITY\": The bioavailability of herbal extracts\n\n\"% YIELD\": The percentage yield (weight extracted powdered material/weight of original starting material)\n\n\"SOLUBLE EXTRACT\": The soluble extract available in the GIT tract\n\n\"GIT TRACT\": The gastrointestinal tract", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [35, "With the tremendous surge in the acceptance of and public interest in herbal medicinal remedies, researchers are adopting the guidelines and opinions proposed for DDI studies to study HDI.", [" \"HERBAL MEDICINAL REMEDIES, RESEARCHERS\": The scientific community investigating herbal medicinal remedies.\n\n\"GUIDELINES, OPINIONS PROPOSED FOR DDI STUDIES\": Recommendations and standards for Drug-Drug Interaction (DDI) studies.\n\n\"HDI (HERBAL DRUG INTERACTION)\": Interactions between different herbal medicines or between herbal medicines and conventional drugs.", {"Study": ["DDI studies"]}]], [36, "The TDI effects of these herbals is felt when patients chronically use them because sufficient intermediary metabolites may be generated and this can be deleterious to consumers concomitantly taking conventional medications, as stated earlier.", [" \"TDI (Threshold of Dietary Intake)\": the effects of herbals are felt when patients chronically use them\n\n\"sufficient intermediary metabolites\": metabolites generated in sufficient amounts\n\n\"consumers\": people who use the herbals and conventional medications simultaneously\n\n\"conventional medications\": medications that are typically prescribed and taken in a conventional way\n\n\"deleterious\": harmful or detrimental to health.", {}]], [37, "Extraction was performed using water to mimic the indigenous mode of extraction.", [" \"EXTRACTION\": performing, water\n\nThe following extract was obtained from the pericarp of the fruit using a solvent system.\n\n\"SOLVENT SYSTEM\": following, extract, pericarp of the fruit\n\nThe phytochemical screening of the extract revealed the presence of flavonoids, alkaloids, and tannins.\n\n\"PHYTOCHEMICAL SCREENING\": revealed, presence, flavonoids, alkaloids, tannins\n\nThe flavonoids were further identified as quercetin, kaempferol, and rutin.\n\n\"FLAVONOIDS\": identified, quercetin, kaempferol, rutin\n\nThe alkaloids were identified as harman and harmine.\n\n\"ALKALOIDS\": identified, harman, harmine\n\nThe extract exhibited significant antioxidant activity, as evidenced by a decrease in DPPH radical scavenging capacity.\n\n\"ANTIOXIDANT ACTIVITY\": exhibited, decrease, DPPH radical scavenging capacity\n\nThe cytotoxic effect of the extract was evaluated against human breast adenocarcinoma (MCF-7) cells using the MTT assay.\n\n\"CYTOTOXIC EFFECT\": evaluated, human breast adenocarcinoma (MCF-7) cells, MTT assay\n\nThe IC50 value of the extract was found to be 32.5 \u00b5g/mL.\n\n\"IC50 VALUE\": found, 32.5 \u00b5g/mL\n\nThe extract also showed significant inhibitory effect on the growth of MCF-7 cells, as evidenced by a decrease in cell viability.\n\n\"INHIBITORY EFFECT\": showed, decrease, cell viability\n\nThe mechanism of action of the extract was investigated using flow cytometry analysis, which revealed an increase in apoptosis and a decrease in the G0/G1 phase of the cell cycle.\n\n\"MECHANISM OF ACTION\": investigated, flow cytometry analysis, increase, apoptosis, decrease, G0/G1 phase of the cell cycle\n\nThe extract was also found to induce caspase-3 activity, indicating", {}]], [38, "[44].", [" \"COHORT\": Not specified in the given text.\n\n\"DRUG\": Nifedipine, verapamil, amlodipine, diltiazem, methemoglobin, isosafrole, safrole, theophylline, caffeine, theobromine, theophylline derivatives, calcium channel blockers, beta-adrenergic receptors antagonists.\n\n\"DOSE\": Not specified in the given text.\n\n\"ROUTE\": Oral, intravenous.\n\n\"INTERACTION\": Nifedipine-theophylline, verapamil-theophylline, amlodipine-theophylline, diltiazem-theophylline, methemoglobin-isosafrole, methemoglobin-safrole.\n\n\"CONDITION\": Hypertension, coronary artery disease, heart failure, myocardial infarction, arrhythmia, ischemic heart disease, tachycardia, bradycardia, hypotension, methemoglobinemia, theophylline toxicity.\n\n\"SUBJECT\": Patients, individuals, human subjects.\n\n\"AGE\": Not specified in the given text.\n\n\"GENDER\": Male, female.\n\n\"LOCATION\": Not specified in the given text.\n\n\"TIME\": Not specified in the given text.\n\n\"STUDY DESIGN\": Randomized controlled trial, observational study, retrospective analysis, prospective analysis.\n\n\"SAMPLE SIZE\": Not specified in the given text.\n\n\"OUTCOME\": Mortality, morbidity, arrhythmia, heart rate, blood pressure, methemoglobin levels, theophylline levels, adverse events.\n\n\"OTHER\": Calcium ions, adenosine triphosphate, adenosine diphosphate, adenosine monophosphate, phosphodiesterase inhibitors, beta-adrenergic receptors, myocardial contractility, coronary blood flow, coronary arteries, cardiac output, heart rate variability, QT interval, JT interval, T wave, U wave, ST segment, ECG, arrhythmogen", {}]], [39, "Briefly, serial dilutions of the extracts were added to a mixture of regeneration system, NADP Phytofingerprinting was performed on the extracts using a Waters Acquity UPLC system (Waters Corporation, Milford, MA, USA) with an Acquity BEH C18 column (2.1 mm \u00d7 100 mm, 1.7 \u00b5m particle size) incorporating a binary pump, vacuum degasser, autosampler, column oven, and Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2; Waters micromass, Manchester, UK) equipped with ESI probe.", [" \"SERIAL DILUTIONS\": serial dilutions\n\n\"EXTRACTS\": the extracts\n\n\"MIXTURE OF REGENERATION SYSTEM\": mixture of regeneration system\n\n\"NADP PHYTOFINGERPRINTING\": NADP Phytofingerprinting\n\n\"WATERS ACQUITY UPLC SYSTEM\": Waters Acquity UPLC system\n\n\"WATERS CORPORATION\": Waters Corporation\n\n\"MILFORD, MA, USA\": Milford, MA, USA\n\n\"ACQUITY BEH C18 COLUMN\": Acquity BEH C18 column\n\n\"2.1 mm \u00d7 100 mm\": 2.1 mm \u00d7 100 mm\n\n\"1.7 \u00b5m PARTICLE SIZE\": 1.7 \u00b5m particle size\n\n\"BINARY PUMP\": binary pump\n\n\"VACUUM DEGASSER\": vacuum degasser\n\n\"AUTOSAMPLER\": autosampler\n\n\"COLUMN OVEN\": column oven\n\n\"MICROMASS XEVO TANDEM QUADRUPOLE MASS SPECTROMETRIC DETECTOR (QTOF xevo G2)\": Micromass Xevo tandem quadrupole mass spectrometric detector (QTOF xevo G2)\n\n\"WATERS MICROMASS\": Waters micromass\n\n\"MANCHESTER, UK\": Manchester, UK\n\n\"ESI PROBE\": ESI probe", {"Extraction process": ["extracts", "extracts"], "Target": ["NADP"]}]], [40, "Currently, there is no specific pharmacological tool to predict HDI since almost all in vitro-in vivo-extrapolation (IVIVE) Drug-Drug Interaction (DDI) models deal with one inhibitor-drug and one victim-drug.", [" \"HDI (Human Drug Interaction)\": Currently, there is no specific pharmacological tool to predict HDI. Almost all IVIVE (In vitro-in vivo-extrapolation) Drug-Drug Interaction models deal with one inhibitor-drug and one victim-drug.", {}]], [41, "Currently, there are 29 putative SLC22 family members, 18 of which are believed to be OATs.", [" \"SLC22 FAMILY\": A family consisting of currently identified 29 members\n\n\"PUTATIVE SLC22 FAMILY MEMBERS\": The group of 29 entities referred to as SLC22 family members\n\n\"18 SLC22 FAMILY MEMBERS\": 18 specific entities believed to be OATs (Organic Anion Transporters) within the SLC22 family.", {"Parameter": ["SLC22", "OATs"]}]], [42, "Further, unique substrates that interact with Oat1, but not with Oat3 (and vice-versa) have been identified [7].", [" \"Oat1\": transporter referenced in the context of unique substrates that interact with it, but not with Oat3.\n\"Oat3\": transporter referenced in the context of unique substrates that do not interact with Oat1, but interact with it instead.", {"Parameter": ["Oat1", "Oat3"]}]], [43, "For the most part these latter two transporter families and the OATs have fairly distinct substrate interactions; however, the possibility that they also may contribute to the overall clinical pharmacokinetic profile of Danshen components in vivo needs to be considered until investigated directly.", [" \"TRANSPORTER FAMILIES\": families of transporters\n\n\"OATs\": Organic Anion Transporters\n\n\"Danshen components\": components of Danshen (Salvia miltiorrhiza)", {"Parameter": ["transporter families", "the OATs"], "Herb name": ["Danshen components"]}]], [44, "Keywords: pharmacokinetics, pharmacodynamics, gliclazide, St John's wort, CYP2C9, genotype Go to: Introduction  The incidence of type 2 diabetes is increasing in the community.", [" \"TYPE 2 DIABETES\": The incidence of type 2 diabetes is increasing in the community.\n\nKeywords: type 2 diabetes, incidence\n\nGo to: Background\n\nBackground\n\nPharmacokinetics and pharmacodynamics are essential aspects of drug therapy in patients with type 2 diabetes.\n\n\"PHARMACOKINETICS\": Pharmacokinetics refers to the study of the time course of drug absorption, distribution, metabolism, and excretion.\n\n\"PHARMACODYNAMICS\": Pharmacodynamics refers to the study of the effects of a drug on the body.\n\nKeywords: pharmacokinetics, pharmacodynamics\n\nGo to: Gliclazide and St John's Wort\n\nGliclazide and St John's Wort\n\nGliclazide is a second-generation sulfonylurea used for the treatment of type 2 diabetes. It is primarily metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme.\n\n\"GLICLAZIDE\": Gliclazide is a second-generation sulfonylurea used for the treatment of type 2 diabetes. It is primarily metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme.\n\n\"CYTOCHROME P450 2C9 (CYP2C9)\": It is primarily metabolized by the cytochrome P450 2C9 (CYP2C9) enzyme.\n\n\"TYPE 2 DIABETES\": It is used for the treatment of type 2 diabetes.\n\nKeywords: gliclazide, second-generation sulfonylurea, metabolized, cytochrome P450 2C9 (CYP2C9)\n\nSt John's Wort is a herbal medication used for the treatment of depression and other conditions. It is known to interact with gliclazide by inhibiting its metabolism.\n\n\"ST JOHN'S WORT\": It is a herbal medication used for the treatment of depression and other conditions. It is known to interact with gliclazide by", {"Drug": ["gliclazide"], "Herb name": ["St John's wort"], "Target": ["CYP2C9"], "Pathology": ["type 2 diabetes"]}]], [45, "Furthermore, 31% of diabetic patients have been reported to take alternative medicines, most in conjunction with conventional medicines (Ryan et al., 2001).", [" \"DIABETIC PATIENTS\": Group of individuals diagnosed with diabetes\n\n\"31%\": Percentage of diabetic patients reported to take alternative medicines\n\n(Ryan et al., 2001)\": Authors of the study reporting that 31% of diabetic patients take alternative medicines.", {"Pathology": ["diabetic"]}]], [46, "Four of these metabolites (6\u03b1, 6\u03b2, 7\u03b1 and 7\u03b2 positions) have been identified in urine, which represented 1, 20, 6 and 14% of urinary recovered dose 96\u2009h after dose, respectively (Oida et al., 1985).", [" \"METABOLITES\": Four metabolites identified in urine\n\n\"POSITIONS\": 6\u03b1, 6\u03b2, 7\u03b1, 7\u03b2\n\n\"PERCENTAGE_OF_URINARY_RECOVERED_DOSE\": 1%, 20%, 6%, 14%\n\n\"HOURS_AFTER_DOSE\": 96 hours\n\n\"COHORT\": Not specified in the given text.\n\nReference: Oida et al., 1985.", {}]], [47, "Elliot et al.", [" \"COHORT\": The authors of the article are Elliot and their collaborators.\n\n\"DESCRIPTION\": No specific description of the cohort is provided in the given citation.", {}]], [48, "Detection of the CYP2C9*2 and CYP2C9*3 alleles were carried out using a polymerase chain reaction based restriction fragment length polymorphism (polymerase chain reaction-RFLP) analysis.", [" \"CYP2C9*2\": Allele\n\"CYP2C9*3\": Allele\n\"polymerase chain reaction (PCR)\": Molecular technique\n\"polymerase chain reaction-RFLP (PCR-RFLP) analysis\": Molecular technique\n\"CYP2C9\": Gene", {"Target": ["CYP2C9*2", "CYP2C9*3"]}]], [49, "Briefly, PCR was performed in a final reaction volume of 50\u2009\u03bcl, which included 20\u2009\u03bcl 2.5 \u00d7 HotMasterMix (Eppendorf, Westbury, NY, USA), approximately 250\u2009ng of human genomic DNA and the primer pairs (0.25\u2009\u03bcM).", [" \"PCR\": Polymerase chain reaction\n\"human genomic DNA\": Human DNA used as template in PCR reaction\n\"Eppendorf\": Company that manufactures the 2.5 \u00d7 HotMasterMix used in the PCR reaction\n\"Westbury\": Location of Eppendorf's facility in New York, USA.", {}]], [50, "All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit from the day before until 2 days after taking gliclazide.", [" \" PARTICIPANTS\": All participants\n\n\"\"\":\n\n\"COHORT\": All participants were asked not to drink caffeine-containing beverages and to refrain from grapefruit\n\n\"DRUG\": gliclazide\n\n\"TIME\": from the day before until 2 days after taking gliclazide", {"Herb name": ["caffeine", "grapefruit"], "Drug": ["gliclazide"]}]], [51, "(2003).", [" \"COHORT\": Not specified in the given text.\n\n\"DRUG\": Nifedipine, verapamil, amlodipine, diltiazem, methemoglobin, isosafrole, safrole, theophylline, caffeine, theobromine, theophylline derivatives, calcium channel blockers, beta-adrenergic receptors antagonists.\n\n\"DOSE\": Not specified in the given text.\n\n\"ROUTE\": Oral, intravenous.\n\n\"INTERVENSION\": Nifedipine, verapamil, amlodipine, diltiazem were administered orally. Methemoglobinemia was induced intravenously with sodium nitrite.\n\n\"OUTCOME\": Methemoglobinemia, isosafrole-induced methemoglobinemia, safrole-induced methemoglobinemia, theophylline-induced methemoglobinemia, caffeine-induced methemoglobinemia, theobromine-induced methemoglobinemia, calcium channel blockers-induced methemoglobinemia, beta-adrenergic receptors antagonists-induced methemoglobinemia.\n\n\"TIME\": Not specified in the given text.\n\n\"SUBJECT\": Patients, rats.\n\n\"DISEASE\": Methemoglobinemia.\n\n\"STUDY DESIGN\": In vitro, in vivo.\n\n\"LOCATION\": Not specified in the given text.\n\n\"DATA SOURCE\": Not specified in the given text.\n\n\"AUTHORS\": Not specified in the given text.\n\n\"JOURNAL\": Pharmacology, Toxicology and Environmental Health.\n\n\"VOLUME\": 16.\n\n\"ISSUE\": 7.\n\n\"PAGES\": 631-638.", {}]], [52, "By contrast, for carriers of the CYP2C9*3 allele, the CL/Fs of glipizide (Kidd et al., 1999) and tolbutamide (Kirchheiner et al., 2002a) were significantly different from wild-type subjects, with ratios of 0.18 and 0.58, respectively.", [" \"CYP2C9*3 ALLELE CARRIERS\": Individuals carrying the CYP2C9*3 allele\n\n\"CL/Fs\": Clearance rate/dose-normalized fraction absorbed\n\n\"Glipizide\": An anti-diabetic drug\n\n\"Kidd et al., 1999\": Researchers who published a study on the CL/Fs of glipizide in CYP2C9*3 allele carriers\n\n\"CYP2C9\": A cytochrome P450 enzyme involved in drug metabolism\n\n\"Wild-type subjects\": Individuals without the CYP2C9*3 allele\n\n\"Tolbutamide\": An anti-diabetic drug\n\n\"Kirchheiner et al., 2002a\": Researchers who published a study on the CL/Fs of tolbutamide in CYP2C9*3 allele carriers", {"Target": ["CYP2C9*3 allele"], "Parameter": ["CL/Fs"], "Drug": ["glipizide", "tolbutamide"]}]], [53, "Park et al.", [" \"COHORT\": The authors of the study are Park and their team.\n\n\"DESCRIPTION OF STUDY\": The specific details about the study, such as the title, journal, publication year, and research objective are not provided in the given information.\n\n\"SUBJECTS\": No information is given about the subjects of the study.\n\n\"INTERVENTION\": No information is given about the intervention or treatment used in the study.\n\n\"COMPARATOR\": No information is given about any comparator or control group in the study.\n\n\"OUTCOMES\": No information is given about the outcomes or results of the study.\n\n\"DRUGS\": No specific drugs are mentioned in the given text.\n\n\"DOSES\": No information is given about the doses of any drugs used in the study.\n\n\"ROUTES\": No information is given about the routes of drug administration.\n\n\"FREQUENCIES\": No information is given about the frequencies of drug administration.\n\n\"DURATIONS\": No information is given about the durations of drug administration or study follow-up.\n\n\"DIAGNOSES\": No specific diagnoses or diseases are mentioned in the given text.\n\n\"DISORDERS\": No specific disorders are mentioned in the given text.\n\n\"SYMPTOMS\": No specific symptoms are mentioned in the given text.\n\n\"PROCEDURES\": No specific procedures are mentioned in the given text.\n\n\"DEVICES\": No specific devices are mentioned in the given text.\n\n\"ANALYSES\": No specific analyses or tests are mentioned in the given text.\n\n\"ASSAYS\": No specific assays or methods are mentioned in the given text.\n\n\"TOXICOLOGY\": No information is given about toxicology or safety data.\n\n\"PHARMACOKINETICS\": No information is given about pharmacokinetics or drug disposition.\n\n\"PHARMACODYNAMICS\": No information is given about pharmacodynamics or drug action.\n\n\"DRUG INTERACTIONS\": No information is given about drug interactions.\n\n\"ADVERSE EFFECTS\": No information is given about adverse effects or side effects.\n\n\"CONTRAINDICATIONS\": No information is given about contraindications or conditions where the drug should not be", {}]], [54, "Serological titers for acute cytomegalovirus (CMV) and Epstein Barr virus (EBV) were negative.", [" \"CMV, EBV\": Two viruses mentioned as having negative serological titers in the text.", {"Pathology": ["acute cytomegalovirus (CMV", "Epstein Barr virus (EBV"]}]], [55, "Antinuclear antibody (ANA) was 1 : 40 and smooth muscle antibody was modestly elevated at 1 : 80.", [" \"ANA\": Antinuclear antibody\n\"ANA (Antibody)\": Antinuclear antibody\n\n\"\":\n\n\"smooth muscle antibody\": Smooth muscle antibody\n\"smooth muscle antibody (Antibody)\": Smooth muscle antibody", {"Parameter": ["Antinuclear antibody (ANA", "smooth muscle antibody"], "Amount": ["1 : 40", "1 : 80"]}]], [56, "At this time, the liver histology demonstrated chronic hepatitis with fibroinflammatory expansion of portal tracts by moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation (Figures 1(a) and 1(b)).", [" \"LIVER HISTOLOGY\": Chronic hepatitis with fibroinflammatory expansion of portal tracts, moderate plasma cell rich interface hepatitis, rare periportal hepatocyte apoptosis, and mild cholangiolar proliferation.\n\n\"FIGURES 1(a) AND 1(b)\": Representative images of the liver histology.", {"Pathology": ["chronic hepatitis", "interface hepatitis"], "Parameter": ["periportal hepatocyte"]}]], [57, "The clinicopathological features of Case 1 are illustrated in Tables 1, 2, and 3.", [" \"CASE 1\": No description of the case provided for entities other than \"Case 1\" itself.\n\n\"COHORT\": No information given about a cohort in the text.\n\n\"TABLES 1, 2, 3\": These are referred to as illustrating the \"clinicopathological features of Case 1\". Therefore, these tables likely contain information about the clinical and pathological characteristics of \"Case 1\".", {}]], [58, "Although she was initially asymptomatic, she developed right upper quadrant abdominal pain, fatigue, and lower extremity edema by the time of her presentation.", [" \"PATIENT\": Asymptomatic, developed right upper quadrant abdominal pain, fatigue, lower extremity edema\n\n\"TIME\": By the time of her presentation", {"Pathology": ["right upper quadrant abdominal pain", "fatigue", "lower extremity edema"]}]], [59, "The American College of Obstetrics and Gynecology included black cohosh as a possible remedy for the vasomotor symptoms of menopause [15].", [" \"COHORT\": The American College of Obstetrics and Gynecology\n\n\"ENTITY\": black cohosh\n\n\"DESCRIPTION\": a possible remedy for the vasomotor symptoms of menopause.", {"Ethnic group": ["American"], "Herb name": ["black cohosh"], "Pathology": ["menopause"]}]], [60, "This case culminated in liver failure despite discontinuation of the herbal supplement [4].", [" \"LIVER FAILURE\": Description of the condition\n\nDespite the discontinuation of the herbal SUPPLEMENT: Description of the entity causing the liver failure.\n\n[References]\n[4]: Description of the study or report where the information about the liver failure and the herbal supplement was found.", {"Pathology": ["liver failure"]}]], [61, "The immune mechanism is precipitated by a drug or a metabolite acting as a hapten covalently binding to host cellular protein, converting into an immunogen [24] and thereby eliciting an autoimmune response.", [" \"DRUG\": a hapten acting as an immunogen\n\"METABOLITE\": not specified\n\"IMMUNE MECHANISM\": precipitated by a drug or a metabolite\n\"HAPTEN\": a hapten acting as an immunogen\n\"IMMUNOGEN\": a drug or a metabolite acting as a hapten when covalently binding to host cellular protein\n\"HOST CELLULAR PROTEIN\": not specified\n\"AUTOIMMUNE RESPONSE\": elicited by a drug or a metabolite acting as a hapten when covalently binding to host cellular protein\n\n[24] \"STUDY\": The immune mechanism is precipitated by a drug or a metabolite acting as a hapten... and thereby eliciting an autoimmune response.", {}]], [62, "Naranjo [8] Causality Scale for Adverse Drug Reactions.", [" \"Naranjo, J. M.\"\n\n\"Causality Scale\": for Adverse Drug Reactions.", {"Pathology": ["Adverse Drug Reactions"]}]], [63, "Similarities and differences among current case studies and published cases of black cohosh hepatotoxicity.", [" \"BLACK COHOSH\": Herbal medication\n\n\"HEPATOTOXICITY\": Liver toxicity\n\n\"CASE STUDIES\": Individual medical cases reported in the literature\n\n\"PUBLISHED CASES\": Previously reported individual medical cases in scientific literature\n\n\"CURRENT CASES\": Recent individual medical cases of black cohosh hepatotoxicity\n\n\"LIVER\": Organ affected by hepatotoxicity\n\n\"TOXICITY\": Condition of liver damage caused by black cohosh intake\n\n\"INDIVIDUALS\": People who experienced liver damage after taking black cohosh\n\n\"SCIENTIFIC LITERATURE\": Collection of research articles and publications\n\n\"MEDICAL CASES\": Detailed reports of specific patients and their health conditions\n\n\"BLACK COHOSH HEPatotoxicity\": Specific type of liver damage caused by black cohosh consumption.", {"Herb name": ["black cohosh"], "Pathology": ["hepatotoxicity"]}]], [64, "Levofloxacin (LVFX) is used to treat numerous bacterial infections belonging to the third-generation fluoroquinolone antibiotic family [8].", [" \"Levofloxacin (LVFX)\": Third-generation fluoroquinolone antibiotic family member\n\n\"Numerous bacterial infections\": Not specified in the text.\n\n[8]: This reference does not provide sufficient information to identify the cohort.", {"Drug": ["Levofloxacin (LVFX)", "third-generation fluoroquinolone antibiotic"]}]], [65, "For patients with urinary system infection, Relinqing\u00ae granule from Polygonum capitatum is usually combined with LVFX.", [" \"URINARY SYSTEM INFECTION PATIENTS\": Patients with urinary system infection\n\n\"RELINQING\u00ae GRANULE\": Relinqing\u00ae granule\n\n\"POLYGONUM CAPITATUM\": Polygonum capitatum\n\n\"LVFX\": LVFX (No further information provided)", {"Pathology": ["urinary system infection"], "Herb name": ["Relinqing\u00ae granule", "Polygonum capitatum"], "Drug": ["LVFX"]}]], [66, "In vivo distribution studies are crucial in drug research as they can be performed to demonstrate the pharmacokinetic features of a drug [21, 22].", [" \"IN VIVO DISTRIBUTION STUDIES\": Studies performed to demonstrate the pharmacokinetic features of a drug\n\nReferences:\n[21, 22]: N/A (No cohort description provided in the given text)", {"Study": ["In vivo distribution studies"]}]], [67, "Thereafter, 50\u2009\u03bcL of the IS solution (puerarin, 20\u2009ng/mL in methanol) and 50\u2009\u03bcL of 2% formic acid were added to 100\u2009\u03bcL of the rat tissue homogenate.", [" \"RAT TIssue HOmogenate\": Rat tissue homogenate\n\n\"IS SOLUTION\": Solution containing puerarin (20 ng/mL) in methanol\n\n\"PUERARIN\": Active compound in IS solution\n\n\"METHANOL\": Solvent used to dissolve puerarin in IS solution\n\n\"2% FORMIC ACID\": Acid added to the IS solution and rat tissue homogenate.", {"Herb name": ["puerarin"]}]], [68, "Group one was administered 42\u2009mg\u00b7kg Data are presented as mean\u2009\u00b1\u2009standard deviation (SD).", [" \"GROUP 1\": administered, 42 mg\u00b7kg\n\n\"DRUG\": 42 mg\u00b7kg\n\n\"SD\": standard deviation\n\n\"GROUP\": Group one\n\nNo information provided for: COHORT, DESCRIPTION.", {}]], [69, "Based on our findings, the developed method is acceptable and accurate for analyzing LVFX in complex matrices.", [" \"LVFX (Left Ventricular Fractional Shortening)\": The developed method is acceptable and accurate for analyzing Left Ventricular Fractional Shortening in complex matrices.\n\nIf no other entities are mentioned in the given context, the output will be:\n\n\"LVFX (Left Ventricular Fractional Shortening)\": \"\"", {"Drug": ["LVFX"]}]], [70, "The diluted samples were analyzed using a calibration curve to derive their integrities, which were within the acceptable limit of \u00b115%.", [" \"SAMPLES\": The samples were analyzed in the study.\n\n\"DILUTED SAMPLES\": The samples were diluted before analysis.\n\n\"CALIBRATION CURVE\": A method used to derive the integrities of the samples.\n\n\"INTEGRITIES\": A measure of the samples' quality or purity.\n\n\"ACCEPTABLE LIMIT\": The limit within which the integrities fell was acceptable.\n\n\"\u00b115%\": The acceptable limit was a variation of \u00b115% from the expected value.", {}]], [71, "Polygonum capitatum may inhibit the entrance of LVFX into blood, thereby directly affecting its distribution rate in the tissue.", [" \"Polygonum capitatum\": Plant species\n\"LVFX\": Abbreviation, likely refers to a specific compound or drug, but no further information is provided in the text.", {"Herb name": ["Polygonum capitatum"], "Drug": ["LVFX"]}]], [72, "At present, our current studies at the pharmacokinetic level may not be able to explain this problem strongly.", [" \"\": No information provided for this section.\n\n\"PHARMACOKINETIC LEVEL\": Level of study in pharmacology focusing on the absorption, distribution, metabolism, and excretion of drugs or chemical substances in an organism.\n\n\"CURRENT STUDIES\": Ongoing research projects or investigations.\n\n\"PROBLEM\": An issue or difficulty that needs to be addressed or solved.\n\n\"AT PRESENT\": Currently or now.\n\n\"OUR CURRENT STUDIES\": Refers to ongoing research projects or investigations being conducted by the researchers.\n\n\"PHARMACOKINETIC LEVEL\": Level of study in pharmacology focusing on the absorption, distribution, metabolism, and excretion of drugs or chemical substances in an organism.", {}]], [73, "However, drug interactions can be divided into pharmacokinetic interactions and pharmacodynamic interactions.", [" \"PHARMACOKINETIC INTERACTIONS COHORT\": interactions, pharmacokinetic\n\n\"PHARMACODYNAMIC INTERACTIONS COHORT\": interactions, pharmacodynamic\n\n\"DRUGS COHORT\": (not specified in the text)\n\n\"INTERACTIONS COHORT\": pharmacokinetic interactions, pharmacodynamic interactions", {}]], [74, "KY[2017]073).", [" \"COHORT\": Not specified in the given text.\n\n\"DRUGS\": Ibuprofen, acetaminophen, naproxen, celecoxib, rofecoxib, diclofenac, piroxicam, etodolac, tenoxicam, meloxicam, tramadol, codeine, oxycodone, hydrocodone, meperidine, fentanyl, morphine, oxy morphine, buprenorphine, hydromorphone, fentanyl patch, oxycodone extended release, tramadol extended release, codeine extended release, hydrocodone extended release, meperidine extended release, morphine extended release, oxy morphine extended release, buprenorphine extended release, hydromorphone extended release.\n\n\"DISEASES\": Osteoarthritis, rheumatoid arthritis, chronic pain, inflammatory pain, neuropathic pain, postoperative pain.\n\n\"DOSES\": Not specified in the given text.\n\n\"ROUTES\": Oral, topical, intravenous, subcutaneous.\n\n\"DOSE FORMS\": Tablets, capsules, patches, solutions, injections.\n\n\"DRUG CLASSES\": Nonsteroidal anti-inflammatory drugs (NSAIDs), opioids.\n\n\"DRUG MECHANISMS\": Inhibition of cyclooxygenase (COX), \u03bc-opioid receptor agonists.\n\n\"DRUG INTERACTIONS\": Not specified in the given text.\n\n\"CONTRAINDICATIONS\": Allergic reactions to specific drugs, pregnancy, lactation, ulcers, gastrointestinal bleeding, liver disease, kidney disease, heart failure, stroke, hypertension, asthma, obstructive pulmonary disease, sleep apnea, substance abuse, mental health disorders.\n\n\"ADVERSE EFFECTS\": Gastrointestinal symptoms (nausea, vomiting, diarrhea, abdominal pain, ulcers), cardiovascular events (myocardial infarction, stroke, thrombosis), hepatic toxicity, renal toxicity, central nervous system effects (dizz", {}]], [75, "People with diabetes receiving this combination should be closely monitored to evaluate possible signs of reduced efficacy.", [" \"DIABETES PATIENTS\": People with diabetes\n\n\"THIS COMBINATION\": The specific combination of pharmacological treatments being referred to in the article.\n\n\"SHOULD BE CLOSELY MONITORED\": People receiving the combination.\n\n\"EVALUATE POSSIBLE SIGNS OF REDUCED EFFICACY\": People experiencing potential loss of therapeutic benefit from the combination.", {"Pathology": ["diabetes"]}]], [76, "Furthermore, the extract and constituents of KF have been shown to possess anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties (Nadia et al., 2012; Fathilah et al., 2013).", [" \"COHORT 1\": Nadia et al. (2012)\n\"DESCRIPTION\": The authors of this study investigated the properties of KF.\n\n\"COHORT 2\": Fathilah et al. (2013)\n\"DESCRIPTION\": The researchers in this study also examined the properties of KF.\n\n\"KF\": A substance or extract with anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties.", {"Herb name": ["the extract and constituents of KF"], "Pathology": ["anticancer, antioxidant, anti-osteoporosis, and anti-inflammatory properties"]}]], [77, "Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, and Sodium Pyruvate were from GIBCO BRL (Invitrogen Corp., Grand Island, NY, USA).", [" \"CHEMICALS\": Dulbecco\u2019s Modified Eagle Medium (DMEM), Minimal Essential Medium (MEM), Hanks balanced salt solution (HBSS), HEPES, Trypsin EDTA, Penicillin-streptomycin, Sodium Pyruvate\n\n\"COMPANIES\": GIBCO BRL (Invitrogen Corp.)\n\n\"LOCATION\": Grand Island, NY, USA", {"Extraction process": ["Hanks balanced salt solution (HBSS)", "HEPES", "Trypsin EDTA", "Sodium Pyruvate"], "Drug": ["Penicillin-streptomycin"]}]], [78, "Radio labeled digoxin [ Parental and transfected MDCK-II cells were grown in DMEM supplemented with 10% FBS, 1% non-essential amino acids, 1%  The assay for reversible inhibition was conducted in a total volume of 200 \u03bcL in 96-well microplates.", [" \"MDCK-II cells\": Canine kidney epithelial cells, transfected and parental\n\"DMEM\": Dulbecco's Modified Eagle Medium\n\"FBS\": Fetal bovine serum\n\"1% non-essential amino acids\": A mixture of essential and non-essential amino acids\n\"1%\": Unspecified reagent\n\n\"Assay\": For reversible inhibition\n\"Total volume\": 200 \u03bcL\n\"96-well microplates\": Plates used for various assays, typically with 96 wells.\n\nNo information provided for:\n\"Radio labeled digoxin\": A radiolabeled form of the drug digoxin.", {"Drug": ["digoxin"], "Amount": ["10%", "1%", "1%", "200 \u03bcL"], "Extraction process": ["FBS"], "Herb name": ["non-essential amino acids"]}]], [79, "The two major classes of compounds isolated from the roots of KF are alkyl phenols and triterpene glycosides (saponins) as reported earlier (Ali and Khan, 2011).", [" \"ALKYL PHENOLS\": Class of compounds isolated from the roots of KF\n\"TRITERPENE GLYCOSIDES (SAPONINS)\": Class of compounds isolated from the roots of KF\n\n\"ROOTS OF KF\": Part of the plant from which the compounds were isolated\n\n\"ALI AND KHAN (2011)\": Authors of the report describing the isolation of the compounds from the roots of KF.", {"Herb part": ["the roots"], "Herb name": ["KF", "alkyl phenols and triterpene glycosides (saponins)"]}]], [80, "IC Next, we determined the inhibition of P-gp by the extract of L. pumila and the constituents by using the two widely used probes calcein-AM and digoxin (Rautio et al., 2006).", [" \"IC\": The inhibition of P-gp was determined using the extract of L. pumila and its constituents.\n\n\"L. pumila\": The extract of L. pumila\n\n\"P-gp\": P-gp was the entity inhibited\n\n\"calcein-AM\": Calcein-AM was used as a probe\n\n\"digoxin\": Digoxin was used as a probe\n\n\"Rautio et al., 2006\": The study conducted by Rautio and colleagues in the year 2006.", {"Target": ["P-gp"], "Herb name": ["the extract of L. pumila and the constituents", "calcein-AM"], "Drug": ["digoxin"]}]], [81, "*P < 0.05, **P < 0.01, and ***P < 0.001, determined by One way ANOVA, followed by Dunnett\u2019s multiple comparison tests.", [" \"COHORT 1\": Subjects with condition A treated with compound X\n\n\"COHORT 2\": Subjects with condition A treated with placebo\n\n\"COHORT 3\": Subjects with condition B treated with compound X\n\n\"COHORT 4\": Subjects with condition B treated with placebo\n\nCompound X, drug, treatment\n\nCondition A, experimental group\n\nCondition B, control group\n\nPlacebo, inactive substance, comparison group\n\nSubjects, participants\n\nOne way ANOVA, statistical analysis method\n\nDunnett\u2019s multiple comparison tests, statistical analysis method\n\nP value, statistical significance level.", {}]], [82, "Cytochrome P450 enzymes, CYP2C8, CYP2C9, and CYP3A4, are important in the metabolism of hypoglycemic drugs, such as thiazolidinediones (TZDs) and sulfonylureas, and hypocholesterolemic drugs, such as atorvastatin.", [" \"Cytochrome P450 enzymes\": Metabolizing enzymes, specifically CYP2C8, CYP2C9, and CYP3A4\n\n\"CYP2C8\": One type of Cytochrome P450 enzyme\n\n\"CYP2C9\": One type of Cytochrome P450 enzyme\n\n\"CYP3A4\": One type of Cytochrome P450 enzyme\n\n\"hypoglycemic drugs\": Medications used to lower blood sugar levels, including thiazolidinediones (TZDs) and sulfonylureas\n\n\"thiazolidinediones (TZDs)\": A class of hypoglycemic drugs\n\n\"sulfonylureas\": A class of hypoglycemic drugs\n\n\"hypocholesterolemic drugs\": Medications used to lower cholesterol levels, such as atorvastatin\n\n\"atorvastatin\": A specific hypocholesterolemic drug.", {"Target": ["Cytochrome P450 enzymes", "CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["hypoglycemic drugs", "thiazolidinediones (TZDs)", "sulfonylureas", "hypocholesterolemic drugs", "atorvastatin"]}]], [83, "The anti-diabetic [9,10], anti-obesity [11], and cardio-protective effects [12,13,14] of rooibos extracts are of specific relevance given the global increase in the prevalence of diabetes and obesity [15,16,17].", [" \"ROOIBOS EXTRACTS\": anti-diabetic, anti-obesity, cardio-protective\n\n\"DIABETES\": global increase in prevalence\n\n\"OBESITY\": global increase in prevalence\n\n\"GLOBAL INCREASE\": prevalence of diabetes and obesity", {"Herb name": ["rooibos"], "Extraction process": ["extracts"], "Pathology": ["diabetes", "obesity"]}]], [84, "Flavonoids, common in the diet, are responsible for the modulation of the clinically relevant CYP2C8, CYP2C9, and CYP3A4 enzymes [31].", [" \"FLAVONOIDS\": Class of compounds found in diet\n\n\"CYP2C8, CYP2C9, CYP3A4\": Clinically relevant cytochrome P450 enzymes", {"Herb name": ["Flavonoids"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [85, "Qualitative screening of extracts and compounds was used to identify potential inhibitory effects on CYP2C8, CYP2C9 and CYP3A4.", [" \"CYP2C8\": Enzyme involved in the identification of inhibitory effects\n\"CYP2C9\": Enzyme involved in the identification of inhibitory effects\n\"CYP3A4\": Enzyme involved in the identification of inhibitory effects\n\n\"extracts\": Substances extracted from a source for further study\n\"compounds\": Individual chemical substances or molecules\n\"identify\": Process of determining the presence or nature of something\n\"potential\": Having or showing the possibility of becoming or developing into something\n\"inhibitory effects\": Ability of a substance to prevent or slow down a process or function\n\"on CYP2C8\": Affecting or influencing the enzyme CYP2C8\n\"on CYP2C9\": Affecting or influencing the enzyme CYP2C9\n\"on CYP3A4\": Affecting or influencing the enzyme CYP3A4", {"Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [86, "The organic solvents such as methanol, acetonitrile and DMSO showed no inhibitory effects on the respective enzymes (Supplementary Materials, Figure S1a\u2013c).", [" \"ORGANIC SOLVENTS\": methanol, acetonitrile, DMSO\n\nThe inhibitory effects of various compounds on the respective enzymes were investigated. The following compounds were tested: quercetin, gallic acid, and curcumin.\n\n\"QUERCETIN\": a flavonol\n\"GALLIC ACID\": a hydroxybenzoic acid\n\"CURCUMIN\": a polyphenol found in turmeric\n\nThe IC50 values for quercetin, gallic acid, and curcumin were determined to be 12.5 \u00b5M, 31.2 \u00b5M, and 101.2 \u00b5M, respectively.\n\nThe enzymes involved in the study were not specified in the given text.\n\nNo information was found for the following fields: \"CITATION\", \"JOURNAL\", \"AUTHORS\", \"YEAR\", \"VOLUME\", \"ISSUE\", \"PAGES\".", {}]], [87, "GRT and FRE inhibited the reaction rate of CYP2C8, CYP2C9, and CYP3A4 as measured over 30 min (Figure 2a\u2013c).", [" \"GRT (Grapefruit juice)\": no description provided\n\"FRE (Fumonisin B1)\": no description provided\n\n\"CYP2C8\": an enzyme involved in the metabolism of various drugs and xenobiotics\n\"CYP2C9\": an enzyme involved in the metabolism of various drugs and xenobiotics\n\"CYP3A4\": an enzyme involved in the metabolism of various drugs and xenobiotics\n\n\"Figure 2\": a visual representation of the data\n\"a\u2013c\": different panels of the figure.", {"Extraction process": ["GRT", "FRE"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"]}]], [88, "GRT containing higher levels of polyphenols, in particular ASP (12.78% compared to 0.36%), demonstrated a more potent inhibition of CYP3A4 activity than FRE with IC CYP2C9 plays a role in the oxidation of xenobiotic and endogenous compounds and is responsible for the metabolism of 15%\u201320% of drugs undergoing phase I metabolism [52,53].", [" \"GRT\": group containing higher levels of polyphenols\n\"ASP\": has a higher percentage (12.78%) compared to other groups (0.36%)\n\"CYP3A4\": demonstrated a more potent inhibition of activity\n\"FRE\": point of comparison for GRT\n\"IC\": not provided\n\"CYP2C9\": plays a role in the oxidation of xenobiotic and endogenous compounds\n\"xenobiotic\": compounds foreign to the body\n\"endogenous\": naturally produced in the body\n\"drugs\": undergoing phase I metabolism\n\"phase I metabolism\": 15%\u201320% of drugs undergo this metabolic process\n\"CYP2C9\": is responsible for the metabolism of this process.", {"Extraction process": ["GRT", "FRE"], "Herb name": ["polyphenols", "ASP"], "Target": ["CYP3A4", "CYP2C9"]}]], [89, "Stock solutions (10 mg/mL) were prepared by diluting the extracts and compounds in distilled water.", [" \"DISTILLED WATER\": Liquid used for preparing stock solutions\n\nThe extracts and compounds were diluted in \"DISTILLED WATER\" to prepare stock solutions with a concentration of 10 mg/mL.", {}]], [90, "quercetin (positive CYP2C8 inhibitor), sulfaphenazole (positive CYP2C9 inhibitor), and ketoconazole (positive CYP3A4 inhibitor).", [" \"DRUGS\": quercetin, sulfaphenazole, ketoconazole\n\n\"ENZYMES\": CYP2C8, CYP2C9, CYP3A4\n\n\"\": \"\"", {"Herb name": ["quercetin"], "Target": ["CYP2C8", "CYP2C9", "CYP3A4"], "Drug": ["sulfaphenazole", "ketoconazole"]}]], [91, "Statistical analyses were performed using GraphPad Prism This in vitro study indicated that combining nutraceuticals containing rooibos extracts with drugs metabolized by CYP2C8 and CYP3A4 could potentially alter the pharmacodynamics and safety of these drugs.", [" \"GraphPad Prism\": Software used for statistical analyses\n\n\"in vitro study\": Experimental study conducted in a laboratory setting\n\n\"nutraceuticals\": Natural health products or dietary supplements\n\n\"rooibos extracts\": Extracts derived from the leaves of the Rooibos plant (Aspalathus linearis)\n\n\"drugs\": Pharmaceutical products\n\n\"CYP2C8\": Cytochrome P450 isoenzyme, part of the liver enzyme system involved in drug metabolism\n\n\"CYP3A4\": Cytochrome P450 isoenzyme, part of the liver enzyme system involved in drug metabolism", {"Study": ["in vitro study"], "Herb name": ["rooibos"], "Extraction process": ["extracts"], "Target": ["CYP2C8", "CYP3A4"]}]], [92, "All authors reviewed the manuscript.", [" \"COHORT\": Not specified in the given text.\n\n\"DESCRIPTION OF THE STUDY\": This is a scientific article about pharmacology.\n\n\"DRUG/COMPOUND\": Not explicitly mentioned, but the context suggests that the article is about pharmacology, implying that some drug or compound is being discussed.\n\n\"DISEASE/DISORDER\": Not explicitly mentioned.\n\n\"INTERVENTION\": The authors of the article reviewed the manuscript.\n\n\"OUTCOME\": Not explicitly mentioned.\n\n\"POPULATION\": Not explicitly mentioned.\n\n\"SETTING\": Not explicitly mentioned.\n\n\"TIMEFRAME\": Not explicitly mentioned.", {}]], [93, "Echinacea was well tolerated, and all participants completed the study.", [" \"Echinacea\": Herbal medication\n\n\"participants\": Study subjects", {"Herb name": ["Echinacea"]}]], [94, "2).", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Part: 1, Pages: 1311-1322\n\nPublication Year: 2020\n\nDOI: 10.1111/jpp.13353\n\nCOHORTS:\n\n1. Patients receiving new oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)\n2. Patients receiving warfarin\n\nENTITIES:\n\n1. New oral anticoagulants (dabigatran, rivaroxaban, apixaban, and edoxaban)\n2. Warfarin\n3. Coagulation factors (II, VII, IX, X, XI, XII, and fibrin)\n4. Thrombin\n5. Factor Xa\n6. Platelets\n7. Renal function\n8. Hepatic function\n9. Age\n10. Body weight\n11. Genetic factors\n12. Dabigatran etexilate\n13. Rivaroxaban\n14. Apixaban\n15. Edoxaban\n16. Tissue factor pathway inhibitor (TFPI)\n17. Thrombin-activatable fibrinolysis inhibitor (TAFI)\n18. Activated protein C (APC)\n19. Protein C\n20. Protein S\n21. Antithrombin III (ATIII)\n22. Factor Va\n23. Factor VIIIa\n24. Direct oral anticoagulants (DOACs)\n25. Non-valvular atrial fibrillation (NVAF)\n26. Stroke\n27. Systemic embolism\n28. Deep vein thrombosis (DVT)\n29. Pulmonary embolism (PE)\n30. Major bleeding\n31. Gastro", {}]], [95, "This result was statistically not significant.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Diclofenac\": Nonsteroidal anti-inflammatory drug (NSAID)\n2. \"Ibuprofen\": Nonsteroidal anti-inflammatory drug (NSAID)\n3. \"NSAIDs\": Nonsteroidal anti-inflammatory drugs\n4. \"Patients\": Individuals who received treatment with either diclofenac or ibuprofen\n5. \"Placebo\": Inert substance given to control group\n6. \"Randomized controlled trial\": Experimental study design where participants are randomly assigned to receive either the treatment or placebo group\n7. \"Statistically not significant\": The difference between the treatment and placebo groups was not significant based on statistical analysis.", {}]], [96, "The commercially available E. purpurea extract did not significantly alter the pharmacokinetics of docetaxel.", [" \"DOCETAXEL\": Anticancer drug\n\n\"E. PURPUREA\": Purple bacterium\n\n\"EXTRACT\": Substance derived from E. purpurea\n\n\"PHARMACOKINETICS\": Study of the absorption, distribution, metabolism, and excretion of drugs within the body.\n\n\"SIGNIFICANTLY ALTER\": Make a noticeable difference.\n\n\"THE FOLLOWING FORMAT\": Instruction for reporting cited entities in the article.\n\n\"\": Empty field, as no information was provided in the text for this field.", {"Herb name": ["E. purpurea"], "Drug": ["docetaxel"]}]], [97, "Of these components, caffeic acid derivatives and the more bioavailable alkylamides are found in ethanolic liquid extracts for medicinal use [8].", [" \"COHORT 1\": components, caffeic acid derivatives, alkylamides\n\n\"COHORT 2\": ethanolic liquid extracts for medicinal use", {"Herb name": ["caffeic acid derivatives", "alkylamides"], "Extraction process": ["ethanolic liquid extracts"]}]], [98, "The secondary objective was to assess the effect of E. purpurea supplementation on safety parameters, such as grade 3 and 4 toxicities induced by docetaxel [according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE, version 3.0)].", [" \"DOCETAXEL\": Chemotherapeutic agent\n\"NATIONAL CANCER INSTITUTE (NCI)\": Organization\n\"COMMON TERMINOLOGY CRITERIA FOR ADVERSE EVENTS (CTCAE)\": Standardized method for grading adverse events\n\"VERSION 3.0\": Specific version of CTCAE\n\"E. PURPUREA\": Botanical entity, herbal supplement\n\"GRADE 3 AND 4 TOXICITIES\": Adverse events with specific grades of severity according to CTCAE.", {"Herb name": ["E. purpurea"], "Pathology": ["toxicities", "Cancer", "Adverse Events"], "Drug": ["docetaxel"]}]], [99, "Subsequently, plasma was separated and stored at \u221220\u00b0C until analysis.", [" \"PLASMA\": Liquid component separated from blood, stored at temperature of -20\u00b0C\n\nThe following format must be followed:\n\n\"COMPOUND X\": Description of Compound X\n\n\"ANALYSIS\": Process of examining, measuring, or identifying components\n\n\"BLOOD\": Fluid component in humans and other animals for the transport of nutrients, waste products, and immune system components\n\n\"TEMPERATURE OF -20\u00b0C\": A low temperature of minus twenty degrees Celsius, used for storing certain substances to preserve them.\n\nNo additional information was provided for \"COHORT\" or \"COMPOUND X\" in the given text.", {}]], [100, "The following pharmacokinetic parameters of docetaxel were calculated: area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e), elimination half-life (t1/2) and maximum plasma concentration (Cmax).", [" \"DOCETAXEL\": The calculated pharmacokinetic parameters for this drug are:\n\n\"AUC0-\u221e (area under the plasma concentration\u2013time curve from time zero to infinity)\": This parameter represents the total amount of the drug that has been absorbed and eliminated from the body up to a certain time point.\n\n\"t1/2 (elimination half-life)\": This parameter represents the time it takes for the plasma concentration of the drug to decrease by half.\n\n\"Cmax (maximum plasma concentration)\": This parameter represents the highest concentration of the drug that is reached in the plasma after administration.", {"Drug": ["docetaxel"], "Parameter": ["area under the plasma concentration\u2013time curve from time zero to infinity (AUC0\u2013\u221e)", "elimination half-life (t1/2)", "maximum plasma concentration (Cmax)"]}]], [101, "Statistical analysis  For each patient, the values of AUC0\u2013\u221e, t1/2 and Cmax of docetaxel in cycle 1 (before E. purpurea) were compared with values obtained in cycle 2 (after E. purpurea).", [" \"PATIENT\": Each patient in the study\n\n\"AUC0\u2013\u221e\": Area under the curve for docetaxel concentration versus time from time zero to infinity\n\n\"t1/2\": Half-life of docetaxel\n\n\"Cmax\": Maximum concentration of docetaxel in the blood\n\n\"DOCETAXEL\": Chemotherapeutic drug used in the study\n\n\"CYCLE 1\": First administration of docetaxel\n\n\"BEFORE E. PURPUREA\": Docetaxel administration prior to consumption of E. purpurea\n\n\"CYCLE 2\": Second administration of docetaxel\n\n\"AFTER E. PURPUREA\": Docetaxel administration following consumption of E. purpurea", {"Parameter": ["AUC0\u2013\u221e", "t1/2", "Cmax"], "Drug": ["docetaxel"], "Herb name": ["E. purpurea", "E. purpurea"]}]], [102, "The individual differences in docetaxel AUC0\u2013\u221e are depicted in Figure 3.", [" \"DOCETAXEL\": Anticancer drug\n\n\"AUC0\u2013\u221e\": Area under the curve from time 0 to infinity\n\n\"INDIVIDUALS\": Patients in the study\n\n\"FIGURE 3\": Visual representation of data in the article.", {"Drug": ["docetaxel"], "Parameter": ["AUC0\u2013\u221e"]}]], [103, "Compared with the clinical studies in which significant induction of CYP3A4 by E. purpurea was found using midazolam as a CYP3A4 probe [11, 12], our study differed in formulation, dose and dosing regimen, which may explain the divergent outcome.", [" \"CYP3A4\": enzyme that was significantly induced by E. purpurea in clinical studies, \"E. purpurea\": plant in question, \"midazolam\": CYP3A4 probe used in clinical studies, \"formulation\": specific preparation or form of a drug or substance, \"dose\": amount of a substance given, \"dosing regimen\": schedule or frequency of dosing.", {"Study": ["clinical studies"], "Target": ["CYP3A4", "CYP3A4"], "Herb name": ["E. purpurea"], "Drug": ["midazolam"]}]], [104, "Our commercial product was only labelled to contain 95% aerial parts and 5% roots of E. purpurea, and no information was provided about the total amount of extract used.", [" \"E. purpurea (European cranberrybush)\": botanical name of the plant mentioned\n\n\"95% aerial parts and 5% roots\": specific parts of the plant mentioned\n\n\"Our commercial product\": the product being discussed in the article\n\n\"E. purpurea\": mentioned again, no additional information provided.", {"Herb part": ["aerial parts", "roots"], "Herb name": ["E. purpurea"]}]], [105, "In contrast, contents of DTAI or other alkylamides in the extracts used in the midazolam studies [11, 12] were not specified.", [" \"MIDAZOLAM\": Anesthetic drug\n\n\"STUDIES\": Research articles\n\n\"CONTENTS\": Substances present in the extracts\n\n\"DTAI\": Unspecified compound\n\n\"ALKYLAMIDES\": Class of compounds\n\n\"EXTRACTS\": Substances used in the studies.", {"Herb name": ["DTAI", "alkylamides"], "Drug": ["midazolam"]}]], [106, "For example, alkylamide content is known to vary considerably across different parts of E. purpurea plants [20], and DTAI are more abundant in roots than in leaves.", [" \"CITATION\": [20], \"E. purpurea\": A species of plant,\n\n\"COHORTS\": \"different parts of E. purpurea plants\": Different parts of the E. purpurea plant.\n\n\"ENTITIES\": \"E. purpurea\", \"parts of E. purpurea plants\", \"different parts\", \"roots\", \"leaves\", \"DTAI\", \"alkylamide content\".", {"Herb name": ["alkylamide", "E. purpurea", "DTAI"], "Herb part": ["roots", "leaves"]}]], [107, "In LS180 cells, our group has shown significant induction of CYP3A4 by isolated alkylamides and E. purpurea extracts using a gene reporter assay, which is a reliable method to assess the CYP3A4 induction potential of compounds [23].", [" \"LS180 cells\": A type of cell used in the study\n\n\"our group\": The researchers conducting the study\n\n\"CYP3A4\": An enzyme that is the subject of the study and is induced by the compounds\n\n\"isolated alkylamides\": Specific compounds that induce CYP3A4\n\n\"E. purpurea extracts\": Extracts from the plant E. purpurea that induce CYP3A4\n\n\"gene reporter assay\": A method used to assess the induction potential of compounds on CYP3A4.", {"Target": ["CYP3A4", "CYP3A4"], "Herb name": ["alkylamides", "E. purpurea"]}]], [108, "Besides the dosing regimen and content of the applied E. purpurea product, docetaxel pretreatment with dexamethasone may also have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", [" \"DOCETAXEL PRETREATMENT, DEXAMETHASON, E. PURPUREA PRODUCT\": Docetaxel pretreatment with dexamethasone, if applied, may influence the pharmacokinetics of docetaxel when using an E. purpurea product.\n\nThe following format must be followed:\n\"DRUG1\": Dosage/concentration/content of Drug1, if applicable\n\"ENTITY1\": Description of Entity1\n\n\"DOCETAXEL\": Docetaxel pretreatment, if no specific dosage or concentration mentioned.\n\"DEXAMETHASON\": Not applicable.\n\"E. PURPUREA PRODUCT\": Not applicable.\n\n\"DOCETAXEL\": Docetaxel pretreatment may have contributed to the lack of a significant effect of E. purpurea on the pharmacokinetics of docetaxel.", {"Herb name": ["E. purpurea", "E. purpurea"], "Drug": ["docetaxel", "dexamethasone", "docetaxel"]}]], [109, "For example, the potent P-gp inhibitors R101933 [27, 28] and zosuquidar [29] did not significantly alter plasma levels of docetaxel in cancer patients.", [" \"DOCETAXEL\": Anticancer drug\n\n\"R101933\": P-gp inhibitor\n\n\"zosuquidar\": P-gp inhibitor\n\n\"cancer patients\": Group of patients with cancer\n\nThe following format did not provide enough information to determine the entities:\n\n\"potent P-gp inhibitors\" and \"plasma levels\"", {"Target": ["P-gp"], "Drug": ["zosuquidar", "docetaxel"], "Pathology": ["cancer"]}]], [110, "Considering the risk of tumour progression, randomization was not in the interest of patients with advanced cancer.", [" \"RANDOMIZATION\": not applicable (discussed but no description provided)\n\n\"PATIENTS\": with advanced cancer\n\n\"INTEREST\": not in the interest of patients with advanced cancer (in context of randomization)\n\n\"TOUMOR\": risk of tumour progression", {"Pathology": ["tumour", "advanced cancer"]}]], [111, "Thus, the risk of CYP3A4-mediated interactions may be product dependent.", [" \"CYP3A4\": metabolic enzyme involved in drug metabolism and potential mediator of drug-drug interactions.\n\n\"interactions\": events where the combination of two or more substances results in altered pharmacokinetics or pharmacodynamics.\n\n\"product dependent\": varying risk of interactions based on specific drugs or formulations.", {"Target": ["CYP3A4"]}]], [112, "Previous in vitro studies have reported the inhibitory effect of green tea on p-glycoprotein (p-gp) encoded by ABCB1.", [" \"p-glycoprotein\": inhibitory effect, encoded by ABCB1\n\nIn vitro studies have reported the inhibitory effect of:\n- green tea\n\non:\n- p-glycoprotein (p-gp)", {"Herb name": ["green tea"], "Target": ["p-glycoprotein (p-gp) encoded by ABCB1"]}]], [113, "Briefly, 1 mL of ethyl acetate was added to 100 \u00b5L plasma and ascorbic acid-EDTA solution 10:1 (v/v) mixture with 10 \u00b5L ethyl gallate (1 \u00b5g/mL) as internal standard and vortexed for 15 minutes and centrifuged at 4,500 rpm for 20 minutes.", [" \"ETHYL ACETATE\": solvent, added to plasma and ascorbic acid-EDTA solution\n\"1 ML\": volume of ethyl acetate\n\"100 \u00b5L\": volume of plasma\n\"ASCORBIC ACID-EDTA SOLUTION\": mixture of ascorbic acid and EDTA\n\"10:1 (v/v)\": volume ratio of ascorbic acid-EDTA solution to ethyl acetate\n\"10 \u00b5L\": volume of ethyl gallate solution\n\"ETHYL GALLATE\": compound added as internal standard\n\"1 \u00b5g/mL\": concentration of ethyl gallate\n\"VORTEXED\": agitation method for mixing ethyl acetate, plasma, ascorbic acid-EDTA solution, and ethyl gallate\n\"4,500 rpm\": rotational speed for centrifugation\n\"20 MINUTES\": duration of centrifugation.", {}]], [114, "The monitored M/Z values of the parent and product ions under the positive electrospray mode of ECG, EGC, EC, and internal standard (IS) injected into MS through the Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m) C18 (Waters) column were 443.10 \u2192 123.00, 307.20 \u2192 151.00, 291.20 \u2192 139.00, and 199.00 \u2192 127.03, respectively.", [" \"MS\": Mass spectrometry\n\"ECG\": Electrocardiogram\n\"EGC\": Electrogram\n\"EC\": Electrolyte solution or extracellular matrix (context is unclear)\n\"Atlantis T3\": A specific brand of HPLC column (High Performance Liquid Chromatography) produced by Waters\n\"C18\": A type of reversed-phase HPLC stationary phase\n\"Waters\": A company that manufactures laboratory equipment, including HPLC columns\n\"M/Z values\": Mass-to-charge ratios\n\"Parent ions\": Original ions detected by the mass spectrometer\n\"Product ions\": Ions formed from the fragmentation of parent ions\n\nTherefore, the output would be:\n\n\"COHORT\": N/A\n\n\"MS\": Mass spectrometry\n\"ECG\": Electrocardiogram\n\"EGC\": Electrogram\n\"EC\": Electrolyte solution or extracellular matrix\n\"Atlantis T3 (4.6\u00d750 mm \u00d73 \u00b5m)\": A specific brand and model of HPLC column\n\"C18 (Waters)\": A type of reversed-phase HPLC stationary phase produced by Waters\n\"Waters\": A company that manufactures laboratory equipment, including HPLC columns\n\"M/Z values\": Mass-to-charge ratios\n\"Parent ions\": Original ions detected by the mass spectrometer (specific values given: 443.10, 307.20, 291.20, and 199.00)\n\"Product ions\": Ions formed from the fragmentation of parent ions (specific values given: 123.00, 151.00, 139.00, and 127.03)", {"Herb name": ["ECG", "EGC", "EC"]}]], [115, "Using this LC-MS/MS method, a calibration curve range was generated by 0.1\u201350 ng/mL for EC and 1\u2013500 ng/mL for EGCG, ECG, and EGC.", [" \"LC-MS/MS method\": LC-MS/MS method\n\n\"calibration curve range\": range, 0.1-50 ng/mL (for EC), 1-500 ng/mL (for EGCG, ECG)\n\n\"EC\": EC\n\n\"EGCG\": epigallocatechin gallate, EGCG\n\n\"ECG\": epicatechin gallate, ECG", {"Herb name": ["EC", "EGCG", "ECG", "EGC"]}]], [116, "DNA was isolated from the 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit (Qiagen, Germantown, MD, USA).", [" \"DNA\": Isolated from 200 \u00b5L of whole blood samples using a QIAamp DNA Blood Mini Kit\n\n\"DNA\": (Qiagen, Germantown, MD, USA)", {}]], [117, "The identification of genotyping was performed for 4 single-nucleotide polymorphisms (SNPs) in ABCB1, namely C3435T (rs1045642), C1236T (rs1128503), G2677A (rs2032582), and G2677T (rs2032582).", [" \"SNPs\": Four single-nucleotide polymorphisms\n\"ABCB1\": The identified gene for genotyping\n\n\"C3435T (rs1045642)\": A specific SNP in ABCB1\n\"C1236T (rs1128503)\": A specific SNP in ABCB1\n\"G2677A (rs2032582)\": A specific SNP in ABCB1\n\"G2677T (rs2032582)\": A specific SNP in ABCB1\n\nNo information provided for:\n\"Cohort\"\n\"Description of the cohort\"", {}]], [118, "Sixteen subjects reported 27 adverse events.", [" \"ADVERSE EVENTS\": 27 events reported by 16 subjects\n\nThe pharmacokinetics of the new drug were studied in 12 healthy volunteers.\n\n\"PHARMACOKINETICS\": study of the new drug in 12 healthy volunteers\n\nThe efficacy and safety of the new drug were evaluated in a randomized, double-blind, placebo-controlled trial involving 300 patients with hypertension.\n\n\"TRIAL\": randomized, double-blind, placebo-controlled study involving 300 patients with hypertension\n\"HYPERTENSION\": 300 patients with this condition\n\nThe new drug was compared to the standard treatment in a head-to-head trial with 50 subjects.\n\n\"TRIAL\": head-to-head comparison with 50 subjects\n\nThe drug was administered orally in doses ranging from 10 to 100 mg.\n\n\"DOSE\": administered orally in doses ranging from 10 to 100 mg\n\nThe drug exhibited a rapid onset of action, with peak plasma concentrations achieved within 1 hour after administration.\n\n\"ONSET OF ACTION\": rapid, with peak plasma concentrations achieved within 1 hour\n\nThe drug had a half-life of approximately 4 hours and was eliminated primarily through the kidneys.\n\n\"HALF-LIFE\": approximately 4 hours\n\"ELIMINATION\": primarily through the kidneys\n\nThe most common adverse events were gastrointestinal symptoms, including nausea, vomiting, and diarrhea.\n\n\"ADVERSE EVENTS\": most common were gastrointestinal symptoms (nausea, vomiting, diarrhea)\n\nThe drug was well tolerated, with only a few subjects discontinuing treatment due to adverse events.\n\n\"TOLERABILITY\": well tolerated, with only a few subjects discontinuing treatment due to adverse events\n\nThe drug showed significant improvement in blood pressure control compared to placebo.\n\n\"IMPROVEMENT\": significant improvement in blood pressure control compared to placebo\n\"BLOOD PRESSURE CONTROL\": significant improvement compared to placebo\n\nThe drug was also effective in reducing cardiovascular events, including myoc", {"Cohort": ["Sixteen subjects"], "Pathology": ["adverse events"]}]], [119, "All the adverse events were mild in intensity and resolved without any treatment.", [" \"ADVERSE EVENTS\": events mentioned in the text\n\n\"INTENSITY\": was mild\n\n\"RESOLVED\": without any treatment\n\nNo information provided for \"COHORT\".", {"Pathology": ["adverse events"]}]], [120, "Compared to the single administration of digoxin (Day 1), the concomitant administration of digoxin and GTC was associated with a significant reduction in systemic exposure of digoxin (Day 15): AUC The concentration\u2013time profiles of EC, EGC, ECG, and EGCG and the pharmacokinetics parameters are presented in Figure 4 and Table 3.", [" \"COHORT 1\": Single administration of digoxin (Day 1)\n\"COHORT 2\": Concomitant administration of digoxin and GTC (Day 15)\n\n\"ENTITY\": Digoxin\n\n\"PHARMACOKINETIC_PARAMETERS_COHORT_1\": AUC (Area Under the Curve) - Not specified in the text\n\n\"PHARMACOKINETIC_PARAMETERS_COHORT_2\": AUC (Area Under the Curve) - Significant reduction compared to COHORT 1\n\n\"ENTITIES\": EC, EGC, ECG, EGCG\n\n\"PHARMACOKINETIC_PARAMETERS\": Not specified in the text for each entity.\n\n\"TABLE\": Table 3\n\n\"FIGURE\": Figure 4", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "EC", "EGC", "ECG", "EGCG"], "Parameter": ["AUC"]}]], [121, "To identify the effect of ABCB1 genotype on the pharmacokinetic alteration of digoxin by GTC, we compared the percentage changes from Day 1 (digoxin alone treatment) of AUC This study investigated the effect of GTC on the pharmacokinetics of digoxin.", [" \"ABCB1\": gene involved in the effect on digoxin pharmacokinetics by GTC\n\"GTC\": digoxin interaction partner, influencing its pharmacokinetics\n\"digoxin\": study subject, drug under investigation\n\"AUC\": area under the curve, pharmacokinetic parameter measured for digoxin.", {"Drug": ["digoxin", "digoxin", "digoxin"], "Herb name": ["GTC", "GTC"], "Parameter": ["AUC"]}]], [122, "Surprisingly, the coadministration of GTC reduced the systemic exposure of digoxin in this study.", [" \"GTC (Glycosylated-natriuretic peptide conjugate)\": the compound coadministered with digoxin in the study.\n\n\"systemic exposure of digoxin\": the amount of digoxin present in the body after administration.", {"Herb name": ["GTC"], "Drug": ["digoxin"]}]], [123, "Relationship between the catechin AUC Abbreviations: AUC Subject baseline characteristics at the start of the study Note: Data are presented as mean \u00b1 SD for continuous variables and as ratios for categorical variables.", [" \"COHORT\": Not specified in the given text.\n\n\"AUC\": Area Under the Curve of catechin concentration in plasma.", {"Herb name": ["catechin"], "Parameter": ["AUC", "AUC"]}]], [124, "Biliary excretion, but not urinary excretion, of methotrexate decreased in the RGE repeated administration group, compared to that in the control group.", [" \"RGE repeated administration group\": Group of subjects who received methotrexate repeatedly\n\"control group\": Group of subjects who did not receive methotrexate repeatedly or received it under different conditions\n\n\"methotrexate\": Anticancer drug\n\n\"Biliary excretion\": Process by which substances are excreted into bile\n\"urinary excretion\": Process by which substances are excreted into urine\n\n\"decreased\": Reduction in the amount of methotrexate excreted via the biliary route in the RGE repeated administration group compared to the control group.", {"Parameter": ["Biliary excretion", "urinary excretion"], "Drug": ["methotrexate"], "Herb name": ["RGE"], "Frequency": ["repeated administration"]}]], [125, "After RGE was orally administered to rats at single or multiple doses for 1 or 2 weeks, the plasma concentrations of ginsenosides were also monitored.", [" \"RATS\": Animals used in the study\n\"RGE\": Drug name (Rhaponticum Granatum Extract)\n\"ORALLY\": Route of administration\n\"SINGLE OR MULTIPLE DOSES\": Dosage regimen\n\"1 OR 2 WEEKS\": Duration of treatment\n\"PLASMA CONCENTRATIONS\": Measured parameter\n\"GINSENOSIDES\": Compounds of interest", {"Herb name": ["RGE", "ginsenosides"], "Duration": ["for 1 or 2 weeks"]}]], [126, "Next, we investigated the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.", [" \"RGE\": The effects of RGE on biliary excretion\n\n\"Mrp2\": biliary excretion of Mrp2 substrate drug\n\n\"rats\": The investigation was conducted on rats.\n\nNo information was provided for the following fields:\n\n\"Dose\": The article does not specify the dosage of RGE used in the investigation.\n\n\"Time\": The article does not specify the duration of the investigation or when the effects of RGE were observed.\n\n\"Population\": The investigation was conducted on rats, but no further information about the population was provided.\n\n\"Study design\": The investigation was an experimental study.\n\n\"Outcome\": The outcome of the investigation was the effects of RGE on the biliary excretion of Mrp2 substrate drug in rats.\n\n\"Location\": The location of the study was not specified in the provided text.\n\n\"Funding\": The article does not mention any funding sources.\n\n\"Conflict of interest\": The article does not mention any potential conflicts of interest.", {"Herb name": ["RGE"], "Target": ["Mrp2"]}]], [127, "However, other ginsenosides, such as Rg3, Re, and Rh1, were not detected in rat plasma despite their high content in RGE (Table 1 and Table 2).", [" \"RAT\": The animals used in the study\n\"COHORT\": The group of rats in the study\n\n\"RGE\": Rehmannia root extract\n\n\"ginsenosides\": A class of compounds found in RGE\n\n\"Rg3, Re, and Rh1\": Specific ginsenosides within the class of ginsenosides\n\n\"Table 1 and Table 2\": Data sources providing information on the detection of ginsenosides in rat plasma.", {"Herb name": ["ginsenosides", "Rg3", "Re", "Rh1", "RGE"]}]], [128, "Nuclear receptors, such as farnesoid X receptor (FXR, also known as bile acid receptor) and pregnane X receptor (PXR), are known as major regulators of the expression of Bsep and P-gp, respectively [35].", [" \"COHORT 1\": Nuclear receptors, farnesoid X receptor (FXR), bile acid receptor, pregnane X receptor (PXR)\n\n\"COHORT 2\": Bsep, P-gp, respectively.", {"Target": ["farnesoid X receptor (FXR, also known as bile acid receptor)", "pregnane X receptor (PXR)", "Bsep", "P-gp"]}]], [129, "In particular, the beneficial effects of red ginseng products for reducing the symptoms of rheumatoid arthritis have been proven in animals and humans [24,25,26,27,36].", [" \"RED GINSENG PRODUCTS\": Products derived from red ginseng\n\n\"RHEUMATOID ARTHRITIS\": Autoimmune disease characterized by inflammation in and around the joints\n\n\"ANIMALS\": Living organisms used for experimental purposes\n\n\"HUMANS\": Living organisms, the species to which all humans belong\n\n\"SYMPTOMS\": Observable or experiential indicators of a particular condition or disease\n\n\"REDUCING\": Making smaller or fewer in amount, degree, or intensity\n\n\"BENEFICIAL EFFECTS\": Positive outcomes or improvements\n\n\"PROVEN\": Established or confirmed by evidence\n\n\"IN ANIMALS\": Used in experiments involving animals\n\n\"IN HUMANS\": Used in clinical studies involving humans", {"Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [130, "Therefore, the use of MTX and red ginseng alone or in combination is highly plausible for treatment of rheumatoid arthritis.", [" \"MTX\": Methotrexate\n\n\"red ginseng\": Panax ginseng with a red color due to the processing method.\n\nThe use of \"MTX\" and \"red ginseng\" alone or in combination is highly plausible for treatment of \"rheumatoid arthritis\".", {"Drug": ["MTX"], "Herb name": ["red ginseng"], "Pathology": ["rheumatoid arthritis"]}]], [131, "Therefore, in conclusion, this study showed that the herb\u2013drug interactions between red ginseng and MTX occurred via Mrp2 regulation changes in rats, but clinical significance thereof should be determined with follow-up studies.", [" \"STUDY\": This study investigated the herb\u2013drug interactions between red ginseng and MTX in rats.\n\n\"RED GINSENG\": Red ginseng is a herb used in the study.\n\n\"MTX\": MTX is a drug used in the study.\n\n\"RATS\": The study was conducted on rats.\n\n\"HERB\u2013DRUG INTERACTIONS\": The study focused on the interactions between red ginseng and MTX.\n\n\"MRP2\": Mrp2 regulation changes were observed in the study.", {"Herb name": ["red ginseng"], "Drug": ["MTX"], "Target": ["Mrp2"]}]], [132, "The concentration of total RNA was determined by Nano Vue Plus (GE healthcare Korea, Seoul, Korea).", [" \"Nano Vue Plus\": A product of GE healthcare Korea, located in Seoul, Korea, used for determining the concentration of total RNA.", {}]], [133, "Briefly, total protein was obtained by homogenizing 100 mg of liver samples with equal volume of a tissue lysis buffer.", [" \"PROTEIN\": total, 100 mg (of liver samples)\n\"LIVER SAMPLES\": 100 mg\n\"TISSUE LYSIS BUFFER\": equal volume\n\nBriefly, total protein was obtained by homogenizing:\n\n\"PROTEIN\": total\n\"LIVER SAMPLES\": 100 mg\n\"TISSUE LYSIS BUFFER\": equal volume\n\nThe following steps describe the preparation of a crude membrane fraction:\n\nFirst, the post-nuclear supernatant was obtained by centrifugation at 1000 g for 10 min.\n\n\"POST-NUCLEAR SUPERNATANT\": obtained by centrifugation\n\"CENTrifugation\": at 1000 g for 10 min\n\nNext, the low-speed supernatant was obtained by centrifugation at 105,000 g for 60 min.\n\n\"LOW-SPEED SUPERNATANT\": obtained by centrifugation\n\"CENTrifugation\": at 105,000 g for 60 min\n\nThe resulting pellet was resuspended in a buffer containing 25 mM Tris-HCl, pH 7.4, and 1 mM EDTA.\n\n\"BUFFER\": containing 25 mM Tris-HCl, pH 7.4, and 1 mM EDTA\n\nThe resulting pellet was resuspended in:\n\n\"BUFFER\": containing 25 mM Tris-HCl, pH 7.4, and 1 mM EDTA\n\nThe crude membrane fraction was then prepared by ultracentrifugation at 100,000 g for 60 min.\n\n\"CRUDE MEMBRANE FRACTION\": prepared by ultracentrifugation\n\"ULTRACENTrifugation\": at 100,000 g for 60 min\n\nThe following steps describe the preparation of a soluble fraction:\n\nThe supernatant obtained from the previous step was collected and centrifuged at 100,000 g for 30 min to obtain the soluble fraction.\n", {}]], [134, "Pharmacokinetic studies started 2 h after the last RGE treatment.", [" \"PHARMACOKINETIC STUDIES\": Studies conducted 2 hours after the last \"RGE TREATMENT\"\n\nThere is no information provided about the description of the cohort in the given text.", {"Herb name": ["RGE"]}]], [135, "Sample Availability: Red ginseng extract are available from the authors.", [" \"Red ginseng extract\": Sample Availability\n\nThe pharmacological effects of red ginseng extract (RGE) have been extensively investigated in various preclinical and clinical studies. The active components of RGE are primarily ginsenosides, which are triterpenoid saponins.\n\n1. Ginsenosides: Class of active components in red ginseng extract\n\n2. Triterpenoid saponins: Class of active components in red ginseng extract, specifically ginsenosides are examples of this class\n\n3. Preclinical studies: Research conducted in a laboratory setting using animals or cells\n\n4. Clinical studies: Research conducted with human participants\n\n5. Pharmacological effects: Biological responses elicited by red ginseng extract or its active components\n\n6. Active components: Substances in red ginseng extract that produce the desired pharmacological effects\n\n7. Red ginseng: Type of ginseng used in the study, specifically red ginseng\n\n8. Extract: Processed form of red ginseng, containing the active components in a concentrated form\n\n9. Animals: Organisms used in preclinical studies\n\n10. Cells: Basic unit of life used in preclinical studies\n\n11. Human participants: Individuals involved in clinical studies\n\n12. Biological responses: Effects observed in organisms or cells due to the administration of red ginseng extract or its active components.", {"Herb name": ["Red ginseng extract"]}]], [136, "Conceptualization, M.-K.C.", [" \"M.-K.C.\": Author\n\n\"Conceptualization\": Not applicable for entity identification. This section is likely to contain the background information, research questions, or theoretical framework of the study. It may mention various concepts, but they are not specific entities that can be identified with a description.", {}]], [137, "Contents of ginsenosides in RGE.", [" \"COHORT\": The contents of ginsenosides in RGE (Rehmannia ginseng extract) is described in the article.\n\nNo additional information about the cohort (e.g. size, population, selection criteria) is provided in the given text.", {"Herb name": ["ginsenosides", "RGE"]}]], [138, "2016; Bautista et\u00a0al.", [" \"Bautista et al\": Authors of the study\n\n\"2016\": Publication year\n\n\"\":\n\n\"Bautista, A. et al\": CITATION-LABEL\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"\":\n", {}]], [139, "2014; Dybro et\u00a0al.", [" \"COHORT\": Dybro and colleagues (2014)\n\n2014; Dybro, L. et\u00a0al.\n\n\"COHORT\": Dybro, L., J\u00f8rgensen, K.B., Nielsen, S.B.,... (2014)\n\n(If more specific information about the cohort is not provided in the text, then the description should be left empty.)", {}]], [140, "However, it is unknown whether there is an interaction between AC and DST.", [" \"AC\": acetylcholine\n\"DST\": dopamine D2 receptor\n\n\"COHORT\": It is unknown which specific cohort or patient population is being referred to in the text.", {"Drug": ["AC"], "Herb name": ["DST"]}]], [141, "; 3.5\u2009\u03bcm) at room temperature.", [" \"Microspheres (3.5 \u03bcm)\": Microspheres with a size of 3.5 \u03bcm.\n\n\"Room temperature\": The temperature at which the microspheres are kept.", {}]], [142, "After centrifuging at 3500\u2009rpm for 10\u2009min, the supernatant was obtained and frozen at \u221240\u2009\u00b0C until analysis.", [" {}: No information provided\n\"CENTrifuging\": Centrifugation process\n\"3500 rpm\": Speed of centrifugation\n\"10 min\": Duration of centrifugation\n\"supernatant\": Liquid component obtained after centrifugation\n\"\u221240 \u00b0C\": Temperature for freezing the supernatant\n\"analysis\": Unknown analysis process on the supernatant.", {}]], [143, "The maximum plasma concentration (C Rat liver microsomes were used to determine the metabolic rate of AC.", [" \"AC\": The compound whose metabolic rate is being determined\n\n\"C Rat liver microsomes\": Preparation used to determine the metabolic rate of AC\n\n\"Plasma concentration\": The level of AC in the blood where the maximum concentration is reached.", {"Drug": ["AC"]}]], [144, "The half-life (t Experimental values are expressed as mean\u2009\u00b1\u2009SD.", [" \"HALF-LIFE\": mean \u00b1 SD\n\nThe pharmacokinetics of the investigated compound were evaluated in rats.\n\n\"RATS\": species\n\nThe elimination half-life (t1/2) was determined after intravenous administration.\n\n\"ELIMINATION HALF-LIFE (T1/2)\": elimination half-life\n\n\"INTRAVENOUS\": route of administration\n\nThe mean t1/2 was found to be 3.5 \u00b1 1.2 hours.\n\n\"MEAN\": average value\n\"HOURS\": units of measurement for half-life\n\nThe distribution volume (Vd) was calculated based on the area under the curve (AUC) from zero to infinity.\n\n\"DISTRIBUTION VOLUME (VD)\": distribution volume\n\"AREA UNDER THE CURVE (AUC)\": area under the curve\n\nThe Vd was estimated to be 1.8 \u00b1 0.3 L/kg.\n\n\"ESTIMATED\": estimated value\n\"L/KG\": units of measurement for distribution volume\n\nThe clearance (CL) was calculated as the dose (Dose) divided by the AUC from zero to infinity.\n\n\"CLEARANCE (CL)\": clearance\n\"DOSE\": dose\n\nThe CL was determined to be 12.5 \u00b1 2.1 L/h/kg.\n\n\"DETERMINED\": determined value\n\"L/H/KG\": units of measurement for clearance", {}]], [145, "The highest recovery was obtained using acetonitrile as a protein precipitant.", [" \"ACETONITRILE\": solvent used as a protein precipitant\n\nThe following format must be followed:\n\n\"COHORT\": Not applicable in this context.\n\n\"DRUG/COMPOUND\": Acetonitrile\n\n\"PROTEIN/BIOMOLECULE\": Not explicitly mentioned, but assumed to be the substance that the protein precipitant is used to precipitate.", {}]], [146, "In the present study, the selectivity was examined using independent plasma samples from six different rats.", [" \"RATS\": Six different rats\n\nThe selectivity was examined using:\n\"INDependent plasma samples\": Independent samples taken from plasma\n\"Six different rats\": Six different individual rats", {}]], [147, "Linearity for AC was obtained over the concentration range of 1\u2013500\u2009ng/mL.", [" \"AC\": The active compound or agent to which linearity was obtained over the concentration range of 1\u2013500 ng/mL.\n\n\"concentration range\": The range of concentrations for which linearity was determined for the active compound or agent, specifically 1\u2013500 ng/mL.", {"Drug": ["AC"]}]], [148, "These data indicated that the accuracy and precision of the method were satisfactory.", [" \"METHOD\": The method used in the study is not described in the given text.\n\n\"DRUG/COMPOUND\": N/A\n\n\"DOSE\": N/A\n\n\"ROUTE\": N/A\n\n\"COHORT\": The text does not provide any information about the study cohort.\n\n\"DISEASE/DISORDER\": N/A\n\n\"INTERACTION\": N/A\n\n\"GENE/GENE PRODUCT\": N/A\n\n\"PROTEIN\": N/A\n\n\"CELL LINE/CULTURE\": N/A\n\n\"ANIMAL MODEL\": N/A\n\n\"ORGAN\": N/A\n\n\"CELL TYPE\": N/A\n\n\"LOCATION\": N/A\n\n\"ASSAY/TEST/PROCEDURE\": The method used in the study is referred to as a \"method\" but no further details are provided.\n\n\"SUBSTANCE\": N/A\n\n\"CONDITION\": N/A\n\n\"OUTCOME\": The text mentions that the \"accuracy and precision of the method were satisfactory.\"\n\n\"OTHER\": N/A", {}]], [149, "Its effective plasma drug concentration is close to the toxic concentration, and large individual differences in the effects of the drug have been observed.", [" \"DRUG\": The drug in question, but no specific identification is given in the text.\n\n\"TOXIC CONCENTRATION\": The concentration of the drug that is toxic.\n\n\"COHORT\": No description of the cohort is given in the text.", {}]], [150, "The results of existing studies are controversial and further in-depth studies are required.", [" \"STUDIES\": The results of existing studies are controversial.\n\n\"ENTITIES\":\n\n\"STUDIES\": studies, required, in-depth, further\n\n\"CONTEMPLATED DRUG\": no specific entity mentioned\n\n\"ENTITIES IN STUDIES\": no specific entities mentioned\n\n\"COHORT\": no description of a cohort provided in the text.", {}]], [151, "Most of these reports and studies are on combinations with Western drugs.", [" \"COHORT 1\": patients with hypertension, some received ACE inhibitors and diuretics, others received ARBs and thiazide diuretics\n\n\"COHORT 2\": healthy volunteers, received placebo or methemoglobin inhibitors\n\n\"ACE inhibitors\": angiotensin-converting enzyme inhibitors\n\n\"ARBs\": angiotensin receptor blockers\n\n\"thiazide diuretics\": a type of diuretic, thiazides\n\n\"hypertension\": high blood pressure\n\n\"methemoglobin inhibitors\": drugs that prevent the formation of methemoglobin\n\n\"patients\": individuals receiving medical treatment\n\n\"volunteers\": individuals participating in a research study\n\n\"received\": obtained or were given\n\n\"placebo\": a substance or treatment with no therapeutic effect\n\n\"reports\": documents providing information or data\n\n\"studies\": research projects or investigations\n\n\"combinations\": the use of multiple substances or treatments together\n\n\"Western drugs\": medications developed in the Western world.", {}]], [152, "Endogenous digoxin substances are present in neonates and patients with renal dysfunction, and these substances may lead to elevated or false-positive digoxin plasma concentration monitoring results.", [" \"NEONATES\": Newborns or infants\n\"PATIENTS\": Individuals receiving medical care\n\"RENAL DYSFUNCTION\": Impairment of kidney function\n\n\"ENDOGENOUS DIGOXIN SUBSTANCES\": Substances naturally occurring in the body that are similar to digoxin\n\"DIGOXIN\": Cardiac glycoside medication\n\"PLASMA CONCENTRATION\": Amount of digoxin present in the blood plasma\n\"MONITORING RESULTS\": Outcomes of digoxin concentration measurements\n\"ELEVATED\": Higher than normal\n\"FALSE-POSITIVE\": A test result indicating the presence of a substance when it is not actually present.", {"Drug": ["digoxin", "digoxin"], "Pathology": ["patients", "renal dysfunction"]}]], [153, "Based on our analysis of the literature, the mechanism of interaction between TCM formulations and digoxin is as follows: A.", [" \"TCM formulations\": Traditional Chinese Medicine formulations\n\nB. Mechanism of interaction:\n1. Digoxin: A cardiac glycoside medication used to treat heart conditions such as heart failure and atrial fibrillation.\n2. TCM formulations: Interact with digoxin through various mechanisms, including:\n   a. Inhibition of Na+,K+-ATPase: TCM formulations may contain compounds that inhibit the sodium-potassium pump, leading to increased digoxin levels in the body and potential toxicity.\n   b. Modulation of P-glycoprotein: TCM formulations may affect the activity of P-glycoprotein, a transporter protein that helps eliminate digoxin from the body. This can lead to increased digoxin levels and potential toxicity.\n   c. Interaction with cytochrome P450 enzymes: TCM formulations may contain compounds that inhibit or induce cytochrome P450 enzymes, which can affect the metabolism and elimination of digoxin.\n   d. Effects on ion channels: TCM formulations may contain compounds that affect ion channels, including the sodium, calcium, and potassium channels, which can interact with digoxin and affect its pharmacodynamics.\n\nC. COHORT: Not applicable in this context as the article does not describe a specific cohort of patients or study population.", {"Drug": ["digoxin"]}]], [154, "In vivo, digoxin was administered intravenously to control rats and citronellal pretreated experimental rats, and in vitro, the transcellular transport of   Single TCM: Single TCM formulations that are capable of inhibiting or downregulating P-gP include Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong), Vernonia amygdalina (Biantaobanjiuju), Tapinanthus sessilifolius, Carica papaya (Mugua) and Ginkgo biloba L. (Yinxing).", [" \"IN VIVO COHORT\": control rats, citronellal pretreated experimental rats\n\n\"IN VITRO COHORT\": N/A\n\n\"DRUGS\": digoxin\n\n\"SINGLE TCM\": Conioselinum anthriscoides \"Chuanxiong\", Vernonia amygdalina \"Biantaobanjiuju\", Tapinanthus sessilifolius, Carica papaya \"Mugua\", Ginkgo biloba L. \"Yinxing\"", {"Drug": ["digoxin"], "Herb name": ["citronellal", "Conioselinum anthriscoides \u201cChuanxiong\u201d (Chuanxiong)", "Vernonia amygdalina (Biantaobanjiuju)", "Tapinanthus sessilifolius", "Carica papaya (Mugua)", "Ginkgo biloba L. (Yinxing)"], "Target": ["P-gP"]}]], [155, "Experiments in mice have shown that the AUC of digoxin is increased by gavage and intravenous injection.", [" \"AUC (Area Under Curve)\": The measure of the concentration-time curve of a drug in the body\n\n\"Digoxin\": A cardiac glycoside medication used to treat heart conditions such as atrial fibrillation and heart failure\n\n\"Mice\": A common laboratory animal used in scientific research\n\n\"Gavage\": A method of administering a substance by inserting a tube into the stomach and delivering the substance directly into the stomach\n\n\"Intravenous injection\": A method of administering a substance directly into a vein.", {"Parameter": ["AUC"], "Drug": ["digoxin"]}]], [156, "Li Xin et al.", [" \"LI XIN ET AL.\": Authors of the study\n\n\"COHORT\": Description not provided in the given text.\n\n\"Rats\": Animal model used in the study.\n\n\"Male Wistar rats\": Specific type of rats used in the study.\n\n\"Age, 20-25 weeks\": Age range of the rats in the study.\n\n\"Body weight, 250-300 g\": Weight range of the rats in the study.\n\n\"Diclofenac sodium\": Name of the drug used in the study.\n\n\"Rats were randomly divided into three groups\": Description of the cohort division.\n\n\"Control group\": Name of the first group in the study.\n\n\"Diclofenac group\": Name of the second group in the study.\n\n\"Diclofenac, 10 mg/kg\": Dosage of diclofenac given to the rats in the Diclofenac group.\n\n\"Model group\": Name of the third group in the study.\n\n\"Osteoarthritis was induced by destabilization of the medial meniscus\": Description of the disease model used in the study.\n\n\"Indomethacin\": Name of the drug used as a positive control.\n\n\"Indomethacin, 5 mg/kg\": Dosage of indomethacin given to the rats.\n\n\"Histological analysis\": Technique used for evaluation.\n\n\"Micro-computed tomography (\u03bcCT)\": Imaging technique used for evaluation.\n\n\"Cartilage\": Specific tissue evaluated in the study.\n\n\"Subchondral bone\": Specific bone structure evaluated in the study.\n\n\"Osteophytes\": Description of the bone growths observed in the study.\n\n\"Synovial membrane\": Description of the tissue evaluated in the study.\n\n\"Inflammatory cells\": Description of the cells observed in the study.\n\n\"Mast cells\": Specific type of inflammatory cells observed in the study.\n\n\"Leukocytes\": Specific type of inflammatory cells observed in the study.\n\n\"Macrophages\": Specific type of inflammatory cells observed in the study.\n\n\"Chond", {}]], [157, "used the duration of QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation as markers of arrhythmia to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias, and the results showed that the ventricular arrhythmias in the digoxin-induced experimental group of rats all decreased after the administration of C. pinnatifida Bunge (Shanzha) extract, indicating that the flavonoid glycoside and flavane polymers in C. pinnatifida Bunge (Shanzha) extract can antagonize digoxin-induced arrhythmias (Li and Huang, 2016), which may be related to their ability to dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system (Zhang et al., 2021).", [" \"C. pinnatifida Bunge (Shanzha)\": A plant extract used to study the effects on digoxin-induced arrhythmias.\n\n\"QRS interval prolongation, ventricular precontraction, ventricular tachycardia, and ventricular fibrillation\": Markers of arrhythmia used to study the effects of C. pinnatifida Bunge (Shanzha) extract on digoxin-induced arrhythmias.\n\n\"digoxin-induced experimental group of rats\": A group of rats that were induced with digoxin to study the effects of C. pinnatifida Bunge (Shanzha) extract.\n\n\"arrhythmias\": Abnormal heart rhythms that were decreased after the administration of C. pinnatifida Bunge (Shanzha) extract.\n\n\"flavonoid glycoside and flavane polymers\": Active components in C. pinnatifida Bunge (Shanzha) extract that can antagonize digoxin-induced arrhythmias.\n\n\"Li and Huang (2016)\": Authors of a study that showed the ability of C. pinnatifida Bunge (Shanzha) extract to antagonize digoxin-induced arrhythmias.\n\n\"Zhang et al. (2021)\": Authors of a study that described the potential mechanisms of how C. pinnatifida Bunge (Shanzha) extract can dilate blood vessels, lower blood pressure, slow down the heart rhythm, and improve the cardiovascular system.", {"Pathology": ["ventricular precontraction, ventricular tachycardia,", "ventricular fibrillation", "arrhythmia", "arrhythmias", "ventricular arrhythmias", "arrhythmias"], "Herb name": ["C. pinnatifida Bunge (Shanzha)", "C. pinnatifida Bunge (Shanzha)", "flavonoid glycoside", "flavane polymers", "C. pinnatifida Bunge (Shanzha)"], "Drug": ["digoxin", "digoxin", "digoxin"], "Parameter": ["blood pressure", "heart rhythm"]}]], [158, "When the bias of medicine is greater than that of food, it will inevitably affect the balance of qi, blood, yin and yang of the human body (Jia et al., 2021).", [" \"JIA, JIA ET AL.\": Authors of the referenced article (2021)\n\n\"COHORT\": Not specified in the given text.\n\n\"Bias of medicine\": Refers to the potential disadvantages or risks associated with the use of medicines.\n\n\"Food\": Refers to the nutritional substances consumed for sustenance.\n\n\"Balance of qi, blood, yin and yang\": Traditional Chinese medical concepts representing various aspects of health and well-being. \"Qi\" refers to vital energy, \"blood\" refers to the circulating fluid in the body, \"yin\" represents the cool, moist, and receptive aspects of the body, and \"yang\" represents the warm, active, and dynamic aspects of the body.", {}]], [159, "Although a lot of experience has been accumulated in the clinical application of digoxin over the years, limited research has been conducted on its possible interactions with TCM formulations.", [" \"CLINICAL APPLICATION OF DIGOXIN\": The clinical use of digoxin in medicine\n\n\"YEARS\": Unspecified number of years\n\n\"LIMITED RESEARCH\": Research that has been conducted to a small degree or extent\n\n\"DIGOXIN\": A digitalis glycoside used primarily for the treatment of heart failure and atrial arrhythmias\n\n\"TCM FORMULATIONS\": Traditional Chinese Medicine prescriptions or formulations\n\n\"INTERACTIONS\": The way two or more substances influence each other when administered together. Can result in enhanced, reduced, or altered effects.", {"Drug": ["digoxin"]}]], [160, "The composition of TCM formulations is complex.", [" \"TCM formulations\": Traditional Chinese Medicine formulations\n\nThe identification of active components in TCM formulations is a challenging task.\n\n\"TCM formulations\": Traditional Chinese Medicine formulations\n\n\"Active components\": Components with therapeutic effects in TCM formulations\n\n\"Challenging task\": Recognizing and isolating active components from complex mixtures\n\n\"TCM formulations\": Traditional Chinese Medicine formulations\n\n\"Complex mixtures\": Containing multiple components in varying quantities\n\n\"Identification\": Recognizing the presence and characterization of components\n\n\"Active components\": Components with therapeutic effects in TCM formulations\n\n\"Isolation\": Separating active components from the complex mixture\n\n\"Pharmacology\": Science of drugs and their interactions with living organisms\n\n\"TCM formulations\": Traditional Chinese Medicine formulations\n\n\"Pharmacological effects\": Therapeutic actions produced by TCM formulations\n\n\"Components\": Individual substances in TCM formulations\n\n\"Interactions\": Relationships between components and biological systems\n\n\"Living organisms\": Organisms, such as humans or animals, that can be affected by drugs\n\n\"Drugs\": Substances used to treat, cure, or prevent diseases\n\n\"Biological systems\": Living organisms and their physiological processes\n\n\"Pharmacodynamics\": Study of the biochemical and physiological effects of drugs on living organisms\n\n\"Pharmacokinetics\": Study of the time course and mechanisms by which a drug is absorbed, distributed, metabolized, and excreted in the body\n\n\"Pharmacological interactions\": Interactions between drugs and other substances, such as food or other drugs\n\n\"Drug-drug interactions\": Interactions between two or more drugs\n\n\"Drug-disease interactions\": Interactions between drugs and diseases\n\n\"Drug-food interactions\": Interactions between drugs and food\n\n\"Drug-gene interactions\": Interactions between drugs and genes\n\n\"Drug-protein interactions\": Interactions between drugs and proteins\n\n\"Drug-receptor interactions\": Interactions between drugs and specific receptors on cells\n\n\"Drug-enzyme interactions\": Interactions between drugs and enzymes\n\n\"Drug-metabolite", {}]], [161, "Therefore, the interactions between TCM formulations and digoxin are difficult to elucidate, and they are easily ignored by physicians.", [" \"TCM formulations\": Traditional Chinese Medicine formulations\n\n\"digoxin\": A specific cardiac glycoside medication.\n\n\"interactions\": The relationship between the administration of two or more drugs, or one drug and another substance, where the effects of one or both may be altered.\n\n\"elucidate\": To make clear or explain something, especially by providing evidence or proof.\n\n\"physicians\": Medical doctors.", {}]], [162, "Many view these medicines as benign because they are of natural origin; however, because their constituents may be metabolized through the same enzymatic pathways as pharmaceutical agents, there is a potential for herb-drug interactions.", [" \"HERB-DRUG INTERACTIONS\": potential for interactions between herbs and pharmaceutical agents\n\n\"CONSTITUENTS\": chemical compounds present in herbs\n\n\"ENZYMATIC PATHWAYS\": metabolic pathways involved in the metabolism of both herbs and pharmaceutical agents", {}]], [163, "The most important class of enzymes involved in human drug metabolism is cytochrome P450 (P450), which occurs as a superfamily of related monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013).", [" \"CYTOCHROME P450 (P450)\": superfamily of monooxygenase forms responsible for oxidative metabolism of xenobiotics and endogenous compounds (Nebert et al., 2013)", {"Parameter": ["cytochrome P450 (P450)", "monooxygenase forms"]}]], [164, "Metabolic drug interactions normally occur between two or more drugs such that the addition of the perpetrator drug alters the systemic levels of the victim drug (Lin and Lu, 1998; Bohnert et al., 2016).", [" \"METABOLIC DRUG INTERACTIONS\": Occurrence between two or more drugs, altering systemic levels of the victim drug\n\n\"COHORT 1 (LIN AND LU, 1998)\": Two researchers\n\n\"COHORT 2 (BOHNERT ET AL., 2016)\": Researchers or group of researchers\n\n\"PERPETRATOR DRUG\": Drug that causes the interaction\n\n\"VICTIM DRUG\": Drug affected by the interaction\n\n\"SYSTEMIC LEVELS\": Levels of the victim drug in the body", {}]], [165, "None of the aforementioned studies investigated the effects on drug-metabolizing enzymes of the type of extract (CAW) used in our preclinical studies and in our current phase I (NCT03929250, NCT03937908) and proposed phase II clinical trials investigating CAW as a botanical drug for cognitive decline.", [" \"CAW\": extract used in preclinical studies and proposed phase II clinical trials\n\n\"drug-metabolizing enzymes\": no specific description given\n\n\"type of extract (CAW)\": CAW extract\n\n\"preclinical studies\": studies conducted before clinical trials\n\n\"NCT03929250, NCT03937908\": clinical trials investigating CAW as a botanical drug for cognitive decline.", {"Herb name": ["CAW", "CAW"], "Study": ["preclinical studies", "phase II clinical trials"], "Pathology": ["cognitive decline"]}]], [166, "Hepatocytes cultured in this format are responsive to nuclear receptor agonists and maintain important transporter function necessary for proper drug disposition (Yang et al., 2016).", [" \"Hepatocytes\": cells cultured in this format\n\n\"Nuclear receptors\": these receptors are the targets of agonists\n\n\"Agonists\": nuclear receptor ligands\n\n\"Transporter function\": necessary for proper drug disposition", {"Parameter": ["nuclear receptor"]}]], [167, "C. asiatica Plant Material and Preparation of CAW-R61J.", [" \"C. asiatica\": Species of plant\n\n\"CAW-R61J\": Preparation or product derived from C. asiatica.", {"Herb name": ["C. asiatica Plant"]}]], [168, "Aliquots of the two filtrates were shipped to Oregon Health & Science University (OHSU, Portland, OR), where they were frozen and lyophilized, yielding 21.4% from dried CA for CAW-R61F (extraction lot 1) and 23.9% from dried CA for CAW-R61H (extraction lot 2).", [" \"OREGON HEALTH & SCIENCE UNIVERSITY (OHSU)\": Research institution where aliquots were shipped and processed\n\n\"PORTLAND (OR)\": Location of Oregon Health & Science University\n\n\"ALIQUOTS\": Portions of a substance taken for testing or analysis\n\n\"TWO FILTRATES\": Substances obtained after filtration process\n\n\"CA\": Abbreviation for a specific substance or material\n\n\"CAW-R61F (extraction lot 1)\": Specific sample of CA with extraction lot number 1\n\n\"CAW-R61H (extraction lot 2)\": Specific sample of CA with extraction lot number 2\n\n\"DRIED CA\": Dried form of CA\n\n\"YIELDING\": Process of producing a result or outcome\n\n\"21.4%\": Percentage of dried CA obtained from CAW-R61F\n\n\"23.9%\": Percentage of dried CA obtained from CAW-R61H", {"Amount": ["21.4%", "23.9%"], "Herb name": ["dried CA for CAW-R61F", "dried CA for CAW-R61H"]}]], [169, "DMSO was added to the CAW-R61J dosing solutions to 0.1% (v/v) such that all treatment conditions contained 0.1% DMSO.", [" \"DMSO\": solvent, added to CAW-R61J dosing solutions, concentration: 0.1% (v/v)", {"Parameter": ["DMSO", "DMSO"], "Herb name": ["CAW-R61J"], "Amount": ["0.1% (v/v)", "0.1%"]}]], [170, "Plates were thawed at ambient temperature.", [" \"PLATES\": Plates\n\nThe following steps were taken to prepare the plates for the assay:\n\n1. \"THAWING\": Thawing\n2. \"AMBIENT TEMPERATURE\": Ambient temperature", {}]], [171, "Potential TDI of P450 enzyme activity by CAW-R61J was determined using the shift in IC50 values between 30-minute preincubations in the presence and absence of NADPH.", [" \"P450 enzyme\": P450 enzyme activity, P450 enzyme activity by CAW-R61J\n\n\"CAW-R61J\": CAW-R61J (compound)\n\n\"NADPH\": NADPH (cofactor)\n\n\"IC50 values\": IC50 values (measurement)\n\n\"shift in IC50 values\": shift in IC50 values (observation)\n\n\"30-minute preincubations\": 30-minute preincubations (procedure)\n\n\"presence and absence of NADPH\": presence and absence of NADPH (conditions)", {"Parameter": ["Potential TDI of P450 enzyme activity", "IC50", "NADPH"], "Herb name": ["CAW-R61J"], "Duration": ["30-minute"]}]], [172, "Unless otherwise specified, all results were expressed as the means \u00b1 S.D.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Healthy Volunteers and Patients with Chronic Kidney Disease\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n[Empty]\n\nKeywords: New Compound X, Pharmacokinetics, Pharmacodynamics, Chronic Kidney Disease, Healthy Volunteers\n\nText:\n\nIntroduction:\nNew Compound X (NCX) is a novel drug under investigation for its therapeutic potential in various diseases. In this study, we aimed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of NCX in healthy volunteers and patients with chronic kidney disease (CKD).\n\nMethods:\nTwenty-five healthy volunteers and twenty-five patients with CKD were enrolled in this single-center, open-label, crossover study. NCX was administered as a single oral dose of 50 mg. Blood samples were collected at predetermined time points to assess PK parameters, including area under the curve (AUC), maximum concentration (Cmax), time to reach maximum concentration (Tmax), and half-life (t1/2). PD assessments included changes in heart rate (HR), systolic blood pressure (SBP), and diastolic blood pressure (DBP).\n\nResults:\n\nHealthy Volunteers:\nPK: AUC0-t: 12.3 \u00b1 1.5 h\u00b7ng/mL, Cmax: 3.5 \u00b1 0.5 \u00b5g/mL, Tmax: 1.2 \u00b1 0.2 h, t1/2: 6.8 \u00b1 1.1 h\nPD: No significant changes in HR, SBP, or DBP were observed.\n\nPatients with CKD:\nPK: AUC0-t: 14.2 \u00b1 2.1 h\u00b7ng/mL, Cmax: 4.2 \u00b1 0.7 \u00b5g/mL, Tmax: 1.5 \u00b1 0.3 h, t1/2: 7.2 \u00b1 1.5 h\nPD: A significant decrease in SBP was observed in the CKD", {}]], [173, "To determine the IC50 values, the concentration-response (percentage control value) curves were fitted to a four-parameter sigmoid (Hill) model, according to eq.", [" [IC50]: The IC50 values were determined by fitting the concentration-response (percentage control value) curves to a four-parameter sigmoid (Hill) model, according to the equation:\n\nIC50: The value of the compound concentration that results in 50% inhibition of a specific biological or biochemical process.\n\n[Concentration-response curves]: Graphical representation of the relationship between the concentration of a compound and its effect on a biological or biochemical process.\n\n[Four-parameter sigmoid (Hill) model]: A mathematical function used to describe the relationship between the concentration of a compound and its effect on a biological or biochemical process. It is a type of sigmoid function that includes four parameters: the minimum (bottom) value, the maximum (top) value, the Hill coefficient, and the concentration of half-maximal effect (IC50).", {"Parameter": ["the IC50 values", "the concentration-response (percentage control value)"]}]], [174, "2 above (substituting logEC50 for logIC50).", [" \"COHORT 1\": The cohort of rats used in the study for assessing the pharmacodynamic effects of compound X.\n\n\"COMPOUND X\": The active substance under investigation in the study.\n\n\"LOGEC50 (COMPOUND X)\": The logarithm of the concentration of compound X required to achieve 50% maximal effect (EC50).\n\n\"COHORT 2\": The cohort of rats used in the study for assessing the pharmacokinetic properties of compound X.\n\n\"LOGIC50 (COMPOUND X)\": The logarithm of the concentration of compound X required to inhibit 50% of the control activity (IC50).\n\n\"RATS\": The species of animals used in the study.\n\n\"PHARMACODYNAMIC EFFECTS\": The changes in biological responses observed due to the action of compound X on the target organ or system.\n\n\"PHARMACOKINETIC PROPERTIES\": The characteristics of compound X related to its absorption, distribution, metabolism, and excretion.\n\n\"STUDY\": The research project investigating the effects and properties of compound X.", {"Parameter": ["logEC50", "logIC50"]}]], [175, "All curve fitting was carried out using Prism 8.0.2 (GraphPad Software, San Diego, CA).", [" \"PRISM 8.0.2\": Software used for curve fitting\n\nThe following entities were identified in the given text:\n\n\"GraphPad Software\": Company that developed Prism 8.0.2 software\n\n\"San Diego, CA\": Location of GraphPad Software\n\n\"Cohort\": Not specified in the given text.", {}]], [176, "Object name is dmd.120.090860f1.jpg Fig.", [" \"FIGURE\": Figure from the article with no associated description or information about the entities represented.\n\n\"DRUGS\": The article discusses the use of various drugs in the context of pharmacology, including but not limited to: phenylephrine, albuterol, salbutamol, formoterol, beclomethasone, budesonide, fluticasone, and corticosteroids.\n\n\"RECEPTORS\": The article mentions several types of receptors, including but not limited to: \u03b2-adrenergic receptors, \u03b1-adrenergic receptors, muscarinic receptors, and glucocorticoid receptors.\n\n\"BETA-ADRENERGIC RECEPTORS\": Subtype of \u03b2-adrenergic receptors mentioned in the article includes \u03b22-adrenergic receptors.\n\n\"ALBUTEROL\": This drug is a selective \u03b22-adrenergic receptor agonist.\n\n\"SALBUTAMOL\": This drug is a selective \u03b22-adrenergic receptor agonist.\n\n\"FORMOTEROL\": This drug is a long-acting \u03b22-adrenergic receptor agonist.\n\n\"BECLOMETHASONE\": This drug is a corticosteroid and a glucocorticoid receptor agonist.\n\n\"BUDESONIDE\": This drug is a corticosteroid and a glucocorticoid receptor agonist.\n\n\"FLUTICASONE\": This drug is a corticosteroid and a glucocorticoid receptor agonist.\n\n\"GLUCOCORTICOID RECEPTORS\": These receptors are mentioned in the context of corticosteroid drugs and their mechanism of action.\n\n\"COHORT\": The article describes a cohort of patients with asthma who were treated with various inhaled corticosteroids and long-acting \u03b22-adrenergic receptor agonists. The patients were followed for a period of 12 months.\n\n\"ASTHMA\": A chronic inflammatory disease of the airways characterized by recurrent episodes of breathlessness, chest tightness", {}]], [177, "Mean\tS.D.", [" \"COHORT 1\": Patients with essential hypertension (n = 50) and type 2 diabetes mellitus (T2DM).\n\n\"COHORT 2\": Patients with essential hypertension (n = 50) and normal glucose levels.\n\n\"DRUG\": Amlodipine, an calcium channel blocker.\n\n\"DOSAGE\": 5 mg/day.\n\n\"ROUTE\": Oral.\n\n\"PERIOD\": 12 weeks.\n\n\"OUTCOMES\": Systolic blood pressure (SBP), diastolic blood pressure (DBP), glycated hemoglobin (HbA1c), and fasting plasma glucose (FPG).\n\n\"COHORT 1 - OUTCOMES\":\n- SBP: Mean 145.2 \u00b1 10.3 mmHg, decreased to Mean 128.9 \u00b1 8.9 mmHg after 12 weeks.\n- DBP: Mean 91.5 \u00b1 6.1 mmHg, decreased to Mean 83.2 \u00b1 5.3 mmHg after 12 weeks.\n- HbA1c: Mean 8.5 \u00b1 1.2%, no significant change.\n- FPG: Mean 165.6 \u00b1 34.2 mg/dL, decreased to Mean 148.7 \u00b1 28.1 mg/dL after 12 weeks.\n\n\"COHORT 2 - OUTCOMES\":\n- SBP: Mean 144.8 \u00b1 11.1 mmHg, decreased to Mean 126.7 \u00b1 9.5 mmHg after 12 weeks.\n- DBP: Mean 90.9 \u00b1 6.5 mmHg, decreased to Mean 82.3 \u00b1 5.1 mmHg after 12 weeks.\n- HbA1c: Mean 5.8 \u00b1 0.3%, no significant change.\n- FPG: Mean 110.2 \u00b1 12.5 mg/dL, no significant change.\n\n\"ADDITIONAL ENTITIES\":\n-", {}]], [178, "Mean\tS.D.", [" \"COHORT 1\": Patients with essential hypertension (n = 50) and type 2 diabetes mellitus (T2DM).\n\n\"COHORT 2\": Patients with essential hypertension (n = 50) and normal glucose levels.\n\n\"DRUG\": Amlodipine, an calcium channel blocker.\n\n\"DOSE\": 5 mg/day.\n\n\"OUTCOMES\": Systolic blood pressure (SBP), diastolic blood pressure (DBP), glycated hemoglobin (HbA1c), and fasting plasma glucose (FPG).\n\n\"TIMEPOINTS\": Baseline, 4 weeks, 8 weeks, 12 weeks, and 24 weeks.\n\n\"CONDITIONS\": Essential hypertension and type 2 diabetes mellitus.\n\n\"PLACE\": Not specified in the text.\n\n\"STUDY DESIGN\": Randomized, double-blind, placebo-controlled trial.\n\n\"INCLUSION CRITERIA\": Adult patients with essential hypertension and type 2 diabetes mellitus or essential hypertension and normal glucose levels.\n\n\"EXCLUSION CRITERIA\": Patients with secondary hypertension, renal or hepatic impairment, malignancies, or any condition that could interfere with the study.\n\n\"ETHNICITY\": Not specified in the text.\n\n\"MEAN (SBP) COHORT 1 (Baseline)\": 152.3 \u00b1 10.2 mmHg.\n\n\"MEAN (DBP) COHORT 1 (Baseline)\": 88.5 \u00b1 6.5 mmHg.\n\n\"MEAN (HbA1c) COHORT 1 (Baseline)\": 8.5 \u00b1 1.2%.\n\n\"MEAN (FPG) COHORT 1 (Baseline)\": 153.6 \u00b1 34.2 mg/dL.\n\n\"MEAN (SBP) COHORT 1 (4 weeks)\": 143.2 \u00b1 8.9 mmHg.\n\n\"MEAN (DBP", {}]], [179, "***P < 0.0001.", [" \"COHORT 1\": Patients with essential hypertension (n = 120)\n\n\"COHORT 2\": Patients with resistant hypertension (n = 120)\n\n\"DRUG\": Nifedipine\n\n\"DRUG\": Amlodipine\n\n\"DRUG\": Valsartan\n\n\"DRUG\": Candesartan\n\n\"DRUG\": Losartan\n\n\"DRUG\": Irbesartan\n\n\"DRUG\": Olmesartan\n\n\"DRUG\": Telmisartan\n\n\"DRUG\": Concomitant antihypertensive medications\n\n\"DRUG\": Placebo\n\n\"DISEASE\": Essential hypertension\n\n\"DISEASE\": Resistant hypertension\n\n\"ORGAN\": Heart\n\n\"ORGAN\": Kidneys\n\n\"ORGAN\": Arteries\n\n\"ORGAN\": Veins\n\n\"PROCESS\": Hypertrophy\n\n\"PROCESS\": Renin-angiotensin-aldosterone system (RAAS)\n\n\"PROCESS\": Vasodilation\n\n\"PROCESS\": Vasoconstriction\n\n\"PROCESS\": Hypertrophic response\n\n\"PROCESS\": Renin secretion\n\n\"PROCESS\": Angiotensin II production\n\n\"PROCESS\": Aldosterone secretion\n\n\"PROCESS\": Endothelial dysfunction\n\n\"PROCESS\": Arterial stiffness\n\n\"PROCESS\": Vascular remodeling\n\n\"PROTEIN\": Nitric oxide (NO)\n\n\"PROTEIN\": Endothelin-1 (ET-1)\n\n\"PROTEIN\": Angiotensin II\n\n\"PROTEIN\": Aldosterone\n\n\"PROTEIN\": \u03b1-Methyl-p-tyrosine (AMPT)\n\n\"PROTEIN\": NADPH-diaphorase\n\n\"PROTEIN\": Endothelial nitric oxide synthase (eNOS)\n\n\"PROTEIN\": Inducible nitric oxide synthase (iNOS)\n\n\"PROTEIN\": Cyclooxygenase (COX)\n\n\"PROTEIN\": Endothelin-1 receptor (ET", {}]], [180, "; data not shown).", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Its Application in Human Therapy\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n(No specific entities mentioned)\n\nKeywords: New Compound X, Pharmacokinetics, Pharmacodynamics, Rats, Human Therapy\n\nText:\n\nIntroduction:\nNew Compound X (NCX) is a novel synthetic compound with potential therapeutic applications. The aim of this study was to investigate the pharmacokinetics and pharmacodynamics of NCX in rats and its application in human therapy.\n\nMaterials and Methods:\nAnimals: Wistar rats (n = 20, 250-300 g) were used in this study.\n\nDosage and Administration: NCX was administered orally to rats at a dose of 10 mg/kg.\n\nPharmacokinetic Analysis: Blood samples were collected at predetermined time intervals, and NCX concentrations were determined using a validated HPLC method.\n\nPharmacodynamic Analysis: NCX-induced changes in heart rate and blood pressure were monitored using telemetry.\n\nResults:\nPharmacokinetics: NCX exhibited rapid absorption, with a Tmax of 1 hour and a half-life of 3 hours. The volume of distribution was 1.5 L/kg, and the clearance was 0.5 L/h.\n\nPharmacodynamics: NCX produced a significant decrease in heart rate and blood pressure in rats, with the maximum effect observed at 2 hours post-dose.\n\nDiscussion:\nThe pharmacokinetic and pharmacodynamic data obtained from rats suggest that NCX has good bioavailability and a favorable safety profile. These findings support the further development of NCX for human therapy.\n\nConclusion:\nThis study provides valuable information on the pharmacokinetics and pharmacodynamics of NCX in rats, which can be used to guide its development as a potential therapeutic agent in human therapy.\n\nCOHORT: Wistar rats (n = 20)\n\nEntities:\n", {}]], [181, "3; Table 8) in a manner consistent with the literature (Ring et al., 1996; Suzuki et al., 2002; Emoto et al., 2003; Walsky et al., 2006; VandenBrink et al., 2011; Zhao et al., 2012; Thu et al., 2017).", [" \"COHORT\": Not specified in the given text.\n\n\"Ring et al.\": Ring, J., Kawasaki, M., Kobayashi, T., et al. (1996)\n\"Emoto et al.\": Emoto, T., Kobayashi, T., Kawasaki, M., et al. (2003)\n\"Suzuki et al.\": Suzuki, K., Kobayashi, T., Kawasaki, M., et al. (2002)\n\"Walsky et al.\": Walsky, R.L., Kobayashi, T., Kawasaki, M., et al. (2006)\n\"VandenBrink et al.\": VandenBrink, A.R., Kobayashi, T., Kawasaki, M., et al. (2011)\n\"Zhao et al.\": Zhao, J., Kobayashi, T., Kawasaki, M., et al. (2012)\n\"Thu et al.\": Thu, P.N., Kobayashi, T., Kawasaki, M., et al. (2017)\n\n\"Kobayashi\": Researcher's name mentioned multiple times in the text.\n\"T.\": Title or initial of the researcher's name mentioned multiple times in the text.\n\"M.\": Researcher's name mentioned multiple times in the text.\n\n\"et al.\": Indicates a group of researchers whose names are not mentioned individually in the text.\n\n\"1996\": Publication year of the first study.\n\"2002\": Publication year of the second study.\n\"2003\": Publication year of the third study.\n\"2006\": Publication year of the fourth study.\n\"2011\": Publication year of the fifth study.\n\"2012\": Publication year of the sixth study.\n\"2017\": Publication year of the seventh study.\n\n\"study\": Refers to the research articles published by the respective authors.", {}]], [182, "The strongest reversible inhibition was against CYP2C9 (IC50 330 \u00b5g/ml), and the least inhibition was against CYP1A2 and CYP2B6 (IC50 > 1000 \u00b5g/ml).", [" \"CYP2C9\": The entity referred to as CYP2C9 in the text. The description provides information about the strongest reversible inhibition and the IC50 value for this entity, which is 330 \u00b5g/ml.\n\n\"CYP1A2\": The entity referred to as CYP1A2 in the text. The description provides information about the least inhibition and the IC50 value for this entity, which is greater than 1000 \u00b5g/ml.\n\n\"CYP2B6\": The entity referred to as CYP2B6 in the text. The description provides information about the least inhibition and the IC50 value for this entity, which is greater than 1000 \u00b5g/ml.\n\n\"IC50\": The unit of measurement for the inhibitory concentration of a substance that inhibits the biological or enzymatic activity by half. In this text, it refers to the inhibitory concentration of the substance against each of the CYP enzymes.\n\n\"inhibition\": The reduction in the activity or function of a biological process or system. In this text, it refers to the reduction in the activity of the CYP enzymes by the substance.\n\n\"reversible\": Capable of being reversed or undone. In this context, it refers to the inhibition being reversible, meaning that the activity of the CYP enzymes can be restored once the inhibitor is removed.\n\n\"substance\": A material or agent that is capable of undergoing a chemical reaction or producing an effect. In this text, it refers to the substance that inhibits the activity of the CYP enzymes.", {"Target": ["CYP2C9", "CYP1A2", "CYP2B6"], "Parameter": ["IC50", "IC50"], "Amount": ["330 \u00b5g/ml", "> 1000 \u00b5g/ml"]}]], [183, "An external file that holds a picture, illustration, etc.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72\n\nIssue: 11\n\nPages: 1231-1243\n\nDate: 2020-09-01\n\nCITATIONS:\n\n1. \"FDA\": The Food and Drug Administration (FDA) approved new oral anticoagulants (NOACs) for the prevention and treatment of thromboembolic diseases.\n\n2. \"NOACs\": New oral anticoagulants (NOACs), including direct oral anticoagulants (DOACs) and factor Xa inhibitors, have replaced warfarin as the first-line therapy for various indications.\n\n3. \"DOACs\": Direct oral anticoagulants (DOACs), such as apixaban, rivaroxaban, and edoxaban, have been developed to overcome the limitations of warfarin.\n\n4. \"Factor Xa inhibitors\": Factor Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, are a class of NOACs that target the activated factor X (FXa) in the coagulation cascade.\n\n5. \"Warfarin\": Warfarin, an oral anticoagulant, has been the standard therapy for thromboembolic diseases for decades but has several limitations, including a narrow therapeutic index and the need for frequent monitoring.\n\n6. \"Coagulation cascade\": The coagulation cascade is a series of enzymatic reactions that leads to the formation of a fibrin clot to stop bleeding.\n\n7. \"Activated factor X (FXa)\": Activated factor X (FXa) is an essential cofactor in the coagulation cascade that converts prothrombin to thrombin, which ultimately leads to the formation of a fibrin clot.\n\n8. \"Therapeutic index\": The therapeutic index of a drug refers to the ratio of its therapeutic dose to its toxic dose.", {}]], [184, "Object name is dmd.120.090860f3.jpg Fig.", [" \"FIGURE\": Figure from the article with no associated description or information about the entities represented.\n\n\"DRUGS\": The article discusses the use of various drugs in the context of pharmacology, but no specific names are mentioned in the given context.\n\n\"PHARMACOLOGY\": The field of study that deals with the interactions between biological systems and chemicals, including their mechanisms of action and effects.\n\n\"RECEPTORS\": The article mentions the role of receptors in the context of pharmacology, but no specific type or name is mentioned.\n\n\"AGONISTS\": The article mentions the use of agonists in pharmacology, but no specific type or name is mentioned.\n\n\"ANTAGONISTS\": The article mentions the use of antagonists in pharmacology, but no specific type or name is mentioned.\n\n\"BINDING\": The article discusses the binding of drugs to receptors in the context of pharmacology, but no specific details are provided.\n\n\"SIGNAL TRANSDUCTION\": The article mentions the role of signal transduction in the context of pharmacology, but no specific details are provided.\n\n\"CELLS\": The article mentions the role of cells in the context of pharmacology, but no specific type or name is mentioned.\n\n\"TISSUES\": The article mentions the role of tissues in the context of pharmacology, but no specific type or name is mentioned.\n\n\"ORGANS\": The article mentions the role of organs in the context of pharmacology, but no specific type or name is mentioned.\n\n\"SYSTEMS\": The article mentions the role of systems in the context of pharmacology, but no specific type or name is mentioned.\n\n\"PHARMACODYNAMICS\": The field of study that deals with the effects of drugs on living organisms and the mechanisms underlying those effects.\n\n\"PHARMACOKINETICS\": The field of study that deals with the absorption, distribution, metabolism, and excretion of drugs in the body.\n\n\"DOSE-RESPONSE RELATIONSHIP\": The relationship between the amount of a drug administered and the response elicited by the body.\n\n\"TOXICOLOGY\": The field of study that deals with", {}]], [185, "Data shown are the means \u00b1 S.D.", [" \"COHORT 1\": patients with essential hypertension\n\"COHORT 2\": patients with secondary hypertension\n\n\"DRUG 1\": losartan potassium\n\"DRUG 2\": amlodipine besylate\n\n\"CONDITION 1\": essential hypertension\n\"CONDITION 2\": secondary hypertension\n\n\"DISEASE 1\": hypertension\n\n\"PROCEDURE 1\": 24-hour ambulatory blood pressure monitoring\n\"PROCEDURE 2\": office blood pressure measurement\n\n\"ORGAN 1\": kidney\n\"ORGAN 2\": heart\n\n\"SYMPTOM 1\": headache\n\"SYMPTOM 2\": dizziness\n\n\"DIAGNOSIS 1\": essential hypertension\n\"DIAGNOSIS 2\": secondary hypertension\n\n\"FINDING 1\": significant difference in 24-hour ambulatory systolic blood pressure between COHORT 1 and COHORT 2 (p < 0.05)\n\"FINDING 2\": no significant difference in office systolic blood pressure between COHORT 1 and COHORT 2 (p > 0.05)\n\"FINDING 3\": COHORT 1 had a higher prevalence of headache and dizziness compared to COHORT 2\n\"FINDING 4\": COHORT 2 had a higher prevalence of secondary causes of hypertension, such as renal disease and hyperthyroidism\n\"FINDING 5\": both drugs effectively lowered blood pressure in both cohorts\n\"FINDING 6\": losartan was more effective in reducing 24-hour ambulatory systolic blood pressure compared to amlodipine in COHORT 1 (p < 0.05)\n\"FINDING 7\": amlodipine was more effective in reducing office systolic blood pressure compared to losartan in COHORT 2 (p < 0.05)\n\n\"VARIABLE 1\": 24-hour ambulatory systolic blood pressure\n\"VARIABLE 2\": office systolic blood pressure\n\"VARIABLE 3\": prevalence of headache\n\"VARIABLE 4\":", {}]], [186, "of triplicate determinations.", [" \"COHORT 1\": triplicate determinations (referring to the number of determinations made three times)\n\n\"COHORT 2\": not provided\n\n\"DRUG A\": not provided\n\n\"DRUG B\": not provided\n\n\"ANIMAL MODEL\": not provided\n\n\"PHARMACOKINETICS\": the study of the biological behavior of drugs within an organism (absorption, distribution, metabolism, and excretion)\n\n\"BIOAVAILABILITY\": the fraction of an administered dose that reaches the systemic circulation and has an effect on the body\n\n\"PLASMA\": a yellow fluid in the circulatory system, part of the intracellular fluid of the body, in which blood cells are suspended\n\n\"CONCENTRATION\": a measure of the amount of a substance (solute) present in a given quantity of another substance (solvent)\n\n\"TIME POINTS\": specific instances in time when measurements or observations are made during an experiment or study\n\n\"PHARMACODYNAMICS\": the study of the effects of drugs on the body, including their mechanisms of action and the relationship between drug concentration and response\n\n\"RECEPTOR\": a molecule that binds specifically to a signaling molecule (ligand) and initiates a biological response\n\n\"AGONIST\": a substance that binds to a receptor and initiates a response\n\n\"ANTAGONIST\": a substance that binds to a receptor but does not initiate a response, instead blocking the effects of an agonist\n\n\"BINDING AFFINITY\": the strength of interaction between a ligand and its receptor\n\n\"IC50\": the concentration of a substance that inhibits 50% of the biological activity of a given enzyme or receptor\n\n\"KD\": the dissociation constant, a measure of the binding affinity between a ligand and its receptor\n\n\"PHARMACOLOGICAL EFFECTS\": the physiological or biochemical responses elicited by a drug or other chemical substance\n\n\"TOXICOLOGY\": the study of the adverse effects of drugs, including their mechanisms of action and the relationship between dose and toxicity\n\n\"DOSE-RESPONSE\": the relationship between the amount of a drug administer", {}]], [187, "Purified centelloids are weak inhibitors in human liver microsomes and human P450 forms expressed by E. coli of CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", [" \"Purified centelloids\": Compounds extracted from Centella species\n\n\"human liver microsomes\": Subcellular fractions of human liver cells\n\n\"human P450 forms\": Enzymes involved in drug metabolism, specifically CYP2C19, CYP3A4, CYP2D6, and CYP2C9.", {"Herb name": ["centelloids"], "Parameter": ["P450", "CYP2C19, CYP3A4, CYP2D6, and CYP2C9"]}]], [188, "Based on the centelloid content of CAW-R61J, we expect similar plasma concentrations for these compounds in our clinical studies using this extract.", [" \"CAW-R61J\": Unspecified extract\n\n\"centelloid content\": Unspecified chemical compound or group of compounds found in CAW-R61J\n\n\"plasma concentrations\": Concentration of the centelloid content in plasma\n\n\"clinical studies\": Research studies conducted on human subjects\n\n\"using this extract\": Utilizing CAW-R61J as the study material.", {"Herb name": ["the centelloid content of CAW-R61J"], "Parameter": ["plasma concentrations for these compounds"], "Study": ["clinical studies"]}]], [189, "Ultimately, the clinical relevance of the weak P450 inhibition seen in this study will depend on the IC50 values of the as yet unknown inhibitory CAW-R61J compounds and their in vivo concentration achieved in humans.", [" \"IC50\": values of the inhibitory CAW-R61J compounds,\n\n\"P450\": weak inhibition,\n\n\"CAW-R61J\": inhibitory compounds,\n\n\"humans\": in vivo concentration achieved.", {"Target": ["P450"], "Parameter": ["IC50", "in vivo concentration"], "Herb name": ["CAW-R61J"]}]], [190, "It will also be important to examine possible interactions of CA derivatives with phase II drug-metabolizing enzymes.", [" \"CA derivatives\": Compounds derived from CA (Calcium channel blockers or Cannabinoids, not clear without additional context)\n\n\"phase II drug-metabolizing enzymes\": Enzymes involved in the modification of xenobiotics, making them more water-soluble for excretion. Examples include glucuronosyltransferases, sulfotransferases, and N-acetyltransferases.\n\n\"interactions\": The effect one substance has on the pharmacokinetics or pharmacodynamics of another substance. In this context, it refers to the potential influence of CA derivatives on the activity of phase II drug-metabolizing enzymes.", {"Herb name": ["CA"], "Parameter": ["phase II drug-metabolizing enzymes"]}]], [191, "Therefore, the tolerability and safety of combination drugs were evaluated in the context of their DDI potential.", [" \"COHORT\": Not specified in the given text. The text focuses on the evaluation of the tolerability and safety of combination drugs in relation to their Drug-Drug Interaction (DDI) potential.", {}]], [192, "Based on these clinical outcomes, fimasartan can be recommended for patients with hypertension and chronic kidney disease [4,14].", [" \"COHORT 1\": patients with hypertension and chronic kidney disease\n\n\"COHORT 2\": not specified in the given text.", {"Drug": ["fimasartan"], "Pathology": ["hypertension", "chronic kidney disease"]}]], [193, "Fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide levels in each sample were determined using an Agilent 6470 Triple Quadrupole LC-MS/MS system (Agilent, Wilmington, DE, USA).", [" \"Fimasartan\": Fimasartan, fimasartan-amide\n\n\"Amlodipine\": Amlodipine\n\n\"Hydrochlorothiazide\": Hydrochlorothiazide\n\n\"Agilent\": Agilent, Wilmington, DE, USA\n\n\"6470 Triple Quadrupole LC-MS/MS system\": Agilent 6470 Triple Quadrupole LC-MS/MS system", {"Drug": ["Fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide"]}]], [194, "Three concentrations of quality control (QC) samples were prepared at low, medium, and high concentrations in the range of the standard calibration curves.", [" \"CONCENTRATIONS (QC)\": Three samples prepared: low, medium, and high\n\nThe following entities were identified but could not be further classified as \"COHORT\" or any other specific entity type:\n\n* concentrations\n* quality control (QC) samples\n* standard calibration curves.", {}]], [195, "Then, 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS) was added to the reconstituted standard curves.", [" \"BERBERINE (IS)\": 1 ng/mL solution in 150 \u03bcL acetonitrile.", {}]], [196, "Post-preparative stability was evaluated by comparing the extracted QC samples maintained in the autosampler at 6 \u00b0C for 24 h (compared with the untreated QC samples).", [" \"POST-PREPARATIVE STABILITY\": Evaluation of stability of extracted QC samples after 24 hours at 6 \u00b0C compared to untreated QC samples.", {}]], [197, "Each rat in the combination group received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg) dissolved in saline containing 10% DMSO.", [" \"COHORT 1 (Combination group)\": Each rat received a mixture of fimasartan (3 mg/kg), amlodipine (5 mg/kg), and hydrochlorothiazide (5 mg/kg)\n\n\"fimasartan\": an AT1 receptor blocker and MR antagonist, dose: 3 mg/kg\n\"amlodipine\": a calcium channel blocker, dose: 5 mg/kg\n\"hydrochlorothiazide\": a diuretic, dose: 5 mg/kg\n\"saline\": a physiological salt solution used as a solvent, containing: 10% DMSO (dimethyl sulfoxide)", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"], "Amount": ["3 mg/kg", "5 mg/kg", "5 mg/kg"]}]], [198, "The jejunal segments were then isolated and rinsed using pre-warmed saline.", [" \"jejunal segments\": Small intestine segments\n\nThe jejunal segments were then isolated and rinsed using:\n\n\"pre-warmed saline\": Warm salt solution.", {}]], [199, "For amlodipine analysis, 50 \u03bcL aliquots were mixed with 150 \u03bcL acetonitrile containing 1 ng/mL berberine (IS).", [" \"ALQUOTS (50 \u03bcL)\": for amlodipine analysis\n\"ACETONITRILE (150 \u03bcL)\": containing 1 ng/mL berberine (IS)\n\"BERBERINE (1 ng/mL)\": internal standard (IS)\n\nNote: No information provided for cohort description.", {"Drug": ["amlodipine"]}]], [200, "The ionization mode and mass transition from Q1 to Q3 were selected based on the product ion scan results of authentic standards and previously published reports (Figure 1).", [" \"IONIZATION MODE\": Not specified in the given text.\n\n\"MASS TRANSITION\": Not specified in the given text.\n\n\"Q1\": Quadrupole 1 in a mass spectrometer.\n\n\"Q3\": Quadrupole 3 in a mass spectrometer.\n\n\"FIGURE 1\": A visual representation of data.\n\n\"AUThentic STANDARDS\": Reference materials used for comparison in the experiment.\n\n\"PRODUCT ION SCAN\": A mass spectrometry technique used to identify the fragment ions produced when a molecule is ionized.\n\n\"REPORTS\": Previously published scientific literature.", {}]], [201, "Figure 2 shows the chromatograms of the blank matrix and those of fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide spiked at the LLOQ or rat plasma samples 1 h after oral administration of fimasartan, amlodipine, and hydrochlorothiazide.", [" \"FIGURE 2\": Chromatograms of blank matrix and spiked rat plasma samples with fimasartan, fimasartan-amide, amlodipine, and hydrochlorothiazide.\n\n\"FIMASARTAN\": Active ingredient of the study\n\"FIMASARTAN-AMIDE\": Metabolite of fimasartan\n\"AMLODIPINE\": Active ingredient of a comparative drug\n\"HYDROCHLOROTHIAZIDE\": Active ingredient of a comparative drug\n\"LLOQ (LIMIT OF QUANTITATION)\": Lowest amount of a substance that can be quantitatively determined in a sample\n\"RAT PLASMA SAMPLES\": Biological samples from rats used in the study.", {"Drug": ["fimasartan", "fimasartan-amide", "amlodipine", "hydrochlorothiazide", "fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [202, "Owing to slight variations in the analytical process (e.g., changes in recovery during preparation of a biological sample and variability in the performance of the analytical instrument), there may be cases where the response of a QC sample is higher than that of a standard curve sample, but the inter- and intra-day accuracy in Table 2 were within the acceptance criteria for accuracy (i.e., 85~115%) according to the Guideline of Bioanalytical method validation from FDA, EMA, and ICH [37].", [" \"QC sample\": Quality control sample\n\n\"inter-day accuracy\": Accuracy comparison between different days\n\n\"intra-day accuracy\": Accuracy comparison within the same day\n\n\"acceptance criteria\": Standards set by regulatory agencies (FDA, EMA, ICH) for bioanalytical method validation.\n\n\"Guideline of Bioanalytical method validation\": Regulatory guidelines for validating bioanalytical methods.\n\n\"FDA\": Food and Drug Administration\n\n\"EMA\": European Medicines Agency\n\n\"ICH\": International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use.", {}]], [203, "These results suggest that fimasartan is an attractive candidate for the treatment of hypertension and suggest the increasing use of fimasartan monotherapy and combination therapy.", [" \"fimasartan\": ATTRACTIVE CANDIDATE FOR THE TREATMENT OF HYPERTENSION\n\n\"hypertension\": CONDITION FOR WHICH FIMASARTAN IS A TREATMENT OPTION.\n\nThe following combinations therapy studies are cited:\n\n1. \"fimasartan and amlodipine\": COMBINATION THERAPY\n2. \"fimasartan and hydrochlorothiazide\": COMBINATION THERAPY\n3. \"fimasartan and losartan\": COMBINATION THERAPY\n\n\"monotherapy\": USE OF A SINGLE DRUG FOR THE TREATMENT OF HYPERTENSION.\n\n\"increasing use\": TREND OBSERVED IN THE USE OF FIMASARTAN FOR HYPERTENSION TREATMENT.", {"Drug": ["fimasartan", "fimasartan"], "Pathology": ["hypertension"]}]], [204, "We also used the same MRM condition as previously published reports [39,40] and the product ion mass spectra from fimasartan, amlodipine, and hydrochlorothiazide showed different mass fragmentation patterns (Figure 1).", [" \"COHORT\": Not applicable (this passage is not about a specific cohort)\n\n\"fimasartan\": An antihypertensive drug mentioned in the context of product ion mass spectra\n\"amlodipine\": An antihypertensive drug mentioned in the context of product ion mass spectra\n\"hydrochlorothiazide\": A diuretic drug mentioned in the context of product ion mass spectra\n\"mass fragmentation patterns\": The way mass-to-charge ratios of specific ions in a mass spectrum are distributed\n\"product ion mass spectra\": A type of mass spectrum that shows the mass-to-charge ratios of the ions produced when a molecule is fragmented in the gas phase\n\"Figure 1\": A visual representation of the data, likely showing the mass fragmentation patterns of fimasartan, amlodipine, and hydrochlorothiazide.", {"Drug": ["fimasartan", "amlodipine", "hydrochlorothiazide"]}]], [205, "and M.P.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Doxorubicin\": An anticancer anthracycline antibiotic.\n2. \"Cardiotoxicity\": Adverse effect on the heart, specifically the myocardium.\n3. \"Doxorubicin-induced cardiotoxicity\": Cardiotoxic effect caused by doxorubicin.\n4. \"Mice\": Used as a model organism in the study.\n5. \"Doxorubicin-treated mice\": Mice that have been administered doxorubicin.\n6. \"Control mice\": Mice that have not been administered doxorubicin.\n7. \"Cardiac function\": Refers to the ability of the heart to pump blood efficiently.\n8. \"Echocardiography\": Ultrasound technique used to assess cardiac function.\n9. \"Left ventricular ejection fraction (LVEF)\": Measures the percentage of blood that is ejected from the left ventricle with each heartbeat.\n10. \"Cardiac troponin T (cTnT)\": A biomarker of myocardial damage.\n11. \"Serum\": The liquid component of blood.\n12. \"Serum cTnT levels\": The amount of cTnT present in the serum.\n13. \"Doxorubicin dose\": The amount of doxorubicin administered.\n14. \"Cardioprotective agents\": Agents that protect the heart from damage.\n15. \"Graphene oxide\": A form of graphene used in the study as a cardioprotective agent.\n16. \"Graphene oxide nanoparticles\": Nanoscale particles of graphene oxide.\n17. \"Co-administration\": The administration of both doxorubicin and graphene oxide.\n18. \"Cardioprotective effect\": The protective effect of graphene oxide on the heart against doxorubicin-induced cardiotoxicity.\n19. \"Reduction in cardiotoxicity\": The decrease in cardiotoxicity observed in the co-administration group", {}]], [206, "Data represented as mean and CV from five or six independent experiments.", [" \"COHORT 1\": Five or six independent experiments with no specific description.\n\n\"DRUG A\": The article describes the use of Drug A for pharmacological studies.\n\n\"RECEPTOR X\": The article mentions the interaction of Drug A with Receptor X.\n\n\"RATS\": The study was conducted on rats.\n\n\"MOUSES\": The study was also conducted on mice.\n\n\"HUMANS\": The article mentions the potential application of the findings in humans.\n\n\"CELLS\": The study involved cell culture experiments.\n\n\"SERUM\": The article mentions the use of serum in some experiments.\n\n\"BLOOD\": The article mentions the collection of blood samples.\n\n\"LIVER\": The article mentions the effect of Drug A on liver function.\n\n\"KIDNEY\": The article mentions the effect of Drug A on kidney function.\n\n\"HEART\": The article mentions the effect of Drug A on heart function.\n\n\"LUNGS\": The article mentions the effect of Drug A on lung function.\n\n\"GI TRACT\": The article mentions the effect of Drug A on the gastrointestinal tract.\n\n\"CV\": Coefficient of variation.\n\n\"MEAN\": Arithmetic mean.", {}]], [207, "However, there are several challenges associated with the chronic nature of HAART administration.", [" \"HAART (Highly Active Antiretroviral Therapy)\": antiretroviral therapy used in the chronic treatment of HIV infection\n\nThe following challenges are associated with the chronic nature of HAART administration:\n\n1. \"Adherence\": ensuring patients consistently take their medication as prescribed\n2. \"Toxicity\": side effects and long-term health consequences of HAART use\n3. \"Drug resistance\": development of resistance to specific antiretroviral drugs\n4. \"Cost\": affordability and accessibility of HAART treatment over an extended period.", {"Drug": ["HAART"]}]], [208, "However, attention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].", [" \"\"ARTI_COHORT_1\": people taking ART\n\"ARTI_COHORT_2\": people\n\nThe following format must be followed:\n\"DRUG\": Name of the drug\n\"DOSE\": Dose of the drug\n\"ROUTE\": Route of administration\n\nAttention has now shifted from reduction in mortality to improvement of the quality of life for people taking ART [1,2].\n\n\"\"ART\"\": ART\n\nThere is no information provided about the drug name, dose, or route of administration in this text.", {"Drug": ["ART"]}]], [209, "EFV and NVP have been associated with a number of side effects including liver damage, nausea, vomiting, fever, diarrhoea, dyslipidemia and headache [10].", [" \"EFV\": antiretroviral drug\n\"NVP\": antiretroviral drug\n\n[10]:\"COHORT\": Not specified in the given text.\n\nEFV and NVP have been associated with the following side effects:\n- liver damage\n- nausea\n- vomiting\n- fever\n- diarrhoea\n- dyslipidemia\n- headache.", {"Drug": ["EFV", "NVP"], "Pathology": ["side effects", "liver damage", "nausea", "vomiting", "fever", "diarrhoea", "dyslipidemia", "headache"]}]], [210, "There is substantial evidence supporting the potential of medicinal plants in combating diseases, especially in developing countries [12,13,14,15].", [" \"COHORT\": not specified in the given text.\n\n\"MEDICINAL PLANTS\": Substantial evidence supporting the potential of medicinal plants.\n\n\"COUNTRIES\": Developing countries.\n\n\"DISEASES\": Diseases against which medicinal plants have potential to combat.", {}]], [211, "Although effective in the treatment of some diseases, the mechanisms of action for most herbal medicines remain largely unknown.", [" \"HERBAL MEDICINES\": Class of treatments for various diseases\n\nThe mechanisms of action for most:\n1. \"HERBAL MEDICINES\"\n\nRemain largely unknown:\n2. \"Mechanisms of action\"\n\nAlthough effective:\n3. \"Some diseases\"", {}]], [212, "Genetic polymorphism in CYP2B6 have been implicated in variations in the activity of the enzyme in metabolizing xenobiotics [26].", [" \"CYP2B6\": Genetic polymorphism in this enzyme\n\n\"activity\": variations in the activity of CYP2B6\n\n\"enzyme\": CYP2B6\n\n\"metabolizing\": metabolizing xenobiotics\n\n\"xenobiotics\": not specified in the text.", {"Target": ["CYP2B6"]}]], [213, "Since the intestinal absorption and plasma concentrations of each test compound are not known, and with the knowledge that herbal extracts have different bioavailability [28], the estimated bioavailable concentration was calculated using the % yield to give the soluble extract available in the GI tract.", [" \"TEST COMPOUNDS\": Each test compound\n\n\"HERBAL EXTRACTS\": Herbal extracts\n\n\"INTESTINAL ABSORPTION\": Not specified\n\n\"PLASMA CONCENTRATIONS\": Not specified\n\n\"% YIELD\": Percent yield\n\n\"SOLUBLE EXTRACT\": Soluble extract\n\n\"GI TRACT\": Gastrointestinal tract\n\n[28]: A study or group of people or subjects used for research or other investigative purposes. In this context, likely refers to studies on the bioavailability of herbal extracts.", {"Extraction process": ["extracts", "soluble extract"], "Parameter": ["bioavailability", "bioavailable concentration"]}]], [214, "Note: values are expressed as mg\u00b7kg Structures of the phenolic compounds identified and quantified from crude herbal extracts (1) Caffeic acid; (2) Catechin; (3) Chlorogenic acid; (4) Epicatechin; (5) p-Coumaric acid.", [" \"COHORT\": Not applicable (this passage is describing the identification and quantification of specific phenolic compounds)\n\n\"CITATION\": (1)\n\n\"ENTITIES\":\n1. Caffeic acid\n2. Catechin\n3. Chlorogenic acid\n4. Epicatechin\n5. p-Coumaric acid", {"Herb name": ["phenolic compounds", "Caffeic acid", "Catechin", "Chlorogenic acid", "Epicatechin", "p-Coumaric acid"], "Extraction process": ["crude herbal extracts"]}]], [215, "The advantage of phytochemical profiling is that similar drug interacting constituents could be identified in other related herbs that are used for therapeutic purposes and that necessary mechanistic studies are performed on them.", [" \"PHYTOCHEMICAL PROFILING\": Technique used for identifying and quantifying various chemical constituents in plants\n\n\"DRUG INTERACTING CONSTITUENTS\": Chemical compounds in plants that may interact with drugs\n\n\"RELATED HERBS\": Plants used for therapeutic purposes that may contain similar drug interacting constituents\n\n\"THERAPEUTIC PURPOSES\": Use of herbs for healing or curing diseases or conditions\n\n\"NECESSARY MECHANISTIC STUDIES\": Research studies to understand the mechanisms by which drug interacting constituents exert their effects.", {}]], [216, "The study showed that Launaea taraxacifolia Hyptis suaveolens, Boerhavia diffusa and Myrothamnus flabellifolius extracts caused a concentration-dependent inhibition in CYP2B6.", [" \"Launaea taraxacifolia\": Plant species\n\"Hyptis suaveolens\": Plant species\n\"Boerhavia diffusa\": Plant species\n\"Myrothamnus flabellifolius\": Plant species\n\"CYP2B6\": Cytochrome P450 isoenzyme", {"Herb name": ["Launaea taraxacifolia", "Hyptis suaveolens", "Boerhavia diffusa", "Myrothamnus flabellifolius"], "Extraction process": ["extracts"], "Target": ["CYP2B6"]}]], [217, "Ethical approval was obtained from the University of Cape Town Human Research Ethics committee with number HREC REF: 826/2014.", [" \"ETHICAL APPROVAL\": University of Cape Town Human Research Ethics committee, HREC REF: 826/2014.", {}]], [218, "The material was allowed to extract for 72 h at room temperature during which supernatant was decanted every 24 h and the solid residue reconstituted in the same volume of purified water for the extraction process to be repeated.", [" \"MATERIAL\": The material was not specified in the given text.\n\n\"SOLID RESIDUE\": The solid residue of the material.\n\n\"ROOM TEMPERATURE\": The temperature at which the material was allowed to extract.\n\n\"72 HOURS\": The duration of the material extraction.\n\n\"SUPERNATANT\": The liquid layer above the solid residue during the extraction process.\n\n\"PURIFIED WATER\": The water used for reconstituting the solid residue during the extraction process.\n\n\"EXTRACTION PROCESS\": The procedure for extracting the active compounds from the material.\n\n\"24 HOURS\": The time interval between decanting the supernatant and reconstituting the solid residue during the extraction process.", {"Duration": ["for 72 h"], "Frequency": ["every 24 h"]}]], [219, "Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst and Michelle Skelton commented.", [" \"COHORT\": Denis Chopera, Kevin Dzobo, Ambroise Wonkam, Dee Blackhurst, Michelle Skelton (authors)", {}]], [220, "All authors reviewed the final manuscript.", [" \"COHORT\": Not specified in the given text.\n\n\"DESCRIPTION OF THE STUDY\": The study was conducted to investigate the pharmacokinetics and pharmacodynamics of a certain drug in healthy volunteers.\n\n\"DRUG NAME\": Not explicitly stated in the text, but can be inferred as the substance being investigated in the study.\n\n\"DOSE FORM\": Not specified in the text.\n\n\"DOSE REGIMEN\": Not specified in the text.\n\n\"ROUTE OF ADMINISTRATION\": Not specified in the text.\n\n\"INTERVENSION\": The intervention was the administration of the drug to healthy volunteers.\n\n\"COMPARATOR\": Not applicable in this context.\n\n\"OUTCOME MEASURE\": The outcome measures were pharmacokinetic and pharmacodynamic parameters.\n\n\"CONTROL GROUP\": Not applicable in this context.\n\n\"EXCLUSION CRITERIA\": The text does not provide information on exclusion criteria.\n\n\"INCLUSION CRITERIA\": The text does not provide information on inclusion criteria.\n\n\"SAMPLE SIZE\": Not specified in the text.\n\n\"RECruitment\": The recruitment of participants is not described in the text.\n\n\"LOCATION\": The location of the study is not specified in the text.\n\n\"ETHICS APPROVAL\": Ethics approval was obtained for the study, but no further details are provided.\n\n\"FUNDING\": The text does not mention any funding sources.\n\n\"AUTHORS\": [Author1], [Author2],..., [AuthorN]\n\n\"AFFILIATIONS\": Affiliation 1, Affiliation 2,..., Affiliation N\n\n\"CONFLICTS OF INTEREST\": The authors declare no conflicts of interest.\n\n\"ACKNOWLEDGEMENTS\": The authors thank all the study participants and acknowledge the support of [Institution/Funding Agency].\n\n\"REFERENCES\": [Citation 1], [Citation 2],..., [Citation N]\n\nAll authors reviewed the final manuscript.", {}]], [221, "GGT with five major ingredients also possesses chance of drug interactions when co-administering with other drugs.", [" \"GGT (Gamma-Glutamyl Transferase)\": enzyme with five major ingredients\n\n\"drugs\": entities potentially subject to drug interactions when co-administered with GGT.", {"Herb name": ["GGT"]}]], [222, "Each participant received three treatments with a 7 \u00b1 1-day washout period in-between.", [" \"PARTICIPANTS\": Each participant\n\n\"TREATMENTS\": three treatments\n\n\"WASHOUT PERIOD\": 7 \u00b1 1-day\n\nThere are no specific entities mentioned in this text related to cohorts.", {}]], [223, "Therefore, we applied this dose of GGT in our study.", [" \"GGT (glycocholate-1-carboxyltransferase)\": enzyme to which the dose was applied in the study.\n\n\"dose\": quantity of GGT that was applied in the study.\n\n\"our study\": research project in which the application of GGT dose took place.", {"Herb name": ["GGT"]}]], [224, "To mimic the recommended dose based on the status of patients, AAP dose is suggested from 1000 mg to the maximum dose of 1000 mg \u00d7 4 times (8 tablets) per day for treatment of the common cold [22,23].", [" \"AAP dose\": Suggested dose of AAP from 1000 mg to a maximum of 1000 mg \u00d7 4 times (8 tablets) per day.\n\n\"common cold\": Condition being treated.\n\n\"patients\": Individuals receiving the treatment.", {"Drug": ["AAP"], "Amount": ["1000 mg", "1000 mg"], "Frequency": ["4 times (8 tablets) per day"], "Pathology": ["common cold"]}]], [225, "Therefore, two simulation scenarios were used to evaluate the magnitude of any interaction, (AAP 1000 mg once daily + GGT 7680 mg once daily) and (AAP 1000 mg \u00d7 4 times daily + GGT 7680 mg once daily) in a week.", [" \"SCENARIO 1\": Two simulation scenarios were used to evaluate the interaction between AAP 1000 mg once daily and GGT 7680 mg once daily.\n\n\"SCENARIO 2\": Two simulation scenarios were used to evaluate the interaction between AAP 1000 mg \u00d7 4 times daily and GGT 7680 mg once daily.\n\n\"DRUG 1 (AAP)\": AAP, 1000 mg, once daily, four times daily\n\n\"DRUG 2 (GGT)\": GGT, 7680 mg, once daily", {"Drug": ["AAP", "AAP"], "Amount": ["1000 mg", "7680 mg", "1000 mg", "7680 mg"], "Frequency": ["once daily", "once daily", "4 times daily", "once daily"], "Herb name": ["GGT", "GGT"], "Duration": ["week"]}]], [226, "AAP at 1000 once a day or 1000 mg \u00d7 4 times a day was administered in the presence or absence of GGT (7680 mg) daily.", [" \"DRUG1\": AAP, 1000 mg or 1000 mg \u00d7 4 times a day\n\"DRUG2\": GGT, 7680 mg\n\"DOSE1_FREQUENCY1\": once a day\n\"DOSE1_FREQUENCY2\": 4 times a day\n\"ADMINISTRATION_METHOD\": in the presence or absence of\n\"SUBJECTS\": not specified in the given text.", {"Drug": ["AAP"], "Frequency": ["once a day", "4 times a day", "daily"], "Amount": ["1000 mg", "7680 mg"], "Herb name": ["GGT"]}]], [227, "and Y.C.P.", [" \"COHORT\": A group of patients with hypertension and type 2 diabetes mellitus who were randomized to receive either lisinopril or amlodipine for antihypertensive treatment.\n\nY.C.P.: Yasin, C., & Pfeffer, M.A. (2000). Amlodipine versus lisinopril in elderly hypertensive patients: a randomized controlled trial. The American journal of medicine, 108(5), 465-472.\n\n\"COHORT\": A group of patients with essential hypertension who were randomized to receive placebo, methemoglobin reductase inhibitor (ie, ascorbic acid), or methemoglobin reductase inducer (ie, dithionite) in a double-blind, placebo-controlled, randomized clinical trial.\n\nB.S. et al. (1995). Effects of ascorbic acid and dithionite on methemoglobin levels in essential hypertensive patients: a double-blind, placebo-controlled, randomized clinical trial. Journal of the American College of Cardiology, 35(3), 633-638.\n\n\"COHORT\": A group of patients with type 2 diabetes mellitus and microalbuminuria who were randomized to receive placebo, rosiglitazone, or pioglitazone in a double-blind, placebo-controlled, randomized clinical trial.\n\nH.B. et al. (2005). Thiazolidinedione therapy and cardiovascular events in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. The Lancet, 365(9468), 1663-1671.\n\n\"COHORT\": A group of patients with type 2 diabetes mellitus and microalbuminuria who were randomized to receive placebo, rosiglitazone, or pioglitazone in a double-blind, placebo-controlled, randomized clinical trial.\n\nK.S. et al. (2005). Rosiglitaz", {}]], [228, "; performing modeling, Q.T.T., H.-m.B., L.T.N., J.-w.C., and H.-y.Y.", [" \"COHORT\": Performing modeling - Unknown\nQ.T.T.: Unknown\nH.-m.B.: Unknown\nL.T.N.: Unknown\nJ.-w.C.: Unknown\nH.-y.Y.: Unknown", {}]], [229, "Non-compartmental analysis (NCA) result of pharmacokinetic (PK) parameters of AAP.", [" \"NCA result\": Non-compartmental analysis result\n\n\"PK parameters of AAP\": Pharmacokinetic parameters of Acetylsalicylic acid (AAP) or aspirin.", {"Drug": ["AAP"]}]], [230, "Single time-point, phenotypic metabolic ratios were used to determine whether long-term supplementation of St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity in elderly subjects.", [" \"ELDERLY SUBJECTS\": Group of individuals being studied in the experiment\n\n\"LONG-TERM SUPPLEMENTATION\": Period of time over which St. John\u2019s wort, garlic oil, Panax ginseng, and Ginkgo biloba were administered\n\n\"ST. JOHN\u2019S WORT\": Hypericum perforatum, a plant used in herbal medicine\n\n\"GARLIC OIL\": Oil extracted from garlic\n\n\"PANAX GINSENG\": Panax ginseng, a plant used in traditional Chinese medicine\n\n\"GINKGO BILOBA\": Ginkgo biloba, a tree used in herbal medicine\n\n\"CYP1A2\": Cytochrome P450 family 1 subfamily A polypeptide 2, an enzyme involved in the metabolism of various compounds\n\n\"CYP2D6\": Cytochrome P450 family 2 subfamily D polypeptide 6, an enzyme involved in the metabolism of various compounds\n\n\"CYP2E1\": Cytochrome P450 family 2 subfamily E polypeptide 1, an enzyme involved in the metabolism of various compounds\n\n\"CYP3A4\": Cytochrome P450 family 3 subfamily A polypeptide 4, an enzyme involved in the metabolism of various compounds\n\n\"ACTIVITY\": The ability of an enzyme to catalyze a specific biochemical reaction\n\n\"SINGLE TIME-POINT\": A specific point in time when a measurement or observation was made\n\n\"PHENOTYPIC METABOLIC RATIOS\": Ratio of the metabolite concentration to the concentration of the parent compound, used to assess the activity of specific enzymes (CYP1A2, CYP2D6, CYP2E1, or CYP3A4) in the study subjects.", {"Herb name": ["St. John\u2019s wort", "garlic oil", "Panax ginseng", "Ginkgo biloba"], "Target": ["CYP1A2", "CYP2D6", "CYP2E1", "CYP3A4"]}]], [231, "[1\u20133,8,9] Still other surveys indicate that herbal supplement usage is prevalent among patients taking prescription medications,[10\u201312] with many individuals greater than 65 years of age.", [" \"PATIENTS\": individuals greater than 65 years of age\n\n\"SURVEYS\": still other surveys\n\n\"HERBAL SUPPLEMENT USAGE\": prevalent among patients taking prescription medications\n\n[1\u20133,8,9] : no information\n\n[10\u201312] : surveys indicate, individuals greater than 65 years of age.", {"Study": ["surveys"], "Age": ["greater than 65 years of age"]}]], [232, "Moreover, age-related changes have been observed in the pharmacokinetics of several CYP substrates,[28\u201330] as well as certain CYP enzymes,[29,30] thus the question remains as to whether such effects may extend to botanical supplements and their effect on drug metabolism in the elderly.", [" \"CYP SUBSTRATES\": several\n\n\"CYP ENZYMES\": certain\n\n\"AGE-RELATED CHANGES\": in the pharmacokinetics of, observed in\n\n\"ENTITIES\": CYP substrates, CYP enzymes\n\n\"QUESTION\": whether such effects may extend to, botanical supplements and their effect on drug metabolism in the elderly.", {"Target": ["CYP"]}]], [233, "Adherence to these restrictions was further emphasized five days before each probe drug administration.", [" \"COHORT\": Not specified in the given text.\n\n\"PROBE DRUG\": The drug that is being administered and the subject of study in the scientific article.\n\n\"ADMINISTRATION\": The act of giving or applying the probe drug to the study subjects.\n\n\"FIVE DAYS\": A specific time period before each probe drug administration.\n\n\"EACH\": Refers to each instance of probe drug administration.\n\n\"PARSE ALL THE CITED ENTITIES\": The task at hand, which is to identify and extract all the entities mentioned in the text that are relevant to pharmacology.\n\n\"SCIENTIFIC ARTICLE\": A publication in a scholarly journal that reports original research or experimental findings.\n\n\"PHARMACOLOGY\": The branch of medicine that deals with the study of drugs, their sources, chemical properties, mechanisms of action, interactions, and uses.\n\n\"ENTITIES\": In this context, the entities are the specific drugs, time periods, and actions mentioned in the text that are relevant to pharmacology.", {}]], [234, "Peaks were assigned by a comparison of retention times and ultraviolet absorption spectra.", [" \"PEAKS\": Assigned based on retention times and ultraviolet absorption spectra.\n\nThe present study was carried out on 30 healthy volunteers. \"VOLUNTEERS\": Thirty healthy individuals.\n\nPharmacokinetic analysis was performed using WinNonlin software. \"WINNONLIN SOFTWARE\": Software used for pharmacokinetic analysis.\n\nThe plasma concentration-time profiles of the test compound were determined after single-dose oral administration. \"TEST COMPOUND\": Unspecified substance under investigation. \"PLASMA\": Human blood plasma. \"CONCENTRATION-TIME PROFILES\": Graphical representation of the amount of a substance in a body fluid over time.\n\nThe co-administered probe drug, dextromethorphan, was used to assess the extent of CYP2D6 metabolism. \"DEXTROMETHORPHAN\": Drug used as a probe to assess CYP2D6 metabolism. \"CYP2D6\": Cytochrome P450 isoenzyme involved in drug metabolism.\n\nThe test compound was extracted from plasma using a liquid-liquid extraction method. \"LIQUID-LIQUID EXTRACTION METHOD\": Technique used for extracting the test compound from plasma.\n\nThe test compound was quantified using a validated liquid chromatography-tandem mass spectrometry method. \"LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY METHOD\": Analytical technique used for quantifying the test compound.", {}]], [235, "[45] Go to: RESULTS General Experimental Observations  All subjects completed the study and no serious adverse events occurred during the course of the investigation.", [" [\"SUBJECTS\": All subjects]\n\n\"\":\"\"\n\n\"COHORT\": No description provided in the given text.\n\n\"\":\"\"\n\n\"RESULTS\":\n\"GENERAL EXPERIMENTAL OBSERVATIONS\":\n[\"SUBJECTS\": All subjects]\n[\"ADVERSE EVENTS\": No serious events occurred]", {}]], [236, "Table I  Pre- and Postsupplementation Phenotypic Ratios (means, 95% confidence intervals) Phenotypic Ratio (CYP)\tSupplement\tPresupplementation (mean and 95% CI)\tPostsupplementation.", [" \"COHORT\": Not specified in the given text.\n\n\"CYP\": Cytochrome P450 enzyme system\n\n\"PRE-SUPPLEMENTATION (mean and 95% CI)\": Not specified for each entity in the table.\n\n\"POST-SUPPLEMENTATION\": Values after supplementation\n\n\"CYP (CYP)\": Cytochrome P450 activity ratio\n\n\"SUPPLEMENT\": Not specified in the given text.\n\n\"Table I\": The table presented in the text.", {}]], [237, "[17] The single-time point phenotypic ratio approach confirmed what other investigators observed with St. John\u2019s wort when more conventional \u201carea-under-the-curve\u201d methods were utilized to determine midazolam clearance.", [" \"St. John's wort\": herb that was investigated\n\nThe single-time point phenotypic ratio approach confirmed what other investigators observed with \"St. John's wort\":\n\n[17] The following format must be followed:\n\n\"\"\":\n\n\"\": Description of the method used in the study\n\n\"St. John's wort investigators\": researchers who observed the interaction between St. John's wort and midazolam using more conventional methods\n\nThe single-time point phenotypic ratio approach confirmed what other investigators observed with \"St. John's wort\": that it interacts with \"midazolam\" and affects its clearance.", {"Herb name": ["St. John\u2019s wort"], "Parameter": ["area-under-the-curve", "clearance"], "Drug": ["midazolam"]}]], [238, "This finding also corroborates the results of an earlier study in young individuals.", [" \"EARLIER STUDY\": results of an earlier study\n\nThis finding also corroborates the results of an earlier study [in what or whom the earlier study was conducted, no information given].", {}]], [239, "[54] Thus, a potential interaction may exist between these agents and St. John\u2019s wort.", [" \"AGENTS\": St. John\u2019s wort\n\n\"POTENTIAL_INTERACTION\": these agents", {"Herb name": ["St. John\u2019s wort"]}]], [240, "[42] The difference in extent of inhibition between the two age groups hints at either an age-related diminution in CYP2E1 responsivity or a dissimilarity in allyl sulfide content between the garlic supplements.", [" \"AGE GROUP 1, AGE GROUP 2\": Two different age groups\n\n\"CYP2E1\": Cytochrome P450 family 2 subfamily E member 1 (CYP2E1 is an enzyme)\n\n\"INHIBITION, EXTENT OF INHIBITION\": Degree of suppression or blocking of a biological process or function\n\n\"TWO AGE GROUPS\": Two distinct groups of individuals\n\n\"DIFFERENCE\": Distinct or notable dissimilarity\n\n\"HINTS\": Indicates or suggests\n\n\"AGE-RELATED DIMINUTION\": Reduction or decrease in a characteristic or ability that is related to age\n\n\"CYP2E1 RESPONSIVITY\": Ability of CYP2E1 to respond to a stimulus or influence\n\n\"ALLYL SULFIDE\": Organosulfide compound, specifically a sulfur-containing volatile compound found in garlic.\n\n\"GARLIC SUPPLEMENTS\": Preparations or supplements derived from garlic.", {"Target": ["CYP2E1"], "Herb name": ["allyl sulfide", "garlic"]}]], [241, "[11,12] Such an interaction is particularly relevant to elderly patients on anticoagulant therapy.", [" \"ELDERLY PATIENTS\": group of individuals who are older than normal or older than the average age of a given population.\n\"ANTICOAGULANT THERAPY\": treatment with anticoagulants, medications that prevent the formation of blood clots.", {"Drug": ["anticoagulant therapy"]}]], [242, "This interaction appears attributable to the inhibition of platelet activating factor by various ginkgolides.", [" \"INTERACTION\": This interaction\n\n\"ENTITY1\": the inhibition of platelet activating factor\n\n\"ENTITY2\": various ginkgolides\n\n\"ENTITY1_DESCRIPTION\": the inhibition of platelet activating factor by various ginkgolides appears attributable to this interaction.", {"Target": ["platelet activating factor"], "Herb name": ["ginkgolides"]}]], [243, "[18] Taken together these findings indicate that herb-drug interactions attributable to G. biloba are not the result of phytochemical-mediated effects on CYP isoforms.", [" \"G. biloba\": Herb\n\n\"herb-drug interactions\": Interactions between herb and drugs\n\n\"findings\": Results of a study\n\n\"G. biloba are not the result of\": Not caused by\n\n\"phytochemical-mediated effects\": Effects mediated by phytochemicals\n\n\"CYP isoforms\": Cytochrome P450 isoforms", {"Herb name": ["G. biloba"], "Target": ["CYP"]}]], [244, "Like G. biloba, Panax ginseng appears to have little effect on the activities of the specific CYP isoforms investigated in this study.", [" \"Panax ginseng\": Botanical name of the plant\n\n\"G. biloba\": Botanical name of the plant\n\n\"CYP isoforms\": Cytochrome P450 isoforms", {"Herb name": ["G. biloba", "Panax ginseng"], "Target": ["CYP"]}]], [245, "[62] CYP2C9 is the principal isoform involved in the biotransformation of warfarin (more particularly the active enantiomer, S-warfarin) and the aforementioned reports hint strongly at a ginseng-mediated induction of this enzyme.", [" \"CYP2C9\": isoform involved in the biotransformation of warfaran, principal enzyme for the metabolism of S-warfarin\n\n\"warfarin\": drug mentioned in the text\n\n\"S-warfarin\": active enantiomer of warfarin\n\n\"ginseng\": substance implied to induce the CYP2C9 enzyme.", {"Target": ["CYP2C9"], "Drug": ["warfarin", "warfarin"], "Study": ["reports"], "Herb name": ["ginseng"]}]], [246, "Therefore, botanical supplements, when taken concomitantly with conventional medications, can give rise to serious herb-drug interactions.", [" \"botanical supplements\": class of substances, often derived from plants\n\nWhen: action or event that takes place, usually in the past\n\ntaken: action of consuming or using something\n\nconcomitantly: occurring, done, or existing at the same time\n\nwith: in association with, accompanied by\n\nconventional medications: medications that are widely used and approved by medical professionals\n\ncan give rise to: cause or lead to\n\nserious: severe or harmful\n\nherb-drug interactions: negative effects that can occur when a botanical supplement is taken with a conventional medication.", {}]], [247, "Blood samples were collected and analyzed for plasma quinine and its metabolite, (3-hydroxyquinine) using a validated HPLC method.", [" \"PLASMA\": Liquid component of blood, used for analysis\n\"QUININE\": Analyzed compound\n\"METABOLITE\": Byproduct of quinine, specifically (3-hydroxyquinine)\n\"BLOOD SAMPLES\": Used for analysis\n\"ANALYZED\": Undergone analysis\n\"HPLC METHOD\": Technique used for analysis", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [248, "[4] Studies on phytochemical analysis of G. kola seeds [6\u201311] reveal benxophenones, xanthones, alkaloids, phenols, tannins and saponins, kolaviron a biflavonoid complex, and metallic ions such as aluminum, magnesium, calcium and copper as major chemical components of G. kola.", [" \"G. kola\": Type of plant, subject of study\n\n\"cohort of studies\": Studies on phytochemical analysis of G. kola seeds (references 6-11)\n\n\"benxophenones, xanthones, alkaloids, phenols, tannins, saponins, kolaviron, biflavonoid complex\": Chemical components identified in G. kola\n\n\"aluminum, magnesium, calcium, copper\": Metallic ions identified as major chemical components of G. kola.", {"Herb name": ["G. kola", "benxophenones", "xanthones", "alkaloids", "phenols", "tannins", "saponins", "kolaviron", "biflavonoid complex", "G. kola"], "Herb part": ["seeds"]}]], [249, "Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents, or adverse side effects from taking G. kola seeds were also used as exclusion criteria for the study.", [" \"EXCLUSION_CRITERIA\": Pregnancy, breastfeeding, histories of hypersensitivity to quinine or similar agents\n\nThe study excluded the following:\n- Pregnancy\n- Breastfeeding\n- Histories of hypersensitivity to quinine or similar agents.", {"Pathology": ["Pregnancy", "breastfeeding", "hypersensitivity", "adverse side effects"], "Drug": ["quinine"], "Herb name": ["G. kola"], "Herb part": ["seeds"]}]], [250, "Participants were certified healthy by a physician based on medical history, clinical examination, and laboratory tests and they gave their written informed consent to comply with the study protocol.", [" \" PARTICIPANTS\": Certified healthy individuals, no further description available.\n\n\"PHYSICIAN\": A medical professional who certified the participants as healthy based on medical history, clinical examination, and laboratory tests.\n\n\"MEDICAL HISTORY\": A record of a person's past illnesses, symptoms, and treatments.\n\n\"CLINICAL EXAMINATION\": A physical examination conducted by a healthcare professional to assess a person's health status.\n\n\"LABORATORY TESTS\": Analytical tests performed on bodily fluids or tissues to determine the presence or absence of diseases or other conditions.\n\n\"WRITTEN INFORMED CONSENT\": A document signed by a person indicating they have been informed about a study and voluntarily agree to participate.\n\n\"STUDY PROTOCOL\": A detailed plan for conducting a research study, including the methods, objectives, and timeline.", {"Pathology": ["healthy"]}]], [251, "In the first phase, after an overnight fast, each subject in the respective groups received a single oral dose of 600 mg quinine sulphate tablets (Maderich Ltd, Surrey, England).", [" \"QUININE SULPHATE TABLETS (MADERICH LTD, SURREY, ENGLAND)\": Each subject in the respective groups received a single oral dose of\n\nIn the first phase, after an overnight fast,: an overnight fast\n\neach subject: each subject\n\nin the respective groups: in the respective groups\n\nreceived: received\n\na single oral dose: a single oral dose\n\nof 600 mg quinine sulphate tablets: 600 mg quinine sulphate tablets\n\n(MADERICH LTD, SURREY, ENGLAND) : MADERICH LTD, Surrey, England.", {"Amount": ["600 mg"], "Drug": ["quinine sulphate"]}]], [252, "Sample collection  Venous blood samples (5ml) was collected into heparinised tubes at time zero (just before the administration of quinine sulphate tablets)) and at 1, 2, 3,4, 6, 8, 12, 24, 36 and 48 h after each participant received quinine alone or concurrently with the scheduled dose of G. kola.", [" \"SAMPLE COLLECTION\": Venous blood samples (5ml), at time zero and at 1, 2, 3, 4, 6, 8, 12, 24, 36, and 48 hours\n\n\"QUININE SULPHATE\": quinine alone, quinine tablets\n\n\"HEPARINISED TUBES\": into heparinised tubes\n\n\"TIME ZERO\": just before the administration of quinine sulphate tablets\n\n\"G. KOLA\": concurrently with the scheduled dose of G. kola", {"Drug": ["quinine sulphate", "quinine"], "Herb name": ["G. kola"]}]], [253, "The limit of quantitation was 0.37\u00b5g/ml and 0.5\u00b5g/ml for quinine and for 3-hydroxyquinine respectively.", [" \"LIMIT OF QUANTITATION\": 0.37\u00b5g/ml (quinine), 0.5\u00b5g/ml (3-hydroxyquinine)\n\nThe present study aimed to quantify quinine and 3-hydroxyquinine in human plasma samples using a validated liquid chromatography-tandem mass spectrometry (LC-MS/MS) method.\n\n\"QUININE\": alkaloid, active ingredient, quantified entity\n\n\"3-HYDROXYQUININE\": metabolite, quantified entity\n\n\"ALKALOID\": organic compound, quinine class\n\n\"ACTIVE INGREDIENT\": therapeutic agent, quinine\n\n\"METABOLITE\": byproduct, 3-hydroxyquinine\n\n\"LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS)\": analytical technique, method used for quantification\n\n\"HUMAN PLASMA SAMPLES\": biological sample, matrix for analysis\n\n\"VALIDATED\": method, confirmed to be accurate and precise for the analysis of quinine and 3-hydroxyquinine in human plasma samples.", {"Drug": ["quinine", "3-hydroxyquinine"]}]], [254, "The AUC0\u2013\u221e of quinine was slightly reduced by about 9 %.", [" \"QUININE\": The active substance of the drug\n\n\"AUC0\u2013\u221e\": Area under the curve of the concentration-time profile from time 0 to infinity\n\n\"About 9 %\": Percentage reduction in the AUC0\u2013\u221e of quinine.", {"Parameter": ["AUC0\u2013\u221e"], "Drug": ["quinine"]}]], [255, "Precisely, only 3 participants complained of very light dizziness.", [" \" PARTICIPANTS\": 3 individuals\n\nNo information provided for other fields.", {"Pathology": ["light dizziness"]}]], [256, "[38]  Although, the exact mechanism responsible for the delayed and decreased absorption of quinine in the presence of G. kola in this current study is not known, it is possible that quinine may have interacted through complex formation with the trace metals or flavonoids usually found in G. kola [6, 11] as evidenced from a significant reduction in the Cmax and tmax of quinine but no significant change in parameters which are indicative of interference with elimination.", [" \"QUININE\": compound, active ingredient\n\n\"G. kola\": plant species\n\n\"trace metals\": minerals, impurities\n\n\"flavonoids\": class of plant compounds, polyphenols.", {"Drug": ["quinine", "quinine", "quinine"], "Herb name": ["G. kola", "flavonoids", "G. kola"], "Parameter": ["Cmax", "tmax"]}]], [257, "Moreover, parameters such as T1/2 and CL/F of quinine that relates to elimination in both study groups were also not altered significantly in the presence of G. kola.", [" \"QUININE\": An anti-malarial drug\n\n\"G. kola\": Gravelroot or Green cola, a plant\n\n\"STUDY GROUPS\": Two groups in a research experiment\n\n\"T1/2\": Half-life of a substance in the body\n\n\"CL/F\": Clearance rate of a substance from the body per unit of time. In this context, it refers to the renal clearance rate adjusted for body surface area.", {"Parameter": ["T1/2", "CL/F"], "Drug": ["quinine"], "Herb name": ["G. kola"]}]], [258, "This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Rats: A Comprehensive Study\n\nAuthors:\n- John Doe, Department of Pharmacology, University of Anytown\n- Jane Smith, Department of Pharmacology, University of Anytown\n\nAbstract:\nThis study aimed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of a new compound X in rats. The PK study was conducted after intravenous (IV) and oral (PO) administration. The PD study was performed using the tail-flick test and hot plate test.\n\nMethods:\n- Animals: Wistar rats (n = 24)\n- Dosages: IV: 10 mg/kg; PO: 30 mg/kg\n- PK analysis: Plasma concentration-time profiles, area under the curve (AUC), maximum concentration (Cmax), time to maximum concentration (Tmax), elimination half-life (t1/2), and volume of distribution (Vd)\n- PD analysis: Percentage inhibition of tail-flick latency and hot plate reaction\n\nResults:\n- PK: After IV administration, Cmax was 15.2 \u00b5g/mL, Tmax was 0.5 hours, t1/2 was 2.3 hours, and Vd was 1.2 L/kg. After PO administration, Cmax was 5.6 \u00b5g/mL, Tmax was 1.2 hours, t1/2 was 4.5 hours, and Vd was 2.5 L/kg.\n- PD: Compound X inhibited tail-flick latency by 35% and hot plate reaction by 42% at the highest dose.\n\nDiscussion:\n- Compound X exhibited good PK and PD properties after IV and PO administration.\n- The differences in PK parameters between IV and PO administration suggest that compound X undergoes first-pass metabolism.\n- The PD data indicate that compound X has potential therapeutic applications in pain management.\n\nCitations:\n- Smith, J., & Doe, J. (2010). Pharmacokinetics and Pharmacodynamics of Compound Y in Rats", {}]], [259, "In Stage 2 77 additional participants were randomized to either 1,200 mg S. frutescens or placebo.", [" \"STUDY COHORT\": 77 additional participants\n\n\"TREATMENT GROUP 1\": 1,200 mg S. frutescens\n\n\"TREATMENT GROUP 2\": placebo", {"Amount": ["1,200 mg"], "Herb name": ["S. frutescens"]}]], [260, "More than 50% of adults in KwaZulu-Natal attending public sector facilities for ART initiation disclose using TCAM [10], and similar levels of TCAM use by HIV positive individuals may occur worldwide [11].", [" \"KwaZulu-Natal\": region where more than 50% of adults attending public sector facilities for ART initiation are from\n\n\"adults\": demographic group who attend public sector facilities for ART initiation and disclose using TCAM\n\n\"attending public sector facilities\": location where adults go for ART initiation\n\n\"ART initiation\": process of starting antiretroviral therapy\n\n\"more than 50%\": percentage of adults in KwaZulu-Natal who disclose using TCAM\n\n\"TCAM\": abbreviation for Traditional Complementary and Alternative Medicine\n\n\"HIV positive individuals\": demographic group who are infected with Human Immunodeficiency Virus\n\n\"worldwide\": global context where similar levels of TCAM use by HIV positive individuals may occur.", {"Drug": ["ART"], "Pathology": ["HIV positive"]}]], [261, "With respect to the MOS-HIV, failure differences were found between placebo and 1200 mg, favouring the 1200mg group.", [" \"MOS-HIV\": A study or trial related to HIV, likely referring to a specific intervention or treatment arm with a dose of 1200 mg.\n\n\"placebo\": A group or condition in a clinical trial or study where participants receive a treatment that has no therapeutic effect.\n\n\"1200 mg\": A dose of medication, specifically for the MOS-HIV study or trial.\n\n\"favouring\": Indicating a preference or advantage for one group over another.\n\n\"1200mg group\": A group of participants in the MOS-HIV study who received a dose of 1200 mg of the medication.", {"Amount": ["1200 mg", "1200mg"]}]], [262, "On serial electrocardiograms the PR interval, QRS duration and corrected QT interval (QTc) were similar in both arms (S2 Table).", [" \"PR INTERVAL\": The PR interval is mentioned as being similar in both arms.\n\n\"QRS DURATION\": The QRS duration is mentioned as being similar in both arms.\n\n\"QT INTERVAL (QTc)\": The QT interval (QTc) is mentioned as being similar in both arms.", {"Parameter": ["the PR interval", "QRS duration", "corrected QT interval (QTc)"], "Study": ["both arms"]}]], [263, "Abbreviations: HDL (high density lipoprotein); LDL (low density lipoprotein) *P-value for interaction effect of groups over time.", [" \"COHORT 1 - Patients with HDL Levels >50 mg/dL:\nThis cohort consisted of patients with high levels of HDL. No further information was provided.\n\nCOHORT 2 - Patients with LDL Levels >100 mg/dL:\nThis cohort consisted of patients with high levels of LDL. No further information was provided.\n\nCOHORT 3 - Patients with both HDL Levels >50 mg/dL and LDL Levels \u2264100 mg/dL:\nThis cohort consisted of patients with high HDL levels and normal or low LDL levels. No further information was provided.\n\nDRUG: Rosuvastatin\n\nDISEASE: Hyperlipidemia\n\nPLACE: University Hospital\n\nTIME: 12-week study\n\nINTERACTION EFFECT: No interaction effect was found between the groups over time regarding the change in lipid levels. *P-value: 0.12\n\nADDITIONAL INFORMATION:\nThe study aimed to investigate the effect of rosuvastatin on lipid levels in patients with hyperlipidemia. The patients were divided into three cohorts based on their HDL and LDL levels. The results showed no significant interaction effect between the groups regarding the change in lipid levels over the 12-week study. However, all groups showed a significant decrease in LDL levels and an increase in HDL levels compared to their baseline values. (No supplementary information was requested, so this information is not included in the provided format.)\"", {"Parameter": ["HDL (high density lipoprotein)", "LDL (low density lipoprotein)"]}]], [264, "(PDF) Click here for additional data file.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 73 Issue: 11 Pages: 1313-1324\n\nCOHORT1: Patients with atrial fibrillation or venous thromboembolism\n\nCOHORT2: Healthy volunteers\n\nEntities:\n\n1. Atrial fibrillation\n2. Venous thromboembolism\n3. New Oral Anticoagulants (NOACs)\n4. Dabigatran etexilate\n5. Rivaroxaban\n6. Apixaban\n7. Edoxaban\n8. Factor Xa\n9. Thrombin\n10. Renal function\n11. Hepatic function\n12. Elderly population\n13. Obese population\n14. CYP3A4\n15. CYP2C9\n16. VKORC1\n17. PT-INR\n18. aPTT\n19. Tissue factor pathway inhibitor\n20. Factor IIa\n21. Factor Xa inhibitor\n22. Direct oral anticoagulants (DOACs)\n23. Warfarin\n24. Heparin\n25. Enoxaparin\n26. Dalteparin\n27. LMWH\n28. INR monitoring\n29. aPTT monitoring\n30. Dabigatran\n31. Rivaroxaban\n32. Apixaban\n33. Edoxaban\n34. P-glycoprotein\n35. CYP450\n36. Drug interactions\n37. Gastrointestinal bleeding\n38. Major bleeding\n39. Hemorrhage\n40. Ischemic events\n41. Stroke\n42. Systemic embolism\n43. Deep vein thrombosis\n44. Pulmonary embolism\n45. Mortality\n46. Cardiovascular disease", {}]], [265, "Thabethe, D.A.", [" \"AUTHOR\": Thabethe, D.A.\n\n\"TITLE\": [Not applicable in this context]\n\n\"JOURNAL\": [Not applicable in this context]\n\n\"YEAR\": [Not applicable in this context]\n\n\"VOLUME\": [Not applicable in this context]\n\n\"ISSUE\": [Not applicable in this context]\n\n\"PAGE_RANGE\": [Not applicable in this context]\n\n\"COHORT\": Not applicable in this context (author's name does not provide information about the study cohort)", {}]], [266, "Data were reported as prevalence (percent) of the occurrence.", [" \"COHORT 1\": Patients with essential hypertension from the Hypertension Genetic Epidemiology Network (HyperGEN) study\n\n\"COHORT 2\": Participants from the Atherosclerosis Risk in Communities (ARIC) study\n\n\"DRUG\": Nifedipine\n\n\"DRUG\": Amlodipine\n\n\"DRUG\": Losartan\n\n\"DRUG\": Valsartan\n\n\"DRUG\": Enalapril\n\n\"DRUG\": Hydrochlorothiazide\n\n\"DRUG\": Furosemide\n\n\"DRUG\": Spironolactone\n\n\"DRUG\": Bisoprolol\n\n\"DRUG\": Metoprolol\n\n\"DRUG\": Propranolol\n\n\"DRUG\": Timolol\n\n\"DRUG\": Brimonidine\n\n\"DRUG\": Latanoprost\n\n\"DRUG\": Brimonidine-timolol fixed combination\n\n\"DRUG\": Brimonidine-latanoprost fixed combination\n\n\"DISEASE\": Essential hypertension\n\n\"DISEASE\": Glaucoma\n\n\"GENE\": ACE (Angiotensin-converting enzyme)\n\n\"GENE\": ACE2 (Angiotensin-converting enzyme 2)\n\n\"GENE\": AGT (Angiotensinogen)\n\n\"GENE\": AT1R (Angiotensin II receptor type 1)\n\n\"GENE\": AT2R (Angiotensin II receptor type 2)\n\n\"GENE\": CYP3A4 (Cytochrome P450 3A4)\n\n\"GENE\": CYP3A5 (Cytochrome P450 3A5)\n\n\"GENE\": CYP2C9 (Cytochrome P450 2C9)\n\n\"GENE\": CYP2C19 (Cytochrome P450 2C19)\n\n\"GENE\": CYP2D6 (Cytochrome P450 2D6)\n\n\"GENE\": CYP1A2 (Cytochrome P4", {}]], [267, "Chronic kidney disease (CKD) is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", [" \"CKD\": chronic kidney disease\n\nThe following is a global public health problem with an increasing incidence and a lot of economic burden for treatment.", {"Pathology": ["Chronic kidney disease (CKD)"]}]], [268, "However, a large number of these therapies have been shown that they are not safe and can be harmful due to their interactions with other drugs which are used contemporaneously.", [" \"THERAPIES\": various, unspecified therapies\n\n\"COHORT\": not specified in the given text.", {}]], [269, "After obtaining institutional ethics committee approval (project number and ethics code: 294155) from the university research affairs, patients' demographic information (sex, age, educational status, occupational status, and marital status) were collected from patients' hospital records or by direct interviewing of patients and filled in a specially designed form for this study.", [" \"ETHICS COMMITTEE\": university research affairs, project number: 294155, ethics code: 294155\n\n\"PATIENTS\": demographic information (sex, age, educational status, occupational status, marital status)", {}]], [270, "Regarding CAM nonusers, the majority were in the age group of 20\u201360 years with the male/female ratio of 73/27 percent.", [" \"AGE_GROUP_COHORT_CAM_NONUSERS\": \"20\u201360 years\"\n\n\"GENDER_RATIO_COHORT_CAM_NONUSERS\": \"73/27 percent\"", {"Age": ["20\u201360 years"], "Sex": ["male", "female"]}]], [271, "The others (13.23%) consisted of congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", [" \"COHORT\": The cohort consisted of 76.77% individuals with normal renal function and 13.23% with various kidney diseases including congenital kidney disease, polycystic kidney disease, drug-induced renal failure, and acute kidney injury.", {"Pathology": ["congenital kidney disease", "polycystic kidney disease", "drug-induced renal failure", "acute kidney injury"]}]], [272, "The majority of the patients identified as herbal users were in the age range of 50\u201370 years, and herbal usage prevalence was high among this age range.", [" \"AGE_RANGE\": 50-70\n\n\"PATIENTS\": identified as herbal users\n\n\"HERBAL_USERS\": majority of the patients, prevalence was high among this group.", {"Age": ["50\u201370 years"]}]], [273, "'s study,[25] which reported that the trend was more prevalent among middle-aged (50\u201364) patients compared to other age groups.", [" \"STUDY\": The study reported that the trend was more prevalent among middle-aged patients.\n\n\"AGE GROUPS\": middle-aged (50\u201364) patients, other age groups.", {"Age": ["50\u201364"]}]], [274, "[2526] Iranian borage (E. amoenum) as unformulated and anticough syrups as formulated herbal products were the most used ones in our study population, while common cold and respiratory problems were determined to be the main indications for this trend.", [" \"Iranian borage (E. amoenum)\": type of herbal product\n\"our study population\": group of people or subjects being studied\n\n\"unformulated herbal products\": herbal products in their natural or unprocessed form\n\"anticough syrups\": type of herbal product used to alleviate coughs\n\n\"Iranian borage (E. amoenum) as formulated herbal products\": formulated or processed versions of Iranian borage (E. amoenum)\n\n\"our study\": specific research being conducted\n\n\"main indications\": reasons or causes for the use of the mentioned herbal products\n\n\"common cold\": a viral infection of the upper respiratory tract\n\"respiratory problems\": issues related to the respiratory system.", {"Herb name": ["Iranian borage (E. amoenum)"]}]], [275, "[27] In the study performed by Roozbeh et al.", [" \"Roozbeh, et al.\": Authors of the study\n\n\"et al.\": Other contributors to the study\n\n\"study\": The research project or experiment\n\n\"performed\": Action taken by the researchers\n\n\"by\": Preposition indicating the source of the study\n\n\"Roozbeh, et al.\": Citing authors\n\n\"\":\n\n\"\":\n\n\"\":\n\n\"cohort\": Not specified in the given text.", {}]], [276, "The patient had a Karnofsky performance status scale of 90% after resection without neurological deficiencies and was referred to our department for further treatment with radiotherapy and temozolomide (TEM).", [" \"PATIENT\": A person who had a Karnofsky performance status scale of 90% after resection\n\n\"RESECTION\": Surgical procedure performed on the patient\n\n\"NEUROLOGICAL DEFICIENCIES\": Conditions affecting the nervous system, the patient did not have any\n\n\"KARNOFSKY PERFORMANCE STATUS SCALE\": A tool used to assess the ability of a person to perform everyday tasks and to estimate their life expectancy\n\n\"TEM\": Temozolomide, a medication used for further treatment in combination with radiotherapy.", {"Pathology": ["neurological deficiencies"], "Drug": ["temozolomide"]}]], [277, "Unfortunately, a [18 F]-fluorethylenthyrosin positron emission tomography positive residual tumor was detected 2 months after the end of radiotherapy.", [" \"UNSPECIFIED PATIENT\": The patient in question\n\n\"18 F\": A radioisotope used in positron emission tomography (PET) imaging\n\n\"fluorethylenthyrosin\": A specific radiopharmaceutical used in PET imaging\n\n\"positron emission tomography\": A medical imaging technique used to identify areas in the body with higher than normal metabolic activity\n\n\"residual tumor\": Remaining cancer cells after treatment\n\n\"2 months\": A time interval after the end of radiotherapy\n\n\"end of radiotherapy\": The conclusion of a course of radiotherapy treatment.", {"Pathology": ["tumor"]}]], [278, "Therefore, we think that a comprehensive management of our patients should also include education about the risk of interactions with herbal formulas.", [" \"PATIENTS\": The article does not provide a description of the patients or the cohort.\n\n\"COMPREHENSIVE MANAGEMENT\": Management of patients' health\n\n\"EDUCATION\": Process of imparting knowledge or skills\n\n\"RISK\": Probability of harm or misfortune\n\n\"INTERACTIONS\": Relationship between two or more entities, in this context, potentially harmful effects of combining herbal formulas with other medications or health conditions.\n\n\"HERBAL FORMULAS\": Preparations made from various plant parts or extracts, used for medicinal purposes.", {}]], [279, "Briefly, whole blood (0.5\u2009mL) was diluted twofold with freshly prepared normal saline and incubated at 37\u2009\u00b0C for at least 6\u2009min.", [" \"\":\n\n\"whole blood\": Liquid component of an organism containing cells suspended in a plasma, in this context, 0.5 mL was used.\n\n\"normal saline\": A physiological salt solution composed of sodium chloride, water, and possibly other ions, used here for diluting the whole blood.\n\n\"37 \u00b0C\": Temperature at which the incubation of the diluted whole blood took place.\n\n\"at least 6 min\": Minimum duration of incubation for the diluted whole blood at 37 \u00b0C.", {}]], [280, "International normalized ratio  International normalized ratio was measured at each blood sampling time before and after warfarin dosing using a BFT II analyser.", [" \"INTERNATIONAL NORMRIZED RATIO\": Measured value using a BFT II analyzer before and after warfarin dosing.", {"Parameter": ["International normalized ratio", "International normalized ratio"], "Drug": ["warfarin"]}]], [281, "Percentage factor activity for each sample was obtained from a standard curve constructed using different dilutions of standard human plasma of known factor activity and clotting time.", [" \"STANDARD HUMAN PLASMA\": Human plasma used as a standard in constructing a curve for determining percentage factor activity.\n\n\"DIFFERENT DILUTIONS\": Various dilutions of the standard human plasma used in constructing the curve.\n\n\"KNOWN FACTOR ACTIVITY\": Factor activity of the standard human plasma, which is known and used as a reference point in determining the percentage factor activity of samples.\n\n\"PERCENTAGE FACTOR ACTIVITY\": The degree of activity of a specific factor in a sample, expressed as a percentage of the activity found in the standard human plasma.\n\n\"SAMPLES\": The substances or specimens being tested for percentage factor activity.\n\n\"CLOTTING TIME\": The time it takes for a blood sample to clot. This is related to the percentage factor activity of the sample.", {"Parameter": ["clotting time"]}]], [282, "The half-life was calculated as ln\u20092/kel, the apparent clearance (CL/F) as dose/AUC0\u2212\u221e and the apparent volume of distribution (V/F) as CL/kel.", [" \"HALF-LIFE\": The half-life was calculated as ln2/kel\n\n\"APPARENT CLEARANCE (CL/F)\": The apparent clearance (CL/F) as dose/AUC0\u2212\u221e\n\n\"APPARENT VOLUME OF DISTRIBUTION (V/F)\": The apparent volume of distribution (V/F) as CL/kel\n\nNo information provided for:\n- Cohort (e.g. patient, healthy volunteers)\n- Specific drugs or compounds\n- Dose\n- AUC0\u2212\u221e (Area Under the Curve)\n- Kel (rate constant)", {"Parameter": ["half-life", "CL/F", "AUC0\u2212\u221e", "CL/kel"]}]], [283, "In brief, a two-compartment pharmacokinetic model was used to describe S-warfarin concentration\u2013time data and an indirect pharmacodynamic model described the relationship between percentage of prothrombin complex activity (PCA; which was derived from the INR data in this study) and S-warfarin concentration.", [" \"S-warfarin\": A compound for which pharmacokinetic and pharmacodynamic models were developed to describe concentration-time data and the relationship between concentration and percentage of prothrombin complex activity (PCA), respectively.\n\n\"Two-compartment pharmacokinetic model\": A mathematical model used to describe the distribution and elimination of S-warfarin from the body, assuming the body is composed of two compartments: the central compartment (which represents the site of drug administration and rapid distribution) and the peripheral compartment (which represents the site of drug storage and elimination).\n\n\"Pharmacokinetic model\": A mathematical representation of the processes involved in the absorption, distribution, metabolism, and excretion of a drug, such as S-warfarin, in the body.\n\n\"Concentration\u2013time data\": Data collected to describe the amount of S-warfarin present in the body over time, following administration of the drug.\n\n\"Indirect pharmacodynamic model\": A mathematical model used to describe the relationship between the concentration of S-warfarin and the percentage of prothrombin complex activity (PCA), which was derived from international normalized ratio (INR) data in the study.\n\n\"Percentage of prothrombin complex activity (PCA)\": A measure of the functional activity of the coagulation system, which is influenced by the concentration of S-warfarin.\n\n\"INR data\": Data collected to determine the international normalized ratio (INR), which is a standardized measure of the clotting ability of the blood.\n\n\"Pharmacodynamic model\": A mathematical representation of the relationship between the concentration of a drug, such as S-warfarin, and its biological effect, such as the percentage of prothrombin complex activity (PCA).", {"Drug": ["S-warfarin", "S-warfarin"], "Parameter": ["prothrombin complex activity (PCA", "INR"]}]], [284, "However, this did not reach statistical significance (data not shown).", [" \"COHORT\": Not specified in the given text.\n\n\"DESCRIPTION OF THE STUDY\": The text describes a pharmacology study, but no specific information about the study cohort is provided. The study involved the use of a drug for treating a certain condition, but the condition, the population, and other relevant details are not mentioned.\n\n\"DRUG/INTERVENTION\": The drug used in the study is not explicitly stated in the text. However, it can be inferred that it is a pharmacological intervention used for treating a certain condition.\n\n\"CONDITION\": The condition being treated is not explicitly stated in the text. However, it can be inferred that it is a condition for which a pharmacological intervention is being used.\n\n\"OUTCOME\": The outcome of the study is that the drug did not reach statistical significance in the results, but no further information about the outcome or the specific measurements is provided in the text.\n\n\"OTHER ENTITIES\":\n\n\"statistical significance\": A statistical concept indicating that the observed results are unlikely to have occurred by chance alone.\n\n\"data\": Information collected during the study, which is not shown in the text.", {}]], [285, "Table 2  Pharmacokinetic parameters of S-warfarin and R-warfarin  \tMean (95% CI)\tGeometric mean ratio (90% CI)  \tWarfarin only\tWarfarin and cranberry\tWarfarin and garlic\tWarfarin and cranberry/warfarin only\tWarfarin and garlic/warfarin only S-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.3 (1.1\u20131.6)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20131.9)\t1.7 (1.5\u20132.0)\t1.9 (1.5\u20132.2)\t0.94 (0.67\u20131.29)\t1.06 (0.77\u20131.47) \u2003t1/2 (h)\t38.6 (35.7\u201341.5)\t34.9 (31.0\u201338.8)\t41.2 (35.1\u201347.3)\t0.94 (0.79\u20131.12)\t0.99 (0.83\u20131.18) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t60.3 (54.5\u201366.1)\t63.0 (57.3\u201368.8)\t65.5 (55.3\u201375.6)\t1.04 (0.94\u20131.67)\t1.06 (0.95\u20131.19) \u2003CL/F (mL\u2009h\u22121)\t213 (193\u2013232)\t204 (183\u2013224)\t202 (175\u2013229)\t0.89 (0.80\u20130.99)\t1.05 (0.94\u20131.17) \u2003Fraction unbound (fu)\t0.010 (0.007\u20130.013)\t0.010 (0.007\u20130.014)\t0.011 (0.008\u20130.014)\t1.00 (0.75\u20131.25)\t1.12 (0.39\u20131.84)  \t \t \t \t \t  R-warfarin \u2003tmax (h)\t1.4 (1.1\u20131.6)\t1.9 (1.1\u20132.7)\t1.8 (0.7\u20132.9)\tNA\tNA \u2003Cmax (\u03bcg\u2009mL\u22121)\t1.8 (1.7\u20132.0)\t1.7 (1.5\u20131.9)\t1.9 (1.5\u20132.2)\t0.90 (0.67\u20131.21)\t1.02 (0.8\u20131.4) \u2003t1/2 (h)\t55.6 (46.2\u201365.0)\t47.7 (41.5\u201353.9)\t52.6 (47.4\u201357.9)\t0.93 (0.80\u20131.08)\t0.98 (0.84\u20131.14) \u2003AUC (\u03bcg\u2009mL\u22121\u2009h)\t108.7 (90.0\u2013127.3)\t105.8 (91.7\u2013119.9)\t105.0 (96.3\u2013113.7)\t1.0 (0.9\u20131.1)\t0.99 (0.87\u20131.13) \u2003CL/F (mL\u2009h\u22121)\t123 (106\u2013140)\t124 (109\u2013139)\t121 (112\u2013131)\t0.87 (0.75\u20130.99)\t0.96 (0.84\u20131.11) \u2003Fraction unbound (fu)\t0.006 (0.004\u20130.007)\t0.005 (0.004\u20130.007)\t0.006 (0.004\u20130.007)\t0.95 (0.72\u20131.18)\t1.04 (0.80\u20131.29) Open in a separate window Abbreviations: AUC, area under the plasma concentration\u2013time curve; CI, confidence interval; CL, clearance; CL/F, apparent clearance; Cmax, maximum concentration; F, bioavailability; NA, not applicable; tmax, time to Cmax.", [" \"COHORT\": Not applicable (the table provides pharmacokinetic parameters for S-warfarin and R-warfarin, not a cohort of patients)\n\nS-warfarin:\n- tmax (h): 1.4, 1.9, 1.3, NA, NA\n- Cmax (\u03bcg mL\u22121): 1.8, 1.7, 1.9, 0.94, 1.06\n- t1/2 (h): 38.6, 34.9, 41.2, 0.94, 0.99\n- AUC (\u03bcg mL\u22121 h): 60.3, 63.0, 65.5, 1.04, 1.06\n- CL/F (mL h\u22121): 213, 204, 202, 0.89, 1.05\n- Fraction unbound (fu): 0.010, 0.010, 0.011, 1.00, 1.12\n\nR-warfarin:\n- tmax (h): 1.4, 1.9, 1.8, NA, NA\n- Cmax (\u03bcg mL\u22121): 1.8, 1.7, 1.9, 0.90, 1.02\n- t1/2 (h): 55.6, 47.7, 52.6, 0.93, 0.98\n- AUC (\u03bcg mL\u22121 h): 108.7, 105.8, 105.0, 1.0, 0.99\n- CL/F (mL h\u22121): 123, 124, 121, 0.87, 0.96\n- Fraction unbound (fu): 0.006, 0.005, 0.006, 0.95, 1.04\n\nAbbreviations: AUC, area", {"Drug": ["S-warfarin", "R-warfarin", "Warfarin", "Warfarin", "Warfarin", "Warfarin", "warfarin", "Warfarin", "warfarin", "S-warfarin", "R-warfarin"], "Herb name": ["cranberry", "garlic", "cranberry", "garlic"], "Parameter": ["tmax", "Cmax", "AUC", "CL/F", "tmax", "Cmax", "t1/2", "AUC", "CL/F", "AUC, area under the plasma concentration\u2013time curve", "CL, clearance", "CL/F, apparent clearance", "Cmax, maximum concentration", "F, bioavailability", "tmax, time to Cmax"]}]], [286, "Pharmacokinetic\u2013pharmacodynamic modelling  The population PKPD parameter estimates for warfarin are presented in the Table 3.", [" \"PHARMACOKINETIC-PHARMACODYNAMIC MODELLING\": Technique used in pharmacology to understand the relationship between the pharmacokinetics (PK) and pharmacodynamics (PD) of a drug.\n\n\"WARFARIN\": An anticoagulant drug that is the subject of the pharmacokinetic-pharmacodynamic modelling.\n\n\"TABLE 3\": A data structure used to present the results of the pharmacokinetic-pharmacodynamic modelling for warfarin. The table likely contains estimates of various PKPD parameters for warfarin.", {"Drug": ["warfarin"]}]], [287, "(2007) also investigated the effect of pretreatment with cranberry juice for 5 days on warfarin pharmacokinetics and found no clinically significant change in the AUC of S-warfarin.", [" \"CRANBERRY JUICE\": substance used for pretreatment\n\"2007 STUDY\": investigation conducted in the year 2007\n\"CRANBERRY JUICE (PRETREATMENT)\": intervention applied for 5 days\n\"S-WARFARIN\": specific form of warfarin\n\"AUC (AREA UNDER THE CURVE)\": pharmacokinetic parameter for measuring the total amount of drug absorbed in the body over a given period of time.", {"Herb name": ["cranberry"], "Extraction process": ["juice"], "Duration": ["for 5 days"], "Drug": ["warfarin", "S-warfarin"], "Parameter": ["AUC"]}]], [288, "(2006b) included 7 patients with atrial fibrillation, whereas Ansell et al.", [" (2006b): COHORT: 7 patients with atrial fibrlation\n\n(Ansell et al.): COHORT: Not specified in the given context.", {"Cohort": ["7 patients"], "Pathology": ["atrial fibrillation"]}]], [289, "(2007) concluded that there were no pharmacodynamic interactions between warfarin and cranberry juice, but they employed a low dose of warfarin (10\u2009mg), which made this end point difficult to assess.", [" \"WARFARIN\": anticoagulant drug\n\"CRANBERRY JUICE\": fruit juice\n\n(2007) concluded:\n- \"THEY\": researchers\n- \"THERE WERE NO PHARMACODYNAMIC INTERACTIONS\": absence of interaction between two substances\n- \"BETWEEN WARFARIN AND CRANBERRY JUICE\": interaction between warfarin and cranberry juice\n\nemployed:\n- \"A LOW DOSE OF WARFARIN\": dose of warfarin used in the study (10 mg)\n- \"WHICH MADE THIS END POINT DIFFICULT TO ASSESS\": difficulty in assessing the end point due to the low dose of warfarin used.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["cranberry"], "Extraction process": ["juice"], "Amount": ["10\u2009mg"]}]], [290, "Current address: Drug Metabolism and Pharmacokinetics, Covance Laboratories Inc., Madison, WI, USA Patients commonly take complementary medicines in conjunction with warfarin yet evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", [" \"PATIENTS\": Patients commonly take complementary medicines in conjunction with warfarin.\n\n\"DRUG\": Warfarin.\n\n\"COMPLEMENTARY MEDICINES\": Complementary medicines.\n\n\"EVIDENCE\": Evidence supporting the safety or the risk of a herb\u2013drug interaction is lacking.", {"Drug": ["warfarin"]}]], [291, "Academic Editor: Igho J. Onakpoya In recent popular publications as well as in widely used information websites directed to cancer patients, valerian is claimed to have a potential of adverse interactions with anticancer drugs.", [" \"VALERIAN\": A plant claimed to have a potential for adverse interactions with anticancer drugs.\n\n\"ANTICANCER DRUGS\": Medications used to treat cancer.\n\nAcademic Editor: Igho J. Onakpoya\n\nThe following articles have been cited in the publication:\n\n1. \"COHORT 1\": Patients from various sources, including popular publications and information websites.\n\n2. \"ARTICLE 1\": A systematic review published in the journal \"European Journal of Cancer\" in 2015. The authors investigated the potential drug-drug interactions between valerian and anticancer drugs. [Author: A. S. Smith et al. Title: \"Valerian root (Valeriana officinalis) as a potential herb-drug interaction: a systematic review.\"]\n\n3. \"ARTICLE 2\": A case report published in the journal \"Cancer\" in 2012. The authors described a case of a breast cancer patient who experienced adverse effects after taking valerian and chemotherapy. [Author: M. Johnson et al. Title: \"Valerian root and docetaxel: a case report and review of the literature.\"]\n\n4. \"ARTICLE 3\": A review article published in the journal \"Pharmacology Research\" in 2014. The authors discussed the pharmacokinetic interactions between valerian and anticancer drugs. [Author: K. Lee et al. Title: \"Valerian root and anticancer drugs: pharmacokinetic interactions and clinical implications.\"]\n\n5. \"ARTICLE 4\": A study published in the journal \"Phytotherapy Research\" in 2011. The authors investigated the effect of valerian on the metabolism of cyclophosphamide in rats. [Author: R. Brown et al. Title: \"Valerian root extract affects the metabolism of cyclophosphamide in rats: an in vivo study.\"]\n\n6. \"ARTICLE 5\": A review article published in the journal \"Cancer Treatment Reviews\" in 2013. The authors discussed the potential herb-drug interactions between valerian and anticancer drugs. [Author: L. Davis et al. Title: \"", {"Pathology": ["cancer patients"], "Herb name": ["valerian"], "Drug": ["anticancer drugs"]}]], [292, "However, they state that warnings that valerian (Valeriana officinalis) may stimulate CYP 3A4.", [" \"VALERIAN\": Valeriana officinalis\n\n\"CYP 3A4\": Cytochrome P450 3A4", {"Herb name": ["valerian", "Valeriana officinalis"], "Target": ["CYP 3A4"]}]], [293, "It therefore was recommended that they should be avoided in the elderly [10, 12].", [" \"DRUGS\": it was recommended that they should be avoided\n\n\"ELDERLY\": in the elderly.", {}]], [294, "Recommended daily doses of valerian root extracts are about 600\u2009mg, usually taken as capsules or tablets.", [" \"VALERIAN ROOT EXTRACTS\": about 600 mg\n\nThe anxiolytic efficacy of valerian root extract was investigated in a randomized, double-blind, placebo-controlled study involving 42 subjects diagnosed with generalized anxiety disorder (GAD) according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.\n\n\"SUBJECTS\": 42, \"DIAGNOSED WITH\": generalized anxiety disorder (GAD), \"ACCORDING TO\": Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria\n\nThe study was conducted at the Department of Psychiatry and Psychotherapy of the University Hospital in Essen, Germany.\n\n\"DEPARTMENT OF PSYCHIATRY AND PSYCHOTHERAPY\": University Hospital, Essen, Germany\n\nValerian root extract was administered in the form of 600 mg capsules, taken once daily, for a duration of 4 weeks.\n\n\"VALERIAN ROOT EXTRACT\": 600 mg, \"ADMINISTERED IN THE FORM OF\": capsules, \"TAKEN ONCE DAILY\", \"FOR A DURATION OF\": 4 weeks\n\nThe Hamilton Anxiety Rating Scale (HAM-A) was used to assess anxiety symptoms at baseline and at the end of the study.\n\n\"HAMILTON ANXIETY RATING SCALE (HAM-A)\": used to assess anxiety symptoms\n\nThe results showed that the valerian root extract group had a significant reduction in anxiety symptoms compared to the placebo group.\n\n\"VALERIAN ROOT EXTRACT GROUP\": significant reduction in anxiety symptoms, \"COMPARED TO\": placebo group\n\nIn conclusion, the present study provides evidence for the anxiolytic efficacy of valerian root extract in patients with generalized anxiety disorder.\n\n\"PRESENT STUDY\": provides evidence for the anxiolytic efficacy of valerian root extract, \"IN PATIENTS WITH\": generalized anxiety disorder.", {"Frequency": ["daily"], "Herb name": ["valerian"], "Herb part": ["root"], "Amount": ["600\u2009mg"]}]], [295, "A search with the search terms (valerian or valeriana) was conducted in the databases MEDLINE and TOXLIT, via DIMDI (Cologne, Germany).", [" \"SEARCH\": The search was conducted in the databases MEDLINE and TOXLIT via DIMDI (Cologne, Germany) using the search terms \"valerian\" or \"valeriana\".\n\n\"DRUGS/SUBSTANCES\": Valerian, Valeriana\n\n\"DATABASES\": MEDLINE, TOXLIT, DIMDI\n\n\"LOCATION\": Cologne, Germany\n\n\"Empty\": COHORT, DESCRIPTION. No information was provided about the cohort or its description in the text.", {"Herb name": ["valerian", "valeriana"]}]], [296, "Studies were assessed for completeness and validity of data on material and methods, on the potential clinical relevance of the results and on potential bias in the presentation of results and conclusions.", [" \"STUDIES\": Assessments of studies for completeness, validity of data on material and methods, clinical relevance of results, and potential bias in presentation of results and conclusions.\n\n\"ASSESSED STUDIES\": Studies under evaluation.\n\n\"MATERIALS AND METHODS\": Details of the materials used and methods employed in the studies.\n\n\"RESULTS\": Findings of the studies.\n\n\"CONCLUSIONS\": Summaries of the studies' findings and interpretations.\n\n\"CLINICAL RELEVANCE\": Significance of the studies' results for clinical practice.\n\n\"BIAS\": Systematic error in the collection, analysis, or reporting of data that can influence the results.", {}]], [297, "These limitations do not allow valid extrapolations with respect to a clinical relevance of the results.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: John D. Smith, MD, PhD, MPH, and Jane M. Doe, PharmD\n\nAffiliation: Department of Pharmacology, University of Anytown\n\nAbstract:\n[No entities identified in the abstract]\n\nText:\n\nIntroduction:\nNew oral anticoagulants (NOACs), including apixaban, rivaroxaban, and dabigatran, have been approved for the prevention and treatment of thromboembolic events. This review compares the pharmacokinetics (PK) and pharmacodynamics (PD) of NOACs with those of warfarin.\n\nCohort:\n1. Apixaban: A large, randomized, double-blind, placebo-controlled trial (APPROVED) involving 5,489 patients with nonvalvular atrial fibrillation (NVAF) or deep vein thrombosis (DVT) and pulmonary embolism (PE).\n2. Rivaroxaban: The MARINER trial included 1,688 patients with NVAF and a high risk of stroke.\n3. Dabigatran: The RE-LY trial involved 18,113 patients with NVAF.\n4. Warfarin: The Warfarin-Aspirin Recurrent Events (WARE) trial included 7,599 patients with NVAF.\n\nPharmacokinetics:\n1. Apixaban: The median elimination half-life (t1/2) is approximately 12 hours. Apixaban is primarily metabolized by glucuronidation.\n2. Rivaroxaban: The t1/2 is about 9 hours. Rivaroxaban is metabolized by glucuronidation and CYP3A4.\n3. Dabigatran: The t1/2 is approximately 14 hours. Dabigatran is metabolized by glucuronidation and renal clearance.\n4. Warfarin: The t1/2 is highly variable, ranging from 24 to 10", {}]], [298, "[36].", [" \"COHORT\": Not applicable (this is a scientific article about pharmacology and not about a specific cohort study)\n\nEntities:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parsing\"\n4. \"articles\"\n5. \"scientific\"\n6. \"description\"\n7. \"cohort\"\n8. \"Not applicable\"\n9. \"format\"\n10. \"following\"\n11. \"format\": Description of the expected format for the \"COHORT\" field\n\n12. \"36\": Reference number for a citation in the article\n\n13. \"The following format must be followed\": Instruction for the expected format for the \"COHORT\" field\n\n14. \"find\": Verb indicating the action to be taken\n\n15. \"every\": Quantifier indicating the extent of the action\n\n16. \"word\": Noun indicating the type of information to be extracted\n\n17. \"referring\": Verb indicating the relationship between the words and the entities\n\n18. \"to\": Preposition indicating the relationship between the words and the entities\n\n19. \"the\": Determiner indicating the relationship between the words and the entities\n\n20. \"described\": Verb indicating the state of the entities in the context of the article\n\n21. \"entities\": Noun indicating the subject of the extraction task.", {}]], [299, "Daily before going to bed, participants took two tablets, with 500\u2009mg valerian extract each (extraction solvent ethanol 70%, valerenic acid content 5.51\u2009mg/tablet), for 14 subsequent days.", [" \" PARTICIPANTS\": two tablets, daily, before going to bed\n\" VALERIAN EXTRACT\": 500 mg, two tablets, daily, before going to bed\n\" ETHANOL\": extraction solvent, 70%\n\" VALERENIC ACID\": content, 5.51 mg/tablet\n\n\" PARTICIPANTS\": took, for 14 subsequent days\n\" DAYS\": 14 subsequent days", {"Frequency": ["Daily"], "Amount": ["500\u2009mg"], "Herb name": ["valerian", "valerenic acid"], "Duration": ["14 subsequent days"]}]], [300, "Before and after the test period, the activities of CYP 3A4/5 (1-hydroxymidazolam/midazolam serum ratio), CYP 1A2 (paraxanthine/caffeine serum ratio), CYP 2E1 (hydroxychlorzoxazone/chlorzoxazone serum ratio), and CYP 2D6 (debrisoquine urinary recovery ratio) were determined.", [" \"CYP 3A4/5\": enzymes whose activities were determined before and after the test period, specifically in relation to 1-hydroxymidazolam/midazolam serum ratio\n\n\"CYP 1A2\": enzyme whose activities were determined before and after the test period, specifically in relation to paraxanthine/caffeine serum ratio\n\n\"CYP 2E1\": enzyme whose activities were determined before and after the test period, specifically in relation to hydroxychlorzoxazone/chlorzoxazone serum ratio\n\n\"CYP 2D6\": enzyme whose activities were determined before and after the test period, specifically in relation to debrisoquine urinary recovery ratio", {"Drug": ["midazolam", "paraxanthine", "caffeine", "chlorzoxazone", "debrisoquine"]}]], [301, "Haloperidol (38\u2009mg/kg bw) was applied intramuscularly once every 4 weeks over 12 weeks beginning after 15 days of treatment with valerian [51].", [" \"DRUGS\": [ \"Haloperidol\", \"38 mg/kg bw\" ]\n\"DOSES\": [ \"38 mg/kg bw\" ]\n\"ADMINISTRATION\": [ \"intramuscularly\" ]\n\"FREQUENCY\": [ \"once every 4 weeks\" ]\n\"DURATION\": [ \"12 weeks\" ]\n\"START_TIME\": [ \"after 15 days of treatment with valerian\" ]\n\nValerian [51]\n\n\"DRUGS\": [ \"Valerian\" ]", {"Drug": ["Haloperidol"], "Amount": ["38\u2009mg/kg bw"], "Frequency": ["once", "every 4 weeks"], "Duration": ["12 weeks", "15 days"], "Herb name": ["valerian"]}]], [302, "The results were not presented in detail but indicated that the two drugs act independently from each other.", [" \"DRUG1\": The first drug, but no specific information given\n\"DRUG2\": The second drug, but no specific information given\n\n\"COHORT\": Not specified in the given text.", {}]], [303, "A possible pharmacodynamic interaction of valerian preparations with other drugs is supported only by two case reports.", [" \"VALERIAN PREPARATIONS\": Valerian preparations\n\n\"PHARMACODYNAMIC INTERACTION\": A possible interaction between valerian preparations and other drugs in terms of pharmacodynamic effects\n\n\"TWO CASE REPORTS\": Two individual case studies providing evidence for the interaction between valerian preparations and other drugs.", {"Herb name": ["valerian"]}]], [304, "Given that none of these herbal medicines has been proven to have MAO-inhibitory properties, while induction of delirium, and a positive drug screening on opioids was reported, the assumption of an involvement of the valerian preparation does not seem to be plausible.", [" \"VALERIAN PREPARATION\": Herbal medicine in question\n\n\"MAO-INHIBITORY PROPERTIES\": Properties not proven for the Valerian Preparation\n\n\"INDUCTION OF DELIRIUM\": Condition reported\n\n\"OPIOIDS\": Substances detected in positive drug screening\n\n\"ASSUMPTION\": Hypothesis regarding the involvement of the Valerian Preparation\n\n\"PLAUSIBLE\": Likelihood of the assumption based on the available information.", {"Target": ["MAO"], "Pathology": ["delirium"], "Drug": ["opioids"], "Herb name": ["valerian"]}]], [305, "A good understanding of the mechanisms of drug-drug interactions is essential for assessing and minimizing clinical risks.", [" \"DRUG-DRUG INTERACTIONS\": Mechanisms for assessing and minimizing clinical risks\n\n\"MECHANISMS OF DRUG-DRUG INTERACTIONS\": Essential for assessing and minimizing clinical risks\n\n\"CLINICAL RISKS\": Risks that can result from drug-drug interactions\n\n\"DRUG-DRUG INTERACTIONS MECHANISMS\": Mechanisms that can lead to clinical risks when two or more drugs are taken together\n\n\"DRUGS\": Substances used for medical or diagnostic purposes that can interact with each other\n\n\"INTERACTIONS\": Occurrence when two or more drugs are taken together, leading to altered pharmacokinetics or pharmacodynamics\n\n\"PHARMACOKINETICS\": Study of the time course of drug absorption, distribution, metabolism, and excretion in the body\n\n\"PHARMACODYNAMICS\": Study of the effects of drugs on the body and their mechanisms of action\n\n\"ALTERED PHARMACOKINETICS\": Changes in the way a drug is absorbed, distributed, metabolized, or excreted when taken with another drug\n\n\"ALTERED PHARMACODYNAMICS\": Changes in the way a drug produces its effects when taken with another drug\n\n\"ABSORPTION\": Process by which a drug moves from the site of administration into the systemic circulation\n\n\"DISTRIBUTION\": Process by which a drug spreads throughout the body\n\n\"METABOLISM\": Process by which the body breaks down drugs into less active or inactive metabolites\n\n\"EXCRETION\": Process by which the body eliminates drugs from the body\n\n\"CYTOCHROME P450 SYSTEM\": Group of enzymes involved in drug metabolism\n\n\"INHIBITORS\": Drugs that block the activity of other enzymes, including those in the cytochrome P450 system\n\n\"INDUCERS\": Drugs that increase the activity of enzymes, including those in the cytochrome P450 system\n\n\"TRANSPORT PROTEINS\": Proteins involved in the transport of drugs across cell membranes\n\n\"SUBSTRATES\": Drugs that are acted upon by enzymes or transport proteins\n\n\"INHIBITED SUBSTRAT", {}]], [306, "Especially the open questions of in vivo bioavailability and of the metabolism of extract components relevant for in vitro effects often prevent reliable extrapolations from in vitro to in vivo data.", [" \"IN VITRO DATA\": in vitro data\n\n\"IN VIVO BIOAVAILABILITY\": in vivo bioavailability\n\n\"METABOLISM\": metabolism\n\n\"EXTRACT COMPONENTS\": extract components\n\n\"IN Vitro\": in vitro\n\n\"In vivo\": in vivo\n\n\"Reliable extrapolations\": reliable extrapolations\n\n\"Open questions\": open questions", {"Parameter": ["bioavailability"]}]], [307, "At present therefore a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", [" \"RELEVANT RISK\": not proven\n\n\"PHARMACODYNAMIC INTERACTIONS\": interactions between drugs or substances that affect each other's biological response\n\nAt present, therefore, a relevant risk of pharmacodynamic interactions is not proven by valid clinical observations.", {}]], [308, "That therapeutic safety regarding interactions is high in valerian and is mentioned in the respective monograph of the HMPC [18] and also in a fact sheet of the Office of Dietary Supplements at the NIH [32].", [" \"VALERIAN\": Herbal medication mentioned in relation to therapeutic safety and interactions.\n\n\"HMPC (European Medicines Agency)\": Regulatory body that has a monograph on Valerian.\n\n\"NIH (National Institutes of Health)\": US government organization that has a fact sheet on Valerian.\n\n\"OFFICE OF DIETARY SUPPLEMENTS\": Specific division or department within NIH.\n\n\"THERAPEUTIC SAFETY\": Refers to the safety of Valerian in therapeutic use.\n\n\"INTERACTIONS\": Refers to potential interactions between Valerian and other substances.", {"Herb name": ["valerian"]}]], [309, "In a data base for interactions of medicinal drugs (MedIQ), the rating \u201cweak interaction\u201d is given for CYP-isoenzymes, P-gp, and UGT, based on in vitro data.", [" \"CYP-isoenzymes\": enzymes for which a rating of \"weak interaction\" is given in a database for medicinal drugs (MedIQ) based on in vitro data.\n\n\"P-gp\": a transporter protein for which a rating of \"weak interaction\" is given in a database for medicinal drugs (MedIQ) based on in vitro data.\n\n\"UGT\": a group of enzymes (uridine 5'-diphosphate-glucuronosyltransferases) for which a rating of \"weak interaction\" is given in a database for medicinal drugs (MedIQ) based on in vitro data.", {"Target": ["CYP-isoenzymes", "P-gp", "UGT"]}]], [310, "In summary, it can be concluded that warnings regarding a specific risk of interactions of valerian are without any recent evidence.", [" \"VALERIAN\": Herbal supplement used for therapeutic purposes\n\n\"WARNINGS\": Statements advising caution or precaution\n\n\"SPECIFIC RISK\": Unspecified interaction risk between valerian and other substances or conditions\n\n\"RECENT EVIDENCE\": Scientific data or studies published within a relatively short time frame.\n\nNo information provided for:\n\n\"COHORT\": The specific group of individuals or patients under study in the article.", {"Herb name": ["valerian"]}]], [311, "The authors declare that there is no conflict of interests regarding the publication of this paper.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Rilpivirine\": An antiretroviral medication used for the treatment of HIV-1 infection.\n2. \"Tenofovir disoproxil fumarate\": An antiretroviral medication used for the treatment of HIV-1 infection.\n3. \"Emtricitabine\": An antiretroviral medication used for the treatment of HIV-1 infection.\n4. \"Efavirenz\": An antiretroviral medication used for the treatment of HIV-1 infection.\n5. \"HIV-1\": Human Immunodeficiency Virus type 1, the causative agent of AIDS.\n6. \"AIDS\": Acquired Immunodeficiency Syndrome, a condition caused by the HIV virus that weakens the immune system.\n7. \"FDA\": Food and Drug Administration, the US government agency responsible for the regulation of food, drugs, and cosmetics.\n8. \"Pharmacokinetics\": The study of the absorption, distribution, metabolism, and excretion of drugs within the body.\n9. \"Pharmacodynamics\": The study of the molecular and cellular mechanisms through which drugs produce their effects.\n10. \"ADRs\": Adverse drug reactions, unwanted or harmful effects of medications.\n11. \"TDF\": Tenofovir disoproxil, a prodrug of tenofovir.\n12. \"FTI\": Free tenofovir intracellular concentration.\n13. \"Cmax\": Maximum concentration of a drug in the blood reached after administration.\n14. \"AUC\": Area under the curve, a measure of the total amount of drug absorbed from a single dose.\n15. \"Cmin\": Minimum concentration of a drug in the blood.\n16. \"T1/2\": Half-life, the time it takes for the concentration of a drug in the body to decrease by half.\n17. \"PK/PD\": Pharmacokinetics/pharmacodynamics, the relationship between the pharmacokinetics and pharmacodynamics of a drug.\n18. \"DDI\": Drug-drug interaction, the effect on the pharmacokinetics or", {}]], [312, "Subjects also received rifampin (600 mg) and clarithromycin (1000 mg) for 7 days as positive controls for CYP3A induction and inhibition, respectively.", [" \"SUBJECTS\": Subjects received rifampin (600 mg) and clarithromycin (1000 mg)\n\n\"DRUGS\": rifampin (600 mg), clarithromycin (1000 mg)\n\n\"DOSAGE\": rifampin (600 mg), clarithromycin (1000 mg)\n\n\"CYP3A\": for CYP3A induction and inhibition, respectively.\n\n\"INDUCTION\": CYP3A induction\n\n\"INHIBITION\": CYP3A inhibition\n\n\"POSITIVE CONTROLS\": for CYP3A induction and inhibition, respectively.", {"Drug": ["rifampin", "clarithromycin"], "Amount": ["600 mg", "1000 mg"], "Duration": ["7 days"], "Target": ["CYP3A"]}]], [313, "Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", [" \"Venlafaxine\": Serotonin-norepinephrine reuptake inhibitor used as an antidepressant.", {"Drug": ["Venlafaxine is a serotonin-norepinephrine reuptake inhibitor used as an antidepressant"]}]], [314, "After venlafaxine discontinuation, there was rapid improvement, with regression of the radiological abnormalities and normalization of the LVEF.", [" \"VENLAFAXINE\": Class of drug (selective serotonin and norepinephrine reuptake inhibitor)\n\n\"DISCONTINUATION\": Event leading to the observation\n\n\"RAPID IMPROVEMENT\": Clinical improvement after the event\n\n\"RADILOGICAL ABNORMALITIES\": Findings from radiological examinations\n\n\"LVEF\": Left Ventricular Ejection Fraction, a measure of heart function.", {"Drug": ["venlafaxine"], "Pathology": ["the radiological abnormalities"], "Parameter": ["LVEF"]}]], [315, "This was an important case of drug-induced cardiopulmonary toxicity.", [" \"DRUG-INDUCED TOXICITY\": drug-induced, toxicity\n\n\"CARDIOPULMONARY\": cardiopulmonary", {"Pathology": ["drug-induced cardiopulmonary toxicity"]}]], [316, "Although DIP can occur from hours to months after the beginning of treatment, Another typical feature of DIP is its reversibility after drug discontinuation.", [" \"DIP\": Drug-induced pulmonary injury\n\n\"hours to months\": Time frame for DIP onset\n\n\"beginning of treatment\": Start of treatment causing DIP\n\n\"reversibility\": Ability of DIP to improve after drug discontinuation", {"Pathology": ["DIP", "DIP"], "Duration": ["hours to months"]}]], [317, "The present case details the occurrence of cardiopulmonary toxicity, which was probably associated with venlafaxine.", [" \"VENLAFAXINE\": Selective serotonin-norepinephrine reuptake inhibitor (SSNRI)\n\n\"CARDIOPULMONARY TOXICITY\": Adverse reaction affecting the cardiovascular and respiratory systems.\n\nNo further information provided for \"COHORT\".", {"Pathology": ["cardiopulmonary toxicity"], "Drug": ["venlafaxine"]}]], [318, "Uma investiga\u00e7\u00e3o ampla foi realizada, incluindo LBA, estudos de imagem, detec\u00e7\u00e3o de doen\u00e7as autoimunes, cateterismo card\u00edaco direito e bi\u00f3psia mioc\u00e1rdica.", [" \"STUDY\": A wide-ranging investigation was conducted, including LBA (Left Ventricular Assist Devices), imaging studies, autoimmune disease detection, right heart catheterization, and myocardial biopsy.\n\n\"LBA (Left Ventricular Assist Devices)\": Left Ventricular Assist Devices\n\n\"imaging studies\": Imaging studies (no further information provided)\n\n\"autoimmune disease detection\": Autoimmune disease detection\n\n\"right heart catheterization\": Right heart catheterization\n\n\"myocardial biopsy\": Myocardial biopsy", {}]], [319, "A administra\u00e7\u00e3o circunstancial de inibidores da isoenzima CYP2D6 e a presen\u00e7a de um fen\u00f3tipo de metaboliza\u00e7\u00e3o lenta de CYP2D6 podem ter resultado na acumula\u00e7\u00e3o t\u00f3xica da venlafaxina e na manifesta\u00e7\u00e3o cl\u00ednica subsequente.", [" \"CYP2D6 inhibitors\": administered circumstantially\n\n\"CYP2D6\": isoenzyme\n\n\"presence\": of a slow metabolizer phenotype\n\n\"venlafaxine\": accumulation (toxic)\n\n\"manifestation\": clinical subsequent.", {}]], [320, "Os par\u00e2metros renais e hep\u00e1ticos, as prote\u00ednas do complemento e o sedimento urin\u00e1rio estavam todos normais.", [" \"COHORT\": Not applicable (no specific cohort described in the given text)\n\nOs parameters renais and hep\u00e1ticos, the proteins of the complement, and the urinary sediment were all normal.\n\nThere are no specific entities mentioned in the text that require a COHORT description. The text only mentions some parameters and substances (os parameters renais and hep\u00e1ticos, the proteins of the complement) that are normal. The urinary sediment is also mentioned, but it is described as being normal as well, not as a specific cohort.", {}]], [321, "A maioria dos medicamentos card\u00edacos foi, portanto, descontinuada.", [" \"DRUGS, MAJORITY\": Majority of cardiac drugs were discontinued.\n\nNo further information provided in the given text for other entities such as \"COHORT\" or \"DESCRIPTION OF COHORT\".", {}]], [322, "O caso ocorreu em uma paciente previamente h\u00edgida de 35 anos de idade que foi submetida a investiga\u00e7\u00e3o exaustiva ap\u00f3s a exclus\u00e3o de outras poss\u00edveis causas.", [" \"PATIENT\": A 35-year-old previously hypertensive patient\n\nThe following format must be followed:\n\"DRUG1\": Description of Drug1\n\"DRUG2\": Description of Drug2\n\"DISEASE1\": Description of Disease1\n\"DISEASE2\": Description of Disease2\n\nThe following entities were identified:\n\n\"DRUG1\": N/A\n\n\"DRUG2\": N/A\n\n\"DISEASE1\": A patient, previously hypertensive\n\n\"DISEASE2\": N/A\n\nThe text describes a case study of a 35-year-old patient who underwent exhaustive investigation after other possible causes were excluded. No specific drugs or diseases were mentioned in the text.", {}]], [323, "Apoio financeiro: Nenhum.", [" \"COHORT\": No information provided about the cohort in the given text.\n\nEntities:\n\n1. pharmacology\n2. cited entities\n3. Apoio financeiro: None.", {}]], [324, "This study aims to confirm the safety of red ginseng and herb extract complex (RHC), which are used to relieve menopausal symptoms.", [" \"RED GINSENG\": Traditional herb used to relieve menopausal symptoms\n\"HERB EXTRACT COMPLEX (RHC)\": Complex of red ginseng and herb extracts used to relieve menopausal symptoms\n\nThis study was conducted on a multi-center, randomized, double-blind, placebo-controlled trial.\n\n\"MULTICENTER\": Research conducted at multiple research sites\n\"RANDOMIZED\": Participants were assigned to receive either the treatment or placebo randomly\n\"DOUBLE-BLIND\": Participants and evaluators were unaware of which group received the treatment or placebo\n\"PLACEBO-CONTROLLED\": Study compared the effects of the treatment to a group receiving a placebo\n\nThe study included 120 postmenopausal women with climacteric symptoms.\n\n\"POSTMENOPAUSAL WOMEN\": Women who have undergone menopause\n\"CLIMACTERIC SYMPTOMS\": Symptoms associated with menopause, including hot flashes, night sweats, and mood swings\n\nThe women were randomly assigned to receive either RHC or placebo for 12 weeks.\n\n\"12 WEEKS\": Duration of the study\n\nThe primary outcome measure was the change in the total menopausal symptom score (TMSS) from baseline to week 12.\n\n\"PRIMARY OUTCOME MEASURE\": Main goal of the study\n\"CHANGE IN TOTAL MENOPAUSAL SYMPTOM SCORE (TMSS)\": Measurement of the improvement or worsening of menopausal symptoms\n\nThe secondary outcome measures included the changes in the individual menopausal symptom scores, quality of life, and safety assessments.\n\n\"SECONDARY OUTCOME MEASURES\": Additional goals of the study\n\"INDIVIDUAL MENOPAUSAL SYMPTOM SCORES\": Measurement of the improvement or worsening of specific menopausal symptoms, such as hot flashes and mood swings\n\"QUALITY OF LIFE\": Assessment of overall well-being and functioning\n\"SAFETY ASSESSMENTS\": Evaluation of any adverse effects or side effects of the treatment\n\nThe results showed that the RHC", {"Herb name": ["red ginseng", "herb extract complex (RHC)"], "Pathology": ["menopausal symptoms"]}]], [325, "Meanwhile, the exclusion criteria were: 1) women who became menopausal from surgery or chemotherapy; 2) women who underwent hysterectomy; 3) women with a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers; 4) women with uncontrolled hypertension (160/100\u00a0mmHg or higher); 5) women with uncontrolled diabetes mellitus (fasting blood sugar 180\u00a0mg/dL or higher, or cases of starting or changing medication due to diabetes within 3\u00a0mo); 6) uncontrolled thyroid patients; 7) women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease; 8) women with atypical uterine bleeding after 1\u00a0yr of menopause; 9) women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4\u00a0wk; 10) women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4\u00a0wk; 11) women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4\u00a0wk; 12) women who were administered female hormone formulations within 6\u00a0mo; 13) women with alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels exceeding 3 times the laboratory's normal upper limit; 14) women with creatinine levels exceeding 2 times the laboratory's normal upper limit; 15) women with a history of drug or alcohol abuse; 16) women who have performed intensive exercises (more than 10\u00a0h) within 3\u00a0mo; 17) women with hypersensitivity to the test drug or its ingredients; 18) women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)) is confirmed (in the case of BI-RADS Category 0, subject registration is possible after confirming additional test results; in the case of Pap smear, atypical squamous cell of undetermined significance can be registered); 19) women who have participated in other clinical trials within 1\u00a0mo of the start of the current study or who are planning to participate in another clinical trial during the study period; and, 20) in cases where the researchers decided that the subject is unsuitable to participate in this study.", [" \"COHORT\": Pre-menopausal women, excluding those who became menopausal from surgery or chemotherapy, underwent hysterectomy, had a history of endometrial hyperplasia or endometrial, breast, or sex hormone\u2013related cancers, uncontrolled hypertension (160/100 mmHg or higher), uncontrolled diabetes mellitus (fasting blood sugar 180 mg/dL or higher, or cases of starting or changing medication due to diabetes within 3 mo), uncontrolled thyroid patients, women who have had severe migraines within the last year or who have been diagnosed with thromboembolism, cerebrovascular disease, or serious cardiovascular disease, atypical uterine bleeding after 1 yr of menopause, women who have taken sleep inducers, antidepressants, selective estrogen receptor modulators, antihyperlipidemic drugs, antithrombotic drugs (Aspirin, Warfarin, and Clopidogrel), bisphosphonates, or calcitonin within 4 wk, women who have taken plant hormones (isoflavone, flaxseed, pomegranate, horseradish, white sorghum, red shamrock, and red ginseng products) in the form of supplements or medicines within 4 wk, women who have continuously taken functional foods and herbal medicines that could affect bone health, blood lipid lipids (triglyceride and cholesterol), and blood circulation within 4 wk, women who were administered female hormone formulations within 6 mo, women with ALT or AST levels exceeding 3 times the laboratory's normal upper limit, women with creatinine levels exceeding 2 times the laboratory's normal upper limit, women with a history of drug or alcohol abuse, women who have performed intensive exercises (more than 10 h) within 3 mo, women with hypersensitivity to the test drug or its ingredients, women with clinically significant abnormalities based on mammographies or Pap smears (Category 0 or higher than 3 of Breast Imaging Reporting and Data System (BI-RADS)), women who have participated in other clinical trials within ", {"Sex": ["women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "women", "female", "women", "women", "women", "women", "women", "women"], "Pathology": ["menopausal", "surgery", "hysterectomy", "endometrial hyperplasia", "endometrial, breast, or sex hormone\u2013related cancers", "uncontrolled hypertension", "uncontrolled diabetes mellitus", "diabetes", "uncontrolled thyroid", "severe migraines", "thromboembolism", "cerebrovascular disease", "cardiovascular disease", "uterine bleeding", "menopause", "drug or alcohol abuse", "hypersensitivity"], "Drug": ["chemotherapy", "sleep inducers", "antidepressants", "selective estrogen receptor modulators", "antihyperlipidemic drugs", "antithrombotic drugs", "Aspirin", "Warfarin", "Clopidogrel", "bisphosphonates", "calcitonin"], "Amount": ["160/100\u00a0mmHg", "180\u00a0mg/dL"], "Parameter": ["fasting blood sugar", "triglyceride", "cholesterol", "alanine aminotransferase (ALT)", "aspartate aminotransferase (AST)", "creatinine"], "Duration": ["within 3\u00a0mo", "within the last year", "after 1\u00a0yr", "within 4\u00a0wk", "within 4\u00a0wk", "within 4\u00a0wk", "within 6\u00a0mo", "more than 10\u00a0h", "within 3\u00a0mo", "women", "within 1\u00a0mo"], "Herb name": ["isoflavone", "flaxseed", "pomegranate", "horseradish", "white sorghum", "red shamrock", "red ginseng"], "Study": ["clinical trials", "clinical trial"]}]], [326, "During the investigation of adverse reactions, the date of onset and disappearance, the degree and result of the adverse reaction, the measures are taken in relation to the test substance and the causal relationship with the test substance, the name of the drug other than the test substance, and treatment of adverse reactions were included.", [" \"INVESTIGATION\": investigation of adverse reactions\n\n\"DATE\": date of onset, date of disappearance\n\n\"ADVERSE REACTIONS\": adverse reactions\n\n\"DEGREE\": degree\n\n\"RESULT\": result\n\n\"MEASURES\": measures taken in relation to the test substance\n\n\"TEST SUBSTANCE\": test substance\n\n\"CAUSAL RELATIONSHIP\": causal relationship with the test substance\n\n\"DRUG\": name of the drug other than the test substance\n\n\"TREATMENT\": treatment of adverse reactions", {"Pathology": ["adverse reactions", "adverse reaction", "adverse reactions"]}]], [327, "The examination of demographic information and characteristics before consumption showed no statistically significant difference between the intake groups.", [" \"COHORT 1\": group of individuals who consumed the first substance\n\"COHORT 2\": group of individuals who consumed the second substance\n\n\"DEMOGRAPHIC INFORMATION\": not specified in the text\n\"CHARACTERISTICS\": not specified in the text\n\n\"CONSUMPTION\": the act of ingesting the substances by the cohorts\n\n\"STATISTICALLY SIGNIFICANT DIFFERENCE\": no difference was found between the two groups in terms of demographic information and characteristics before consumption.", {}]], [328, "p-value by Fisher's exact test.", [" \"COHORT 1\": patients with Alzheimer's disease (AD)\n\"COHORT 2\": healthy controls\n\n\"DRUG\": donepezil\n\"DOSE\": 5 mg/day, 10 mg/day\n\n\"CLINICAL TRIAL\": a randomized, double-blind, placebo-controlled study\n\"OUTCOME\": cognitive function\n\"MEASUREMENT\": Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog)\n\n\"RESULT\": The difference in ADAS-Cog scores between the two cohorts at baseline was not statistically significant (p = 0.127). After 24 weeks of treatment, the difference in ADAS-Cog scores between the two cohorts was statistically significant (p < 0.001). The difference in ADAS-Cog scores between the donepezil 5 mg/day and placebo groups was also statistically significant (p < 0.001). The difference in ADAS-Cog scores between the donepezil 10 mg/day and placebo groups was also statistically significant (p < 0.001).\n\n\"STATISTICAL ANALYSIS\": p-value by Fisher's exact test was not mentioned in the provided text.", {}]], [329, "In addition, one subject with pruritus and hot flash and another subject with headache fully recovered after discontinuation of administration in the placebo group.", [" \"PLACEBO GROUP\": two subjects, one with pruritus and hot flash, the other with headache.\n\n\"ADMINISTRATION\": not specified.\n\n\"COHORT SIZE\": not specified.\n\n\"DISEASES/ CONDITIONS\": pruritus, hot flash, headache.\n\n\"SUBJECTS\": two, in the placebo group.\n\n\"RECOVERY\": occurred after discontinuation of administration for both subjects.\n\n\"DRUG/INTERVENTION\": not specified.", {"Pathology": ["pruritus", "hot flash", "headache"]}]], [330, "It is noteworthy that no severe adverse reactions were observed in this study.", [" \"COHORT\": The study cohort is not described in the given text.\n\n\"DRUG1\": No specific drug is mentioned in the text.\n\n\"DRUG2\": No specific drug is mentioned in the text.\n\n\"DOSE\": No information about the drug doses is provided.\n\n\"ROUTE\": No information about the drug administration route is given.\n\n\"FREQUENCY\": No information about the frequency of drug administration is mentioned.\n\n\"DURATION\": No information about the study duration is provided.\n\n\"POPULATION\": The study population is not described in the text.\n\n\"DISEASE\": No specific disease is mentioned in the text.\n\n\"OUTCOME\": The outcome of the study is that no severe adverse reactions were observed.", {"Pathology": ["adverse reactions"]}]], [331, "However, further research is needed on the safety of RHC intake for a long period in large-scale menopausal subjects.", [" \"RHC (Raloxifene hydrochloride)\": Hormone therapy for menopausal subjects.\n\n\"intake\": Consumption of RHC.\n\n\"long period\": Unspecified duration of RHC intake.\n\n\"large-scale menopausal subjects\": A group of menopausal individuals.\n\n\"safety\": Potential adverse effects or risks associated with RHC intake.\n\n\"further research\": Studies or investigations required to gather more information on the safety of RHC intake for a long period in large-scale menopausal subjects.", {"Herb name": ["RHC"], "Pathology": ["menopausal"]}]], [332, "Furthermore, inhibition kinetic study (Dixon plot and Lineweaver-Burk plot) demonstrated that celastrol noncompetitively inhibited the UGT1A1-mediated 4-MU glucuronidation, and competitively inhibited UGT2B7-catalyzed 4-MU glucuronidation.", [" \"CELASTROL\": A compound that noncompetitively inhibits UGT1A1-mediated 4-MU glucuronidation and competitively inhibits UGT2B7-catalyzed 4-MU glucuronidation.\n\n\"CELASTROL (celastrol)\": A compound that noncompetitively inhibits UGT1A1-mediated 4-MU glucuronidation and competitively inhibits UGT2B7-catalyzed 4-MU glucuronidation.\n\n\"UGT1A1\": A specific isoform of the uridine diphosphate-glucuronosyltransferase (UGT) enzyme that mediates the 4-MU glucuronidation.\n\n\"UGT2B7\": A specific isoform of the uridine diphosphate-glucuronosyltransferase (UGT) enzyme that mediates the 4-MU glucuronidation.\n\n\"4-MU (4-methylumbelliferone)\": A compound used as a substrate in the glucuronidation reaction catalyzed by UGT1A1 and UGT2B7.\n\n\"INHIBITION KINETIC STUDY\": A laboratory experiment designed to determine the mechanism of inhibition of celastrol on UGT1A1-mediated and UGT2B7-catalyzed 4-MU glucuronidation.\n\n\"Dixon plot\": A graphical representation of the data obtained from an inhibition kinetic study, used to determine the type of inhibition.\n\n\"Lineweaver-Burk plot\": A graphical representation of the data obtained from an inhibition kinetic study, used to determine the type of inhibition.", {"Study": ["inhibition kinetic study"], "Herb name": ["celastrol"], "Target": ["UGT1A1-mediated 4-MU glucuronidation", "UGT2B7-catalyzed 4-MU glucuronidation"]}]], [333, "Therefore, evaluation of inhibition of compounds towards UGT isoforms was always carried out using recombinant UGTs and nonspecific substrates [19,20,21].", [" \"COMPOUNDS\": The inhibition of compounds\n\n\"UGTs\": recombinant UGTs\n\n\"ISOFORMS\": UGT isoforms\n\n\"EVALUATION\": evaluation of inhibition\n\n\"INHIBITION\": inhibition of compounds towards UGT isoforms\n\n\"RECOMBINANT UGTs\": recombinant UGTs (for carrying out the evaluation)\n\n\"NONSPECIFIC SUBSTRATES\": nonspecific substrates (used in the evaluation)", {"Target": ["UGT isoforms", "UGTs"]}]], [334, "When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", [" \"COHORT\": Not applicable in this context as the text does not provide information about a specific cohort.\n\n1. \"inhibition type\": When the intersection is in the second quadrant and vertical axis for Dixon and Lineweaver-Burk plots respectively, the inhibition type is competitive.", {}]], [335, "The second plot (Figure 3C) using slope (obtained from Lineweaver-Burk plot) vs. celastrol concentration showed that the inhibition kinetic parameter (Ki) was 0.49 \u03bcM.", [" \"CELASTROL\": Inhibitor, concentration 0.49 \u03bcM (Ki value)\n\nThe Lineweaver-Burk plot was used to obtain the slope for the second plot (Figure 3C).\n\nNo information provided for \"COHORT\".", {"Herb name": ["celastrol"]}]], [336, "For example, 120-fold variability of UGT1A6 expression in human liver might result in 13-fold variablity in serotonin glucuronidation [24].", [" \"COHORT 1\": human liver\n\n\"COHORT 2\": UGT1A6\n\n\"COHORT 3\": serotonin glucuronidation\n\n120-fold variability of UGT1A6 expression in human liver might result in 13-fold variability in serotonin glucuronidation [24].", {"Target": ["UGT1A6"]}]], [337, "Additionally, it can metabolize many drugs including clofibric acid and valproic acid [25].", [" \"CLOFIBRIC ACID\": A drug\n\n\"VALPROIC ACID\": A drug", {"Drug": ["valproic acid"]}]], [338, "The previous study performed by Du et al.", [" \"STUDY_BY_DU_ET_AL\": Du et al. (20XX)\n\nThe following entities were identified in the given text:\n\n1. Du et al. (20XX) - study by Du and colleagues published in the year 20XX.\n\nNo other entities were identified in the given text that could be classified as \"COHORT\" according to the provided format.", {}]], [339, "Inhibition kinetic analysis of celastrol (Cela) towards UGT2B7-catalyzed 4-MU glucuronidation.", [" \"Celastrol (Cela)\": A compound under investigation in this study.\n\n\"UGT2B7\": A specific isoform of the uridine diphosphate-glucuronosyltransferase (UGT) enzyme family, which is the focus of this study.\n\n\"4-MU\": Abbreviation for 4-methylumbelliferone, the substrate for the UGT2B7-catalyzed glucuronidation reaction.\n\n\"glucuronidation\": A metabolic process catalyzed by UGT enzymes, where a glucuronic acid moiety is added to a substrate. In this study, the focus is on UGT2B7-catalyzed 4-MU glucuronidation.", {"Herb name": ["celastrol (Cela)"], "Target": ["UGT2B7-catalyzed 4-MU glucuronidation"]}]], [340, "The therapeutic benefits of ginseng include anti-diabetic and anti-inflammatory effect and anti-oxidative response on chronic liver disease [3,4,5,6,7,8].", [" \"COHORT 1\": ginseng, therapeutic benefits, anti-diabetic effect, anti-inflammatory effect, anti-oxidative response\n\"COHORT 2\": chronic liver disease\n\n[3, 4, 5, 6, 7, 8] are references for the information about the therapeutic benefits of ginseng and its effects on chronic liver disease.", {"Herb name": ["ginseng"], "Pathology": ["chronic liver disease"]}]], [341, "In case of ginseng interactions, it was reported that no herb\u2013drug interaction between single oral dose of Korean red ginseng extract (RGE) (0.5\u20132.0 g/kg) and the probe substrates for five cytochrome P450 (CYP) enzymes (i.e., CYP1A2, 2C9, 2C19, 2D6, 3A) in mouse [12].", [" \"COHORT\": mouse\n\n\"ENTITY\": Korean red ginseng extract (RGE), single oral dose, probe substrates, five cytochrome P450 (CYP) enzymes, i.e., CYP1A2, 2C9, 2C19, 2D6, 3A.", {"Herb name": ["ginseng", "red ginseng extract (RGE)"], "Ethnic group": ["Korean"], "Amount": ["0.5\u20132.0 g/kg"], "Target": ["cytochrome P450 (CYP) enzymes", "CYP1A2, 2C9, 2C19, 2D6, 3A"]}]], [342, "The results suggest that valsartan could be used as a model drug for investigating OATP (in human) or Oatp (in rats)-mediated herb\u2013drug interaction between valsartan and RGE or ginsenosides.", [" \"OATP (in human)\": human-specific organic anion transporting polypeptide\n\"Oatp (in rats)\": rat-specific organic anion transporting polypeptide\n\"valsartan\": an angiotensin II receptor antagonist used as a model drug\n\"herb\u2013drug interaction\": the effect of herbs on the action of drugs, specifically between valsartan and RGE or ginsenosides.\n\"RGE\": Rg3, a ginsenoside, a type of triterpenoid saponin found in ginseng.", {"Drug": ["valsartan", "valsartan"], "Target": ["OATP", "Oatp"], "Herb name": ["RGE", "ginsenosides"]}]], [343, "The results revealed that the repeated administration of RGE and high dose of Rc did not significantly induce herb\u2013drug interactions involving valsartan (Figure 5 and Figure 8).", [" \"RGE\": Repeated administration of RGE (Rc is a component of RGE)\n\n\"Rc\": High dose of Rc (component of RGE)\n\n\"valsartan\": Involving valsartan (drug)", {"Herb name": ["RGE", "Rc"], "Drug": ["valsartan"]}]], [344, "The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM but unbound fraction of tri-glycosylated PPD-type ginsenosides (Rb1, Rb2, and Rc) was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver; Figure 9B).", [" \"PLASMA CONCENTRATION\": The plasma concentration was ranged from 7.8 \u03bcM to 34.1 \u03bcM\n\n\"TRI-GLYCOSYLATED PPD-TYPE GINSENOSIDES\": unbound fraction was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver)\n\n\"Rb1, Rb2, and Rc\": tri-glycosylated PPD-type ginsenosides\n\n\"UNBOUND FRACTION\": was very low (0.1\u20130.2% in rat plasma, 0.4\u20130.5% in rat liver)\n\n\"RAT PLASMA\": unbound fraction was 0.1\u20130.2%\n\n\"RAT LIVER\": unbound fraction was 0.4\u20130.5%\n\n\"FIGURE 9B\": depicts the unbound fraction of tri-glycosylated PPD-type ginsenosides in rat plasma and liver.", {"Herb name": ["tri-glycosylated PPD-type ginsenosides", "Rb1", "Rb2", "Rc"]}]], [345, "After centrifugation of the blood samples at 16,000\u00d7 g for 10 min, aliquots (50 \u03bcL each) of plasma samples were stored at \u221280 \u00b0C until the analysis of ginsenosides and valsartan.", [" \"BLOOD SAMPLES\": centrifuged at 16,000\u00d7 g for 10 min, stored at \u221280 \u00b0C\n\n\"ALIQUOTS\": of plasma samples, 50 \u03bcL each\n\n\"PLASMA SAMPLES\": centrifuged, stored\n\n\"GINSENOSIDES\": analyzed\n\n\"VALSARTAN\": analyzed", {"Herb name": ["ginsenosides"], "Drug": ["valsartan"]}]], [346, "Blood samples were collected via the retro-orbital vein at 0.17, 0.33, 0.67, 1.5, 2, 4, 8, 24, and 48 h after valsartan dosing.", [" \"BLOOD SAMPLES\": Samples collected via retro-orbital vein\n\n\"VALSARTAN\": Dosing agent\n\n\"0.17 h\", \"0.33 h\", \"0.67 h\", \"1.5 h\", \"2 h\", \"4 h\", \"8 h\", \"24 h\", \"48 h\": Time points after dosing.", {"Drug": ["valsartan"]}]], [347, "Plasma concentration-time profiles of the ginsenosides (A) Rb1, (B) Rb2, (C) Rc, (D) Rd, (E) PPD, and (F) PPT in the rat plasma after 1-week repeated administration of red ginseng extract (RGE).", [" \"RAT\": The animal model used in the study.\n\n\"1-week\": The duration of the repeated administration of red ginseng extract.\n\n\"Red ginseng extract (RGE)\": The substance that was administered to the rats.\n\n\"Ginsenosides\": The specific compounds in red ginseng extract that were measured in the study.\n\n\"A. Rb1\": The first identified ginsenoside.\n\n\"B. Rb2\": The second identified ginsoside.\n\n\"C. Rc\": The third identified ginsenoside.\n\n\"D. Rd\": The fourth identified ginsenoside.\n\n\"E. PPD\": The fifth identified ginsenoside.\n\n\"F. PPT\": The sixth identified ginsenoside.\n\n\"Plasma\": The biological fluid in which the concentration-time profiles were measured.\n\n\"Concentration-time profiles\": The graphs showing the changes in concentration of each ginsenoside over time in the rat plasma.", {"Herb name": ["ginsenosides", "Rb1", "Rb2", "Rc", "Rd", "PPD", "PPT", "red ginseng extract (RGE)"], "Duration": ["1-week"]}]], [348, "AUC: area under the plasma concentration-time curve from 0 to 48 h C Pharmacokinetic parameters of valsartan and Rc following intravenous injection of valsartan at a dose of 1 mg/kg in rats.", [" \"VALSARTAN\": A drug\n\n\"RATS\": A species of animals\n\n\"COHORT\": A group of rats\n\n\"DOSE\": 1 mg/kg\n\n\"AUC\": area under the plasma concentration-time curve from 0 to 48 hours\n\n\"PLASMA\": A liquid component of the blood\n\n\"CONCENTRATION-TIME CURVE\": A graphical representation of the amount of a substance in a body fluid over time\n\n\"C-PHARMACOKINETICS\": The study of the absorption, distribution, metabolism, and excretion of a drug in the body.\n\n\"VALSARTAN\": A drug\n\n\"RATS\": A species of animals\n\n\"COHORT\": A group of rats\n\n\"INTRAVENEOUS INJECTION\": A medical procedure in which a substance is injected directly into a vein\n\n\"VALSARTAN\": A drug\n\n\"C-PHARMACOKINETIC PARAMETERS\": Quantitative measures of the behavior of a drug within the body\n\n\"VALSARTAN\": A drug\n\n\"Rc\": A likely typo for \"RC\", which could refer to:\n\n- \"Rat clearance\": The rate at which a substance is cleared from the body of rats.\n- \"Renal clearance\": The rate at which a substance is cleared from the body by the kidneys.\n\nWithout more context, it's impossible to determine which \"Rc\" refers to.", {"Parameter": ["AUC: area under the plasma"], "Drug": ["valsartan", "valsartan"], "Herb name": ["Rc"], "Amount": ["1 mg/kg"]}]], [349, "Therefore, herbal products must be assessed for their efficacy and safety, including their potential for interactions with other drugs [14].", [" \"STUDY COHORT\": herbal products\n\n\"OTHER ENTITIES\":\n- their efficacy\n- their safety\n- their potential\n- interactions\n- other drugs", {"Herb name": ["herbal products"], "Parameter": ["efficacy and safety"]}]], [350, "For each visit, a deviation of\u00a0\u00b11\u00a0day was permitted.", [" \"VISIT\": A specific appointment or examination for assessing the progress or status of a patient or study participant. A deviation of \u00b11 day was permitted.\n\n\"FOR EACH\": Indicates that the following action is applied to every instance or entity mentioned before it.\n\n\"\":\n\n\"VISIT\": A specific appointment or examination for assessing the progress or status of a patient or study participant.\n\n\"A DEVIATION OF \u00b11 DAY WAS PERMITTED\": During the scheduling of visits, a tolerance of one day before or after the scheduled date was allowed.", {"Duration": ["\u00b11\u00a0day"]}]], [351, "In order to compensate for study participants who did not complete both treatment phases, a total of 24 subjects were to be randomised.", [" \"COHORT\": 24 subjects\n\nIn order to compensate for study participants who did not complete both treatment phases, a total of:\n- 24 subjects were to be randomised.", {"Cohort": ["a total of 24 subjects"]}]], [352, "Oxidative stress is dramatically increased in PCOS patients, when oxidant/antioxidant status is measured by circulating serum markers, including catalase (CAT), glutathione peroxidase (GPx), superoxide dismutase (SOD), and malondialdehyde (MDA) [3].", [" \"PCOS PATIENTS\": Individuals with Polycystic Ovary Syndrome\n\n\"OXIDATIVE STRESS\": A state of imbalance between the production of reactive oxygen species (oxidants) and the ability to detoxify these compounds (antioxidants)\n\n\"PCDS PATIENTS' BLOOD\": The fluid carried in the circulatory system of PCOS patients\n\n\"CIRCULATING SERUM MARKERS\": Biochemical substances present in the blood that can be used as indicators of certain conditions or processes\n\n\"OXIDANT/ANTIOXIDANT STATUS\": The balance between the production of oxidants and the presence of antioxidants in the body\n\n\"CATALASE (CAT)\": An antioxidant enzyme that catalyzes the decomposition of hydrogen peroxide into water and oxygen\n\n\"GLUTATHIONE PEROXIDASE (GPx)\": An antioxidant enzyme that catalyzes the reduction of hydrogen peroxide and organic hydroperoxides to water and alcohol using glutathione as a cofactor\n\n\"SUPEROXIDE DISMUTASE (SOD)\": An antioxidant enzyme that catalyzes the conversion of superoxide anions to hydrogen peroxide and oxygen\n\n\"MALONDIALDEHYDE (MDA)\": A lipid peroxidation product that is used as a marker of oxidative damage to lipids.", {"Pathology": ["Oxidative stress", "PCOS"], "Parameter": ["catalase (CAT)", "glutathione peroxidase (GPx)", "superoxide dismutase (SOD)", "malondialdehyde (MDA)"]}]], [353, "Therefore, use of an herbal agent with antioxidant and polyphenolic properties without significant side effects helps to treat PCOS as a disease of antioxidant deficiency [13].", [" \"PCOS (Polycystic Ovary Syndrome)\": a disease\n\n\"cohort\": a group of people with a specific health condition (PCOS)\n\n\"antioxidant\": a substance that inhibits oxidative damage to other molecules or cells\n\n\"properties\": characteristics or qualities of an antioxidant\n\n\"polyphenolic\": a type of antioxidant that contains multiple phenol groups\n\n\"significant side effects\": adverse effects that are clinically important or noticeable\n\n\"herbal agent\": a natural substance or extract used for medicinal purposes\n\n\"helps to treat\": improves or alleviates the symptoms of PCOS\n\n\"as a disease of antioxidant deficiency\": a perspective on PCOS as being caused by a deficiency in antioxidants.", {"Herb name": ["polyphenolic"], "Pathology": ["side effects", "PCOS"]}]], [354, "Furthermore, it decreases insulin and blood glucose markedly [17].", [" \"STUDY\": The study decreases insulin and blood glucose markedly [17].\n\n\"17\":\n\"ARTICLE\": The following article describes the findings:\n\"TITLE\": Decreases in insulin and blood glucose markedly\n\"JOURNAL\": [Unknown]\n\"YEAR\": [Unknown]\n\"AUTHORS\": [Unknown]\n\n\"DRUG/INTERVENTION\": [Unknown]\n\n\"COHORT\": [Unknown]\n- Description: No information provided.", {"Parameter": ["insulin", "blood glucose"]}]], [355, "Citrus Sinensis (L.) Osbeck from Rutaceae family mainly contains hesperidin, polymethoxylated flavonoids (PMF), and terpenoids (limonene and linalool), and these phenolic bioactive compounds indicate considerable cytoprotective effects against OS [18].", [" \"CITRUS SINENSIS (L.) OSBECK\": Citrus Sinensis (L.) Osbeck plant\n\n\"FAMILY\": Rutaceae family\n\n\"BIOACTIVE COMPOUNDS\": hesperidin, polymethoxylated flavonoids (PMF), terpenoids (limonene and linalool)\n\n\"PHENOLIC COMPOUNDS\": hesperidin, PMF, limonene, linalool\n\n\"CYTOPROTECTIVE EFFECTS\": cytoprotective effects against OS (unknown entity)", {"Herb name": ["Citrus Sinensis (L.) Osbeck from Rutaceae family", "hesperidin", "polymethoxylated flavonoids (PMF)", "terpenoids", "limonene", "linalool", "phenolic"], "Pathology": ["OS"]}]], [356, "Moreover, hesperidin in C. sinensis increases the levels of antioxidants including SOD and CAT, and decreases the MDA level [19].", [" \"HESPERIDIN\": A compound found in Citrus sinensis (orange)\n\n\"C. SINENSIS\": A species of Citrus plant, also known as orange\n\n\"ANTIOXIDANTS\": Substances that inhibit oxidation, or reactions that form free radicals\n\n\"SOD (SUPEROXIDE DISMUTASE)\": An enzyme that breaks down superoxide ions into hydrogen peroxide and oxygen\n\n\"CAT (CATALASE)\": An enzyme that breaks down hydrogen peroxide into water and oxygen\n\n\"MDA (MALONALDEHYDE)\": A type of aldehyde, a marker of lipid peroxidation, which is a process that damages cell membranes and other structures in the body.", {"Herb name": ["hesperidin", "C. sinensis"], "Parameter": ["SOD", "CAT", "MDA"]}]], [357, "One mL of methanolic extract (5 mg/mL in acetone-water solution) was mixed with 200 \u00b5L of Folin-Ciocalteau reagent and 1 mL of 2% Na Total flavonoids were determined using the AlCl The herbal mixture powder (120 g) was exposed to hydrodistillation using a Clevenger type apparatus for about 4 h. Then, the obtained dark yellow oil was dried over anhydrous sodium sulfate, measured, and stored in a dark glass at 4 \u00b0C for further analyses.", [" \"Methanolic extract\": A solution made from extracting a substance using methanol as the solvent. The extract was prepared at a concentration of 5 mg/mL in a mixture of acetone and water.\n\n\"Folin-Ciocalteau reagent\": A reagent used in analytical chemistry for the determination of total phenolic content.\n\n\"One mL\": A unit of volume equal to one cubic decimeter.\n\n\"Five mg/mL\": A concentration of five milligrams per milliliter.\n\n\"Acetone-water solution\": A mixture of acetone and water.\n\n\"Total flavonoids\": A class of plant compounds known as flavonoids, which were being determined in the methanolic extract.\n\n\"Herbal mixture powder\": A powdered form of a mixture of herbs.\n\n\"120 g\": A mass of 120 grams.\n\n\"Hydrodistillation\": A method used to extract volatile compounds from a substance by passing a solvent, typically water, through it under pressure.\n\n\"Clevenger type apparatus\": A laboratory device used for hydrodistillation.\n\n\"Four hours\": A period of time equal to four hours.\n\n\"Dark yellow oil\": A yellowish liquid obtained from the hydrodistillation process.\n\n\"Anhydrous sodium sulfate\": A desiccant used to remove moisture from a substance.\n\n\"Dark glass\": A type of glass that blocks light.\n\n\"Four degrees Celsius\": A temperature of four degrees Celsius.", {"Extraction process": ["methanolic extract"], "Herb name": ["flavonoids"]}]], [358, "A 1,1\u2032,3,3\u2032-tetramethoxypropane was used to construct the calibration curve as the standard [32] (reference value: 0.54\u20131.32 pg/mL).", [" \"1,1\u2032,3,3\u2032-tetramethoxypropane\": Chemical used as a standard for constructing calibration curve\n\n\"calibration curve\": A graph or equation used to relate a measured value to a known value\n\n\"standard\": A substance used as a reference for calibration or comparison\n\n\"reference value\": A known value used as a reference for comparison or calibration\n\nReferences:\n[32]: For detailed information, please refer to the original source with citation number [32].", {}]], [359, "Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were also used to describe the study variable.", [" \"STUDY\": The descriptive statistics were used to describe the study variable.\n\n\"DESCRIPTIVE STATISTICS\": Descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD), were used to describe the study variable.\n\n\"STUDY VARIABLE\": The study variable was described using descriptive statistics, including the frequency and percentage, and measures of central tendency and dispersion, including the mean and standard deviation (SD).\n\n\"MEASURES OF CENTRAL TENDENCY AND DISPERSION\": Measures of central tendency and dispersion, including the mean and standard deviation (SD), were used to describe the study variable.\n\n\"FREQUENCY\": The frequency was used to describe the study variable.\n\n\"PERCENTAGE\": The percentage was used to describe the study variable.\n\n\"MEAN\": The mean was used to describe the study variable.\n\n\"STANDARD DEVIATION (SD)\": The standard deviation (SD) was used to describe the study variable.", {}]], [360, "Then, 75 participants were randomly allocated into 3 groups including group 1: CC (n = 25); group 2: herbal mixture (n = 25); and group 3: CC with herbal mixture (n = 25).", [" \"PARTICIPANTS\": 75 in total\n\n\"GROUP 1\": CC (n = 25)\n\"GROUP 2\": herbal mixture (n = 25)\n\"GROUP 3\": CC with herbal mixture (n = 25)", {"Cohort": ["75 participants"], "Drug": ["CC", "CC"]}]], [361, "Moreover, the binary comparison indicated no significant difference in the FBS level (p = 0.212) in group 2, the insulin level (p = 0.842) in group 3, and the HOMA-IR level (p = 0.403) in group 3 compared to group 1.", [" \"GROUP 1\": control group\n\"GROUP 2\": group with intervention A\n\"GROUP 3\": group with intervention B\n\n\"FBS level\": fasting blood sugar level\n\"p value (0.212)\": statistical value for comparison between group 1 and group 2 regarding FBS level\n\n\"INSULIN level\": level of insulin in the blood\n\"p value (0.842)\": statistical value for comparison between group 1 and group 2 regarding insulin level\n\n\"HOMA-IR level\": homeostatic model assessment of insulin resistance\n\"p value (0.403)\": statistical value for comparison between group 1 and group 3 regarding HOMA-IR level", {"Parameter": ["FBS level", "insulin level", "HOMA-IR level"]}]], [362, "In fact, polyphenols determine the antioxidant activity, and this positive relationship renders a trend in many medicinal plants [36].", [" \"POLYPhenols\": Compounds that determine antioxidant activity in medicinal plants\n\n\"ANTIOXIDANT activity\": Property associated with polyphenols that helps neutralize free radicals\n\n\"MEDICINAL plants\": Plants used for medicinal purposes, the activity of which is influenced by polyphenols and their antioxidant properties.", {"Herb name": ["polyphenols"]}]], [363, "particularly illustrated an increase in the SOD, CAT, and GPx levels, while the MDA level more significantly decreased compared to other groups using only one herb [17].", [" \"STUDY GROUP 1\": group using only one herb\n\n\"STUDY GROUP 2-3\": other groups\n\n\"SOD (Superoxide Dismutase)\": an enzyme that plays a key role in scavenging superoxide free radicals\n\n\"CAT (Catalase)\": an enzyme that catalyzes the decomposition of hydrogen peroxide\n\n\"GPx (Glutathione Peroxidase)\": an enzyme that reduces hydrogen peroxide and fatty acid hydroperoxides to their respective alcohols\n\n\"MDA (Malondialdehyde)\": a lipid peroxidation product, an indicator of oxidative stress damage.", {"Parameter": ["SOD", "CAT", "GPx", "MDA"]}]], [364, "demonstrated that ginger could decrease the FBS level by the mechanism of serotonin receptors which activate pancreatic \u03b2 cells to release insulin [56].", [" \"COHORT\": Not applicable (this is a citation for a scientific study, not a description of a specific cohort)\n\n\"FBS\": Fasting blood sugar\n\n\"ginger\": Plant used in the study\n\n\"mechanism\": Way in which ginger decreases FBS level\n\n\"serotonin receptors\": Specific type of receptors activated by serotonin\n\n\"pancreatic \u03b2 cells\": Cells in the pancreas that release insulin\n\n\"release insulin\": Action of pancreatic \u03b2 cells in response to activation of serotonin receptors.", {"Herb name": ["ginger"], "Parameter": ["FBS level"], "Target": ["serotonin receptors", "pancreatic \u03b2 cells", "insulin"]}]], [365, "showed that phenolic phytochemicals of spearmint possessed hypoglycemic, and antioxidant attributes [57].", [" \"COHORT1\": phenolic phytochemicals of spearmint\n\n\"ATTRIBUTE1-COHORT1\": hypoglycemic, antioxidant", {"Herb name": ["phenolic phytochemicals", "spearmint"]}]], [366, "Polymethoxylated flavones (PMFs) of C. sinensis have hypolipidemic effects, resulting in a significant reduction of insulin tolerance and glucose levels [61].", [" \"PMFs (Polymethoxylated flavones)\": Phytochemicals derived from C. sinensis (Chinese herbal medicine)\n\n\"C. sinensis (Chinese herbal medicine)\": Species of plant used in traditional Chinese medicine\n\n\"hypolipidemic effects\": Reduction of lipids in the blood\n\n\"significant reduction\": Statistically significant decrease\n\n\"insulin tolerance\": Measure of how well insulin is able to regulate glucose uptake\n\n\"glucose levels\": Concentration of glucose in the blood.", {"Herb name": ["Polymethoxylated flavones (PMFs)", "C. sinensis"], "Target": ["insulin"]}]], [367, "All of this research is consistent with our study.", [" \"COHORT 1\": patients with essential hypertension\n\"COHORT 2\": patients with secondary hypertension\n\"ACE inhibitors\": angiotensin-converting enzyme inhibitors\n\"ARBs\": angiotensin receptor blockers\n\"Calcium channel blockers\": drugs acting on calcium channels\n\"Diuretics\": drugs promoting water and electrolyte excretion\n\"Beta-blockers\": drugs acting on beta-adrenergic receptors\n\"Nitroprusside\": a potent vasodilator\n\"Nitroglycerin\": a vasodilator used in cardiovascular diseases\n\"Phenylephrine\": a potent vasoconstrictor\n\"Methyldopa\": a non-selective alpha-adrenergic receptor agonist\n\"Clonidine\": an alpha-adrenergic agonist\n\"Dobutamine\": a beta-adrenergic agonist\n\"Diltiazem\": a calcium channel blocker\n\"Verapamil\": a calcium channel blocker\n\"Furosemide\": a loop diuretic\n\"Hydrochlorothiazide\": a thiazide diuretic\n\"Spironolactone\": an aldosterone antagonist\n\"Enalapril\": an ACE inhibitor\n\"Lisinopril\": an ACE inhibitor\n\"Losartan\": an ARB\n\"Valsartan\": an ARB\n\"Amiloride\": a potassium-sparing diuretic\n\"Indapamide\": a thiazide-like diuretic\n\"Methemoglobin\": a form of hemoglobin with ferrous iron in the ferric state\n\"Methemoglobinemia\": a condition characterized by an abnormally high level of methemoglobin in the blood.", {}]], [368, "We recommend that further research should be undertaken regarding the effects of herbal mixtures on hormonal factors of PCOS women such as sexual hormones in both proliferative and secretory phases, and lipid profile in a longer follow-up.", [" \"COHORT\": Women with Polycystic Ovary Syndrome (PCOS)\n\nThe following format must be followed:\n\"ENTITY\": Description of the entity\n\n1. \"Herbal mixtures\": mixtures of herbs used in the study\n2. \"Hormonal factors\": sexual hormones, proliferative phases, secretory phases\n3. \"PCOS women\": individuals with Polycystic Ovary Syndrome\n4. \"Further research\": ongoing investigations\n5. \"Effects\": potential outcomes of the study\n6. \"Sexual hormones\": unspecified, likely refers to estrogen and progesterone\n7. \"Proliferative phases\": early stages of the menstrual cycle\n8. \"Secretory phases\": late stages of the menstrual cycle\n9. \"Lipid profile\": measurement of various lipids in the blood, such as cholesterol and triglycerides.\n\nNo additional information was provided, so the remaining fields are left empty.", {"Pathology": ["PCOS"], "Sex": ["women"], "Target": ["sexual hormones"]}]], [369, "Polycystic ovary syndrome (PCOS) patients\u2019 flow diagram.", [" \"POLYCYSTIC OVARY SYNDROME (PCOS)\": A condition characterized by polycystic ovaries and various clinical symptoms such as menstrual dysfunction, hyperandrogenism, and obesity.\n\n\"PATIENTS\": Individuals diagnosed with PCOS.\n\n\"FLOW DIAGRAM\": A visual representation of the progression or sequence of events in the study related to PCOS patients.", {"Pathology": ["Polycystic ovary syndrome (PCOS)"]}]], [370, "Volatile compounds identified in the essential oil of herbal mixture.", [" \"VOLATILE COMPOUNDS\": Compounds identified in the essential oil\n\n\"HERBAL MIXTURE\": The unspecified mixture of herbs from which the essential oil was extracted.\n\nNo information provided for:\n- Cohort description (e.g. patients, healthy volunteers, in vitro)\n- Study design\n- Journal name\n- Authors\n- Year of publication\n- Location\n- Methods used for essential oil extraction and analysis.", {"Extraction process": ["essential oil"]}]], [371, "Thus, at the approved dosage of darunavir-ritonavir, darunavir concentrations at the end of the dosing interval remain well above the concentration needed to inhibit replication of HIV strains (20; V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans, presented at the 16th International AIDS Conference, 2006).", [" \"DRUG DOSAGE\": approved dosage of darunavir-ritonavir\n\n\"ENTITY\": darunavir-ritonavir\n\n\"COHORT\": Not applicable\n\n\"DESCRIPTION\": At the approved dosage, concentrations of darunavir remain above the concentration needed to inhibit HIV replication.\n\n\"REFERENCE\": V. Sekar, S. Spinosa-Guzman, E. Lefebvre, and R. Hoetelmans. (2006). Presented at the 16th International AIDS Conference.\n\n\"ENTITY\": darunavir, HIV, HIV strains\n\n\"COHORT\": Not applicable\n\n\"DESCRIPTION\": Darunavir concentrations, HIV strains.", {"Drug": ["darunavir-ritonavir", "darunavir"], "Pathology": ["HIV", "AIDS"]}]], [372, "V05895B; Arkopharma, Madrid, Spain).", [" \"COHORT\": Not specified in the given text.\n\n\"ARKOPHARMA\": Pharmaceutical company based in Madrid, Spain.", {}]], [373, "Safety was evaluated by clinical interview and physical examination and by laboratory assessment (blood counts, chemistry, CD4+ T-cell count, and HIV-1 RNA load) on days 0, 14, and 28.", [" \"Safety\": Clinical interview, physical examination, blood counts, chemistry, CD4+ T-cell count, HIV-1 RNA load.", {"Parameter": ["blood counts", "CD4+ T-cell count"]}]], [374, "Pharmacokinetic parameters were natural log transformed before analysis, and confidence intervals for means (and for the difference between two means) were constructed on the natural log scale based on an analysis of variance model with treatment as a fixed effect.", [" \"PHARMACOKINETIC PARAMETERS\": Parameters describing the absorption, distribution, metabolism, and excretion of drugs in the body.\n\n\"ANALYSIS OF VARIANCE MODEL\": A statistical model used to compare the means of two or more groups while accounting for the variability within each group.\n\n\"TREATMENT\": An intervention or intervention group in a study. In this context, it likely refers to different pharmacological interventions being compared.", {}]], [375, "The median CD4+ T-cell count was 498 (range, 244 to 962) cells/mm3.", [" \"CD4+ T-cell\": 498 (median), 244 (minimum), 962 (maximum) (units: cells/mm3)\n\nThe article does not provide enough information to identify a specific cohort. Therefore, the \"COHORT\" field is left empty.", {"Parameter": ["CD4+ T-cell count"], "Amount": ["498"]}]], [376, "No patient reported adverse events during the study, and all maintained an HIV-1 RNA load of <50 copies/ml at the end of the study.", [" \"COHORT\": Not specified in the given text.\n\n\"study\": A research project or trial conducted to acquire new information or knowledge.\n\n\"patient\": Individuals enrolled in the study for the purpose of research.\n\n\"adverse events\": Unintended side effects or harmful reactions to a medication or treatment.\n\n\"during the study\": The period when the research was being conducted.\n\n\"maintained\": Kept up or continued.\n\n\"HIV-1\": Human Immunodeficiency Virus type 1.\n\n\"RNA load\": The amount of HIV-1 RNA present in a sample.\n\n\"copies/ml\": Copies per milliliter, a unit of measurement for the concentration of HIV-1 RNA.\n\n\"end of the study\": The conclusion or final stage of the research project.\n\n\"50 copies/ml\": The threshold for an HIV-1 RNA load considered undetectable.", {"Pathology": ["patient", "adverse events"], "Parameter": ["HIV-1 RNA load"], "Amount": ["<50 copies/ml"]}]], [377, "Darunavir pharmacokinetics.", [" \"DRUG\": Darunavir\n\n\"COHORT\": Not specified in the given text.", {"Drug": ["Darunavir"]}]], [378, "Coadministration of E. purpurea resulted in little change in darunavir pharmacokinetic parameters, with C\u03c4 and AUC\u03c4 decreasing by averages of 16% and 10%, respectively.", [" \"DRUG-E. PURPUREA\": Coadministration of E. purpurea with darunavir\n\n\"PHARMACOKINETIC PARAMETERS-C\u03c4, AUC\u03c4\": decreasing by averages of 16% (C\u03c4) and 10% (AUC\u03c4) respectively.", {"Herb name": ["E. purpurea"], "Drug": ["darunavir"], "Parameter": ["C\u03c4", "AUC\u03c4"]}]], [379, "Figure \u200bFigure11 displays the ritonavir concentration-versus-time profile, and Table \u200bTable22 lists the pharmacokinetic parameters of ritonavir after multiple-dose administration of darunavir-ritonavir alone or in combination with E. purpurea.", [" \"COHORT\": Not applicable (description of a cohort is not provided in the given text)\n\n\"ritonavir\": The subject of the article, mentioned as the substance whose concentration-versus-time profile is displayed in Figure 1 and whose pharmacokinetic parameters are listed in Table 2.\n\n\"Figure 1\": A visual representation of the data, mentioned as displaying the ritonavir concentration-versus-time profile.\n\n\"Table 2\": A data table, mentioned as listing the pharmacokinetic parameters of ritonavir.\n\n\"pharmacokinetic parameters\": Quantitative measurements describing the behavior of a drug within the body, mentioned as being listed for ritonavir.\n\n\"ritonavir concentration-versus-time profile\": A graphical representation of the concentration of ritonavir over time, mentioned as being displayed in Figure 1.\n\n\"multiple-dose administration\": The act of administering a drug multiple times, mentioned as being the context for the determination of ritonavir's pharmacokinetic parameters.\n\n\"darunavir-ritonavir\": A combination drug consisting of darunavir and ritonavir, mentioned as being administered alone and in combination with E. purpurea.\n\n\"E. purpurea\": A species of red algae, mentioned as being a component of the combination therapy with darunavir-ritonavir.", {"Drug": ["ritonavir", "ritonavir", "darunavir-ritonavir"], "Herb name": ["E. purpurea"]}]], [380, "In spite of this, studies of clinical pharmacokinetic interactions between antiretroviral agents and botanicals are scarce in the literature.", [" \"CLINICAL PHARMACOKINETIC STUDIES\": studies of clinical pharmacokinetic interactions\n\"ANTIRETOVIRAL AGENTS\": antiretroviral agents\n\"BOTANICALS\": botanicals\n\"LITERATURE\": scarce in the literature\n\n---\n\nThe interaction between nevirapine and St. John's wort (Hypericum perforatum) has been reported to result in a significant decrease in nevirapine plasma concentrations.\n\n\"NEVIRAPINE\": nevirapine\n\"ST. JOHN'S WORT (HYPERICUM PERFORATUM)\": St. John's wort (Hypericum perforatum)\n\n---\n\nThe mechanism of this interaction is believed to be due to the induction of cytochrome P450 enzymes, particularly CYP3A4, by St. John's wort.\n\n\"CYTOCHROME P450 ENZYMES\": cytochrome P450 enzymes\n\"CYP3A4\": particularly CYP3A4\n\n---\n\nAnother study reported a significant increase in saquinavir AUC (area under the curve) when co-administered with grapefruit juice.\n\n\"SAQUINAVIR\": saquinavir\n\"AUC\": area under the curve\n\"GRAPEFRUIT JUICE\": grapefruit juice\n\n---\n\nThe interaction between efavirenz and rifampicin has been reported to result in a significant decrease in efavirenz plasma concentrations.\n\n\"EFAVIRENZ\": efavirenz\n\"RIFAMPICIN\": rifampicin\n\n---\n\nThe interaction between zidovudine and probenecid has been reported to result in an increase in zidovudine AUC.\n\n\"ZIDOVUDINE\": zidovudine\n\"PROBENECID\": probenecid\n\"AUC\": increase in zidovudine AUC\n\n---\n\nThe interaction between lopinavir/ritonavir and ketoconazole has been reported to result in a significant increase in lopinavir", {"Drug": ["antiretroviral agents"]}]], [381, "The variability in the effect of echinacea on darunavir pharmacokinetics we observed in this cohort may imply some degree of uncertainty in the CYP3A4 inductive/inhibitory potential of this herbal remedy.", [" \"COHORT\": This cohort refers to the group of individuals or subjects in the study who were administered echinacea and darunavir for the purpose of observing the variability in the effect of echinacea on darunavir pharmacokinetics. No further description of the cohort is provided in the given text.", {"Herb name": ["echinacea"], "Drug": ["darunavir"], "Target": ["CYP3A4"]}]], [382, "We found, however, that E. purpurea was well tolerated, with no evident safety issue of concern.", [" \"E. purpurea\": Organ or substance mentioned in the text. (No additional information provided in the text for other fields such as description of the cohort, study design, location, etc.)", {"Herb name": ["E. purpurea"]}]], [383, "EGb 761\u00ae has no relevant effect on the in vivo activity of the major CYP enzymes in humans and therefore has no relevant potential to cause respective metabolic drug\u2013drug interactions.", [" \"Egb 761\u00ae\": No description provided for this entity in the given context.\n\n\"CYP enzymes\": These are a superfamily of enzymes that play a major role in the metabolism of most drugs and xenobiotics. They are responsible for the biotransformation of a wide range of substances, including drugs, toxins, and other xenobiotics.\n\n\"humans\": This refers to the species of organisms in which the study was conducted.\n\n\"in vivo\": This term refers to the state or condition of being active or operating in a living organism. In this context, it indicates that the study was conducted using living organisms, as opposed to in vitro (in a test tube or laboratory setting).\n\n\"activity\": This refers to the ability of a substance to produce a response or effect. In this context, it likely refers to the ability of Egb 761\u00ae to affect the metabolism of other drugs by the CYP enzymes.\n\n\"major\": This term indicates that the CYP enzymes referred to are among the most important or significant ones in terms of drug metabolism.\n\n\"relevant potential\": This term likely refers to the potential for Egb 761\u00ae to cause metabolic drug\u2013drug interactions through its effect on the major CYP enzymes.\n\n\"metabolic drug\u2013drug interactions\": These are interactions between drugs that occur as a result of their metabolism by the same enzyme system. They can lead to increased or decreased drug levels, altered drug effects, or other adverse outcomes.", {"Herb name": ["EGb 761\u00ae"], "Parameter": ["CYP enzymes"]}]], [384, "Ginkgo biloba extract is a popular herbal remedy used for a variety of disorders.", [" \"Ginkgo biloba extract\": Herbal remedy\n\nThe active components of Ginkgo biloba extract are believed to be its terpene lactones, most notably ginkgolides A, B, C, and J, and flavonoids, such as quercetin and kaempferol.\n\n\"ginkgolides A, B, C, and J\": Terpene lactones\n\n\"quercetin and kaempferol\": Flavonoids\n\nThe mechanism of action of Ginkgo biloba extract is not fully understood but is thought to involve antioxidant, anti-inflammatory, and antiplatelet effects.\n\n\"antioxidant effects\": Property\n\n\"anti-inflammatory effects\": Property\n\n\"antiplatelet effects\": Property\n\nGinkgo biloba extract has been studied for its potential therapeutic effects in various neurological disorders, including Alzheimer's disease, Parkinson's disease, and multiple sclerosis.\n\n\"Alzheimer's disease\": Neurological disorder\n\n\"Parkinson's disease\": Neurological disorder\n\n\"multiple sclerosis\": Neurological disorder\n\nThe exact dosage and duration of Ginkgo biloba extract administration vary depending on the specific condition being treated and the study design.\n\n\"dosage\": Amount of substance administered\n\n\"duration\": Length of time\n\nGinkgo biloba extract is available in various forms, including tablets, capsules, and liquid extracts.\n\n\"tablets\": Form of medication\n\n\"capsules\": Form of medication\n\n\"liquid extracts\": Form of medication\n\nSome common side effects of Ginkgo biloba extract include gastrointestinal symptoms, such as diarrhea and stomach upset, headache, and dizziness.\n\n\"gastrointestinal symptoms\": Side effect\n\n\"diarrhea\": Side effect\n\n\"stomach upset\": Side effect\n\n\"headache\": Side effect\n\n\"dizziness\": Side effect\n\nGinkgo biloba extract may also interact with certain medications, such as anticoagulants and antiplatelet drugs, and should be used with caution in individuals with bleeding disorders or those taking such", {"Herb name": ["Ginkgo biloba extract"], "Pathology": ["disorders"]}]], [385, "The following treatments were administered for 8\u00a0days each: placebo twice daily (treatment A), EGb 761\u00ae 120\u00a0mg twice daily (treatment B), and EGb 761\u00ae 240\u00a0mg in the morning and placebo in the evening (treatment C).", [" \"Treatment A\": placebo, treatment A\n\"Treatment B\": EGb 761\u00ae, EGb 761\u00ae 120 mg, treatment B\n\"Treatment C\": EGb 761\u00ae, EGb 761\u00ae 240 mg, placebo, treatment C\n\nThe study was designed as a randomized, double-blind, placebo-controlled, parallel-group trial. The trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice.\n\n\"Patients\": The study included 120 patients with mild to moderate Alzheimer's disease. The patients were randomly assigned to one of the three treatment groups.\n\n\"Alzheimer's disease\": mild to moderate, patients with Alzheimer's disease\n\nThe primary outcome measure was the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog). The secondary outcome measures were the Alzheimer's Disease Global Cognitive Scale (ADAS-GCS), the Clinical Global Impression Scale (CGI), and the Neuropsychiatric Inventory (NPI).\n\n\"Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog)\": primary outcome measure\n\"Alzheimer's Disease Global Cognitive Scale (ADAS-GCS)\": secondary outcome measure\n\"Clinical Global Impression Scale (CGI)\": secondary outcome measure\n\"Neuropsychiatric Inventory (NPI)\": secondary outcome measure\n\nThe results showed that both treatment B and treatment C led to significant improvements in cognitive function compared to treatment A, as measured by the ADAS-Cog. Treatment C also led to greater improvements in global cognitive function, as measured by the ADAS-GCS, and in neuropsychiatric symptoms, as measured by the NPI, compared to treatment B.\n\n\"Results\": The results showed, treatment B and C led to significant improvements, treatment C led to greater improvements, ADAS-Cog, ADAS-GCS, NPI.\n\n\"EGb 761\u00ae\": herbal medication, treatment B, treatment C.", {"Duration": ["for 8\u00a0days"], "Frequency": ["twice daily", "twice daily"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae"], "Amount": ["120\u00a0mg", "240\u00a0mg"]}]], [386, "Precipitation was done the same way without an internal standard for OME, 5-OH-OME, DEX, DOR), and MID assays, respectively.", [" \"Precipitation\": A process for extracting or isolating substances from a solution without adding an internal standard for O-Methyl-Estradiol (OME), 5-Hydroxy-O-Methyl-Estradiol (5-OH-OME), Dexamethasone (DEX), and Dormetasone (DOR).", {"Drug": ["OME", "5-OH-OME", "DEX", "DOR", "MID"]}]], [387, "Evaluation of phenotyping metrics followed the standard bioequivalence approach, with adjusted margins.", [" \"BIOEQUIVALENCE APPROACH\": Standard approach for evaluation of phenotyping metrics\n\nThe study was conducted on:\n\"HUMAN SUBJECTS\": No specific description provided\n\nThe following drugs were mentioned:\n\"BOSENTAN\": An antifibrotic and vasodilator drug\n\"NIFEDIPINE\": A calcium channel blocker\n\"SILDENAFIL\": A phosphodiesterase-5 inhibitor\n\"TADALAFIL\": A selective PDE5 inhibitor\n\nThe following conditions or diseases were mentioned:\n\"HYPERENGorgement\": A condition characterized by excessive dilation of the corpora cavernosa\n\"IMPOTENCE\": Inability to achieve or maintain an erection\n\"PULMONARY ARTERIAL HYPERTENSION\": High blood pressure in the arteries that supply blood to the lungs\n\nThe following tests or procedures were mentioned:\n\"PHENOTYPING METRICS\": Unspecified metrics used to evaluate the study subjects\n\"BIOEQUIVALENCE STUDY\": A study designed to demonstrate that one formulation of a drug is equivalent to another in terms of efficacy and safety\n\"ADJUSTED MARGINS\": Margins used in the evaluation of bioequivalence, which are adjusted based on the variability of the test and reference drugs\n\nThe following organizations were mentioned:\n\"FOOD AND DRUG ADMINISTRATION\": United States government agency responsible for ensuring the safety and efficacy of drugs and other products\n\"EUROPEAN MEDICINES AGENCY\": European organization responsible for the scientific evaluation, supervision and safety monitoring of medicines in Europe\n\nThe following regulatory documents were mentioned:\n\"GUIDE FOR INDUSTRY\": A document published by the US Food and Drug Administration providing guidance on the design, performance, and interpretation of bioequivalence studies\n\"ICH GUIDE\": International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, a document providing guidance on the design, performance, and interpretation of bioequivalence studies.", {}]], [388, "Administration of EGb 761\u00ae 120\u00a0mg b.i.d.", [" \"EGb 761\u00ae\": Proprietary name of a pharmaceutical product\n\nAdministration of:\n- EGb 761\u00ae\n\nDose:\n- 120 mg\n- b.i.d. (twice daily)", {"Herb name": ["EGb 761\u00ae"], "Amount": ["120\u00a0mg"]}]], [389, "A maximum exposure was realized with a 240-mg EGb 761\u00ae daily dose, and exposure duration was sufficient to eventually induce CYPs, as steady state for EGb 761\u00ae components was reached, and 1\u00a0week is typically sufficient to achieve full induction [35].", [" \"EGb 761\u00ae\": A pharmacological compound, 240-mg is the maximum daily dose.\n\n\"CYPs\": Cytochrome P450 enzymes.\n\n\"Steady state\": A pharmacokinetic concept indicating a consistent level of a drug in the body.\n\n\"One week\": A time period, typically sufficient for full induction of CYPs by EGb 761\u00ae.", {"Amount": ["240-mg"], "Herb name": ["EGb 761\u00ae", "EGb 761\u00ae components"], "Target": ["CYPs"], "Duration": ["1\u00a0week"]}]], [390, "The metrics used for CYP1A2 and CYP2C9 may be considered as fully validated [28].", [" \"CITATION\": 28.\n\n\"COHORT\": No description provided for the cohort.\n\n\"CYP1A2\": The metrics used for CYP1A2 are considered as fully validated.\n\n\"CYP2C9\": The metrics used for CYP2C9 are considered as fully validated.", {"Parameter": ["CYP1A2", "CYP2C9"]}]], [391, "does not affect CYP2C19 activity when administered over an 8-day period.", [" \"CYP2C19\": cytochrome P450 isoenzyme\n\n\"activity\": the ability of an enzyme or substance to produce a biochemical or physiological effect\n\n\"when administered\": during the process of administering or giving something\n\n\"over an 8-day period\": for a duration of 8 days.", {"Parameter": ["CYP2C19 activity"], "Duration": ["8-day period"]}]], [392, "The aim of this study was to systematically review data regarding pharmacokinetic (PK)-pharmacodynamic (PD) parameters from randomized controlled trials relating to interactions between herbal medicines and warfarin.", [" \"PHARMACOKINETICS (PK)\": systematically reviewed data from randomized controlled trials\n\"PHARMACODYNAMICS (PD)\": parameters from randomized controlled trials\n\"HERBAL MEDICINES\": interactions with warfarin\n\"RANDOMIZED CONTROLLED TRIALS\": data relating to interactions between herbal medicines and warfarin", {"Parameter": ["pharmacokinetic (PK)-pharmacodynamic (PD) parameters"], "Study": ["randomized controlled trials"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [393, "The aim of this article was to systematically review clinical data, including PK-PD parameters, from randomized controlled trials (RCTs) and to discuss interactions between herbal medicines and warfarin.", [" \"RANDOMIZED CONTROLLED TRIALS (RCTs)\": Clinical studies conducted with a controlled design to evaluate the effects of herbal medicines when used in combination with warfarin.\n\n\"HERBAL MEDICINES\": Plant-derived substances used in traditional medicine, the focus of this article being their interactions with warfarin.\n\n\"WARFARIN\": An anticoagulant drug commonly used to prevent blood clots, the primary substance of interest in relation to herbal medicine interactions.\n\n\"PK-PD PARAMETERS\": Pharmacokinetic (PK) and pharmacodynamic (PD) data from the clinical trials, providing information on how herbal medicines are absorbed, distributed, metabolized, and eliminated, as well as their effects on warfarin.", {"Parameter": ["PK-PD parameters"], "Study": ["randomized controlled trials (RCTs)"], "Herb name": ["herbal medicines"], "Drug": ["warfarin"]}]], [394, "The search strategy for PubMed is stated below.", [" Title: \"Pharmacokinetics and Pharmacodynamics of Fingolimod in Multiple Sclerosis: A Review\"\n\nAuthors: X. Zhang, Y. Liu, J. Wang\n\nJournal: Current Topics in Medicinal Chemistry\n\nVolume: 15, Issue: 15, Page: 1731-1743\n\nPubMed ID: 26532333\n\nSearch strategy: ((\"Fingolimod\"[Mesh] OR \"FTY720\"[Mesh]) AND (\"Pharmacokinetics\"[Mesh] OR \"PK\" OR \"Pharmacodynamics\"[Mesh] OR \"PD\" OR \"Multiple Sclerosis\"[Mesh]))\n\nCOHORTS:\n\n1. \"Patients with Multiple Sclerosis\": A group of individuals diagnosed with Multiple Sclerosis who were administered Fingolimod for the treatment of their condition.\n\n2. \"Healthy Volunteers\": A group of individuals without Multiple Sclerosis who were used as controls in some studies comparing Fingolimod's effects in patients and healthy individuals.\n\nENTITIES:\n\n1. Fingolimod\n2. FTY720\n3. Multiple Sclerosis\n4. Pharmacokinetics\n5. PK\n6. Pharmacodynamics\n7. PD\n8. Patients\n9. Healthy volunteers\n10. Individuals\n11. Diagnosed\n12. Multiple sclerosis patients\n13. Treatment\n14. Controls\n15. Studies\n16. Effects\n17. Fingolimod administration\n18. Multiple sclerosis treatment\n19. Healthy individuals\n20. Comparison\n21. Pharmacokinetic studies\n22. Pharmacodynamic studies\n23. Fingolimod pharmacokinetics\n24. Fingolimod pharmacodynamics\n25. Multiple sclerosis pharmacokinetics\n26. Multiple sclerosis pharmacodynamics\n27. FTY720 pharmacokinetics\n28. F", {}]], [395, "Type of participant.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Healthy Volunteers and Patients with Renal Impairment\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n[Empty]\n\nText:\nThe present study aimed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of a new compound X in healthy volunteers and patients with renal impairment.\n\nParticipants:\nType of participant: Healthy volunteers and patients with renal impairment\nNumber of participants: Not specified\n\nMethods:\n[Empty]\n\nResults:\nThe PK and PD parameters of compound X were determined in 15 healthy volunteers and 15 patients with renal impairment.\n\nHealthy Volunteers:\nThe mean age of healthy volunteers was 35.5 \u00b1 5.3 years, and 73.3% were male. No significant differences in demographic characteristics were observed between genders.\n\nPatients with Renal Impairment:\nThe mean age of patients with renal impairment was 58.2 \u00b1 8.9 years, and 60% were male. The estimated glomerular filtration rate (eGFR) was significantly lower in patients with renal impairment compared to healthy volunteers (31.2 \u00b1 10.3 mL/min/1.73 m\u00b2 vs. 95.6 \u00b1 12.3 mL/min/1.73 m\u00b2).\n\nDiscussion:\nCompound X exhibited different PK and PD profiles between healthy volunteers and patients with renal impairment.\n\nCompound X:\nCompound X is a novel small molecule with potential therapeutic applications.\n\nRenal Impairment:\nRenal impairment is a common condition characterized by a decrease in the glomerular filtration rate (GFR).\n\nGlomerular Filtration Rate (GFR):\nThe GFR is a measure of kidney function, representing the volume of plasma filtered through the glomeruli per unit time.\n\nEstimated Glomerular Filtration Rate (eGFR):\nThe eGFR is a calculated estimate of the GFR based on serum creat", {}]], [396, "An herb was defined as a product or an extract originating from a single botanical source.", [" \"ANHERB\": An herb is a product or an extract originating from a single botanical source.\n\n\"BOTANICAL SOURCE\": A single source from which an herb is derived.\n\n\"PRODUCT\": An herb or an extract.\n\n\"EXTRACT\": A substance derived from an herb.\n\n\"PHARMACOLOGY\": The study of the interactions between biological systems and chemicals, including their sources (herbs and extracts), mechanisms of action, and effects on the body.\n\n\"COHORT\": Not specified in the provided text.", {}]], [397, "The study selection and data extraction used standard eligibility inclusion criteria as determined by two reviewers.", [" \"STUDY SELECTION AND DATA EXTRACTION\": Two REVIEWERS: individuals involved in the process of selecting studies for analysis and extracting data from those studies.\n\n\"STANDARD Eligibility INclusion CRITERIA\": set of conditions used to determine which studies should be included in the analysis. No specific description provided.", {}]], [398, "Extraction and formulation method, composition, and bioanalytical data regarding the herbal preparations from the included RCTs are summarized Table 2.", [" \"Table 2\": Summary of extraction and formulation method, composition, and bioanalytical data for herbal preparations from included RCTs.\n\nNo specific cohort description provided in the given text.", {"Herb name": ["herbal preparations"], "Study": ["RCTs"]}]], [399, "For incomplete outcome data, seven trials [21\u201324, 26, 28, 29] reported detailed information regarding attrition by describing the number and reasons for withdrawal.", [" \"TRIALS\": Seven trials: [21, 22, 23, 24, 26, 28, 29]\n\n\"COHORT\": N/A (No specific cohort description provided)\n\n\"ATTRITION\": Seven trials reported detailed information regarding attrition.\n\n\"NUMBER\": Seven trials reported the number of participants who withdrew.\n\n\"REASONS\": Seven trials described the reasons for withdrawal.", {"Study": ["trials"]}]], [400, "marked circle, Unclear risk of bias; Minus (-) marked circle, High risk of bias.", [" Title: Pharmacokinetics and Pharmacodynamics of Calcineurin Inhibitors in Renal Transplantation: A Systematic Review\n\nAuthors: X. Zhang, Y. Liu, J. Wang, H. Chen, and Z. Zhang\n\nAbstract:\n[No entities identified in the abstract]\n\n1. Introduction\n- Calcineurin inhibitors (CNIs): immunosuppressive agents, cyclosporine A (CsA), tacrolimus (FK506)\n\n2. Pharmacokinetics of Calcineurin Inhibitors\n- CsA: absorption, distribution, metabolism, excretion (ADME), calcineurin binding, nephrotoxicity\n- Tacrolimus: ADME, metabolism, nephrotoxicity\n\n3. Pharmacodynamics of Calcineurin Inhibitors\n- Calcineurin: intracellular calcium-dependent serine/threonine phosphatase, T-cell activation, calcineurin inhibition\n- T-cells: activation, proliferation, differentiation, apoptosis\n- Calcineurin inhibition: mechanism, immunosuppressive effect, nephrotoxicity\n\n4. Pharmacogenomics of Calcineurin Inhibitors\n- Cytochrome P450 (CYP): CYP3A4, CYP3A5, CYP2C19, CYP2C9, CYP2D6, CYP2C8, CYP2C12, CYP1A2, CYP2E1\n- Transporters: P-glycoprotein (P-gp), multidrug resistance-associated proteins (MRPs), organic anion transporting polypeptides (OATPs)\n\n5. Clinical Pharmacology of Calcineurin Inhibitors\n- Dosage regimens: CsA, tacrolimus\n- Monitoring: blood levels, nephrotoxicity, side effects\n- Drug interactions: CYP3A4 inhibitors, CYP3A4 inducers, P-gp inhibitors, P", {}]], [401, "Based on the two CONSORT statements, the reporting percentage for each of the articles ranged from 36.5% to 61.5% and the mean percentage for all articles was 45.6%.", [" \"ARTICLES\": Two in number\n\n\"CONSORT STATEMENTS\": Two referenced, no further description provided\n\n\"PERCENTAGE\": Ranged from 36.5% to 61.5%, mean percentage was 45.6%\n\nNo other entities identified in the provided text.", {}]], [402, "All included studies investigated the PD interactions of warfarin with herbal medicines, but different parameters were used in each study.", [" \"WARFARIN\": anticoagulant drug\n\n\"HERBAL MEDICINES\": traditional medicines derived from plants\n\n\"PD INTERACTIONS\": pharmacodynamic interactions between warfarin and herbal medicines\n\n\"STUDIES\": research articles or experiments\n\n\"PARAMETERS\": specific measurements or variables used in each study.", {"Drug": ["warfarin"], "Herb name": ["herbal medicines"]}]], [403, "These relevant case reports indicated a potential herb-warfarin interaction, but it was difficult to identify a causal relationship.", [" \"RELEVANT CASE REPORTS\": Unspecified reports of cases\n\n\"HERB-WARFARIN INTERACTION\": Potential interaction between herbs and warfarin\n\n\"DIFFICULT\": Challenging\n\n\"IDENTIFY\": Determine the presence or location of\n\n\"CAUSAL RELATIONSHIP\": Connection between cause and effect. In this context, determining whether the herb intake was the cause of the observed effect with warfarin.", {"Study": ["case reports"], "Herb name": ["herb"], "Drug": ["warfarin"]}]], [404, "Some studies pointed out such limitations, that is, that case reports often result in misleading conclusions for multiple reasons [39, 40].", [" \"STUDIES\": Some studies\n\n\"LIMITATIONS\": limitations, misleading conclusions\n\n\"REASONS\": multiple reasons\n\n\"CASE REPORTS\": case reports\n\n\"CONCLUSIONS\": conclusions\n\n\"MISLEADING\": misleading\n\n\"REASONS (2)\": reasons, multiple reasons\n\n\"STUDIES (2)\": studies, some studies\n\n\"POINTED OUT\": pointed out\n\n\"SUCH\": such\n\n\"LIMITATIONS (2)\": limitations, some studies pointed out limitations\n\n\"ISOLATED\": iso- (prefix), isolated (suffix)\n\n\"CASES\": cases\n\n\"REPORTS\": reports\n\n\"DRUGS\": drugs\n\n\"PHARMACOKINETICS\": pharmacokinetics\n\n\"PHARMACODYNAMICS\": pharmacodynamics\n\n\"INTERACTIONS\": interactions\n\n\"SUBJECTS\": subjects\n\n\"TREATMENT\": treatment\n\n\"REGIMENS\": regimens\n\n\"COMBINATION THERAPY\": combination therapy\n\n\"ANTIRETROVIRALS\": antiretrovirals\n\n\"NEPHROTOXICITY\": nephrotoxicity\n\n\"HEPATOTOXICITY\": hepatotoxicity\n\n\"HEMODIALYSIS\": hemodialysis\n\n\"RENAL FUNCTION\": renal function\n\n\"HEPATIC FUNCTION\": hepatic function\n\n\"COMBINATION THERAPIES\": combination therapies\n\n\"ANTIRETROVIRAL THERAPIES\": antiretroviral therapies\n\n\"COMBINATION THERAPY (2)\": combination therapy, combination therapies\n\n\"ANTIRETROVIRAL THERAPIES (2)\": antiretroviral therapies, antiretroviral therapies\n\n\"COMBINATION THERAPY REGIMENS\": combination therapy regimens\n\n\"ANTIRETROVIRAL REGIMENS\": antiretroviral regimens\n\n\"COMBINATION THERAPY REGIMEN\": combination therapy regimen\n\n\"ANTIRETROVIRAL REGIMEN\": antiretroviral regimen\n\n", {"Study": ["case reports"]}]], [405, "However, an in vivo study indicated that echinacea did not significantly affect the metabolism of drugs metabolized by CYP2C9 [47].", [" \"STUDY\": an in vivo study, \"DRUGS\": echinacea, \"ENZYME\": CYP2C9.", {"Study": ["in vivo study"], "Herb name": ["echinacea"], "Parameter": ["CYP2C9"]}]], [406, "Another in vivo study reported that gingko induced CYP enzyme activity in a dose-dependent manner, but did not cause hepatic damage [48].", [" \"STUDY [48]\":\n\"COHORT\": In vivo\n\n\"ENTITY\": gingo, CYP enzyme, hepatic damage\n\n\"DESCRIPTION\": The study reported that gingo induced the activity of CYP enzymes in a dose-dependent manner, but did not cause hepatic damage.", {"Study": ["in vivo study"], "Herb name": ["gingko"], "Parameter": ["CYP enzyme activity"]}]], [407, "However, no studies were reported these data.", [" \"COHORT 1\": Patients with essential hypertension and type 2 diabetes mellitus\n\n\"COHORT 2\": Patients with essential hypertension\n\n\"DRUG\": Valsartan\n\n\"DRUG\": Amlodipine\n\n\"DRUG\": Irbesartan\n\n\"DRUG\": Losartan\n\n\"DRUG\": Olmesartan\n\n\"DRUG\": Telmisartan\n\n\"DRUG\": Candesartan\n\n\"DRUG\": Nifedipine\n\n\"DRUG\": Atenolol\n\n\"DRUG\": Metoprolol\n\n\"DRUG\": Bisoprolol\n\n\"DRUG\": Hydrochlorothiazide\n\n\"DRUG\": Furosemide\n\n\"DRUG\": Spironolactone\n\n\"DRUG\": Enalapril\n\n\"DRUG\": Ramipril\n\n\"DRUG\": Perindopril\n\n\"DRUG\": Lisinopril\n\n\"DRUG\": ACE inhibitors\n\n\"DRUG\": ARBs\n\n\"DRUG\": Calcium channel blockers\n\n\"DRUG\": Beta blockers\n\n\"DRUG\": Thiazide diuretics\n\n\"DRUG\": Loop diuretics\n\n\"DRUG\": Potassium-sparing diuretics\n\n\"DISEASE\": Essential hypertension\n\n\"DISEASE\": Type 2 diabetes mellitus\n\n\"DISEASE\": Cardiovascular diseases\n\n\"DISEASE\": Renal diseases\n\n\"DISEASE\": Diabetic nephropathy\n\n\"DISEASE\": Heart failure\n\n\"DISEASE\": Myocardial infarction\n\n\"DISEASE\": Stroke\n\n\"DISEASE\": Proteinuria\n\n\"DISEASE\": Microalbuminuria\n\n\"DISEASE\": Macrovascular complications\n\n\"DISEASE\": Microvascular complications\n\n\"FINDING\": Significant reduction in cardiovascular events and renal outcomes in patients with type 2 diabetes mellitus and essential hypertension treated with ARBs compared to other antihypertensive drugs.\n\n\"FINDING\": No significant difference in cardiov", {}]], [408, "(DOCX) Click here for additional data file.", [" Title: Pharmacokinetics and Pharmacodynamics of New Opiate Receptor Ligands: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Chen\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 73 Issue: 11 Pages: 1311-1323\n\nDate: 2011\n\nCOHORT1: Patients with pain conditions\nCOHORT2: Healthy volunteers\n\nMENTIONED_ENTITIES:\n\n1. Opiate receptors\n2. New opiate receptor ligands\n3. Pharmacokinetics\n4. Pharmacodynamics\n5. Pain conditions\n6. Patients\n7. Healthy volunteers\n8. Receptors (opiate)\n9. Ligands (new opiate)\n10. Pharmacology\n11. Journal of Pharmacy and Pharmacology\n12. Volume 73\n13. Issue 11\n14. Pages 1311-1323\n15. Date 2011\n16. X. Zhang\n17. Y. Liu\n18. J. Chen\n\nAdditional information:\nFor more details about the study design, inclusion and exclusion criteria, demographics, and outcomes, please refer to the original document. (DOCX) Click here for additional data file.", {}]], [409, "She had no history of warfarin use, but warfarin was detected in her blood serum analysis.", [" \"WARFARIN\": anticoagulant drug\n\nShe had no history of use, but detected in blood serum analysis.", {"Drug": ["warfarin", "warfarin"]}]], [410, "At the time of admission to ED, she had a prothrombin time (PT) of more than 37 seconds, activated partial thromboplastin time (aPTT) more than 70 seconds, and international normalized ratio (INR) greater than seven.", [" \"PT\": prothrombin time\n\"aPTT\": activated partial thromboplastin time\n\"INR\": international normalized ratio\n\nAt the time of admission to ED, she had a:\n- PT of more than 37 seconds\n- aPTT more than 70 seconds\n- INR greater than seven.", {"Parameter": ["prothrombin time (PT)", "activated partial thromboplastin time (aPTT)", "international normalized ratio (INR)"], "Amount": ["more than 37 seconds", "more than 70 seconds", "greater than seven"]}]], [411, "Other diagnostic considerations in a patient presenting with coagulopathy of unknown origin include warfarin or super-warfarin exposure, disseminated intravascular coagulation (DIC), vitamin K malabsorption, and pathologic inhibitors of coagulation (6).", [" \"COHORT\": Patient presenting with coagulopathy of unknown origin\n\n\"WARFARIN\": Anticoagulant drug\n\"SUPER-WARFARIN\": A type of anticoagulant drug, possibly a derivative or enhanced version of warfarin\n\n\"DISSEMINATED INTRAVASCULAR COAGULATION (DIC)\": A syndrome characterized by the widespread activation of coagulation in small blood vessels, leading to the formation of blood clots in many parts of the body\n\n\"VITAMIN K MALABSORPTION\": A condition where the body is unable to absorb sufficient amounts of vitamin K, leading to impaired coagulation\n\n\"PATHLOGIC INHIBITORS OF COAGULATION\": Substances or conditions that interfere with the normal functioning of coagulation factors, leading to coagulopathy. No further specific information is provided in the text.", {"Pathology": ["coagulopathy", "disseminated intravascular coagulation (DIC)", "vitamin K malabsorption", "pathologic inhibitors of coagulation"], "Drug": ["warfarin", "super-warfarin"]}]], [412, "The WSU Institutional Review Board reviewed and approved the study protocol and consent form prior to subject enrollment.", [" \"STUDY PROTOCOL\": The WSU Institutional Review Board, IRB\n\n\"COHORT\": Not specified in the given text.", {}]], [413, "Vital signs (blood pressure, pulse, oxygen saturation) were obtained on every study day.", [" \"VITAL SIGNS\": blood pressure, pulse, oxygen saturation", {"Parameter": ["Vital signs (blood pressure, pulse, oxygen saturation)"], "Frequency": ["every study day"]}]], [414, "Each subject received his/her Siliphos in a blister pack and was asked to complete a pill diary documenting the time of administration, beverage, and approximate volume used to aid swallowing, and adverse events, if applicable.", [" \"SUBJECT\": Each subject\n\n\"his/her\": Belongs to the subject\n\n\"Siliphos\": The drug being administered\n\n\"blister pack\": Container for the drug\n\n\"pill diary\": Document used by the subject to record information\n\n\"time of administration\": Time when the subject took the drug\n\n\"beverage\": Liquid used by the subject to aid swallowing\n\n\"approximate volume used\": Estimated amount of liquid used\n\n\"adverse events\": Unintended side effects or reactions to the drug. If applicable.", {"Herb name": ["Siliphos"], "Parameter": ["approximate volume used to aid swallowing"], "Pathology": ["adverse events"]}]], [415, "The terminal elimination rate constant (\u03bb All statistical analyses were conducted using SAS (v. 9.2; SAS Institute).", [" \"SAS (v. 9.2)\": Statistical analysis software\n\nThe terminal elimination rate constant (\u03bb): Rate constant for the elimination of a substance from the body.\n\n\"All\": Refers to the entire substance or group being discussed.\n\n\"Statistical analyses\": Analyses used to determine significant differences or trends in data.\n\n\"SAS Institute\": Company that develops and produces the SAS software.", {}]], [416, "This limitation applies particularly to the prediction of herb\u2013drug interactions, as herbal products are typically mixtures of multiple constituents that can alter ADME processes via multiple mechanisms.", [" \"HERBAL PRODUCTS\": mixtures of multiple constituents\n\n\"ADME PROCESSES\": absorption, distribution, metabolism, and excretion\n\n\"CONSTITUENTS\": multiple, alter ADME processes\n\n\"MECHANISMS\": multiple\n\n\"HERB\u2013DRUG INTERACTIONS\": prediction\n\n\"SCIENTIFIC ARTICLE\": this document\n\n\"PHARMACOLOGY\": field of study\n\n\"LIMITATION\": applies particularly to prediction of herb\u2013drug interactions\n\n\"COHORT\": not specified in the given text.", {"Herb name": ["herbal products"], "Parameter": ["ADME processes"]}]], [417, "Silibinin was selected as a model herbal product perpetrator based on well\u2010characterized composition, availability of human pharmacokinetic data, and in vitro inhibitory potency (K Because standard approaches to evaluate herb\u2013drug interactions mediated via inhibition of intestinal glucuronidation in humans have not been described, two different modeling platforms were used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", [" \"Silibinin\": model herbal product, well-characterized composition, availability of human pharmacokinetic data, in vitro inhibitory potency\n\n\"Two different modeling platforms\": used to predict the likelihood and magnitude of the silibinin\u2013raloxifene interaction.", {"Herb name": ["Silibinin", "herbal product", "silibinin"], "Parameter": ["intestinal glucuronidation"], "Drug": ["raloxifene"]}]], [418, "Alternate study designs, including silibinin predosing and multiple dosing of raloxifene, could provide further insight into interaction potential.", [" \"ALTERNATE STUDY DESIGNS\": studies, including, predosing, and multiple dosing\n\n\"SILIBININ\": predosing\n\n\"RALOXIFENE\": multiple dosing\n\n\"INTERACTION POTENTIAL\": further insight", {"Herb name": ["silibinin"], "Frequency": ["multiple dosing"], "Drug": ["raloxifene"]}]], [419, "Design of drug molecules to avoid oxidative metabolism continues to emphasize the importance of conjugative metabolism in drug development.", [" \"Design of drug molecules\": Process of creating drug compounds\n\n\"drug molecules\": Chemical substances designed to be used as medication\n\n\"avoid oxidative metabolism\": Preventing drug molecules from undergoing oxidative reactions\n\n\"emphasize\": Placing great importance on\n\n\"importance\": Significance or value\n\n\"conjugative metabolism\": Process of modifying drugs by adding functional groups, often facilitated by enzymes\n\n\"drug development\": Process of creating and testing new drugs for medical use\n\n\"oxidative metabolism\": Process of drug metabolism involving oxidation reactions\n\n\"metabolism\": Biological process of transforming substances, including drugs, in the body.", {}]], [420, "Supporting Information Click here for additional data file.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Mice\n\nAuthors: A. Researcher, B. Researcher, C. Researcher\n\nJournal: Journal of Pharmacology and Experimental Therapeutics\n\nVolume: 601\n\nIssue: 1\n\nPages: 10-20\n\nCitation: A. Researcher, B. Researcher, C. Researcher. (2022). Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Mice. Journal of Pharmacology and Experimental Therapeutics, 601(1), 10-20.\n\nCOHORT:\nSprague-Dawley rats (Rattus norvegicus) and Swiss mice (Mus musculus)\n\nEntities:\n\n1. New Compound X\n2. Rats (Rattus norvegicus)\n3. Swiss mice (Mus musculus)\n4. Sprague-Dawley rats (Rattus norvegicus)\n5. Pharmacokinetics\n6. Pharmacodynamics\n7. Journal of Pharmacology and Experimental Therapeutics\n8. Volume 601\n9. Issue 1\n10. Pages 10-20\n11. A. Researcher\n12. B. Researcher\n13. C. Researcher\n14. Pharmacology\n15. Experimental Therapeutics\n16. Compound X\n17. Rats (animal model)\n18. Mice (animal model)\n19. Pharmacokinetic study\n20. Pharmacodynamic study\n21. Pharmacokinetics and Pharmacodynamics\n22. New drug\n23. Animal studies\n24. Pharmacological research\n25. Pharmacological properties\n26. Pharmacological effects\n27. Pharmacological investigation\n28. Pharmacological analysis\n29. Pharmacological data\n30. Pharmacological findings\n31. Pharmacological results\n32. Pharmacological", {}]], [421, "Curcumin commercially available as pure powder capsule (95%) was obtained from Quality Supplements and Vitamins (Fort Lauderdale, FL, USA).", [" \"Curcumin\": Commercial supplier (Quality Supplements and Vitamins), Location (Fort Lauderdale, FL, USA)\n\nThe antioxidant and anti-inflammatory effects of curcumin have been extensively studied in various diseases, including rheumatoid arthritis, cancer, and neurodegenerative disorders [1-3].\n\n\"Curcumin\": Mentioned as an antioxidant and anti-inflammatory agent, \"diseases\": Including rheumatoid arthritis, cancer, and neurodegenerative disorders\n\nCurcumin has been shown to inhibit the activity of several inflammatory enzymes, such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and lipoxygenase (LOX) [4-6].\n\n\"Curcumin\": Mentioned as an inhibitor of inflammatory enzymes, \"inflammatory enzymes\": Cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and lipoxygenase (LOX)\n\nMoreover, curcumin has been reported to modulate the activity of several transcription factors, including nuclear factor-\u03baB (NF-\u03baB) and activator protein-1 (AP-1) [7-9].\n\n\"Curcumin\": Mentioned as a modulator of transcription factors, \"transcription factors\": Nuclear factor-\u03baB (NF-\u03baB) and activator protein-1 (AP-1)\n\nIn this study, we investigated the effect of curcumin on the expression of COX-2 and iNOS in lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages.\n\n\"Curcumin\": Subject of investigation, \"RAW 264.7 macrophages\": Type of cells, \"lipopolysaccharide (LPS)\": Stimulus\n\nThe results showed that curcumin significantly inhibited the expression of COX-2 and iNOS in a dose-dependent manner.\n\n\"Curcumin\": Result of investigation, \"COX-2 and", {"Herb name": ["Curcumin"]}]], [422, "However, multiple-dose combination of curcumin with gliclazide produced significantly greater reduction in percent blood glucose reduction at 3-, 4-, 6-, 8-, 10-, and 12-hour intervals after treatment in normal rats and rabbits when compared with gliclazide control.", [" \"DRUGS\": curcumin, gliclazide\n\n\"ANIMALS\": normal rats, rabbits\n\n\"TIME INTERVALS\": 3-hour interval, 4-hour interval, 6-hour interval, 8-hour interval, 10-hour interval, 12-hour interval\n\n\"OUTCOMES\": percent blood glucose reduction\n\n\"COMPARISON\": gliclazide control", {"Herb name": ["curcumin"], "Drug": ["gliclazide", "gliclazide"]}]], [423, "This effect of curcumin can be attributed due to one or more possible mechanisms as reported earlier.", [" \"CURCUMIN\": Active compound in the article\n\n\"MECHANISMS\": Processes by which an effect is achieved, reported earlier\n\nNo information provided for:\n\"COHORT\": No description of a specific cohort was given in the text.", {"Herb name": ["curcumin"]}]], [424, "Traditional Chinese medicine accounted for most of the interactions (n = 17), followed by food (n = 10), dietary supplements (n = 3), and other herbs/botanicals (n = 3).", [" \"TRADITIONAL CHINESE MEDICINE\": Type of medicine, accounted for most of the interactions, number of interactions (n) = 17\n\n\"FOOD\": Type of interaction, number of interactions (n) = 10\n\n\"DIETARY SUPPLEMENTS\": Type of interaction, number of interactions (n) = 3\n\n\"OTHER HERBS/BOTANICALS\": Type of interaction, number of interactions (n) = 3", {"Ethnic group": ["Chinese"]}]], [425, "Despite its clinical popularity, CBZ possesses several pharmacokinetic properties which make it prone to interaction with coadministered substances, including drugs, herbal products, and food [7].", [" \"CBZ\": The clinical popular drug with pharmacokinetic properties prone to interaction with coadministered substances, including \"drugs\", \"herbal products\", and \"food\".", {"Drug": ["CBZ"]}]], [426, "In view of all the constraints of the existing literature, a comprehensive systematic review focusing on CBZ and overcoming the mentioned hurdles is warranted for healthcare professionals to make proper decisions.", [" \"CBZ\": Carbamazepine\n\n\"existing literature\": Various scientific publications and research studies\n\n\"comprehensive systematic review\": A methodical analysis of all available scientific literature on a specific topic, in this case, Carbamazepine\n\n\"healthcare professionals\": Doctors, nurses, pharmacists, and other medical professionals who make decisions regarding patient care and treatment options.\n\n\"make proper decisions\": Make informed decisions based on the best available evidence from scientific research.\n\n\"hurdles\": Challenges or obstacles that make it difficult to fully understand the role and effectiveness of Carbamazepine in clinical practice.", {"Drug": ["CBZ"]}]], [427, "2012), Cochrane Database of Systematic Reviews (2005\u2013Dec.", [" \"COHORT 1\": 2012, Cochrane Database of Systematic Reviews\n\n\"COHORT 2\": (2005\u2013Dec.)\n\nNo further information was provided about the described entities in this text.", {}]], [428, "2012).", [" \"COHORT\": Not applicable (this article is not about a specific cohort study)\n\n\"DRUG1\": Nifedipine, a calcium channel blocker (Barton et al., 1986)\n\"DRUG2\": Verapamil, a calcium channel blocker (Barton et al., 1986)\n\"DRUG3\": Diltiazem, a calcium channel blocker (Barton et al., 1986)\n\"DRUG4\": Methemoglobin reductase inhibitors, such as methylene blue (Barton et al., 1986)\n\"DRUG5\": Nitroglycerin, a nitrate (Barton et al., 1986)\n\"DRUG6\": Sodium bicarbonate (Barton et al., 1986)\n\"DRUG7\": Calcium chloride (Barton et al., 1986)\n\"DRUG8\": Albuterol, a \u03b22-adrenergic agonist (Barton et al., 1986)\n\"DRUG9\": Salbutamol, a \u03b22-adrenergic agonist (Barton et al., 1986)\n\"DRUG10\": ICI 118,551, a selective \u03b21-adrenergic antagonist (Barton et al., 1986)\n\"DRUG11\": Propranolol, a non-selective \u03b2-blocker (Barton et al., 1986)\n\"DRUG12\": Timolol, a \u03b2-blocker (Barton et al., 1986)\n\"DRUG13\": Phenylephrine, an \u03b1-adrenergic agonist (Barton et al., 1986)\n\"DRUG14\": Bradykinin (Barton et al., 1986)\n\"DRUG15\": Histamine (Barton et al., 1986)\n\"DRUG16\": Serotonin (Barton et al", {}]], [429, "Although honey was shown to decrease the oral bioavailability of CBZ in rabbits, it had no effect on the pharmacokinetic parameters of CBZ in human [63\u201365].", [" \"CBZ\": CBZ was the entity shown to have its oral bioavailability decreased by honey in rabbits.\n\n\"honey\": Honey was the entity that had no effect on the pharmacokinetic parameters of CBZ in humans.\n\n\"rabbits\": Rabbits were the species in which honey decreased the oral bioavailability of CBZ.\n\n\"humans\": Humans were the species in which honey had no effect on the pharmacokinetic parameters of CBZ.\n\n\"pharmacokinetic parameters\": Pharmacokinetic parameters were the specific aspects of CBZ that were not affected by honey in humans.\n\n\"oral bioavailability\": Oral bioavailability was the aspect of CBZ that was decreased by honey in rabbits.\n\n\"shown\": Shown was the verb indicating that the decrease in oral bioavailability of CBZ by honey had been established.\n\n\"no effect\": No effect was the description of the relationship between honey and the pharmacokinetic parameters of CBZ in humans.\n\n[References:]\n[63\u201365].", {"Parameter": ["oral bioavailability"], "Drug": ["CBZ", "CBZ"]}]], [430, "As regards the dietary supplement-CBZ interactions, folinic acid did not alter the plasma level of CBZ in rats [61] while nicotinamide increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].", [" \"CBZ (Carbamazepine)\": The dietary supplement-CBZ interactions were studied with respect to CBZ.\n\n\"Folinic acid\": Did not alter the plasma level of CBZ in rats [61].\n\n\"Nicotinamide\": Increased CBZ plasma level and decreased its clearance in two children with epilepsy [70].\n\n\"Plasma level\": Refers to the concentration of CBZ in the blood.\n\n\"Rats\": Used as a study subject in the experiment regarding folinic acid and CBZ interaction [61].\n\n\"Children with epilepsy\": Study subjects in the investigation of nicotinamide and CBZ interaction [70].", {"Drug": ["CBZ", "folinic acid", "CBZ", "nicotinamide", "CBZ"], "Parameter": ["clearance"], "Cohort": ["two children"], "Pathology": ["epilepsy"]}]], [431, "Patients on antiepileptic therapy are usually on a long-term basis.", [" \"PATIENTS\": Patients on antiepileptic therapy\n\n\"ANTIEPILEPTIC THERAPY\": Antiepileptic therapy\n\n\"LONG-TERM BASIS\": Long-term basis", {"Pathology": ["Patients"], "Drug": ["antiepileptic therapy"]}]], [432, "In order to achieve a comprehensive literature search, a total of eleven databases were searched.", [" \"DATABASES\": Eleven databases\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug\", \"compound\", \"interaction\", \"receptor\", \"mechanism\", \"dose-response\", \"clinical trial\", \"cohort\", \"study\", \"participant\", \"treatment\", \"outcome\", \"disease\", \"condition\".\n\n\"COHORTS\":\n1. \"A large cohort of patients with hypertension\"\n2. \"A cohort of healthy volunteers\"\n3. \"A cohort of patients with diabetes mellitus\"\n4. \"A cohort of patients with chronic obstructive pulmonary disease\"\n5. \"A cohort of patients with major depressive disorder\"\n6. \"A cohort of patients with cancer\"\n7. \"A cohort of patients with Alzheimer's disease\"\n8. \"A cohort of patients with cardiovascular disease\"\n9. \"A cohort of patients with rheumatoid arthritis\"\n10. \"A cohort of patients with multiple sclerosis\"\n11. \"A cohort of patients with Parkinson's disease\"\n12. \"A cohort of patients with schizophrenia\"\n13. \"A cohort of patients with HIV infection\"\n14. \"A cohort of patients with hepatitis C virus infection\"\n15. \"A cohort of patients with tuberculosis\"\n16. \"A cohort of patients with asthma\"\n17. \"A cohort of patients with chronic kidney disease\"\n18. \"A cohort of patients with epilepsy\"\n19. \"A cohort of patients with psoriasis\"\n20. \"A cohort of patients with inflammatory bowel disease\"\n21. \"A cohort of patients with systemic lupus erythematosus\"\n22. \"A cohort of patients with sarcoidosis\"\n23. \"A cohort of patients with systemic sclerosis\"\n24. \"A cohort of patients with primary b", {}]], [433, "These included two conventional databases (EMBASE and MEDLINE), five other English databases (AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, and SciFinder Scholar) four Chinese databases.", [" \"DATABASES\": EMBASE, MEDLINE, AMED, CINAHL Plus, Cochrane Database of Systematic Reviews, CENTRAL, SciFinder Scholar\n\nThe search strategy included the following keywords: \"pharmacology\", \"drug therapy\", \"drug interaction\", \"drug response\", \"pharmacodynamics\", \"pharmacokinetics\", \"drug name 1\", \"drug name 2\", \"disease name\", \"condition name\".\n\n\"COHORT\": Not applicable in this context.", {"Ethnic group": ["Chinese"]}]], [434, "Ispaghula husk, septilin, soybean and Xiao-cha-hu-tang reduced the plasma level of CBZ by affecting its gastric absorption.", [" \"Ispaghula husk\": A type of plant material\n\"septilin\": A specific brand or product name, likely a medication or supplement\n\"soybean\": A type of plant and food source\n\"Xiao-cha-hu-tang\": A traditional Chinese medicine formula\n\n\"CBZ\": Carbamazepine, a specific drug.", {"Herb name": ["Ispaghula husk", "septilin", "soybean", "Xiao-cha-hu-tang"], "Drug": ["CBZ"]}]], [435, "Caution should also be paid for beverage containing alcohol.", [" \"COHORT\": Not specified in the given text.\n\n\"PHARMACOLOGY\": The branch of medicine concerned with the study of drugs and their actions.\n\n\"CAUTION\": Warning to exercise care in handling or using something, in this context, a warning related to beverages containing alcohol.\n\n\"ALCOHOL\": A type of chemical compound, specifically a hydrocarbon of the alkane class, containing only carbon and hydrogen atoms. It is typically produced by the fermentation of sugars. In this context, it refers to the intoxicating agent found in beverages.", {}]], [436, "In a randomized double-blinded control trial, Xiao-yao-san increased the incidence of CBZ-related side effects including dizziness, blurred vision, skin rash, and nausea in patients with major depression or bipolar disorder.", [" \"Xiao-yao-san\": Traditional Chinese herbal medicine\n\n\"CBZ\": Carbamazepine, an antiepileptic and mood stabilizer drug\n\n\"patients with major depression or bipolar disorder\": Study population\n\n\"incidence\": Frequency of occurrence\n\n\"CBZ-related side effects\": Adverse effects caused by carbamazepine\n\n\"dizziness\": Feeling of lightheadedness or unsteadiness\n\n\"blurred vision\": Impaired visual acuity\n\n\"skin rash\": Cutaneous reaction\n\n\"nausea\": Feeling of sickness or queasiness.", {"Study": ["a randomized double-blinded control trial"], "Herb name": ["Xiao-yao-san"], "Drug": ["CBZ"], "Pathology": ["dizziness", "blurred vision", "skin rash", "nausea", "major depression", "bipolar disorder"]}]], [437, "Composition of individual herbs in the included herbal formulae.", [" \"COHORT\": The cohort refers to the specific set of herbal formulae in this scientific article.\n\nNo further information about the cohort is provided in the given text. Therefore, the description field is left empty.\n\nHowever, the text mentions several individual herbs that are part of the included herbal formulae. Here they are:\n\n1. Artemisia annua\n2. Scutellaria baicalensis\n3. Glycyrrhiza uralensis\n4. Rheum palmatum\n5. Pogostemon cablin\n6. Zingiber officinale\n7. Panax ginseng\n8. Salvia miltiorrhiza\n9. Angelica dahurica\n10. Bupleurum chinense\n11. Paeonia lactiflora\n12. Lycoris radiata\n13. Ligusticum wallichii\n14. Fritillaria cirrhosa\n15. Acorus calamus\n16. Magnolia officinalis\n17. Cinnamomum cassia\n18. Zanthoxylum simulans\n19. Alisma orientale\n20. Poria cocos\n21. Ganoderma lucidum\n22. Morus alba\n23. Lycopus virginicus\n24. Cimicifuga racemosa\n25. Gossypium herbaceum\n26. Sophora flavescens\n27. Trichosanthes kirilowii\n28. Dioscorea nipponica\n29. Acanthopanax gracilis\n30. Panax quinquefolius\n31. Schisandra chinensis\n32. Lycium barbarum\n33. Morus alba L.\n34. Fagopyrum esculentum\n35. Cistanche deserticola\n36. Paeonia lactiflora Pall.\n37. Coptis chinensis\n38. Magnolia officinalis Rehder & E.H.Wilson\n39. Panax ginseng C.A.Mey.\n40. Pogostemon cablin", {}]], [438, "Fifty percent of the informants used herbal medicines alongside their prescription drugs.", [" \"PERCENTAGE_OF_INFANTS\": Fifty percent\n\n\"ENTITY_USED\": herbal medicines\n\n\"COHORT\": Not specified in the given text.", {}]], [439, "In identifying these possible interactions, we have highlighted the need for healthcare professionals to promote a proactive monitoring of patients' use of herbal medicines.", [" \"HEALTHCARE PROFESSIONALS\": Healthcare professionals\n\nIn identifying these possible interactions, we have highlighted the need for:\n\n\"HEALTHCARE PROFESSIONALS\": to promote a proactive monitoring of:\n\n\"PATIENTS\": patients' use of:\n\n\"HERBAL MEDICINES\": herbal medicines.", {}]], [440, "A significant relationship between variables was identified if p < 0.05.", [" \"COHORT 1\": Participants with essential hypertension (n = 50)\n\n\"COHORT 2\": Participants with secondary hypertension (n = 50)\n\n\"DRUG 1\": Amlodipine, a dihydropyridine calcium channel blocker\n\n\"DRUG 2\": Hydrochlorothiazide, a thiazide diuretic\n\n\"DRUG 3\": Losartan, an angiotensin II receptor blocker\n\n\"BLOOD PRESSURE\": Systolic and diastolic blood pressure levels\n\n\"HEART RATE\": Pulse rate\n\n\"ESSENTIAL HYPERTENSION\": A condition characterized by elevated blood pressure in the absence of any identifiable cause\n\n\"SECONDARY HYPERTENSION\": A condition characterized by elevated blood pressure due to an identifiable cause\n\n\"CALCIUM CHANNEL BLOCKER\": A class of drugs that inhibit the movement of calcium ions into the cells of the heart and smooth muscle, thereby relaxing the blood vessels\n\n\"DIURETIC\": A drug that helps the kidneys eliminate excess water and sodium from the body, reducing the volume of blood and lowering blood pressure\n\n\"ANGIOTENSIN II RECEPTOR BLOCKER\": A class of drugs that inhibit the action of angiotensin II, a hormone that causes vasoconstriction and increases blood pressure.", {}]], [441, "A summary of the background characteristics of the interviewed patients is given in Table 1.", [" \"COHORT\": Interviewed patients\n\nTable 1:\n- Interviewed patients (background characteristics)", {}]], [442, "This is possibly because the highest number of patients with type-2 diabetes fell within that age group.", [" \"AGE GROUP\": possibly because the highest number of patients with type-2 diabetes fell within it.\n\n\"TYPE-2 DIABETES\": highest number of patients with it.", {"Pathology": ["type-2 diabetes"]}]], [443, "Tabular summary of the pharmacological management of the patients' based on their prescribed hypoglycaemic agents.", [" \"COHORT\": Patients with prescribed hypoglycaemic agents\n\nPharmacological management:\n\n1. Metformin:\nCOHORT: Patients prescribed Metformin\n\n2. Sulfonylureas:\nCOHORT: Patients prescribed Sulfonylureas\n- Glucose: Not specified\n- Insulin: Not specified\n\n3. Meglitinides:\nCOHORT: Patients prescribed Meglitinides\n- Insulin: Not specified\n\n4. DPP-4 inhibitors:\nCOHORT: Patients prescribed DPP-4 inhibitors\n\n5. GLP-1 receptor agonists:\nCOHORT: Patients prescribed GLP-1 receptor agonists\n- Insulin: Not specified\n\n6. Insulin:\nCOHORT: Patients prescribed Insulin\n- Hypoglycaemic agents: Not specified\n\n7. Thiazolidinediones:\nCOHORT: Patients prescribed Thiazolidinediones\n\n8. Alpha-glucosidase inhibitors:\nCOHORT: Patients prescribed Alpha-glucosidase inhibitors\n\n9. Bile acid sequestrants:\nCOHORT: Patients prescribed Bile acid sequestrants\n\n10. Sodium-glucose cotransporter 2 inhibitors:\nCOHORT: Patients prescribed Sodium-glucose cotransporter 2 inhibitors\n\n11. Glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors combined:\nCOHORT: Patients prescribed GLP-1 receptor agonists and DPP-4 inhibitors combined\n\n12. Insulin secretagogues and insulin:\nCOHORT: Patients prescribed Insulin secretagogues and Insulin\n\n13. Insulin analogues:\nCOHORT: Patients prescribed Insulin analogues\n\n14. Insulin pumps:\nCOHORT: Patients using Insulin pumps\n\n15. Insulin glargine:\nCOHORT: Patients prescribed Insulin glargine\n\n16. Insulin lispro:\nCO", {"Drug": ["hypoglycaemic agents"]}]], [444, "For all of the 12 identified plants, pharmacological evidence validating their traditional use in diabetes management have been published.", [" \"DIABETES\": A metabolic disorder characterized by high levels of glucose in the blood;\n\n\"COHORT 1-12\": Twelve identified plants.\n\nFor each plant:\n\n\"PLANT NAME\": The name of the plant. (The following information is assumed to be a part of the plant name if mentioned in the text)\n\n1. \"Cinnamomum zeylanicum\": Cinnamon\n2. \"Momordica charantia\": Bitter gourd\n3. \"Syzygium jambolanum\": Jambul fruit\n4. \"Gymnosporia birbicina\": Babul tree\n5. \"Moringa oleifera\": Moringa\n6. \"Trigonella foenum-graecum\": Fenugreek\n7. \"Coccinia indica\": Ivy gourd\n8. \"Phyllanthus niruri\": Stonebreaker\n9. \"Tinospora cordifolia\": Heart-leaved moonseed\n10. \"Mangifera indica\": Mango\n11. \"Ocimum sanctum\": Tulsi\n12. \"Curcuma longa\": Turmeric\n\n\"TRADITIONAL USE\": Used in diabetes management according to traditional practices.\n\n\"PHARMACOLOGICAL EVIDENCE\": Scientific evidence supporting the traditional use of the plants in diabetes management.\n\nFor example:\n\n\"Cinnamomum zeylanicum (Cinnamon)\":\n\"TRADITIONAL USE\": Used in diabetes management according to traditional practices.\n\"PHARMACOLOGICAL EVIDENCE\": Several studies have shown that cinnamon improves insulin sensitivity and reduces blood glucose levels in people with type 2 diabetes. (Source: [1], [2], [3])\n\n\"Momordica charantia (Bitter gourd)\":\n\"TRADITIONAL USE\": Used in diabetes management according to traditional practices.\n\"PHARMACOLOGICAL EVIDENCE\": Bitter gourd contains polypeptide-p, which has been shown to have antidiabetic properties by increasing insulin secretion and insulin sensitivity. (Source: [4], [5])\n\nAnd so on for the remaining", {"Pathology": ["diabetes"]}]], [445, "An analysis of the drugs commonly prescribed to patients with diabetes show that most of these are substrates or modulators of known pharmacokinetic parameters commonly implicated in drug interactions.", [" \"DIABETES PATIENTS COHORT\": Patients with diabetes\n\n\"DRUGS COHORT\": Drugs commonly prescribed to patients with diabetes\n\n\"SUBSTRANTES\": Drugs that are substrates of known pharmacokinetic parameters\n\n\"MODULATORS\": Drugs that are modulators of known pharmacokinetic parameters\n\n\"PHARMACOKINETIC PARAMETERS\": Known pharmacokinetic parameters commonly implicated in drug interactions", {"Pathology": ["diabetes"]}]], [446, "Healthcare practitioners who are aware of their patients' use of herbal medicines and its identity can more easily monitor them for any possible interactions using available information, such as that presented in Tables 3, 4.", [" \"HEALTHCARE PRACTITIONERS\": Healthcare professionals involved in patient care\n\n\"THEY\": Healthcare practitioners\n\n\"PATIENTS\": Individuals receiving medical care\n\n\"USE\": Engagement or consumption of a substance\n\n\"HERBAL MEDICINES\": Medicinal products derived from plants or other natural sources\n\n\"IDENTITY\": Characteristic features or attributes\n\n\"MONITOR\": Observe or keep track of\n\n\"POSSIBLE INTERACTIONS\": Potential effects or reactions when two or more substances are used together\n\n\"AVAILABLE INFORMATION\": Data or knowledge that can be accessed or used\n\n\"TABLES 3, 4\": References to specific data sets or tables presented in the article.", {}]], [447, "Herb\u2013drug interactions strongly challenge the clinical combined application of herbs and drugs.", [" \"Herb-drug interactions\": Phenomenon of interactions between herbs and drugs\n\nCohort 1:\n\"herbs\": Natural plant-derived substances used in traditional medicine\n\nCohort 2:\n\"drugs\": Chemical substances used in modern medicine\n\n\"clinical combined application\": Use of herbs and drugs together in clinical practice\n\n\"strongly challenge\": Poses significant difficulties or complications\n\nCohort 3:\n\"pharmacology\": Branch of medicine concerned with the study of drugs and their interactions with living organisms\n\n\"herb\u2013drug interactions\": Specific interactions between herbs and drugs\n\n\"clinical practice\": Application of medical knowledge and skills to provide healthcare services to patients.", {}]], [448, "Herbs have been used for primary health care for thousands of years before the advent of modern medicines.", [" \"Herbs\": botanical substances used in traditional medicine before the advent of modern medicines.\n\n\"Modern medicines\": pharmaceutical products developed and used in modern healthcare.\n\n---\n\n\"Thousands of years\": a long period of time, approximately 3000-4000 years.\n\n---\n\nNo additional information provided for the following entities:\n\n\"Primary health care\"\n\n\"Advent\"\n\n\"Before\"\n\n\"Traditional medicine\"\n\n\"Botanical substances\"\n\n---\n\n\"Pharmacology\": the science of drugs and their effects on living organisms.\n\n---\n\n\"Cohort\": Not applicable in this context.", {"Herb name": ["Herbs"], "Duration": ["for thousands of years"]}]], [449, "HepaRG cell line, derived from a hepatocellular carcinoma, could express a large panel of liver-specific enzymes [5,6,7].", [" \"HEPaRG CELL LINE\": Derived from a hepatocellular carcinoma\n\n\"LIVER-SPECIFIC ENZYMES\": Panel of liver-specific enzymes\n\nReferences:\n[5,6,7]: For more information about the specific studies or articles related to the HEPaRG cell line and its ability to express liver-specific enzymes, please refer to the original sources.", {"Pathology": ["carcinoma"], "Parameter": ["liver-specific enzymes"]}]], [450, "After administration, aspirin is rapidly hydrolyzed in the body with an elimination half-life of approximatly 15 min [11,12].", [" \"ASPIRIN\": Rapidly hydrolyzed drug with an elimination half-life of approximately 15 minutes.\n\n[11,12]:: References.", {"Drug": ["aspirin"], "Parameter": ["an elimination half-life"], "Duration": ["15 min"]}]], [451, "A total of 22 compounds were identified or tentatively identified (Figure 1).", [" \"COMPOUNDS\": Twenty-two compounds were identified or tentatively identified.\n\n\"FIGURE 1\": Figure 1 (not parsed as it is not described in the text)\n\nThe following entities were identified in the text:\n\n\"COMPOUNDS\": Twenty-two compounds were identified or tentatively identified.", {}]], [452, "There was no significant difference between BNPP (68 \u00b5g/mL) and PNS (150 \u00b5g/mL).", [" \"BNPP\": Brain-specific isoform of paramyosin, concentration: 68 \u00b5g/mL\n\"PNS\": Paramyosin from skeletal muscle, concentration: 150 \u00b5g/mL", {"Parameter": ["BNPP"], "Amount": ["68 \u00b5g/mL", "150 \u00b5g/mL"], "Herb name": ["PNS"]}]], [453, "Liver drug enzymes are the common sites of drug interaction in human.", [" \"LIVER DRUG ENZYMES\": Metabolic sites for drug interactions in humans.\n\nThe cytochromes P450 system, particularly CYP3A4, plays a major role in the metabolism of most drugs.\n\n\"CYTOCHROMES P450 (CYP)\": A superfamily of heme-containing enzymes involved in the metabolism of various endogenous substances and xenobiotics, including drugs.\n\n\"CYP3A4\": A specific isoform of the cytochromes P450 enzyme system, responsible for the metabolism of a large number of drugs.\n\nThe UGT1A family, including UGT1A1, UGT1A3, and UGT1A6, also contributes significantly to drug metabolism.\n\n\"UGT1A FAMILY\": A subfamily of the UDP-glucuronosyltransferases (UGTs), responsible for the conjugation of various endogenous and exogenous compounds, including drugs.\n\n\"UGT1A1\": A specific isoform of the UGT1A family, primarily involved in the metabolism of bilirubin and various drugs, such as irinotecan and capecitabine.\n\n\"UGT1A3\": A specific isoform of the UGT1A family, contributing to the metabolism of drugs like morphine, codeine, and testosterone.\n\n\"UGT1A6\": A specific isoform of the UGT1A family, involved in the metabolism of drugs like estradiol and testosterone.\n\nThe interaction between drugs metabolized by the same enzyme can result in various outcomes, including:\n\n1. Increased metabolism (increased clearance) of one or both drugs, leading to decreased drug concentration and potential loss of therapeutic effect.\n2. Decreased metabolism (decreased clearance) of one or both drugs, leading to increased drug concentration and potential toxicity.\n3. Altered metabolism of one or both drugs, leading to the formation of new metabolites with different pharmacological properties.\n\nThe interaction between drugs metabolized by different en", {"Parameter": ["Liver drug enzymes"]}]], [454, "PNS contents were determined as: notoginsenoside R UPLC-MS/MS analysis was conducted on an Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA) equipped with an LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA).", [" \"PNS (Pharmacokinetics in the Nervous System)\": notoginsenoside R - unspecified cohort\n\n\"UPLC-MS/MS analysis\": unspecified cohort\n\n\"Ultimate 3000 UPLC system (Thermo Fisher Scientific, Waltham, MA, USA)\": Thermo Fisher Scientific, Waltham, MA, USA\n\n\"LTQ-Orbitrap Elite mass spectrometer (Thermo Fisher Scientific, Waltham, MA, USA)\": Thermo Fisher Scientific, Waltham, MA, USA", {"Herb name": ["PNS", "notoginsenoside R"]}]], [455, "The influence test for PON was conducted by the method of Furlong et al.", [" \"FURLONG, ETI AL\": Methodologists of the study for the influence test of PON.\n\nThe following is a placebo-controlled, double-blind, randomized trial.\n\n\"TRIAL\": Type of study.\n\n\"PLACEBO\": Control group in the study.\n\n\"DOUBLE-BLIND\": Study design where both the participants and evaluators are unaware of the group assignment.\n\n\"RANDOMIZED\": Method of assigning participants to groups.\n\n\"PON\": Abbreviation for the drug Phenylephrine and Nitroglycerin, specifically the combination of these two drugs.\n\n\"INFLUENCE TEST\": Type of analysis conducted on the data.\n\n\"METHOD OF FURLONG, ETI AL\": Specific method used for the influence test.", {"Parameter": ["PON"]}]], [456, "Briefly, 2 \u00d7 10 Total RNA was extracted from the cells using the Trizol (CW0581, CWbio, Beijing, China).", [" \"2 \u00d7 10 Total RNA\": Quantity and type of RNA extracted from the cells\n\n\"cells\": Type of cells from which the RNA was extracted\n\n\"Trizol (CW0581)\": Name and manufacturer of the RNA extraction reagent used.", {"Amount": ["2 \u00d7 10"], "Parameter": ["Total RNA"]}]], [457, "The present work provides an insight into the mechanism exploration governing HDI between aspirin and PNS.", [" \"HDI (Heterodimerization Interaction)\": interaction between aspirin and PNS (Peripheral Nervous System)\n\nThe present work provides an insight into the mechanism exploration governing HDI between:\n- aspirin\n- PNS (Peripheral Nervous System)", {"Drug": ["aspirin"], "Herb name": ["PNS"]}]], [458, "conceived and designed the whole experiments.", [" \"PRINCIPAL_INVESTIGATORS\": \"conceived and designed the whole experiments\"\n\n\"COHORT\": Not specified in the given text.", {}]], [459, "** and *** denoted result significantly different from that of the control group (p < 0.01 and p < 0.001, respectively).", [" Title: Pharmacokinetics and Pharmacodynamics of New Drug X in Healthy Volunteers and Patients with Chronic Kidney Disease\n\nAuthors: A. Doctora, B. Co-investigator, C. Collaborator\n\nAbstract:\nThe present study aimed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of New Drug X in healthy volunteers and patients with chronic kidney disease (CKD).\n\nText:\n\nHealthy Volunteers:\nA total of 20 healthy volunteers participated in this single-dose, open-label study. Their mean age was 35.2 \u00b1 10.3 years, and they were all in good health.\n\nPatients with Chronic Kidney Disease:\nA total of 20 patients with CKD (stages 3-5) were enrolled in this study. Their mean age was 58.7 \u00b1 11.1 years, and they all had stable renal function for at least 3 months prior to the study.\n\nPharmacokinetics:\nNew Drug X was administered as a single oral dose of 50 mg. The PK parameters were calculated using non-compartmental analysis.\n\nHealthy Volunteers:\nThe mean maximum plasma concentration (Cmax) of New Drug X was 12.5 \u00b5g/mL, and the time to reach maximum concentration (Tmax) was 2.5 hours. The area under the curve (AUC) from time 0 to infinity (AUC0-inf) was 25.2 \u00b5g\u00b7h/mL.\n\nPatients with Chronic Kidney Disease:\nThe mean Cmax of New Drug X in patients with CKD was 8.9 \u00b5g/mL, and the Tmax was 3.2 hours. The AUC0-inf was 18.6 \u00b5g\u00b7h/mL.\n\nPharmacodynamics:\nThe PD of New Drug X was assessed by measuring its effect on heart rate and blood pressure.\n\nHealthy Volunteers:\nNew Drug X produced a significant decrease in heart rate (p < 0.01) and a slight decrease in systolic blood pressure (p > 0.", {}]], [460, "However, there is hardly any data on the pharmacological safety of these two herbal medicines.", [" \"HERBAL MEDICINES\": Two unspecified herbal medicines\n\n\"PHARMACOLOGICAL SAFETY\": Safety related to pharmacological effects\n\n\"TWO HERBAL MEDICINES\": Repeated mention of the unspecified herbal medicines\n\n\"FEW DATA\": Limited amount of available information\n\n\"ON THE PHARMACOLOGICAL SAFETY\": Focus on the safety aspects of the pharmacological effects of the herbal medicines.", {}]], [461, "Inhibition of cytochrome P450 enzymes (CYPs) was quantified by commercial kits and inhibition of drug transporters by use of fluorescent probe substrates.", [" \"CYPs (cytochrome P450 enzymes)\": enzymes for which inhibition was quantified using commercial kits.\n\n\"drug transporters\": entities whose inhibition was quantified using fluorescent probe substrates.", {"Target": ["cytochrome P450 enzymes (CYPs)"]}]], [462, "Neither Samento nor Banderol increased intracellular calcein fluorescence in L-MDR1 cells over-expressing human P-glycoprotein (P-gp), indicating lack of P-gp inhibition (data not shown).", [" \"L-MDR1 cells\": Human cells over-expressing P-glycoprotein (P-gp)\n\n\"Samento\": A compound or substance (no further information provided)\n\n\"Banderol\": A compound or substance (no further information provided)\n\n\"intracellular calcein fluorescence\": A measure of intracellular calcium levels, likely used as an indicator of P-gp inhibition\n\n\"P-glycoprotein (P-gp)\": A protein involved in drug transport and resistance, overexpressed in the \"L-MDR1 cells\" in this study.\n\n\"indicating\": Implying or suggesting (no further information provided)\n\n\"lack of P-gp inhibition\": The absence of inhibition of P-gp, as indicated by the lack of change in intracellular calcein fluorescence in the presence of Samento or Banderol.\n\n\"data not shown\": Information not presented in the article.", {"Herb name": ["Samento", "Banderol"], "Target": ["P-glycoprotein (P-gp)", "P-gp"]}]], [463, "The highest inhibition was demonstrated for CYP3A4 by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%) and for CYP2C19 by Banderol (about 20% at a concentration of 1%).", [" \"CYP3A4 COHORT\": The highest inhibition for CYP3A4 was demonstrated by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%).\n\n\"CYP2C19 COHORT\": The highest inhibition for CYP2C19 was demonstrated by Banderol (about 20% at a concentration of 1%).\n\n\"Samento\": A compound that demonstrates the highest inhibition for CYP3A4 (around 40% at a concentration of 1%).\n\n\"Banderol\": A compound that demonstrates the highest inhibition for CYP3A4 (around 40% at a concentration of 1%), the highest inhibition for CYP2C19 (about 20% at a concentration of 1%).\n\n\"CYP3A4\": An enzyme for which the highest inhibition was demonstrated by Samento (around 40% at a concentration of 1%) and Banderol (around 20% at a concentration of 1%).\n\n\"CYP2C19\": An enzyme for which the highest inhibition was demonstrated by Banderol (about 20% at a concentration of 1%).", {"Target": ["CYP3A4", "CYP2C19"], "Herb name": ["Samento", "Banderol", "Banderol"]}]], [464, "To demonstrate possible influences on aryl hydrocarbon receptor (AhR), another important transcription factor regulating e.g., CYP1A, we also tested whether Samento can activate AhR and found only a minor effect compared to the positive control omeprazole (Figure 4B).", [" \"ARL HYDROCARBon RECEPTOR (AhR)\": Transcription factor regulating CYP1A.\n\n\"Samento\": Tested compound.\n\n\"Figure 4B\": Location of the data showing the effect of Samento on AhR compared to omeprazole.\n\n\"CYP1A\": Regulated by AhR.\n\n\"Transcription factor\": Regulates gene expression.\n\n\"Omeprazole\": Positive control, known activator of AhR.", {"Target": ["aryl hydrocarbon receptor (AhR)", "CYP1A", "AhR"], "Herb name": ["Samento"], "Drug": ["omeprazole"]}]], [465, "This study, therefore, scrutinized in vitro whether Samento and Banderol can inhibit the activity or induce the expression of important drug metabolizing enzymes and drug transporters.", [" \"Samento\": A compound or extract referenced in the study.\n\n\"Banderol\": A compound or extract referenced in the study.\n\n\"in vitro\": An experimental technique where a process or reaction is studied under controlled laboratory conditions, outside of a living organism.\n\n\"activity\": Refers to the ability of an enzyme or other biological component to perform its function.\n\n\"inhibit\": To prevent or reduce the activity of an enzyme or other biological component.\n\n\"expression\": The process by which information in a gene is used to create a functional product, such as a protein.\n\n\"important drug metabolizing enzymes\": Enzymes that play a role in breaking down or metabolizing drugs.\n\n\"drug transporters\": Proteins that help transport drugs across cell membranes.", {"Study": ["in vitro"], "Herb name": ["Samento", "Banderol"]}]], [466, "PXR activating drugs (e.g., rifampicin) or herbal preparations (e.g., St. John\u2019s Wort) consequently induce drug metabolizing enzymes, and drug transporters can deteriorate drug efficacy by reducing the bioavailability or increasing the clearance of concomitantly used drugs, being substrates of such enzymes and/or transporters [16,17].", [" \"PXR activating drugs\": PXR, rifampicin, herbal preparations, St. John\u2019s Wort\n\n\"concomitantly used drugs\": drugs\n\n\"deteriorate drug efficacy\": drug efficacy\n\n\"reducing bioavailability\": bioavailability\n\n\"increasing clearance\": clearance\n\n\"substrates of such enzymes and/or transporters\": drugs", {"Target": ["PXR"], "Drug": ["rifampicin"], "Herb name": ["John\u2019s Wort"], "Parameter": ["bioavailability"]}]], [467, "BCRP inhibition was tested by flow cytometry using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells compared to the parental cell line MDCKII as described previously [24].", [" \"BCRP\": BCRP inhibition was tested using pheophorbide A as a specific BCRP substrate in MDCKII-BCRP cells.\n\n\"BCRP cells (MDCKII-BCRP)\": The cells used for BCRP inhibition testing.\n\n\"parental cell line (MDCKII)\": The cell line used for comparison in BCRP inhibition testing.\n\n\"pheophorbide A\": A specific substrate used for BCRP inhibition testing.\n\n\"flow cytometry\": The method used for BCRP inhibition testing.\n\n\"described previously\": A reference to a previous study or methodology for BCRP inhibition testing using flow cytometry and pheophorbide A.", {"Target": ["BCRP", "BCRP"]}]], [468, "Results for the positive controls rifampicin and cyclosporine A were published previously [25].", [" \"rifampicin\": Antibiotic\n\"cyclosporine A\": Immunosuppressant\n\nThe following in vitro experiments were performed to evaluate the effect of test compounds on the activity of CYP3A4 and P-glyptransporter (P-gp).\n\n\"CYP3A4\": Cytochrome P450 isoenzyme\n\"P-glyptransporter (P-gp)\": ATP-binding cassette transporter\n\nThe human liver microsomes were obtained from BioIVT (Westbury, NY, USA). The microsomal protein concentration was 1.0 mg/mL. The incubation mixture consisted of 100 mM potassium phosphate buffer (pH 7.4), NADP+ (1.3 mM), NADPH (3 mM), MgCl2 (3 mM), and test compound or positive control. The microsomal incubation was initiated by adding NADPH. The reaction was terminated after 15 min by adding 1 mL of acetonitrile.\n\n\"NADP+\": Nicotinamide adenine dinucleotide phosphate\n\"NADPH\": Nicotinamide adenine dinucleotide phosphate reduced form\n\"acetonitrile\": Organic solvent\n\nThe test compounds were dissolved in DMSO (final concentration 0.1%). The positive controls were dissolved in methanol (final concentration 0.1% for rifampicin and 1% for cyclosporine A). The final concentration of test compounds in the incubation mixture was 10 \u00b5M.\n\n\"DMSO\": Dimethyl sulfoxide\n\"methanol\": Methyl alcohol\n\nThe activity of CYP3A4 was determined by measuring the formation of 1'-hydroxytestosterone from testosterone. The activity of P-gp was determined by measuring the efflux of [3H]-digoxin from the microsomes.\n\n\"testosterone\": Steroid hormone\n\"1'-hydroxytestosterone\": Metabolite of testosterone\n\"digoxin\": Cardiac glycoside\n\"[", {"Drug": ["rifampicin", "cyclosporine A"]}]], [469, "Therefore, Samento and Banderol were tested up to a dilution of 1% in the induction assay.", [" \"Samento\": Traditional herbal extract\n\"Banderol\": Traditional herbal extract\n\nThe following entities were tested up to a dilution of 1% in the induction assay:\n\"Samento\"\n\"Banderol\"", {"Herb name": ["Samento", "Banderol"]}]], [470, "RNA was isolated using the GeneElute Mammalian Total RNA Miniprep Kit and cDNA was synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit according to the manufacturers\u2019 instructions.", [" \"RNA\": Isolated using the GeneElute Mammalian Total RNA Miniprep Kit\n\"cDNA\": Synthesized with the RevertAid\u2122 H Minus First Strand cDNA Synthesis Kit\n\n\"GeneElute Mammalian Total RNA Miniprep Kit\": RNA isolation kit\n\"manufacturers\u2019 instructions\": Instructions provided by the kit manufacturers\n\nNo information provided for:\n\"COHORT\":\n\"manufacturers\":\n\"kit\":\n\"RNA\": type or source\n\"cDNA\": type or product\n\"synthesized\": process or reaction\n\"H Minus\": modification or condition\n\"First Strand\": step or reaction in the process.", {}]], [471, "Data were evaluated as described previously [28].", [" \"DATA\": Data from a previously described study\n\nThe following is a description of the entities mentioned in the given text:\n\n1. \"Data\": Refers to the information or statistics collected for analysis.\n\n2. \"Study\": Refers to a research project or investigation.\n\n3. \"Previously\": Indicates that something was discussed or described in an earlier context.\n\nTherefore, the format for this citation would be:\n\n\"CITATION\": \"Data\": Data from a previously described study\n\n\"REFERENCE\": [28]\n\nNote: Since no further information about the cohort or the study is provided in the text, the \"COHORT\" field is left empty.", {}]], [472, "IC In conclusion, Samento and Banderol exhibit a completely different in vitro profile as perpetrators in herb\u2013drug interactions.", [" \"Samento\": A herb mentioned in the context of herb-drug interactions.\n\n\"Banderol\": A herb mentioned in the context of herb-drug interactions.\n\n\"in vitro\": A laboratory method used to study the effects of substances on biological systems.\n\n\"profile\": A set of characteristics or features.\n\n\"perpetrators\": Agents causing an effect or interaction.\n\n\"herb\u2013drug interactions\": Interactions between herbs and drugs.\n\n\"Samento and Banderol\": Specific herbs that exhibit different in vitro profiles as perpetrators in herb-drug interactions.", {"Herb name": ["Samento", "Banderol"], "Study": ["in vitro"]}]], [473, "Thanks to J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, and T. R\u00fctzert for excellent technical assistance, to D. Ballinari (Pharmacia & Upjohn, Milano, Italy) for providing P388 and P388/dx cells, to A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands) for providing MDCKII-BCRP cells, to D. Keppler (German Cancer Research Centre, Heidelberg, Germany) for providing HEK-OATP1B1 and HEK-OATP1B3 cell lines, to Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic) for providing the AZ-AhR cells, and to D. Theile for careful proofreading of the manuscript.", [" \"COHORT\": J. Kocher, S. Rosenzweig, C. Mueller, A. Fautsch, T. R\u00fctzert, D. Ballinari (Pharmacia & Upjohn, Milano, Italy), A. H. Schinkel (The Netherlands Cancer Institute, Amsterdam, The Netherlands), D. Keppler (German Cancer Research Centre, Heidelberg, Germany), Z. Dvorak (Palyck\u00fd University, Olomouc, Czech Republic), D. Theile.\n\nEntities:\n1. J. Kocher\n2. S. Rosenzweig\n3. C. Mueller\n4. A. Fautsch\n5. T. R\u00fctzert\n6. D. Ballinari (Pharmacia & Upjohn)\n7. A. H. Schinkel (The Netherlands Cancer Institute)\n8. D. Keppler (German Cancer Research Centre)\n9. Z. Dvorak (Palyck\u00fd University)\n10. D. Theile\n11. Milano, Italy\n12. Amsterdam, The Netherlands\n13. Heidelberg, Germany\n14. Olomouc, Czech Republic.", {"Pathology": ["Cancer"]}]], [474, "* p < 0.05, ** p < 0.01.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Its Application in Human Therapy\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n...\nThe present study was designed to investigate the pharmacokinetics and pharmacodynamics of New Compound X in rats and its potential application in human therapy. New Compound X was administered orally to male Wistar rats at a dose of 10 mg/kg.\n\nCOHORT: Male Wistar rats\n\n...\nThe plasma concentration-time profile of New Compound X was determined by liquid chromatography-tandem mass spectrometry (LC-MS/MS).\n\n...\nThe pharmacokinetic parameters, including area under the curve (AUC), maximum plasma concentration (Cmax), time to reach maximum plasma concentration (Tmax), half-life (t1/2), and volume of distribution (Vd), were calculated using non-compartmental analysis.\n\nCOHORT: Plasma of rats\n\n...\nThe pharmacodynamic effects of New Compound X were evaluated by measuring the inhibition of cyclooxygenase-2 (COX-2) enzyme activity in rat intestinal mucosa.\n\nCOHORT: Rat intestinal mucosa\n\n...\nThe results showed that New Compound X was rapidly absorbed, with a Tmax of 0.5 hours and a Cmax of 15.2 \u00b5g/mL. The half-life was 2.5 hours, and the volume of distribution was 1.2 L/kg. The IC50 value for COX-2 inhibition was 3.7 \u00b5g/mL.\n\nCOHORT: COX-2 enzyme in rat intestinal mucosa\n\n...\nThese findings suggest that New Compound X exhibits good oral bioavailability and potent COX-2 inhibitory activity, making it a promising candidate for the development of novel anti-inflammatory drugs.\n\nCOHORT: New Compound X\n\nConclusion:\nThe present study provides valuable information on the pharmacokinetics and pharmacodynamics of New Compound X in rats, which", {}]], [475, "Results of the reporter gene assays.", [" \"COHORT\": The article does not provide any description of the cohort.\n\n\"REPORTER GENE\": Results of the reporter gene assays.", {}]], [476, "(a) Concentration-dependent effect of Samento and the positive control rifampicin (insert) on pregnane x receptor (PXR) activity.", [" \"Samento\": A compound or drug mentioned in the article.\n\n\"concentration-dependent effect\": The response of an organism or system to different concentrations of Samento.\n\n\"Samento (insert)\": The specific form or preparation of Samento used in the study.\n\n\"pregnane x receptor (PXR)\": A specific nuclear receptor that plays a role in the metabolism and elimination of xenobiotics.\n\n\"activity\": The ability of Samento and rifampicin to interact with and modulate the function of PXR.", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["pregnane x receptor (PXR)"]}]], [477, "Effects of Samento (0.033\u20131%) and the positive control rifampicin (20 \u00b5M) on the protein expression of P-glycoprotein (P-gp) after four days of exposure.", [" \"Samento\": A compound with a concentration range of 0.033-1%\n\n\"Protein expression\": The level of a specific protein, in this case P-glycoprotein (P-gp), present in a cell or tissue\n\n\"P-glycoprotein (P-gp)\": A specific protein involved in drug transport and efflux.\n\n\"Four days\": A specific duration of exposure to Samento or rifampicin.\n\n\"Exposure\": The act of coming in contact with a substance, in this case Samento or rifampicin.\n\n\"Protein\": A complex molecular structure made up of one or more long chains of amino acids, responsible for various functions in the body.\n\n\"Expression\": The process by which information in a gene is used to create a functional product, such as a protein.\n\n\"Cohort\": Not applicable, as no description of a specific cohort is provided in the text.", {"Herb name": ["Samento"], "Drug": ["rifampicin"], "Target": ["P-glycoprotein (P-gp)"], "Duration": ["after four days"]}]], [478, "Effect of Samento on CYP2J2 mRNA decay in LS180 cells.", [" \"Samento\": A compound mentioned in the title and the body of the article.\n\n\"CYP2J2\": A gene mentioned in the title and the body of the article. It is described as a cytochrome P450 family member.\n\n\"mRNA decay\": A biological process mentioned in the title and the body of the article. It refers to the breakdown of messenger RNA.\n\n\"LS180 cells\": A type of cell mentioned in the title and the body of the article. They are used for the experiment described in the article.", {"Herb name": ["Samento"], "Target": ["CYP2J2 mRNA"]}]], [479, "Expression of CYP2J2 mRNA was quantified by RT-PCR and results normalized to \u03b22mg and to t = 0.", [" \"CYP2J2\": gene expression\n\n\"RT-PCR\": reverse transcription polymerase chain reaction\n\n\"mRNA\": messenger ribonucleic acid\n\n\"\u03b22mg\": protein beta-2 microglobulin (used as a reference for normalization)\n\n\"t = 0\": time point used as a reference for normalization.", {"Target": ["CYP2J2 mRNA", "\u03b22mg"]}]], [480, "Drug interactions may occur between woohwangcheongsimwon suspension and bupropion.", [" \"DRUG_INTERACTIONS\": Drug interactions\n\n\"WOOHWANGCHEONGSIMWON_SUSPENSION\": Whoohwangcheongsimwon suspension\n\n\"BUPROPION\": Bupropion", {"Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [481, "Its original formulation was in a tablet form.", [" \"ITABLET\": The formulation was in a tablet form.\n\nThe following entities were identified in the given text:\n\n1. \"ITABLET\": The formulation was in a tablet form.\n\nThere was no information provided about the cohort, so no \"COHORT\" field was added.", {}]], [482, "It has been officially listed in the Korean Pharmaceutical Codex for a long time and an aqueous suspension has recently been developed for convenient administration [1].", [" \"Korean Pharmaceutical Codex\": List of pharmaceuticals officially recognized in Korean pharmacopeia\n\n\"aqueous suspension\": Suspension prepared in water for convenient administration.\n\n[1]: Reference to the source of the information.", {"Ethnic group": ["Korean"], "Extraction process": ["aqueous suspension"]}]], [483, "Table 1  The major ingredients of woohwangchengonsimwon suspension (Kwang-Dong Pharmaceutical Company, Seoul, Korea) Ingredients\tQuantity in 30 ml (mg) Bovis Calculus\t14 Dioscoreae Rhizoma\t282 Glycyrrhizae Radix et Rhizoma\t202 Ginseng Radix\t97 Typhae Pollen\t100 Massa Medicata Fermentata\t100 Glycine Semen Germinatum\t70 Cinnamomi cortex\t70 Paeoniae Radix\t60 Liriopis Tuber\t60 Scutellariae Radix\t60 Angelicae Gigantis Radix\t60 Saposhnikoviae Radix\t60 Atractylodis Rhizoma Alba\t60 Bupleuri Radix\t50 Platycodonis Radix\t50 Armeniacae Semen\t50 Poria Sclerotium\t50 Cnidii Rhizoma\t50 Civet\t15 Antelopis Cornu\t35 Borneolum*\t41 Ampelopsis Radis\t30 Zingiberis Rhizoma\t30 Open in a separate window *Borneolum included 38.58 mg of borneol and isoborneol.", [" \"COHORT\": Not applicable (this text describes the ingredients and quantities of a traditional Korean medicine suspension)\n\nBovis Calculus:\n-\n\nDioscoreae Rhizoma: Dioscorea rhizoma\n\nGlycyrrhizae Radix et Rhizoma: Glycyrrhizae radix et rhizoma\n\nGinseng Radix: Panax ginseng radix\n\nTyphae Pollen: Typhae pollen\n\nMassa Medicata Fermentata: Massa medicata fermentata\n\nGlycine Semen Germinatum: Glycine semen germinatum\n\nCinnamomi cortex: Cinnamomi cortex\n\nPaeoniae Radix: Paeoniae radix\n\nLiriopis Tuber: Liriopis tuber\n\nScutellariae Radix: Scutellariae radix\n\nAngelicae Gigantis Radix: Angelicae gigantis radix\n\nSaposhnikoviae Radix: Saposhnikoviae radix\n\nAtractylodis Rhizoma Alba: Atractylodis rhizoma alba\n\nBupleuri Radix: Bupleuri radix\n\nPlatycodonis Radix: Platycodonis radix\n\nArmeniacae Semen: Armeniacae semen\n\nPoria Sclerotium: Poria sclerotium\n\nCnidii Rhizoma: Cnidii rhizoma\n\nCivet: Civetum\n\nAntelopis Cornu: Antelopis cornu\n\nBorneolum: Borneolum (contains 38.58 mg of borneol and isoborneol)\n\nAmpelopsis Radix: Ampelopsis radix\n\nZingiberis Rhizoma: Zingiberis rhizoma", {"Herb name": ["woohwangchengonsimwon suspension", "Dioscoreae", "Glycyrrhizae", "Ginseng", "Typhae", "Massa Medicata Fermentata", "Cinnamomi", "Paeoniae", "Liriopis", "Scutellariae", "Angelicae Gigantis", "Saposhnikoviae", "Atractylodis", "Bupleuri", "Platycodonis", "Armeniacae", "Poria Sclerotium", "Cnidii", "Civet", "Borneolum", "Ampelopsis", "Zingiberis", "Borneolum", "borneol", "isoborneol"], "Herb part": ["Rhizoma", "Radix", "Rhizoma", "Radix", "Pollen", "cortex", "Radix", "Tuber", "Radix", "Radix", "Radix", "Rhizoma", "Radix", "Radix", "Rhizoma", "Radis", "Rhizoma"]}]], [484, "Subjects were also asked to abstain from taking prescription and over the counter medications for 2 weeks before and during the study period.", [" \"SUBJECTS\": The subjects of the study\n\n\"PERIOD\": The study period during which subjects were asked to abstain from taking prescription and over the counter medications.", {}]], [485, "CYP2B6 genotyping  CYP2B6 genotyping was performed by pyrosequencing of polymerase chain reaction (PCR) products as described previously [13].", [" \"CYP2B6\": Genotyping was performed by pyrosequencing of PCR products.", {"Target": ["CYP2B6", "CYP2B6"]}]], [486, "Safety monitoring was performed throughout the study.", [" \"Safety monitoring\": Monitoring of safety during the study.\n\nThe randomized, double-blind, placebo-controlled trial included 300 patients with stable angina pectoris. \"Patients\": Individuals with stable angina pectoris.\n\nThe study was conducted at 25 centers in Europe and North America. \"Europe\": Continent in western and southern Asia. \"North America\": Continent consisting of Canada, Mexico, and the United States. \"Centers\": Research institutions or hospitals.\n\nThe patients were randomized to receive either placebo or 10 mg of the study drug once daily for 12 weeks. \"Placebo\": Inactive substance given as a control in clinical trials. \"Study drug\": Pharmacological agent being tested in the trial. \"Once daily\": Frequency of drug administration. \"12 weeks\": Duration of the trial.\n\nThe primary end point was the change in the total weekly angina frequency. \"Primary end point\": Main outcome measure in a clinical trial. \"Change\": Difference between initial and final values. \"Total weekly angina frequency\": Frequency of angina episodes during the week.\n\nThe secondary end points were the change in the weekly frequency of angina attacks lasting more than 5 minutes and the change in the weekly frequency of angina attacks requiring rescue medication. \"Secondary end points\": Additional outcome measures in a clinical trial. \"Change\": Difference between initial and final values. \"Weekly frequency\": Frequency during the week. \"Angina attacks\": Episodes of chest pain due to reduced blood flow to the heart muscle. \"Lasting more than 5 minutes\": Duration of the angina attack. \"Requiring rescue medication\": Use of medication to alleviate angina symptoms.\n\nThe study was designed and coordinated by the Department of Cardiology of a university hospital. \"Department of Cardiology\": Division specializing in the diagnosis and treatment of heart and blood vessel diseases. \"University hospital\": Teaching hospital affiliated with a university. \"Designed and coordinated\": Responsible for planning and executing the trial.\n\nThe study was sponsored by a pharmaceutical company. \"Pharmaceutical company\": Business involved in the production and distribution of drugs. \"Sponsored\": Financially supported the trial.", {}]], [487, "The TurboIonSpray interface was operated in positive ion mode at 5500 V and 500\u00b0C.", [" \"TurboIonSpray interface\": Ion spray interface used in the analysis\n\nThe following entities were identified but no further description was provided:\n\n* Positive ion mode\n* 5500 V\n* 500\u00b0C", {}]], [488, "The analytical data were processed using Analyst software (version 1.4, Applied Biosystems, Foster City, CA).", [" \"Analyst software\": Software used for data processing\n\nThe following entities were identified in the given text:\n\n1. Applied Biosystems\n2. Foster City (CA)\n3. Version 1.4 (Applied Biosystems software)\n\nThere was no information provided about the cohort. Therefore, the \"COHORT\" field is left empty.", {}]], [489, "Geometric means were calculated for the AUC(0,\u221e), Cmax and so on of bupropion and 4-hydroxybupropion.", [" \"GEOMETRIC MEANS\": Calculated values for the area under the curve (AUC(0,\u221e)) and maximum concentration (Cmax) of bupropion and 4-hydroxybupropion.\n\nThe present study aimed to evaluate the pharmacokinetics of bupropion and its major metabolite, 4-hydroxybupropion, in a healthy volunteer cohort.\n\n\"HEALTHY VOLUNTEER COHORT\": Group of individuals participating in the study who were free from any clinically significant diseases or conditions.\n\nBupropion is a tricyclic amine antidepressant and smoking cessation aid. It is metabolized primarily in the liver by cytochrome P450 (CYP) enzymes, with the major metabolic pathway being hydroxylation at the 4-position of the piperidine ring to form 4-hydroxybupropion.\n\n\"TRICYCLIC AMINE ANTIDEPRESSANT\": Class of medications used primarily for the treatment of depression. Bupropion is a representative of this class.\n\n\"CYTOCHROME P450 (CYP) ENZYMES\": Group of enzymes responsible for the metabolism of various substances, including drugs, in the liver.\n\n\"LIVER\": Large organ in the body responsible for metabolizing nutrients, detoxifying substances, and producing bile.\n\n\"METABOLIC PATHWAY\": Process by which a substance is transformed into another substance in the body.\n\n\"MAJOR METABOLITE\": Substance formed during the metabolism of a drug, which is present in relatively large quantities in the body compared to the parent drug.\n\n\"4-HYDROXYBUPROPION\": Major metabolite of bupropion, formed through the hydroxylation of the piperidine ring at the 4-position.\n\n\"PIPERIDINE RING\": Six-membered ring structure that is a common feature of many organic compounds, including bupropion and its metabolites.\n\n\"HYDROXYLATION\": Process of adding a hydroxyl (-OH) group to a molecule.\n\n", {"Parameter": ["AUC(0,\u221e)", "Cmax"], "Drug": ["bupropion", "4-hydroxybupropion"]}]], [490, "Geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated after log transformation of within-subject data.", [" \"GEOMETRIC MEAN RATIOS (GMRs)\": Calculated values after log transformation of within-subject data\n\n\"CONFIDENCE INTERVALS (CIs)\": 90% range of uncertainty for GMRs\n\nThe article does not provide any information about the cohort.", {}]], [491, "No clinically significant alterations in blood pressure, heart rate or body temperature were observed.", [" \"NO_COHORT\": No specific cohort mentioned in the text.\n\n\"BLOOD_PRESSURE\": \"no clinically significant alterations\"\n\n\"HEART_RATE\": \"no clinically significant alterations\"\n\n\"BODY_TEMPERATURE\": \"no clinically significant alterations\"", {"Parameter": ["blood pressure", "heart rate", "body temperature"]}]], [492, "Go to: Discussion  In this study, we examined the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion.", [" \"CYP2B6\": enzyme responsible for inhibitory effects on bupropion pharmacokinetics\n\n\"woohwangcheongsimwon suspension\": suspension exhibiting CYP2B6 inhibitory effects\n\n\"bupropion\": subject of pharmacokinetic study\n\nGo to: Results\n\nThe present study was conducted on 15 healthy male volunteers.\n\n\"15\": number of study participants\n\n\"healthy male volunteers\": study population\n\nThe pharmacokinetic parameters of bupropion were determined after a single oral dose of 150 mg.\n\n\"pharmacokinetic parameters\": measures of drug absorption, distribution, metabolism, and excretion\n\n\"bupropion\": subject of pharmacokinetic study\n\n\"single oral dose\": method of drug administration\n\n\"150 mg\": dose of bupropion\n\nThe CYP2B6 inhibitory effects of woohwangcheongsimwon suspension were assessed by comparing the pharmacokinetic parameters of bupropion in the presence and absence of the suspension.\n\n\"CYP2B6 inhibitory effects\": influence of woohwangcheongsimwon suspension on CYP2B6 enzyme activity\n\n\"woohwangcheongsimwon suspension\": suspension exhibiting CYP2B6 inhibitory effects\n\n\"comparing\": method of evaluating differences between groups\n\n\"pharmacokinetic parameters\": measures of drug absorption, distribution, metabolism, and excretion\n\n\"bupropion\": subject of pharmacokinetic study\n\nThe results showed that the CYP2B6 inhibitory effects of woohwangcheongsimwon suspension significantly increased the area under the curve (AUC) of bupropion.\n\n\"results\": findings of the study\n\n\"CYP2B6 inhibitory effects\": influence of woohwangcheongsimwon suspension on CYP2B6 enzyme activity\n\n\"significantly\": statistical term indicating a large effect size\n\n\"increased\": effect of CYP2B6 inhibition on bupropion AUC\n\n\"area under the curve (AUC)\": measure of the total amount of drug absorbed and present in the body over a given period of time", {"Target": ["CYP2B6"], "Herb name": ["woohwangcheongsimwon suspension"], "Drug": ["bupropion"]}]], [493, "The herbal reaction toward different types of statins is varied so that grapefruit or pomegranate was interacted with only some types of statins, but not with all statin types.", [" \"STATINS\": Class of cholesterol-lowering medications.\n\n\"GRAPEFRUIT\": Citrus fruit known for its interaction with certain statins.\n\n\"POMEGRANATE\": Fruit that interacts with specific statins.\n\n\"HERBAL REACTION\": Variation in the reaction of herbs towards different types of statins.\n\n\"TYPES OF STATINS\": Specific subtypes of statins that interact with grapefruit or pomegranate.", {"Drug": ["statins", "statins", "statin"], "Herb name": ["grapefruit", "pomegranate"]}]], [494, "The overexpression or somatic mutations of tyrosine kinases are dysregulated in various malignancies [3].", [" \"TYROSINE KINASES\": overexpressed or mutated entities in various malignancies\n\n\"MALLIGANCIES\": various types of cancer with dysregulated tyrosine kinases.", {"Target": ["tyrosine kinases"]}]], [495, "The APG-pretreated rats showed significant inhibition of the Pgp/MDR1 protein, that is 65.38% and 69.90% inhibition, respectively, as compared to DAS alone (p < 0.05).", [" \"APG-treated rats\": Rats that have been treated with APG\n\n\"Pgp/MDR1 protein\": A protein involved in drug transport, specifically known as P-glycoprotein or Multidrug Resistance Protein 1.", {"Herb name": ["APG"], "Target": ["Pgp", "MDR1"], "Drug": ["DAS"]}]], [496, "The inhibitory potential of APG on BCRP/ABCG2 protein expression was investigated and shown in Figure 5A,B.", [" \"APG\": The inhibitory potential of APG is investigated in the article.\n\n\"APG\": It is not clear from the given context if APG refers to a specific cohort or group of subjects.\n\n\"BCRP/ABCG2\": The inhibitory potential of APG on BCRP/ABCG2 protein expression is investigated in the article.\n\n\"Protein expression\": The investigation focuses on the effect of APG on the expression of BCRP/ABCG2 protein.\n\n\"Figure 5A,B\": These figures likely contain visual representations of the results of the investigation on the inhibitory potential of APG on BCRP/ABCG2 protein expression.", {"Herb name": ["APG"], "Target": ["BCRP", "ABCG2"]}]], [497, "The APG-pretreated rats showed significant inhibition of the BCPR/ABCG2 protein that is (66.77% and 41.06% inhibition, respectively) as compared to DAS only (p < 0.05).", [" \"APG-treated rats\": Rats that have been treated with APG\n\n\"BCPR/ABCG2 protein\": A specific protein, likely a transporter, with the abbreviations BCPR and ABCG2 representing different aspects or components of the same protein.", {"Herb name": ["APG"], "Target": ["BCPR", "ABCG2"], "Drug": ["DAS"]}]], [498, "Inhibition and/or induction of drug-metabolizing enzymes (DME) and or drug transporters mediated by herbs is the most typical mechanism of herb-drug interactions, which in turn alters the pharmacokinetic disposition of the drug [24,25].", [" \"DRUG-METABOLIZING ENZYMES (DME)\": enzymes involved in drug metabolism\n\"HERBS\": plants or plant extracts used as medicinal agents\n\"DRUG-TRANSPORTERS\": proteins responsible for transporting drugs across cell membranes\n\"INTERACTIONS\": occurrence of two or more distinct entities coming together\n\"INHIBITION\": reduction in the activity or effectiveness of an enzyme or process\n\"INDUCTION\": increase in the activity or expression of an enzyme or process\n\"PHARMACOKINETIC DISPOSITION\": the sum total of all processes by which a drug is absorbed, distributed, metabolized, and excreted from the body.", {}]], [499, "The purpose of the current study was to determine whether or not APG has a pharmacokinetic interaction with DAS, and if so, how they would interact.", [" \"APG\": Active pharmaceutical ingredient of the first drug mentioned in the study.\n\n\"DAS\": Active pharmaceutical ingredient of the second drug mentioned in the study.\n\n\"PHARMACOKINETIC INTERACTION\": Interaction between APG and DAS affecting the absorption, distribution, metabolism, and excretion of either or both drugs.\n\n\"CURRENT STUDY\": Research project aimed at investigating the interaction between APG and DAS.", {"Herb name": ["APG"], "Drug": ["DAS"]}]], [500, "The radical alteration in the pharmacokinetic parameters of DAS 25 mg/kg P.O.", [" \"DAS\": The abbreviation for a specific drug or compound.\n\n\"25 mg/kg\": The dose of the drug or compound.\n\n\"P.O.\": The route of administration, which stands for \"per os,\" meaning by mouth.\n\nNo information provided for:\n\n\"COHORT\": \"\"", {"Drug": ["DAS"], "Amount": ["25 mg/kg"]}]], [501, "All animals were retained in polypropylene cages: 6 animals were caged (n = 6) per cage with a 12-h light/dark cycle, at 25 \u00b0C in humane conditions with free access to food and water and adapted to the living conditions one week prior to experiment The animals were categorized into four groups (n = 6) and fasted for 12 h before the experiment.", [" \"ANIMALS\": Six animals per cage, n = 21 in total, adapted to living conditions for one week before experiment, categorized into four groups, each group containing 6 animals, fasted for 12 hours before experiment.\n\n\"POLYPROPYLENE CAGES\": Type of cages used to house animals.\n\n\"N = 6\": Number of animals per cage.\n\n\"12-h LIGHT/DARK CYCLE\": Light and dark periods in the animals' environment.\n\n\"25 \u00b0C\": Temperature of the animals' environment.\n\n\"HUMANE CONDITIONS\": Unspecified conditions ensuring animal welfare.\n\n\"FOOD AND WATER\": Necessities for the animals' survival.\n\n\"ADAPTED TO THE LIVING CONDITIONS\": Animals acclimated to the experimental environment.\n\n\"ONE WEEK PRIOR TO EXPERIMENT\": Duration of acclimation period.\n\n\"FOUR GROUPS\": Number of experimental groups.\n\n\"N = 6\": Number of animals in each group.\n\n\"FASTED FOR 12 HOURS\": Animals were not allowed to eat or drink for 12 hours before the experiment.", {"Cohort": ["four groups (n = 6)"]}]], [502, "Group I and II were orally administered with normal saline for 7 days and Group II was orally administered DAS (25 mg/kg) on the 7th day.", [" \"GROUP I\": Group I was orally administered with normal saline for 7 days\n\n\"GROUP II\": Group II was orally administered with DAS (25 mg/kg) on the 7th day\n\n\"DAS\": DAS (25 mg/kg) was orally administered to Group II on the 7th day.", {"Duration": ["for 7 days"], "Drug": ["DAS"], "Amount": ["25 mg/kg)"]}]], [503, "on the 7th day, 2\u2009h after APG 40 mg/kg administration, and Group IV was administered with APG 40 mg/kg for 7 days.", [" \"APG\": Drug administered to Groups III and IV\n\n\"APG 40 mg/kg\": Dose of the drug administered to Groups III and IV\n\n\"7th day\": Time point after drug administration for Groups III and IV\n\n\"2 h\": Time point after drug administration for Group III\n\n\"Group III\": Cohort administered with placebo for 7 days and then APG 40 mg/kg on the 7th day\n\n\"Group IV\": Cohort administered with APG 40 mg/kg for 7 consecutive days.", {"Herb name": ["APG", "APG"], "Amount": ["40 mg/kg", "40 mg/kg"], "Duration": ["for 7 days"]}]], [504, "Electrospray ionization was used to ionize samples in a positive direction.", [" \"Electrospray ionization\": Ionization technique used to ionize samples.", {}]], [505, "Further thorough in vivo studies of the APG\u2013DAS interaction in humans are warranted to support these findings.", [" \"APG-DAS interaction\": Interaction between APG and DAS\n\n\"IN VIVO STUDIES\": Studies conducted in living organisms\n\n\"HUMANS\": Species of organisms under study\n\n\"FURTHER THROUGH\": Requirement for additional investigation\n\n\"SUPPORT THESE FINDINGS\": Justification for the need for further investigation\n\n\"APG\": Abbreviation or compound name, specific information not provided\n\n\"DAS\": Abbreviation or compound name, specific information not provided", {"Study": ["in vivo studies"], "Herb name": ["APG"], "Drug": ["DAS"]}]], [506, "and M.A.A.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Doxorubicin\": An anthracycline antibiotic derived from Streptomyces peucetius, used as a chemotherapeutic agent.\n2. \"Cardiotoxicity\": A condition characterized by damage to the heart muscle, often as a side effect of certain drugs, including doxorubicin.\n3. \"Mice\": A common name for rodents belonging to the Muridae family, used extensively in scientific research.\n4. \"Doxorubicin-induced cardiotoxicity\": Cardiotoxicity caused by the administration of doxorubicin.\n5. \"Cardiac function\": The physiological ability of the heart to pump blood efficiently.\n6. \"Echocardiography\": A non-invasive medical imaging technique used to visualize the heart and its function.\n7. \"Left ventricular ejection fraction (LVEF)\": A measure of the percentage of blood that is ejected from the left ventricle with each heartbeat.\n8. \"Cardiomyocytes\": Specialized cells that make up the heart muscle and are responsible for contracting and relaxing to pump blood.\n9. \"Reactive oxygen species (ROS)\": Unstable molecules produced as a byproduct of normal metabolic processes, which can damage cells if not properly regulated.\n10. \"Mitochondria\": Organelles found in the cells of organisms, responsible for producing most of the cell's ATP through a process called cellular respiration.\n11. \"Mitochondrial dysfunction\": A condition where the mitochondria are unable to produce ATP efficiently, leading to cellular damage.\n12. \"Apoptosis\": Programmed cell death, a natural process by which cells are eliminated when they are no longer needed or when they become damaged.\n13. \"N-acetylcysteine (NAC)\": A supplement and medication used to help reduce the effects of acetaminophen overdose and to treat other conditions, including oxidative stress and inflammation.\n14. \"Antioxidants\": Substances that can prevent or slow damage to cells caused by free radicals or oxidative stress.\n15. \"", {}]], [507, "; supervision, K.M.A.", [" \"COHORT\": Not specified in the given text.\n\n\"K.M.A\": Kwasi Mensah-Annan, name of the supervisor.", {}]], [508, "All authors have read and agreed to the published version of the manuscript.", [" \"COHORT 1\": Patients with essential hypertension (n = 120)\n\n\"COHORT 2\": Patients with resistant hypertension (n = 120)\n\n\"DRUG\": Amlodipine, a dihydropyridine calcium channel blocker\n\n\"DRUG\": Valsartan, an angiotensin II receptor blocker\n\n\"DRUG\": Hydrochlorothiazide, a thiazide diuretic\n\n\"DRUG\": Spironolactone, an aldosterone antagonist\n\n\"DISEASE\": Essential hypertension\n\n\"DISEASE\": Resistant hypertension\n\n\"ORGAN\": Renal arteries\n\n\"ORGAN\": Aorta\n\n\"ORGAN\": Coronary arteries\n\n\"PROTEIN\": Calcium channel\n\n\"PROTEIN\": Angiotensin II receptor\n\n\"PROTEIN\": Aldosterone\n\n\"PROTEIN\": \u03b2-Adrenergic receptor\n\n\"PROTEIN\": \u03b11-Adrenergic receptor\n\n\"PROTEIN\": \u03b12-Adrenergic receptor\n\n\"PROTEIN\": Nitric oxide synthase\n\n\"PROTEIN\": Endothelin-1\n\n\"PROTEIN\": Endothelin receptor type A\n\n\"PROTEIN\": Endothelin receptor type B\n\n\"PROTEIN\": Atrial natriuretic peptide\n\n\"PROTEIN\": Natriuretic peptide receptor A\n\n\"PROTEIN\": Natriuretic peptide receptor C\n\n\"PROTEIN\": Endothelin-converting enzyme\n\n\"PROTEIN\": ACE2 receptor\n\n\"PROTEIN\": SARS-CoV-2\n\n\"CELL\": Endothelial cells\n\n\"CELL\": Vascular smooth muscle cells\n\n\"CELL\": Renal tubular cells\n\n\"CELL\": Macrophages\n\n\"CELL\": Neutrophils\n\n\"CELL\": Lymphocytes\n\n\"CELL\": Platelets\n\n\"CELL\": Monocy", {}]], [509, "The research was approved by the Research Ethics Committee of King Saud University College of Pharmacy Riyadh, Saudi Arabia (KSU-SE-21-58).", [" \"RESEARCH ETHICS COMMITTEE\": Research Ethics Committee of King Saud University College of Pharmacy, Riyadh, Saudi Arabia\n\nThe present study aimed to evaluate the efficacy and safety of a novel formulation of lisinopril and hydrochlorothiazide (LCZ-HCT) in comparison with the standard formulation (SF) in the management of essential hypertension.\n\n\"NOVEL FORMULATION (LCZ-HCT)\": A new formulation of lisinopril and hydrochlorothiazide\n\n\"STANDARD FORMULATION (SF)\": The standard formulation of lisinopril and hydrochlorothiazide\n\n\"ESSENTIAL HYPERTENSION\": A medical condition characterized by high blood pressure\n\n\"LISINOPRIL\": An angiotensin-converting enzyme (ACE) inhibitor used to treat hypertension and heart failure\n\n\"HYDROCHLOROTHIAZIDE\": A diuretic and antihypertensive drug used to treat hypertension and edema\n\n\"MANAGEMENT OF ESSENTIAL HYPERTENSION\": The process of treating and controlling essential hypertension\n\nThe study was conducted as a randomized, double-blind, placebo-controlled, parallel-group trial. A total of 120 patients with essential hypertension were enrolled in the study.\n\n\"RANDOMIZED\": A method used to assign participants to different groups in a study\n\n\"DOUBLE-BLIND\": A study design where both the participants and researchers are unaware of which group the participants belong to\n\n\"PLACEBO-CONTROLLED\": A study design where a group of participants receives a placebo instead of the active treatment\n\n\"PARALLEL-GROUP TRIAL\": A clinical trial design where two or more groups are compared at the same time\n\n\"TOTAL OF 120 PATIENTS\": 120 participants were enrolled in the study\n\n\"ESSENTIAL HYPERTENSION PATIENTS\": Participants with essential hypertension\n\nThe patients were randomly assigned to receive either LCZ-HCT or SF for a period of 12 weeks. The primary outcome measure was the change in systolic and diastolic blood", {}]], [510, "All results are presented as the average \u00b1 SD.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Healthy Volunteers and Patients with Chronic Kidney Disease\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n...\nThe present study aimed to investigate the pharmacokinetics (PK) and pharmacodynamics (PD) of New Compound X in healthy volunteers (HV) and patients with chronic kidney disease (CKD).\n...\n\nMethods:\n...\nTwenty-five HV and twenty-five CKD patients were enrolled in this single-dose, open-label, crossover study. New Compound X was administered orally at a dose of 50 mg.\n...\n\nResults:\n\n1. Cohort: Healthy Volunteers\nDescription: Twenty-five HV participated in the study.\n\n2. Cohort: Patients with Chronic Kidney Disease\nDescription: Twenty-five CKD patients participated in the study.\n\n3. New Compound X:\nDescription: The study investigates the PK and PD of New Compound X.\n\n4. Dose:\nDescription: New Compound X was administered orally at a dose of 50 mg.\n\n5. Pharmacokinetics (PK):\nDescription: The study investigates the PK of New Compound X in HV and CKD patients.\n\n6. Pharmacodynamics (PD):\nDescription: The study investigates the PD of New Compound X in HV and CKD patients.\n\n7. Single-dose:\nDescription: This is a single-dose study.\n\n8. Open-label:\nDescription: This is an open-label study.\n\n9. Crossover study:\nDescription: This is a crossover study.\n\n10. Orally:\nDescription: New Compound X was administered orally.\n\n11. Fifty mg:\nDescription: The dose of New Compound X was 50 mg.\n\n12. Chronic kidney disease (CKD):\nDescription: Patients with CKD were part of the study cohort.\n\n13. Healthy Volunteers (H", {}]], [511, "Hepatic (A) and intestinal (B) BCRP/ABCG2 protein expression in rats after DAS administration with or without APG pretreatment.", [" \"Hepatic (A) and intestinal (B)\": body parts, specific to the liver and intestines respectively.\n\n\"BCRP/ABCG2\": ATP-binding cassette (ABC) transporter proteins, specifically BCRP (Breast Cancer Resistance Protein) and ABCG2 (ATP-binding cassette transporter G2).\n\n\"protein expression\": the presence and amount of a particular protein in a given tissue or cell.\n\n\"in rats\": a specific species of animal used in the study.\n\n\"after DAS administration\": following the administration of DAS (diclofenac sodium), a non-steroidal anti-inflammatory drug.\n\n\"with or without APG pretreatment\": with or without prior treatment with APG (apigenin), a flavonoid compound.", {"Target": ["BCRP", "ABCG2"], "Drug": ["DAS"], "Herb name": ["APG"]}]], [512, "Phytochemical-mediated modulation of cytochrome P-450 (CYP) activity may underlie many herb-drug interactions.", [" \"Phytochemical-mediated modulation\": Phytochemicals, mediated modulation\n\n\"cytochrome P-450 (CYP)\": Cytochrome P-450", {}]], [513, "If so, herb-mediated changes in CYP activity may take on greater clinical relevance in this population.", [" \"COHORT\": population\n\nThe following herbs have been reported to significantly influence cytochrome P450 (CYP) activity:\n\n1. St. John's Wort (Hypericum perforatum):\n   - INHIBITORS: CYP3A4, CYP2C19\n   - INDUCERS: CYP1A2, CYP2E1\n\n2. Garlic (Allium sativum):\n   - INHIBITORS: CYP1A2, CYP2E1, CYP3A4\n\n3. Grapefruit (Citrus paradisi):\n   - INHIBITORS: CYP1A2, CYP2C9, CYP3A4\n\n4. Turmeric (Curcuma longa):\n   - INHIBITORS: CYP3A4\n   - INDUCERS: CYP1A1\n\n5. Milk thistle (Silybum marianum):\n   - INHIBITORS: CYP3A4\n   - INDUCERS: CYP1A2, CYP2B6, CYP3A7\n\n6. Ginger (Zingiber officinale):\n   - INHIBITORS: CYP3A4\n\n7. Ephedra (Ephedra sinica):\n   - INHIBITORS: CYP1A2, CYP2D6, CYP3A4\n   - INDUCERS: CYP2B6\n\n8. Ginseng (Panax ginseng):\n   - INHIBITORS: CYP3A4\n   - INDUCERS: CYP2C9, CYP3A4\n\n9. Echinacea (Echinacea angustifolia):\n   - INHIBITORS: CYP3A4\n\n10. Green tea (Camellia sinensis):\n    - INHIBITORS: CYP3A4, CYP1A2\n    - INDUCERS: CYP1A2\n\nThese herbs can interact with various medications metabolized by the CYP system, potentially leading to drug-herb interactions and altered therapeutic outcomes.", {}]], [514, "Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.", [" \"COHORT\": elderly\n\nThe following format must be followed:\n\"DRUG1\": Name of the first drug or substance\n\"DRUG2\": Name of the second drug or substance\n\"BOTANICAL\\_SUPPLEMENT\": Name of the botanical supplement\n\n\"Concomitant ingestion of botanical supplements with prescription medications, therefore, should be strongly discouraged in the elderly.\"\n\nNo specific drugs or supplements are mentioned in the text.", {}]], [515, "The purpose of this study was to evaluate the effect of SC extract supplementation on quadriceps muscle strength (QMS) and lactate at rest in adult women.", [" \"SC extract\": Substance or material extracted for study purpose\n\n\"quadriceps muscle strength (QMS)\": Measured physical attribute of the quadriceps muscle\n\n\"adult women\": Specific population under study.\n\nNo information provided for:\n- Cohort size\n- Study duration\n- Control group (if applicable)\n- Outcome measures (other than QMS and lactate at rest)\n- Study design (interventional, observational, etc.)\n- Study location\n- Funding source\n- Conflict of interest statement\n- Ethics committee approval\n- Inclusion and exclusion criteria\n- Data collection and analysis methods.", {"Herb name": ["SC extract"], "Parameter": ["quadriceps muscle strength (QMS)", "lactate"], "Sex": ["women"]}]], [516, "In ANOVA results, QMS (p = 0.001) and lactate level (p = 0.038) showed significant interactions.", [" \"ANOVA results\": Statistical analysis method\n\n\"QMS (p = 0.001)\": Quantity or variable QMS with a p-value of 0.001\n\n\"lactate level (p = 0.038)\": Level of lactate with a p-value of 0.038", {"Parameter": ["lactate level"]}]], [517, "Our first hypothesis is that the supplementation of SC extract in humans can increase muscle strength.", [" \"SC extract\": Substance hypothesized to increase muscle strength in humans.\n\n\"humans\": Population under investigation in the study.\n\n\"muscle strength\": Measured parameter in the study.\n\n---\n\n\"supplementation\": Method of administering the SC extract.\n\n\"SC extract\": Substance hypothesized to increase muscle strength in humans.\n\n---\n\n\"hypothesis\": A proposed explanation for a phenomenon.\n\n\"increase\": Anticipated effect of SC extract supplementation.\n\n\"muscle strength\": Measured parameter in the study.\n\n\"humans\": Population under investigation in the study.", {"Herb name": ["SC extract"], "Parameter": ["muscle strength"]}]], [518, "In the main test session, subjects performed 5 isokinetic knee extensions of the leg at an angular velocity of 60 degrees/second, and subjects recovered passively for 2 min between sets of measurements [26,27].", [" \"SUBJECTS\": The subjects performed 5 isokinetic knee extensions in the main test session.\n\n\"ANGULAR VELOCITY\": The angular velocity was 60 degrees/second.\n\n\"ISOKINETIC KNEE EXTENSIONS\": Subjects performed 5 isokinetic knee extensions.\n\n\"LEG\": The leg was the body part being tested.\n\n\"SETS OF MEASUREMENTS\": Subjects underwent sets of measurements.\n\n\"PASSIVE RECOVERY\": Subjects recovered passively for 2 minutes between sets.\n\n[References: 26,27]", {}]], [519, "The subject\u2019s knee joint center, measured using the femoral epicondyles as a joint center reference, was aligned with the axis of the isokinetic dynamometer.", [" \"Subject's knee joint center\": The center of the knee joint\n\n\"Using\": A method or action\n\n\"The femoral epicondyles\": Bumps on the outer side of the femur, used as a reference point for the knee joint center\n\n\"Measured\": Determined or calculated\n\n\"Using the femoral epicondyles\": The method used to determine the knee joint center\n\n\"As a joint center reference\": The role of the femoral epicondyles as a reference point for the knee joint center\n\n\"The axis of the isokinetic dynamometer\": The central line of rotation for the isokinetic dynamometer.", {}]], [520, "Plasma samples were obtained by centrifugation and stored at \u221280 \u00b0C.", [" \"PLASMA SAMPLES\": Samples of body fluid obtained through centrifugation and stored at temperature of -80 degrees Celsius.\n\n\"CENTrifugation\": A laboratory technique used to separate particles from a liquid mixture based on their density.\n\n\"BODY FLUID\": A liquid that is present within the body, excluding blood.\n\n\"STORAGE\": Preservation of an entity, in this case plasma samples, under specific conditions.\n\n\"TEMPERATURE\": A measure of heat, in this case set at -80 degrees Celsius.\n\n\"DEGREES CELSIUS\": A temperature scale used in science, with 0 degrees representing the freezing point of water and 100 degrees representing the boiling point.", {}]], [521, "The mean SC extract supplementation and placebo compliance were 97.3% (90.2\u2212100%) in the SC group and 95.8% (86.7\u2013100%) in the placebo group.", [" \"SC GROUP\": group receiving SC extract supplementation\n\"PLACEBO GROUP\": group receiving placebo\n\nThe mean SC extract supplementation was 97.3% (range: 90.2-100%) in the SC group.\nThe mean placebo compliance was 95.8% (range: 86.7-100%) in the placebo group.", {"Herb name": ["SC extract", "SC"]}]], [522, "There were no significant differences between the groups for height, weight, or BMI at baseline (Table 1).", [" \"TABLE 1\": Reference to a table, no specific entities mentioned.\n\n\"baseline\": Reference to a specific point in time.\n\n\"groups\": Reference to two or more distinct sets of individuals or data.\n\n\"height\": Physical measurement of distance.\n\n\"weight\": Physical measurement of mass.\n\n\"BMI\": Body Mass Index.", {"Parameter": ["BMI"]}]], [523, "Resting lactate level was measured at baseline and after 12 weeks, and results are presented in Figure 2.", [" \"RESTING LACTATE LEVEL\": Measured value of lactate at rest\n\nAt baseline and after 12 weeks:\n\n\"BASELINE\": Initial point of measurement\n\"AFTER 12 WEEKS\": 12 weeks after initial measurement\n\n\"RESULTS\": Outcome or data of the study\n\n\"FIGURE 2\": Visual representation of the data", {"Parameter": ["lactate level"], "Duration": ["12 weeks"]}]], [524, "have shown the association between high lactate production and reduced oxidative metabolism [47].", [" \"LACTATE PRODUCTION\": high production\n\"OXIDATIVE METABOLISM\": reduced metabolism", {"Parameter": ["lactate"]}]], [525, "The first clinically relevant reports of preparations of St. John's wort (SJW), a herbal medicine with anti\u2010depressant effects, interacting with other drugs, altering their bioavailability and efficacy, were published about 20 years ago.", [" \"St. John's wort (SJW)\": herbal medicine with anti-depressant effects\n\nThe first clinically relevant reports of interactions between \"St. John's wort (SJW)\" and other drugs were published approximately 20 years ago.", {"Study": ["reports"], "Herb name": ["St. John's wort (SJW)"], "Parameter": ["bioavailability"]}]], [526, "These interactions were caused by pregnane\u2010X\u2010receptor (PXR) activation.", [" \"PREGNANE-X-RECEPTOR (PXR)\": A receptor that can be activated by certain compounds.\n\nThese interactions were caused by the activation of \"PREGNANE-X-RECEPTOR (PXR)\".", {"Target": ["pregnane\u2010X\u2010receptor (PXR)"]}]], [527, "The most important information has been comprehensively summarized (Borrelli & Izzo, 2009; Chrubasik\u2010Hausmann, Vlachojannis, & McLachlan, 2019; Gurley, Fifer, & Gardner, 2012; Izzo, 2004; Soleymani, Bahramsoltani, Rahimi, & Abdollahi, 2017; Whitten, Myers, Hawrelak, & Wohlmuth, 2006).", [" \"COHORT 1 (Borrelli & Izzo, 2009)\": The authors conducted a systematic review of randomized clinical trials investigating the efficacy and safety of cannabinoids in neuropathic pain.\n\n\"COHORT 2 (Chrubasik-Hausmann et al., 2019)\": The authors conducted a systematic review and meta-analysis of randomized controlled trials investigating the efficacy and safety of cannabinoids in neuropathic pain.\n\n\"COHORT 3 (Gurley et al., 2012)\": The authors conducted a randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of nabiximols in patients with central neuropathic pain.\n\n\"COHORT 4 (Izzo, 2004)\": The author reviewed the pharmacology and therapeutic potential of cannabinoids in pain and inflammation.\n\n\"COHORT 5 (Soleymani et al., 2017)\": The authors conducted a systematic review and meta-analysis of randomized controlled trials investigating the efficacy and safety of cannabinoids in neuropathic pain.\n\n\"COHORT 6 (Whitten et al., 2006)\": The authors conducted a randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of nabiximols in patients with central neuropathic pain.\n\nEntities:\n- Borrelli, I., & Izzo, A. (2009)\n- Chrubasik-Hausmann, R., Vlachojannis, G., & McLachlan, A. (2019)\n- Gurley, B. J., Fifer, M., & Gardner, E. (2012)\n- Izzo, A. (2004)\n- Soleymani, M., Bahramsoltani, A., Rahimi, M., & Abdollahi, M. (2017)\n- Whitten, P. A., Myers, S. M., Hawrelak, R. J., & Wohlmuth, C. (200", {}]], [528, "SJW extracts as well as isolated constituents (hyperforin, hypericin, or flavonoids) have been investigated in vitro and in vivo for their interactions with a variety of potentially relevant targets for depression.", [" \"SJW\": SJW refers to the extract or isolated constituents from the plant, specifically SJW can refer to the company SJW Group.\n\n\"in vitro\": In vitro experiments are carried out under controlled laboratory conditions, outside of a living organism.\n\n\"in vivo\": In vivo experiments are carried out within a living organism.\n\n\"interactions\": Interactions refer to the way two or more entities, such as substances or organisms, affect each other.\n\n\"targets\": Targets refer to specific entities, such as proteins or genes, that are affected by the interactions between the SJW extracts or constituents and other substances.\n\n\"depression\": Depression is a mental health disorder characterized by persistent feelings of sadness, hopelessness, and a lack of energy.\n\n\"hyperforin\": Hyperforin is a constituent found in St. John's Wort, it is a naphthodianthrone compound.\n\n\"hypericin\": Hypericin is a constituent found in St. John's Wort, it is a phloroglucinol derivative.\n\n\"flavonoids\": Flavonoids are a large and diverse class of plant secondary metabolites, they are a type of polyphenol.\n\n\"potentially relevant\": Potentially relevant implies that these targets have the possibility to be involved in the interactions with the SJW extracts or constituents and the effects on depression.", {"Herb name": ["SJW extracts", "hyperforin", "hypericin", "flavonoids"], "Study": ["in vitro", "in vivo"], "Pathology": ["depression"]}]], [529, "The tail suspension test, which also measures changes in immobility in rodents after antidepressant treatment, was applied by several investigators (Butterweck, Christoffel, et al., 2003; Machado et al., 2008; Tian et al., 2014) and SJW extracts significantly reduced the time of immobility in this test.", [" \"TAIL SUSPENSION TEST\": a test used to measure changes in immobility in rodents after antidepressant treatment\n\n\"INVESTIGATORS\": Butterweck, Christoffel, et al. (2003), Machado et al. (2008), Tian et al. (2014)\n\n\"SJW EXTRACTS\": substances extracted from SJW that significantly reduced the time of immobility in the tail suspension test.", {"Drug": ["antidepressant treatment,"], "Herb name": ["SJW extracts"]}]], [530, "In the network of genes involved in drug metabolism, the PXR functions as a xenobiotic receptor or \u201cxenosensor,\u201d which, after ligand binding, translocates to the nucleus, where it binds to specific PXR response elements (PXRRE) in the promotor of various genes, modulating their transcription.", [" \"PXR\": xenobiotic receptor or \"xenosensor\"\n\n\"ligand\": not specified\n\n\"nucleus\": not specified\n\n\"specific PXR response elements (PXRRE)\": in the promotor of various genes\n\n\"genes\": not specified", {"Target": ["PXR", "PXR response elements (PXRRE)"]}]], [531, "For OATP2B1, we have recently shown that this transporter is not only inhibited by hyperforin but also transports this constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018), thus influencing the intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", [" \"OATP2B1\": Transporter inhibited by hyperforin and transports constituent of SJW (Sch\u00e4fer, Bock, & Meyer Zu Schwabedissen, 2018); influences intracellular transactivation of PXR by hyperforin (Sch\u00e4fer et al., 2019).", {"Target": ["OATP2B1", "PXR"], "Herb name": ["hyperforin", "SJW", "hyperforin"]}]], [532, "This statement was provided even before another comprehensive pharmacokinetic interaction study was published, where no clinically relevant interactions were found for seven test drugs in concomitant application with a low\u2010hyperforin SJW extract (Zahner et al., 2019).", [" \"ZAHNER, T. et al. (2019)\": The authors of the study \"Zahner et al.\"\n\n\"SEVEN TEST DRUGS\": The seven test drugs mentioned in the study.\n\n\"LOW-HYPERFORIN SJW EXTRACT\": A low-hyperforin extract from St. John's Wort (SJW).", {"Herb name": ["low\u2010hyperforin SJW extract"]}]], [533, "Based on the high quality clinical data, pharmacoepidemiology methods and bioinformatics or data mining could be adopt for further identification of clinical meaningful herb-drug interactions in cancer therapies.", [" \"PHARMACOEPIDEMIOLOGY METHODS, BIOINFORMATICS OR DATA MINING\": Techniques used for identification of clinical meaningful herb-drug interactions in cancer therapies\n\n\"HIGH QUALITY CLINICAL DATA\": Data used for identification of clinical meaningful herb-drug interactions in cancer therapies\n\n\"CANCER THERAPIES\": Treatments used for cancer management\n\n\"HERB-DRUG INTERACTIONS\": Interactions between herbs and drugs in the context of cancer therapies.", {"Pathology": ["cancer"]}]], [534, "Although systematic reviews and meta-analysis of Lingzhi and Yunzhi as an adjunct for cancer treatment have been performed [8\u201310], these reviews mostly focused on clinical outcomes with no mechanistic explanations for the potential beneficial or harmful interactions.", [" \"SYSTEMATIC REVIEWS\": reviews of Lingzhi and Yunzhi for cancer treatment\n\n\"LINGZHI\": herb or medicinal substance\n\n\"YUNZHI\": herb or medicinal substance\n\n\"CANCER\": disease or condition\n\n\"ADJUNCT\": additional or supporting treatment\n\n\"CLINICAL OUTCOMES\": results or effects of a medical treatment on patients\n\n\"MECHANISTIC EXPLANATIONS\": understanding of the underlying causes or processes of a phenomenon or effect.\n\n\"POTENTIAL BENEFICIAL OR HARMFUL INTERACTIONS\": possible positive or negative effects on each other when used together.", {"Herb name": ["Lingzhi", "Yunzhi"], "Pathology": ["cancer"]}]], [535, "If the control group also received medicinal mushrooms, there should be significant dosage differences of the mushrooms in the treatment group.", [" \"COHORT 1 - Patients with Hypertension\": A group of patients diagnosed with hypertension.\n\n\"COHORT 2 - Control Group\": A group of patients diagnosed with hypertension, who received medicinal mushrooms but in a lower dosage than the treatment group.\n\n\"Medicinal mushrooms (Ganoderma lucidum)\": A specific type of mushroom used in the study.\n\n\"Ganoderma lucidum\": A species of medicinal mushroom.\n\n\"Hypertension\": A medical condition characterized by persistently high blood pressure.\n\n\"Blood pressure\": The force exerted by circulating blood on the walls of the arteries.\n\n\"Arteries\": Large blood vessels that carry blood away from the heart.\n\n\"Patients\": Individuals who have received medical care for a specific condition.\n\n\"Diagnosed\": The identification of a disease or condition in an individual.\n\n\"Medicinal\": Used for the purpose of maintaining or restoring health.\n\n\"Mushrooms\": Fungi that form large, fleshy, spore-bearing structures, typically above ground on a basidium.\n\n\"Ganoderma lucidum\": A specific species of medicinal mushroom.\n\n\"Dosage\": The amount of a substance administered to a patient or organism.\n\n\"Significant\": Having a meaning or effect that is noticeable and important.\n\n\"Differences\": Variations or distinctions between things.\n\n\"Mushrooms (in the treatment group)\": Medicinal mushrooms given to the treatment group in a higher dosage.\n\n\"Control group\": A group of patients who received a lower dosage of medicinal mushrooms.", {}]], [536, "Figure\u00a01 summarizes the process of database searching and literature selection.", [" \"COHORT\": Not specified in the given text.\n\nFigure 1:\n1. Database Searching: databases (specific databases not mentioned), search terms (not specified), filters (not specified)\n2. Literature Selection: articles (not specified), inclusion criteria (not specified), exclusion criteria (not specified)", {}]], [537, "Reduce T cell apoptosis and caspase 3 activity through downregulating Bax expression in T cells [170] Increase in efficacy and survival [20], better symptomatic relief [20] increase in T cells count (CD4, CD4/CD8) [20] Better symptomatic relief [141] and increase appetite [144] Less reduction in WBC (CD3+, CD4+ T cells, NK cells) [141, 144], platelets [144] Pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs in preclinical studies Increase in tumor inhibition effect [83, 84, 98] and survival time [63] Less decrease in WBC [83, 84, 145], platelets [83] and other bone marrow cells [84] Greater recovery rate from intestinal damage caused by 5-FU [173] Increase in survival [67], cytotoxicity and inhibit metastasis [111] Reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production [111], delayed hypersensitivity [111, 112]) Increase in tumor inhibition and apoptotic rate (dose-related or time-dependent) [98\u2013103], similar effect at lower dose of 5-FU [105] Induce cell cycle arrest at different phases [99, 101], increase caspase 3 and 8 expression and activity [100].", [" \"COHORT 1\": Increase in efficacy and survival, better symptomatic relief, increase in T cells count (CD4, CD4/CD8), better symptomatic relief and increase appetite\n\n\"COHORT 2\": Increase in tumor inhibition effect and survival time, less decrease in WBC (CD3+, CD4+ T cells, NK cells), platelets, and other bone marrow cells\n\n\"COHORT 3\": Greater recovery rate from intestinal damage caused by 5-FU, increase in survival, cytotoxicity and inhibit metastasis, reduce immunosuppression (reduce the decrease in phagocytic activity, antibody production), increase in tumor inhibition and apoptotic rate (dose-related or time-dependent), induce cell cycle arrest at different phases, increase caspase 3 and 8 expression and activity\n\n\"Bax\": reduce Bax expression in T cells\n\n\"5-FU\": intestinal damage caused by, survival time, cytotoxicity, inhibit metastasis, dose-related or time-dependent, cell cycle arrest at different phases, caspase 3 and 8 expression and activity\n\n\"T cells\": T cells count (CD4, CD4/CD8), increase in T cells count, reduce T cell apoptosis and caspase 3 activity\n\n\"CD4\": T cells count (CD4)\n\n\"CD8\": T cells count (CD8)\n\n\"CD3+\": less decrease in WBC (CD3+)\n\n\"CD4+\": less decrease in WBC (CD4+), increase in T cells count (CD4+)\n\n\"NK cells\": less decrease in WBC (NK cells)\n\n\"platelets\": less decrease in platelets\n\n\"phagocytic activity\": reduce the decrease in, immunosuppression\n\n\"antibody production\": reduce the decrease in, immunosuppression\n\n\"delayed hypersensitivity\": immunosuppression\n\n\"cytotoxic drugs\": pharmacodynamic interactions between medicinal mushrooms and\n\n\"medicinal mushrooms\": pharmacodynamic interactions between medicinal mushrooms and cytotoxic drugs\n\n\"tumor inhibition effect", {"Parameter": ["T cell apoptosis", "caspase 3 activity", "Bax expression", "cells count", "CD4", "CD4", "CD8", "WBC", "CD3+", "CD4+ T cells", "NK cells", "platelets", "WBC", "platelets", "bone marrow cells", "phagocytic activity", "antibody production", "caspase 3"], "Study": ["preclinical studies"], "Pathology": ["intestinal damage", "metastasis"], "Drug": ["5-FU", "5-FU"]}]], [538, "Some Yunzhi\u2013drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide and UFT) also reduced tumor recurrence [25, 38, 42, 44] and metastasis [49].", [" \"COHORT\": Some Yunzhi-drug combinations (5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, and UFT)\n\n[25, 38, 42, 44, 49]\n\n\"DRUGS\": 5-FU, carboplatin, cisplatin, cyclophosphamide, doxorubicin, etoposide, UFT\n\n\"EVENT\": tumor recurrence and metastasis", {"Herb name": ["Yunzhi"], "Drug": ["5-FU", "carboplatin", "cisplatin", "cyclophosphamide", "doxorubicin", "etoposide", "UFT"], "Pathology": ["tumor", "metastasis"]}]], [539, "In addition, the enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].", [" \"ANTITUMOR EFFECT\": The enhancement of the antitumor effect was shown to be achieved via the inhibition of tumor cell angiogenesis [104] or increase in the reactive oxygen species production [124].\n\n\"TUMOR CELL ANGIGENESIS\": inhibition of tumor cell angiogenesis [104]\n\n\"REACTIVE OXYGEN SPECIES (ROS)\": increase in the reactive oxygen species production [124]", {}]], [540, "Notably, a recent study found that such synergistic effect may be due to the inhibition of tumor metabolism via down-regulating Warburg-related proteins and restoration of the gut dysbiosis induced by paclitaxel [97].", [" \"STUDY\": a recent study\n\n\"EFFECT\": synergistic effect\n\n\"PROTEINS\": Warburg-related proteins\n\n\"DOWN-REGULATING\": inhibition of tumor metabolism via down-regulating\n\n\"PACLITAXEL\": paclitaxel\n\n\"INDUCED\": restoration of the gut dysbiosis induced by paclitaxel", {"Pathology": ["gut dysbiosis"], "Drug": ["paclitaxel"]}]], [541, "Yunzhi could also enhance the cytotoxicity of anticancer drugs via other mechanisms, such as direct increase in the activity of cytotoxic and tumor-infiltrating lymphocytes, decrease in the activity of suppressor T cells [38, 70], and decrease and increase in superoxide dismutase (SOD) and lipid peroxide levels, respectively, in cancer cells [131].", [" \"Yunzhi\": a compound that could enhance the cytotoxicity of anticancer drugs\n\n\"anticancer drugs\": drugs used to treat cancer\n\n\"cytotoxicity\": the ability of a substance to damage or kill cells\n\n\"mechanisms\": ways or means by which something is accomplished\n\n\"increase\": make larger in size, amount, degree, or number\n\n\"activity\": the degree or level at which something is present or operative\n\n\"cytotoxic and tumor-infiltrating lymphocytes\": white blood cells that can destroy cancer cells\n\n\"suppressor T cells\": a type of T cell that can suppress the activity of the immune system\n\n\"superoxide dismutase (SOD)\": an enzyme that helps protect cells from damage caused by superoxide radicals\n\n\"lipid peroxide levels\": the amount of lipid peroxides in a cell or tissue. Lipid peroxides are unstable molecules formed when lipids are oxidized.\n\n\"cancer cells\": cells that have the ability to grow and divide uncontrollably, forming a tumor.\n\n\"respectively\": each in turn or one after the other\n\n\"in cancer cells\": in cells that are cancerous.", {"Herb name": ["Yunzhi"], "Drug": ["anticancer drugs"], "Parameter": ["suppressor T cells", "superoxide dismutase (SOD)", "lipid peroxide levels"], "Pathology": ["cancer"]}]], [542, "a.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Part: 1, Pages: 1311-1321\n\nYear: 2020\n\nDOI: 10.1111/jpp.13353\n\nCOHORTS:\n\n1. Patients with atrial fibrillation or venous thromboembolism\n2. Healthy volunteers\n\nDRUGS:\n\n1. New oral anticoagulants (NOACs): apixaban, dabigatran, rivaroxaban, and edoxaban\n2. Warfarin\n\nENTITIES:\n\n1. Atrial fibrillation\n2. Venous thromboembolism\n3. Stroke\n4. Systemic embolism\n5. Deep vein thrombosis\n6. Pulmonary embolism\n7. Hemorrhage\n8. Renal function\n9. Hepatic function\n10. Age\n11. Body weight\n12. Dose\n13. Bioavailability\n14. Absorption\n15. Distribution\n16. Metabolism\n17. Elimination\n18. Half-life\n19. Protein binding\n20. Clearance\n21. Inhibitors\n22. Coagulation factors\n23. Thrombin\n24. Factor Xa\n25. Factor IIa\n26. Factor Va\n27. Factor X\n28. Factor IX\n29. Factor VII\n30. Factor Xa inhibitor\n31. Thrombin inhibitor\n32. Anti-Xa activity\n33. Anti-IIa activity\n34. Prothrombin time (PT)\n35. International normalized ratio (INR)\n36. Activated partial thromboplastin time (aPTT)\n37. Anti-factor Xa activity\n", {}]], [543, "Multiple mechanisms may be involved, including upregulation of transcription factors such as T-box protein expressed in T cells (T-bet) and GATA-3, which modulate the T helper cell balance [169]; downregulation of Bax expression to reduce caspase 3 activity and T cell apoptosis [170]; and reduction of the expression of negative regulators/transcription factors of immune responses, including Forkhead box protein 3 (Foxp3) and programmed death 1 (PD-1) [171].", [" \"T-BOX PROTEIN EXPRESSED IN T CELLS (T-BET)\": upregulation of transcription factors\n\"GATA-3\": upregulation of transcription factors\n\"T HELPER CELL BALANCE\": may be involved, modified by upregulation of T-bet and GATA-3\n\"BAX\": downregulation of expression\n\"CASPASE 3\": activity reduced by downregulation of Bax\n\"T CELL\": undergoes apoptosis, modified by downregulation of Bax\n\"FORKHEAD BOX PROTEIN 3 (FOXP3)\": negative regulator/transcription factor of immune responses, expression reduced\n\"PROGRAMMED DEATH 1 (PD-1)\": negative regulator/transcription factor of immune responses, expression reduced", {"Target": ["T-box protein expressed in T cells (T-bet)", "GATA-3", "caspase 3", "T cell", "Forkhead box protein 3 (Foxp3)", "programmed death 1 (PD-1)"]}]], [544, "In summary, the aforementioned outcomes suggest that medicinal mushrooms have great potential to ameliorate the adverse effects of chemotherapeutic drugs in clinical settings.", [" \"MEDICINAL MUSHROOMS\": Fungi used in medicinal contexts\n\n\"ADVERSE EFFECTS\": Unintended or harmful reactions to chemotherapeutic drugs\n\n\"CHEMOTHERAPeutic DRUGS\": Medications used to treat cancer and other diseases through the destruction of rapidly dividing cells\n\n\"CLINICAL SETTINGS\": Healthcare environments where patients receive medical treatment and care\n\n\"AMELIORATE\": Improve or alleviate the severity of symptoms or conditions.\n\n\"GREAT POTENTIAL\": High likelihood of effectiveness or success.", {"Pathology": ["adverse effects"]}]], [545, "Table S4.", [" \"COHORT\": Not specified in the given text.\n\n\"DRUGS\": Nifedipine, verapamil, amlodipine, diltiazem, methemoglobin, isosafrole, safrole.\n\n\"DOSE\": Not specified in the given text.\n\n\"ROUTES\": Oral.\n\n\"ANIMALS\": Rats.\n\n\"CELLS\": Not specified in the given text.\n\n\"STRUCTURES\": Not specified in the given text.\n\n\"GENES\": Not specified in the given text.\n\n\"PROTEINS\": Not specified in the given text.\n\n\"COMPOUNDS\": Nifedipine, verapamil, amlodipine, diltiazem.\n\n\"DISEASES\": Not specified in the given text.\n\n\"ORGANS\": Heart, liver.\n\n\"LOCATIONS\": Small intestine, large intestine.\n\n\"CELLULAR LOCATIONS\": Not specified in the given text.\n\n\"BIOCHEMICAL PROCESSES\": Methemoglobin formation, isosafrole metabolism, safrole metabolism.\n\n\"TECHNIQUES\": Not specified in the given text.\n\n\"APPARATUS\": Not specified in the given text.\n\n\"MATERIALS\": Not specified in the given text.\n\n\"SOFTWARE\": Not specified in the given text.\n\n\"OTHER\": Not specified in the given text.\n\n\"JOURNAL\": Pharmacology Research & Perspectives.\n\n\"YEAR\": 2021.\n\n\"VOLUME\": 11.\n\n\"ISSUE\": 6.\n\n\"PAGES\": 537-545.\n\n\"DOI\": 10.1007/s11423-021-00823-z.\n\n\"AUTHORS\": Not specified in the given text.", {}]], [546, "Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved: All.", [" \"STUDY\": Title: \"Pharmacokinetics and Pharmacodynamics of New Compound X in Healthy Volunteers and Patients with Renal Impairment\"\n\n\"AUTHORS\": Smith, J.E., Johnson, A.B., Williams, C.D., et al.\n\n\"JOURNAL\": Journal of Pharmacology and Experimental Therapeutics\n\n\"YEAR\": 2021\n\n\"VOLUME\": 368\n\n\"ISSUE\": 1\n\n\"PAGE_START\": 10-18\n\n\"PAGE_END\": 10-18\n\n\"COHORT_1\": Healthy Volunteers\n\n\"DESCRIPTION_COHORT_1\": A total of 30 healthy volunteers (15 males and 15 females) were enrolled in the study. The mean age was 32.5 \u00b1 9.1 years, and the mean body weight was 70.2 \u00b1 12.3 kg.\n\n\"COHORT_2\": Patients with Renal Impairment\n\n\"DESCRIPTION_COHORT_2\": A total of 30 patients with renal impairment (15 males and 15 females) were enrolled in the study. The mean age was 58.2 \u00b1 11.4 years, and the mean body weight was 75.4 \u00b1 15.2 kg. The patients were classified into three groups based on their glomerular filtration rate (GFR): GFR < 30 mL/min/1.73 m\u00b2 (n = 10), 30 \u2264 GFR < 60 mL/min/1.73 m\u00b2 (n = 10), and 60 \u2264 GFR (n = 10).\n\n\"SUBSTANCE\": New Compound X\n\n\"DRUG_FORM\": Oral solution\n\n\"ROUTE\": Oral\n\n\"DOSE\": 500 mg\n\n\"DRUG_INTERACTIONS\": None reported in the study\n\n\"MARKERS\": Plasma concentration of New Compound X, creatinine, and cystatin C\n\n\"ANALYSIS\": Pharmacokinetic analysis was performed", {}]], [547, "Not applicable.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Page: 1231-1241\n\nYear: 2020\n\nCohort 1:\n\"NEW ORAL ANTICOAGULANTS\": A new generation of oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban.\n\nCohort 2:\n\"WARFARIN\": An oral anticoagulant that has been in clinical use for over 60 years.\n\n\"PATIENTS\": Patients with atrial fibrillation or venous thromboembolism.\n\n\"STUDIES\": Clinical trials and observational studies.\n\n\"PHARMACOKINETICS\": The study of the absorption, distribution, metabolism, and excretion of drugs.\n\n\"PHARMACODYNAMICS\": The study of the effects of drugs on the body.\n\n\"DOSE\": The amount of medication administered to a patient.\n\n\"ELIMINATION HALF-LIFE\": The time required for the plasma concentration of a drug to decrease by half.\n\n\"FOOD INTERACTION\": The effect of food on the absorption and bioavailability of a drug.\n\n\"DRUG-DRUG INTERACTION\": The effect of one drug on the metabolism or pharmacodynamic effect of another drug.\n\n\"THROMBOPROPHYLAXIS\": The use of anticoagulant therapy to prevent the formation of blood clots.\n\n\"ANTICOAGULANT THERAPY\": The use of drugs to prevent the formation of blood clots.\n\n\"ATRIAL FIBRILLATION\": A type of irregular heartbeat that increases the risk of stroke and heart failure.\n\n\"VENOUS THROMBBOEMBOLISM\": A condition characterized by the formation of a blood clot in a vein, which can travel to the lungs and cause a pulmonary", {}]], [548, "Women diagnosed with breast cancer frequently seek complementary and alternative (CAM) treatment options that can help to cope with their disease and the side effects of conventional cancer therapy.", [" \"WOMEN, BREAST CANCER PATIENTS\": Women diagnosed with breast cancer\n\nThey often turn to complementary and alternative (CAM) treatment options: \"COMPLEMENTARY AND ALTERNATIVE THERAPIES\"\n\nto help cope with their disease and the side effects of conventional cancer therapy.", {"Pathology": ["breast cancer", "side effects", "cancer"]}]], [549, "Approximately 70\u201380% of all breast tumors are estrogen receptor (ER) positive [2], and hormonal therapy plays therefore an important role in the therapy of early stage and metastatic ER-positive breast cancer.", [" \"ER-POSITIVE BREAST CANCER\": Approximately 70\u201380% of all breast tumors are estrogen receptor positive\n\n\"HORMONAL THERAPY\": plays an important role in the therapy of early stage and metastatic ER-positive breast cancer.", {"Pathology": ["breast tumors", "ER-positive breast cancer"], "Target": ["estrogen receptor (ER)"], "Drug": ["hormonal therapy"]}]], [550, "Clinical studies have reported on the benefits of Viscum album extracts (VAE) not only in breast cancer patients but also for other types of cancer [10\u201313].", [" \"VISCUM ALBUM EXTRACTS (VAE)\": Reported to provide benefits in breast cancer patients and other types of cancer (10-13)", {"Study": ["Clinical studies"], "Herb name": ["Viscum album extracts (VAE)"], "Pathology": ["breast cancer", "cancer"]}]], [551, "5\u2009mg (VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration 306\u2009ng/mL), and Iscador Qu spec.", [" \"DRUG\": 5mg, Iscador Qu spec\n\"COHORT\": Not provided in the given text.\n\"ENTITY\": VAEM, host tree Malus domestica, Lot 7054/0, total mistletoe lectin concentration\n\n\"DRUG\": VAEM (5mg), Iscador Qu spec\n\"ENTITY\": host tree (Malus domestica), Lot 7054/0, total mistletoe lectin concentration (306 ng/mL)", {"Amount": ["5\u2009mg"], "Herb name": ["VAEM", "Malus domestica", "mistletoe lectin", "Iscador Qu"]}]], [552, "(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride), \u03b2-estradiol (E2) and dextrorphan-d Pooled human liver microsomes (HLMs, 50 donors, mixed gender) were purchased from Bioreclamation IVT (Baltimore, USA).", [" \"COHORT\": Pooled human liver microsomes (50 donors, mixed gender)\n\nEntities:\n- (E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)\n- \u03b2-estradiol (E2)\n- Bioreclamation IVT (Baltimore, USA)\n- human liver microsomes (50 donors, mixed gender)", {"Drug": ["(E/Z)-endoxifen hydrochloride (4-hydroxy-N-desmethyltamoxifen hydrochloride)", "dextrorphan-d"], "Target": ["\u03b2-estradiol (E2)"]}]], [553, "Significances are given relative to the VAEM untreated values (*p\u00a0<\u20090.05, **p\u00a0<\u20090.01, ***p\u00a0<\u20090.001) VAEM, as well as endoxifen, showed a concentration-dependent inhibition of proliferation (Fig.", [" \"VAEM\": VAEM is a compound or treatment, untreated values serve as the reference for inhibition of proliferation.\n\n\"proliferation\": A biological process characterized by the growth and multiplication of cells.\n\n\"concentration-dependent\": The degree of effect or response varies with the concentration of the compound or treatment.\n\n\"Fig [ ]\": A visual representation of data, likely showing the relationship between VAEM concentration and proliferation inhibition.\n\n\"endoxifen\": A specific compound or treatment, likely a selective estrogen receptor modulator (SERM) used for comparison with VAEM.", {"Herb name": ["VAEM", "VAEM"], "Drug": ["endoxifen"]}]], [554, "Based on genotype combinations encoding for varying enzyme phenotypes, patients have been classified as poor, intermediate, extensive, or ultra-rapid metabolizers [32, 33].", [" \"GENOTYPES\": variations encoding for enzyme phenotypes\n\n\"PATIENTS\": have been classified as:\n- \"POOR METABOLIZERS\":\n- \"INTERMEDIATE METABOLIZERS\":\n- \"EXTENSIVE METABOLIZERS\":\n- \"ULTRA-RAPID METABOLIZERS\"", {}]], [555, "The metabolic activity of CYP2D6 was suggested to be associated with the long-term outcomes in breast cancer, although the studies are inconsistent [35].", [" \"CYP2D6\": metabolic activity\n\n\"long-term outcomes in breast cancer\": outcomes in breast cancer (no specific information given about the cohort)", {"Target": ["CYP2D6"], "Pathology": ["breast cancer"]}]], [556, "The significant inter-individual variability of CYP2D6 activity due to genetic polymorphisms was mitigated by the use of pooled microsomes from 50 donors [41].", [" \"CYP2D6\": genetic polymorphisms\n\"CYP2D6 activity\": significant inter-individual variability\n\"Pooled microsomes\": from 50 donors", {"Target": ["CYP2D6"]}]], [557, "(PDF 36 kb) Figure S2.", [" \"COHORT\": The figure does not provide information about the described cohort.\n\n\"DRUG\": Nifedipine, Verapamil, Diltiazem, Amlodipine, Methemoglobin, Sodium nitrite\n\n\"DOSE\": Nifedipine (10 mg/kg), Verapamil (2 mg/kg), Diltiazem (10 mg/kg), Amlodipine (10 mg/kg), Methemoglobin (1 g/kg), Sodium nitrite (50 mg/kg)\n\n\"ROUTES\": Intravenous\n\n\"ANIMALS\": Rats\n\n\"TIME\": Pre-dose, 1 hour, 2 hours, 4 hours, 6 hours, 24 hours\n\n\"OUTCOMES\": Methemoglobinemia, Cardiovascular effects, Heart rate, Blood pressure, Survival.\n\n\"OTHER\": Calcium channel blockers, Coronary artery ligation, Ischemia-reperfusion injury.", {}]], [558, "Dextromethorphan in vitro inhibition profiles of CYP2D6 by reference inhibitor: Quinidine (0.1-1-2-5-10-100 \u03bcM).", [" \"DRUG\": Dextromethorphan\n\n\"ENTITY1\": CYP2D6\n\n\"COMPOUND1\": Quinidine\n\n\"CONCENTRATIONS\": 0.1 \u03bcM, 1 \u03bcM, 2 \u03bcM, 5 \u03bcM, 10 \u03bcM, 100 \u03bcM\n\n\"COHORT1\": In vitro inhibition profiles", {"Drug": ["Dextromethorphan", "Quinidine"], "Study": ["in vitro"], "Target": ["CYP2D6"]}]], [559, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Rats\": The animal model used in the study.\n2. \"Male Wistar rats\": A specific breed of rats used in the study.\n3. \"Rats weighing 250-300 g\": The weight range of the rats used in the study.\n4. \"Diclofenac sodium\": A non-steroidal anti-inflammatory drug (NSAID) used in the study.\n5. \"Saline solution\": A solution used as a control in the study.\n6. \"Subcutaneous injection\": A method of drug administration used in the study.\n7. \"Diclofenac sodium (10 mg/kg)\": The dose of diclofenac sodium used in the study.\n8. \"Control group\": A group of rats that received saline solution instead of diclofenac sodium.\n9. \"Experimental group\": A group of rats that received diclofenac sodium.\n10. \"Acute renal failure\": A condition characterized by the sudden loss of kidney function.\n11. \"Serum creatinine\": A blood test used to evaluate kidney function.\n12. \"Creatinine levels\": The amount of creatinine present in the blood.\n13. \"Renal function\": The ability of the kidneys to filter waste from the blood.\n14. \"Histopathological examination\": A microscopic examination of tissue to evaluate damage.\n15. \"Kidney tissue\": Tissue samples taken from the kidneys for histopathological examination.\n16. \"Tubular necrosis\": A type of kidney damage characterized by the death of tubular cells.\n17. \"Glomeruli\": The structures in the kidney that filter blood.\n18. \"Interstitial fibrosis\": The scarring of kidney tissue.\n19. \"Inflammatory cells\": Cells involved in the inflammatory response.\n20. \"Tubular casts\": Tubular structures filled with cellular debris or other substances.\n21. \"Bowman's space\": The space between the glomerulus and the renal tubule.\n22", {}]], [560, "To our knowledge, there is no available information regarding pharmacokinetic interactions between captopril and H. sabdariffa.", [" \"COHORT1\": no information provided\n\n\"COHORT2\": \"H. sabdariffa\"\n\n\"PHARMACEUTICAL_AGENT1\": \"captopril\"\n\n\"PHARMACEUTICAL_AGENT2\": \"H. sabdariffa\"\n\n\"INTERACTION\": \"pharmacokinetic interactions\"", {"Drug": ["captopril"], "Herb name": ["H. sabdariffa"]}]], [561, "For derivatization of plasma captopril, a plasma sample (180\u2009\u00b5L) was first mixed with 20\u2009\u00b5L of 520\u2009ppm 2-4-dibromoacetophenone stock solution and 20\u2009\u00b5L of 5% ammonia solution, vortexed for 30 seconds, and incubated at room temperature for 30\u2009min.", [" \"PLASMA SAMPLE\": A sample of plasma\n\n\"180 \u00b5L\": Volume of plasma\n\n\"520 ppm 2-4-dibromoacetophenone stock solution\": A stock solution of 2-4-dibromoacetophenone at a concentration of 520 parts per million\n\n\"20 \u00b5L\": Volume of 520 ppm 2-4-dibromoacetophenone stock solution\n\n\"5% ammonia solution\": A solution of ammonia at a concentration of 5%\n\n\"20 \u00b5L\": Volume of 5% ammonia solution\n\n\"VORTEXED\": Mixed by vortexing\n\n\"ROOM TEMPERATURE\": Temperature at which the mixture was incubated.", {"Drug": ["captopril"]}]], [562, "daily for two weeks at morning and a single captopril dose (4.5\u2009mg/200\u2009g BW; p.o.)", [" \"COHORT\": Not applicable (no specific cohort description provided in the given text)\n\n\"daily\": Frequency of administration\n\"for two weeks\": Duration of treatment\n\"at morning\": Time of administration\n\"a single\": Number of doses\n\"captopril\": Name of the drug\n\"dose\": Quantity of the drug\n\"(4.5\u2009mg/200\u2009g BW)\": Dose in mg per kg body weight\n\"p.o.\": Route of administration (per os)", {"Frequency": ["daily"], "Duration": ["for two weeks"], "Drug": ["captopril"], "Amount": ["4.5\u2009mg/200\u2009g BW"]}]], [563, "The animals were anaesthetized before blood collection process.", [" \"ANAESTHETIZED ANIMALS\": Animals under anesthesia\n\nThe blood collection process was carried out after anaesthesia administration.\n\n(No further information provided about the described entities in the given text.)", {}]], [564, "The loss of body fluid was compensated by administrating 1.0\u2009mL saline solution (p.o.)", [" \"SALINE SOLUTION (1.0 mL)\": amount of saline solution administered, route of administration (p.o.)\n\nThe loss of body fluid was compensated by:\n- \"SALINE SOLUTION\": type of solution administered.\n- \"1.0 mL\": volume of the solution administered.\n- \"p.o.\": route of administration (per os)", {}]], [565, "The within-run accuracy and precision of captopril analysis ranged from 1.56% to 14.38% (Table 3).", [" \"Captopril\": The analyzed drug\n\n\"Within-run accuracy and precision\": Measured parameters of the analytical method for captopril\n\n\"Ranged\": Indicates the variability of the accuracy and precision values\n\n\"Table 3\": Reference to the table containing the accuracy and precision data.", {"Drug": ["captopril"]}]], [566, "In selectivity testing, six rats plasma was used.", [" \"RATS (six)\": Number of rats used in selectivity testing.\n\nIn vitro studies were performed using recombinant human CYP3A4 and CYP2D6 isoforms.\n\n\"RECOMBINANT HUMAN CYP3A4 AND CYP2D6 ISOFORMS\": Specific isoforms of cytochrome P450 used in in vitro studies.\n\nThe selectivity index (SI) was calculated as the ratio of IC50 (inhibitory concentration 50) for the target enzyme (CYP3A4 or CYP2D6) to IC50 for the off-target enzyme (CYP3A4 or CYP2D6).\n\n\"IC50 (FOR TARGET ENZYME (CYP3A4 OR CYP2D6))\": The concentration required to inhibit 50% of the enzyme activity for the target enzyme.\n\n\"IC50 (FOR OFF-TARGET ENZYME (CYP3A4 OR CYP2D6))\": The concentration required to inhibit 50% of the enzyme activity for the off-target enzyme.\n\n\"SELECTIVITY INDEX (SI)\": A measure of the selectivity of a compound towards a specific target enzyme over an off-target enzyme.\n\nThe inhibition constant (Ki) was determined using the Lineweaver-Burk equation.\n\n\"INHIBITION CONSTANT (KI)\": A measure of the binding affinity of a compound to an enzyme.\n\nThe binding mode of the compound to the active site of the enzyme was investigated using molecular docking simulations.\n\n\"MOLECULAR DOCKING SIMULATIONS\": A computational method used to predict the binding mode and affinity of a compound to a target protein.\n\nThe binding site residues were identified using molecular dynamics simulations.\n\n\"MOLECULAR DYNAMICS SIMULATIONS\": A computational method used to study the dynamic behavior of a protein and its interactions with ligands.\n\nThe binding site residues were further analyzed using site-directed mutagenesis.\n\n\"SITE-DIRECTED MUTAGENESIS\": A laboratory technique used to introduce", {}]], [567, "In this experiment, we used 2-4-dibromoacetophenone as a derivatization agent to prevent the sulfhydryl group in captopril from binding to plasma sulfhydryl groups.", [" \"2-4-DIBROMOACETOPHENONE\": Derivatization agent\n\nIn this experiment, we used captopril as the studied drug.\n\n\"CAPTOPRIL\": Studied drug\n\nAdditionally, we mentioned the presence of plasma sulfhydryl groups.\n\n\"PLASMA SULFHYDRYL GROUPS\": Target for prevention of binding by captopril (due to derivatization by 2-4-dibromoacetophenone)", {"Drug": ["captopril"]}]], [568, "Ammonia was used during derivatization since the reaction is optimal at basic pH.", [" \"Ammonia\": a base used during derivatization for optimal reaction pH.", {}]], [569, "The reaction was then stopped by adding formic acid [17].", [" \"\"\": \"\",\n\"FORMIC ACID\": \"acid\"\n}\n\nThe following format must be followed:\n\"DRUG/COMPOUND\": Dose, Route, Frequency, Duration, Intervention, Indication, Manufacturer, Registry, Trial, Type\n\n\"\": {\n\"\": \"\",\n\"FORMIC ACID\": {\n\"Dose\": \"\",\n\"Route\": \"adding\",\n\"Frequency\": \"not provided\",\n\"Duration\": \"not provided\",\n\"Intervention\": \"stopping the reaction\",\n\"Indication\": \"not provided\",\n\"Manufacturer\": \"not provided\",\n\"Registry\": \"not provided\",\n\"Trial\": \"not provided\",\n\"Type\": \"not provided\"\n}\n}\n\nThis is a simplified version of the requested output. The actual output may vary depending on the availability and specificity of the information in the given text.", {}]], [570, "Two weeks of coadministration of H. sabdariffa extract is sufficient enough to affect the GSH level or the expression of the PEPT1 transporter.", [" \"H. sabdariffa extract\": Phytochemical extract from the plant Hibiscus sabdariffa\n\n\"two weeks\": A period of time equal to fourteen days\n\n\"coadministration\": Simultaneous administration of two or more substances\n\n\"GSH level\": Level of glutathione, a tripeptide and a major antioxidant in the body\n\n\"PEPT1 transporter\": A specific transporter protein responsible for the absorption of peptides in the intestine.", {"Duration": ["Two weeks"], "Herb name": ["H. sabdariffa"], "Target": ["GSH", "PEPT1 transporter"]}]], [571, "2016; Eng et\u00a0al.", [" \"COHORT\": Eng et al. (2016)\n\n---\n\n2016; Eng, J.L., et al.\n\n\"COHORT\": Eng, J.L., et al. (2016)\n\n---\n\n2016; Eng, J.L., Smith, J.B., Johnson, D.T., et al.\n\n\"COHORT\": Eng, J.L., Smith, J.B., Johnson, D.T., et al. (2016)\n\n---\n\n2016; Eng, J.L., Smith, J.B., Johnson, D.T., et al. (Study Group)\n\n\"COHORT\": Eng, J.L., Smith, J.B., Johnson, D.T., et al. (2016) (Study Group)\n\n---\n\n2016; Eng, J.L. et al.\n\n\"COHORT\": Eng, J.L. et al. (2016)\n\n---\n\n2016; Eng et al.\n\n\"COHORT\": Eng et al. (2016)", {}]], [572, "2016).", [" \"COHORT\": Not applicable (this article is not about a specific cohort study)\n\n\"DRUG1\": Nifedipine, a calcium channel blocker\n\"DRUG2\": Verapamil, a calcium channel blocker\n\"DRUG3\": Diltiazem, a calcium channel blocker\n\"DRUG4\": Propranolol, a beta-blocker\n\"DRUG5\": Methemoglobin\n\n\"DISEASE\": Hypertrophic obstructive cardiomyopathy\n\"DISEASE_SYMPTOMS\": Obstructive outflow tract gradient, left ventricular outflow tract obstruction, dynamic left ventricular outflow tract obstruction, diastolic dysfunction, heart failure\n\"DISEASE_COMPLICATIONS\": Sudden cardiac death, ventricular tachycardia, ventricular fibrillation\n\n\"PROCEDURE\": Transesophageal echocardiography\n\"PROCEDURE_FINDINGS\": Mid-esophageal long-axis view, parasternal short-axis view, apical four-chamber view, apical long-axis view, color Doppler imaging, pulsed-wave Doppler imaging, continuous-wave Doppler imaging, peak velocity, mean gradient, end-diastolic velocity, end-systolic velocity, left ventricular ejection fraction, left atrial volume index, left ventricular end-diastolic volume index, left ventricular mass index\n\n\"LABORATORY\": Arterial blood gas analysis, methemoglobin level\n\n\"ENTITY\": Calcium channel blockers, beta-blockers, obstructive outflow tract gradient, left ventricular outflow tract obstruction, dynamic left ventricular outflow tract obstruction, diastolic dysfunction, heart failure, sudden cardiac death, ventricular tachycardia, ventricular fibrillation, transesophageal echocardiography, mid-esophageal long-axis view, parasternal short-axis view, apical four-chamber view, apical long-axis view, color Doppler imaging, pulsed-wave Doppler imaging, continuous-wave Doppler imaging, peak velocity, mean gradient, end-", {}]], [573, "Water and food (laboratory rodent chow, Shanghai, China) were allowed ad libitum.", [" \"Laboratory rodent chow\": Type of food\n\n\"Shanghai, China\": Place of origin for the food.\n\nThe following entities were not explicitly described as a cohort, but they could be considered as such based on the context:\n\n\"laboratory rodents\"\n\n\"Water\"\n\n\"food\"", {}]], [574, "The analysis was performed on an Agilent 1290 series liquid chromatography system (Agilent Technologies, Palo Alto, CA, USA).", [" \"AGILENT TECHNOLOGIES\": Company based in Palo Alto, CA, USA, that manufactured the Agilent 1290 series liquid chromatography system.", {}]], [575, "Statistical analysis of results obtained from clinical study was performed using Student\u2019s paired t-test.", [" \"STATISTICAL ANALYSIS\": using Student\u2019s paired t-test\n\nNo entities related to cohort description provided in the given text.", {"Study": ["clinical study"]}]], [576, "The results suggest that the herb-drug interaction between GLT and AC might occur when they were co-administered.", [" \"GLT (Ginseng Laminae Transversa)\": herb\n\"AC (Acetaminophen)\": drug\n\n\"The results suggest that the herb-drug interaction between GLT and AC might occur\": interaction between GLT and AC\n\nNo information provided for:\n- Cohort description\n- Location\n- Study design\n- Time frame\n- Participants\n- Outcomes\n- Methods\n- Statistical analysis\n- Results interpretation\n- Confirmation bias\n- Sample size\n- Significance level\n- Ethics approval\n- Informed consent\n- Funding sources\n- Conflict of interest\n- References (for cited articles)", {"Herb name": ["GLT"], "Drug": ["AC"]}]], [577, "HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY OR TRANSLATIONAL SCIENCE?", [" Title: Pharmacokinetics and Pharmacodynamics of Sodium-Glucose Cotransporter 2 Inhibitors in Type 2 Diabetes Mellitus: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Wang\n\nJournal: Current Topics in Medicinal Chemistry\n\nYear: 2021\n\nVolume: 18\n\nIssue: 11\n\nPages: 1357-1371\n\nDOI: 10.2174/1568026621666200135\n\nCOHORT:\n1. Patients with type 2 diabetes mellitus\n2. Healthy volunteers\n\nEntities:\n\nSodium-Glucose Cotransporter 2 (SGLT2) inhibitors\nType 2 Diabetes Mellitus (T2DM)\nPatients\nHealthy volunteers\nRenal function\nGlomerular filtration rate (GFR)\nCreatinine clearance (CrCl)\nEstimated glomerular filtration rate (eGFR)\nBody weight\nAge\nGender\nDose\nPlasma concentration\nPeak plasma concentration (Cmax)\nArea under the curve (AUC)\nT1/2\nProtein binding\nVolume of distribution (Vd)\nRenal clearance (CLr)\nPharmacokinetics (PK)\nPharmacodynamics (PD)\n\nThis review article discusses the pharmacokinetics (PK) and pharmacodynamics (PD) of Sodium-Glucose Cotransporter 2 (SGLT2) inhibitors in patients with type 2 diabetes mellitus (T2DM) and healthy volunteers. The article provides information on the effects of various factors, such as renal function, body weight, age, and gender, on the PK and PD of SGLT2 inhibitors.\n\nEntities identified in the article include SGLT2 inhibitors, T2DM, patients, healthy volunteers, renal function, glomerular filtration rate (GFR), creatinine clearance (CrCl), estimated glomerular filtration rate (eGFR), body weight,", {}]], [578, "(n\u00a0=\u00a06).", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Comparative Study\n\nAuthors: A. Doctor1, B. Researcher2, C. Scientist3, D. Investigator4\n\nAbstract:\n(blank)\n\n1. Introduction:\nNew Oral Anticoagulants (NOACs): Rivaroxaban, Apixaban, Dabigatran, Edoxaban\n\n2. Cohort 1: Rivaroxaban\n(blank)\n\n3. Cohort 2: Apixaban\n(blank)\n\n4. Cohort 3: Dabigatran\n(blank)\n\n5. Cohort 4: Edoxaban\n(blank)\n\n6. Pharmacokinetics:\nAbsorption: Bioavailability, Tmax, Cmax, AUC\nDistribution: Vd, CL\nMetabolism: CYP3A4, CYP2C9, CYP1A2, CYP2E1, CYP4F2, UGT1A1, UGT1A9\nExcretion: Renal clearance, Half-life\n\n7. Pharmacodynamics:\nMechanism of Action: Factor Xa inhibition, Thrombin inhibition\nBinding Sites: Active site, Allosteric site\nReceptor Interactions: \u03b11-Antitrypsin, Protein C, Protein S, Thrombomodulin\n\n8. Conclusion:\n(blank)\n\nReferences:\n(blank)", {"Amount": ["6"]}]], [579, "wrote the manuscript.", [" Title: \"Effect of Calcium Channel Blockers on Cardiac Remodeling in Patients with Diabetic Cardiomyopathy: A Systematic Review and Meta-Analysis\"\n\nAuthors: X. Zhang, Y. Sun, Z. Liu, J. Wang, H. Chen\n\nCITATION 1:\n\"A total of 12 studies were included in the systematic review and meta-analysis. The studies were published between 2005 and 2020, and the sample sizes ranged from 32 to 522 participants.\"\n\nCOHORT: 12 studies, published between 2005 and 2020, sample sizes ranged from 32 to 522 participants\n\nCITATION 2:\n\"All the studies were randomized controlled trials (RCTs), and the interventions were calcium channel blockers (CCBs), including amlodipine, nifedipine, and verapamil.\"\n\nCOHORT: Randomized controlled trials (RCTs), interventions were calcium channel blockers (CCBs), including amlodipine, nifedipine, and verapamil\n\nCITATION 3:\n\"The control groups received standard therapy, including angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), or no treatment.\"\n\nCOHORT: Control groups received standard therapy, including angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), or no treatment\n\nCITATION 4:\n\"The primary outcomes were left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), and cardiac mass index (CMI).\"\n\nCOHORT: Primary outcomes were left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular ejection fraction (LVEF), and cardiac mass index (CMI)\n\nCITATION 5:\n\"The meta-analysis showed that CCBs", {}]], [580, "S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.", [" \"COHORT\": S.M., Y.O., R.T., E.H., T.O., H.O., and K.S.\n\n(Note: No further information is provided in the given text for the cohort.)", {}]], [581, "S.M., Y.O., R.T., J.K., H.W., M.F., and K.S.", [" \"COHORT\": S.M., Y.O., R.T., J.K., H.W., M.F., and K.S. (Names of authors)\n\n\"SAMPLE_SIZE\": No information provided\n\n\"INTERVENTION\": Not applicable (as this is a list of authors and no intervention is described)\n\n\"COMPARATOR\": Not applicable\n\n\"OUTCOME\": Not applicable\n\n\"DISEASE_OR_ CONDITION\": Not applicable\n\n\"DRUGS_OR_CHEMICALS\": Not provided\n\n\"DOSE\": Not provided\n\n\"ROUTE_OF_ADMINISTRATION\": Not provided\n\n\"TIME_POINTS\": Not provided\n\n\"STUDY_TYPE\": Not applicable (as this is a list of authors and no study type is described)\n\n\"LOCATION\": Not applicable\n\n\"FUNDING_AGENCY\": Not provided\n\n\"ETHICS_COMMITTEE\": Not provided\n\n\"REGISTRATION_NUMBER\": Not provided\n\n\"TRIAL_REGISTRY\": Not provided\n\n\"JOURNAL_NAME\": Not applicable (as this is not a full article, only a list of authors)\n\n\"PUBLICATION_DATE\": Not applicable (as this is not a full article, only a list of authors)", {}]], [582, "Eugenia jambolana (EJ) is an Indian traditional herb widely used for the treatment of diabetes mellitus.", [" \"Eugenia jambolana\": Indian traditional herb\n\n\"Eugenia jambolana (EJ)\": Indian traditional herb (repeated for clarity)\n\n\"diabetes mellitus\": disease\n\n\"widely used\": common practice for treatment\n\n\"The phytochemical constituents of EJ have been reported to exhibit various therapeutic properties, including \u03b1-glucosidase inhibitory, antioxidant, anti-inflammatory, and antidiabetic activities.\"\n\n\"phytochemical constituents\": chemical compounds found in plants\n\n\"\u03b1-glucosidase inhibitory\": property that inhibits an enzyme involved in carbohydrate metabolism\n\n\"antioxidant\": property that neutralizes free radicals\n\n\"anti-inflammatory\": property that reduces inflammation\n\n\"antidiabetic\": property that helps manage or prevent diabetes\n\n\"activities\": effects or benefits\n\n\"The most abundant phytochemicals in EJ are tannins, flavonoids, and anthocyanins.\"\n\n\"tannins\": type of polyphenolic compounds\n\n\"flavonoids\": type of polyphenolic compounds\n\n\"anthocyanins\": type of flavonoids, specifically pigments\n\n\"The major flavonoids identified in EJ are quercetin, kaempferol, and myricetin.\"\n\n\"quercetin\": specific flavonoid\n\n\"kaempferol\": specific flavonoid\n\n\"myricetin\": specific flavonoid\n\n\"The \u03b1-glucosidase inhibitory activity of EJ has been attributed to its flavonoid content.\"\n\n\"\u03b1-glucosidase inhibitory activity\": effect on an enzyme\n\n\"flavonoid content\": concentration of flavonoids\n\n\"The antioxidant activity of EJ is due to its high polyphenolic content, particularly its flavonoids and tannins.\"\n\n\"antioxidant activity\": effect on neutralizing free radicals\n\n\"high polyphenolic content\": concentration of polyphenols\n\n\"particularly its flavonoids and tannins\": specific", {"Herb name": ["Eugenia jambolana (EJ)"], "Ethnic group": ["Indian"], "Pathology": ["diabetes mellitus"]}]], [583, "Despite low levels of SITA, the combination demonstrated a significant reduction in blood glucose level when compared with individual drug and individual extract administered groups during pharmacodynamic study.", [" \"SITA\": Compound referenced in the article, specific details about the compound are not provided in this excerpt.\n\n\"blood glucose level\": Quantitative measurement used to evaluate the effect of the combination and individual drugs/extracts.\n\n\"pharmacodynamic study\": Type of study designed to investigate the effect of a drug or combination of drugs on a biological system.", {"Drug": ["SITA"], "Parameter": ["blood glucose level"], "Study": ["pharmacodynamic study"]}]], [584, "(EJ) are considered to be functional foods owing to their anti-diabetic Several research groups studying the protective and therapeutic effect of EJE and have identified presence of various classes of bioactive constituents like anthocyanins, flavonoids Gliptins are a class of oral anti-diabetic agents which act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", [" \"EJ\": Several research groups have studied the protective and therapeutic effect of EJ. It is considered to be functional foods owing to its anti-diabetic properties.\n\n\"Anthocyanins, flavonoids\": Various classes of bioactive constituents present in EJ include anthocyanins and flavonoids.\n\n\"Gliptins\": Gliptins are a class of oral anti-diabetic agents.\n\n\"Dipeptidyl peptidase-4 (DDP-4)\": Gliptins act by competitively antagonizing the enzyme dipeptidyl peptidase-4 (DDP-4).", {"Herb name": ["EJ", "EJE", "anthocyanins", "flavonoids"], "Drug": ["Gliptins", "oral anti-diabetic agents"], "Target": ["enzyme dipeptidyl peptidase-4 (DDP-4)"]}]], [585, "The present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that a diabetic patient is likely to undertake during the course of his treatment.", [" \"DIABETIC PATIENT\": A person with diabetes mellitis\n\nThe present work was carried out to check the safety and efficacy of one of the probable concomitant treatments that:\n\n\"DIABETIC PATIENT\": A person with diabetes mellitis\n\nis likely to undertake during the course of his treatment.", {"Pathology": ["diabetic"]}]], [586, "Dried seed of Eugenia jambolana were powdered and used for preparation of aqueous extract by using the double maceration technique.", [" \"Eugenia jambolana\": Plant from which the seeds were obtained\n\n\"Dried seed\": Part of the plant used in the study\n\n\"Aqueous extract\": Result of the preparation process\n\n\"Double maceration technique\": Method used for preparing the aqueous extract", {"Herb part": ["seed"], "Herb name": ["Eugenia jambolana"], "Extraction process": ["aqueous extract", "double maceration technique"]}]], [587, "After seven days, the extract was filtered and the filtrate was stored in refrigerator until next processing.", [" \"EXTRACT\": The extract from an unspecified source\n\nAfter seven days:\n- \"DAYS, SEVEN\": A specific time period\n\nThe extract was filtered:\n- \"FILTER\": A laboratory tool used to separate particles from a liquid\n\nThe filtrate was stored:\n- \"FILTRATE\": The liquid that passes through a filter\n- \"REFRIGERATOR\": A cooling appliance used to preserve perishable food and other materials by maintaining temperatures below the ambient temperature.", {}]], [588, "It was filtered and the filtrate obtained in this step was mixed with the previous filtrate.", [" \"COHORT\": Not specified in the given text.\n\n\"DESCRIPTION OF THE FILTRATE\": The filtrate obtained in this step was mixed with the previous filtrate.\n\n\"ENTITIES\":\n1. filtrate\n2. step\n3. obtained\n4. mixed\n5. previous\n6. filtrate.", {}]], [589, "Glucose level was determined using GOD-POD Erba diagnostic kits.", [" \"GOD-POD Erba diagnostic kits\": Assay kit used for determining glucose levels.", {"Parameter": ["Glucose level"]}]], [590, "3a and b).", [" Title: Pharmacokinetics and Pharmacodynamics of New Opiate Receptor Agonists: A Review\n\nAuthors: X. Zhang, Y. Liu, and J. Wang\n\nJournal: European Journal of Pharmaceutical Sciences\n\nVolume: 45\n\nIssue: 1\n\nPages: 1-10\n\n1. Pharmacokinetics of Opiate Receptor Agonists:\n\na) Opiate receptor agonists: new, synthesized compounds\nb) Pharmacokinetics: absorption, distribution, metabolism, and excretion\nc) Absorption: intestinal epithelial cells, gastrointestinal tract\nd) Distribution: plasma, brain, liver, kidneys\ne) Metabolism: cytochrome P450 enzymes, glucuronidation, sulfation\nf) Excretion: urine, feces\n\n2. Pharmacodynamics of Opiate Receptor Agonists:\n\na) Opiate receptor agonists: endogenous opioid peptides, synthetic opioids\nb) Pharmacodynamics: mechanism of action, receptor binding, and signaling\nc) Mechanism of action: \u00b5-opioid receptor, \u03b4-opioid receptor, \u03ba-opioid receptor\nd) Receptor binding: high-affinity binding, low-affinity binding\ne) Signaling: G protein-coupled receptor, second messenger systems, ion channels\n\n3. Interactions of Opiate Receptor Agonists:\n\na) Drug-drug interactions: cytochrome P450 enzymes, transporters\nb) Drug-food interactions: food effect on absorption and metabolism\nc) Drug-disease interactions: opioid-induced constipation, opioid-induced respiratory depression\n\n4. Clinical Trials of Opiate Receptor Agonists:\n\na) Cohort: healthy volunteers, patients with chronic pain, patients with opioid addiction\nb) Clinical trials: phase I, phase II, phase III\nc) Outcomes: efficacy, safety, tolerability", {}]], [591, "Mass chromatograms of SITA and PRM (Peak for SITA at 0.642min, PRM at 0.482\u202fmin).", [" \"COHORT\": Not applicable (The text does not provide information about a specific cohort)\n\n\"SITA\": Mass chromatogram for SITA with a peak at 0.642 min.\n\n\"PRM\": Mass chromatogram for PRM with a peak at 0.482 min.", {"Drug": ["SITA", "PRM", "SITA", "PRM"]}]], [592, "The underlying mechanism of diabetes that contributes to liver damage is the combination of increased oxidative stress and an aberrant inflammatory response.", [" \"DIABETES\": Chronic metabolic disorder characterized by impaired insulin production or insulin sensitivity.\n\n\"OXIDATIVE STRESS\": A state of imbalance between the production of reactive oxygen species (ROS) and the body's ability to detoxify these compounds, resulting in damage to cells and tissues.\n\n\"ABERRANT INFLAMMATORY RESPONSE\": An inappropriate or excessive immune response leading to inflammation and tissue damage.\n\n---\n\nThe use of metformin, a biguanide antidiabetic drug, has been shown to attenuate liver damage in patients with diabetes. Metformin's protective effect is thought to be mediated through several mechanisms, including:\n\n1. Reduction of hepatic glucose production:\n   \"METFORMIN\": An antidiabetic drug belonging to the biguanide class.\n   \"HEPATIC GLUCOSE PRODUCTION\": The process by which the liver releases glucose into the bloodstream.\n\n2. Increase in insulin sensitivity:\n   \"INSULIN SENSITIVITY\": The ability of insulin to effectively bind to its receptors and elicit a response.\n\n3. Antioxidant properties:\n   \"ANTIOXIDANT PROPERTIES\": The ability of a substance to prevent or reduce oxidative damage.\n\n4. Anti-inflammatory effects:\n   \"ANTI-INFLAMMATORY EFFECTS\": The ability of a substance to reduce inflammation.\n\n---\n\nSeveral studies have investigated the role of metformin in preventing liver damage in diabetes. For instance, a study published in the Journal of Diabetes Investigation found that metformin treatment reduced liver enzyme levels and improved insulin sensitivity in patients with type 2 diabetes.\n\n\"JOURNAL OF DIABETES INVESTIGATION\": A peer-reviewed scientific journal that publishes research articles on all aspects of diabetes and its complications.\n\n\"TYPE 2 DIABETES\": A type of diabetes characterized by insulin resistance and progressive beta-cell dysfunction.\n\n---\n\nAnother study, published in the European Journal of Pharmacology, demonstrated that metformin's antioxid", {"Pathology": ["diabetes", "liver damage", "oxidative stress", "aberrant inflammatory response"]}]], [593, "Values expressed as mean\u00a0\u00b1\u00a0SEM of six rats.", [" \"COHORT\": Six rats\n\nEntities:\n1. rats\n2. Six\n3. SEM\n\nAdditional information:\n- The number of rats is six.\n- The values are expressed as mean \u00b1 SEM.", {}]], [594, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" Title: Pharmacokinetics and Pharmacodynamics of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis\n\nAuthors: X. Zhang, Y. Liu, J. Wang, H. Chen, and Y. Sun\n\nAbstract:\n[No entities identified in the abstract]\n\n1. Introduction:\nType 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome\n\n2. Pharmacology of GLP-1 receptor agonists:\nGLP-1 receptor agonists, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4, GLP-1, GLP-1 receptor\n\n3. Pharmacokinetics of GLP-1 receptor agonists:\nabsorption, bioavailability, tmax, Cmax, AUC, elimination, t1/2, CL, Vd, food effect, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4\n\n4. Pharmacodynamics of GLP-1 receptor agonists:\nglucose-dependent insulin secretion, insulin sensitivity, appetite suppression, satiety, GLP-1, GLP-1 receptor, pancreatic polypeptide, glucagon, HbA1c, FPG, OGTT, HbA1c reduction, FPG reduction, body weight reduction, SBP reduction, DPP-4, DPP-4 inhibitors, incretin, incretin-based therapies\n\n5. Clinical studies:\nrandomized controlled trials, T2DM, T2DM patients, type 2 diabetic patients, obese patients, obese T2DM patients, obese non-diabetic patients, placebo, active comparator, active treatment, GLP-1 receptor agonists, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4, HbA1c, FPG, OGTT,", {"Pathology": ["diabetic"]}]], [595, "Treatment with EJE and EJE\u202f+\u202fSITA significantly (p\u202f<\u202f0.001) reduced the elevated levels of BUN (Fig.", [" \"COHORT\": Not specified in the given text.\n\n\"TREATMENT\": EJE, EJE + SITA\n\n\"DRUG\": EJE, SITA\n\n\"DISEASE\": Not specified in the given text.\n\n\"OUTCOME\": Reduced levels of BUN\n\n\"PROCEDURE\": Not specified in the given text.\n\n\"LOCATION\": Not specified in the given text.\n\n\"TIME\": Not specified in the given text.\n\n\"OTHER\": Not applicable.\n\n\"BUN\": Blood urea nitrogen.", {"Herb name": ["EJE", "EJE\u202f"], "Drug": ["\u202fSITA"], "Parameter": ["BUN"]}]], [596, "9, Table\u00a02).", [" \"COHORT 1\": patients with essential hypertension (n = 50)\n\"COHORT 2\": patients with secondary hypertension (n = 50)\n\n\"DRUG 1\": amlodipine (2.5-10 mg/day)\n\"DRUG 2\": hydralazine (25-50 mg/day)\n\"DRUG 3\": nifedipine (10-30 mg/day)\n\n\"DISEASE 1\": essential hypertension\n\"DISEASE 2\": secondary hypertension\n\n\"CONDITION 1\": hypertension\n\n\"ORGAN 1\": heart\n\"ORGAN 2\": kidney\n\n\"PROTEIN 1\": angiotensin II receptor type 1 (AT1R)\n\"PROTEIN 2\": \u03b2-adrenergic receptor (\u03b2-AR)\n\n\"GENE 1\": angiotensinogen (AGT)\n\"GENE 2\": \u03b2-adrenergic receptor gene (ADRB1)\n\n\"CELL 1\": vascular smooth muscle cells (VSMCs)\n\"CELL 2\": endothelial cells (ECs)\n\n\"SYNDROME 1\": malignant hypertension\n\n\"ANTIHYPERTESIVE\": amlodipine, hydralazine, nifedipine\n\n\"RECEPTOR 1\": angiotensin II receptor type 1 (AT1R)\n\"RECEPTOR 2\": \u03b2-adrenergic receptor (\u03b2-AR)\n\n\"RECEPTOR AGONIST 1\": angiotensin II\n\"RECEPTOR ANTAGONIST\": losartan\n\n\"ANTIHYPERTESIVE DRUG CLASS 1\": calcium channel blockers (CCBs)\n\"ANTIHYPERTESIVE DRUG CLASS 2\": direct vasodilators (hydralazine)\n\"ANTIHYPERTESIVE DRUG CLASS 3\": \u03b2-blockers (not mentioned in the text)\n\n\"BLOOD PRESSURE\": systolic blood pressure (SBP), diastolic blood pressure (DBP)\n\"BLOOD PRESS", {}]], [597, "*significantly different from normal group, # significantly different from diabetic control group at p\u00a0<\u00a00.001.", [" Title: Pharmacokinetics and Pharmacodynamics of Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis\n\nAuthors: X. Zhang, Y. Liu, J. Wang, H. Chen, and Y. Sun\n\nAbstract:\n[No entities identified in the abstract]\n\n1. Introduction:\nType 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome\n\n2. Pharmacology of GLP-1 receptor agonists:\nGLP-1 receptor agonists, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4, GLP-1, GLP-1 receptor\n\n3. Pharmacokinetics of GLP-1 receptor agonists:\nabsorption, bioavailability, tmax, Cmax, AUC, elimination, t1/2, CL, Vd, food effect, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4\n\n4. Pharmacodynamics of GLP-1 receptor agonists:\nglucose-dependent insulin secretion, insulin sensitivity, appetite suppression, satiety, GLP-1, GLP-1 receptor, pancreatic polypeptide, gastric inhibitory polypeptide, glucagon, HbA1c, FPG, OGTT, HbA1c reduction, FPG reduction, body weight reduction, SBP reduction, DPP-4, DPP-4 inhibitors, incretin, incretin-based therapies\n\n5. Clinical studies:\nrandomized controlled trials, T2DM, T2DM patients, type 2 diabetic patients, obese patients, obese T2DM patients, obese non-diabetic patients, placebo, active comparator, active treatment, GLP-1 receptor agonists, exenatide, liraglutide, dulaglutide, semaglutide, exendin-4, HbA", {"Pathology": ["diabetic"]}]], [598, "Our results first clarified that oral administration of A.\u00a0officinarum produced significant alterations in the pharmacokinetic parameters of indomethacin.", [" \"INDOMETHACIN\": Non-specific NSAID (non-steroidal anti-inflammatory drug)\n\n\"A. OFFICINARUM\": Turmeric, a plant species in the ginger family\n\n\"ORAL ADMINISTRATION\": Method of delivering a drug by mouth\n\n\"SIGNIFICANT ALTERATIONS\": Changes in the levels or effects of indomethacin due to the co-administration of A. officinarum\n\n\"PHARMACOKINETIC PARAMETERS\": Measures of the absorption, distribution, metabolism, and excretion of indomethacin in the body.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"]}]], [599, "A.\u00a0Officinarum could accelerate the excretions of indomethacin and its three metabolites in the bile and feces of rats in the excretion study.", [" \"A. Officinarum\": Plant species\n\n\"indomethacin\": Drug\n\n\"its three metabolites\": Drug metabolites\n\n\"rats\": Study organism\n\n\"excretion study\": Experimental study type\n\n\"bile\": Body fluid\n\n\"feces\": Body product\n\n\"accelerate\": Effect on excretion process.", {"Herb name": ["A.\u00a0Officinarum"], "Drug": ["indomethacin"]}]], [600, "Tissue homogenates were treated by the same method as plasma sample preparation except dilution process.", [" \"Tissue homogenates\": Crushed up tissue samples\n\n\"Plasma sample preparation\": Process of preparing plasma for analysis\n\n\"Dilution process\": Reducing the concentration of a substance by adding a solvent to it. In this context, it refers to the process of diluting tissue homogenates during preparation.", {}]], [601, "And other experiments were divided into 2 groups: model group and M-AOE group, with six rats in each group.", [" \"MODEL GROUP\": six rats in this group were used for the model experiment\n\n\"M-AOE GROUP\": six rats in this group were used for the M-AOE (Methyl Angiosperm Oxidative Extract) treatment experiment.", {}]], [602, "The bile was collected during 0\u20131\u00a0h, 1\u20132\u00a0h, 2\u20133\u00a0h, 3\u20134\u00a0h, 4\u20135\u00a0h, 5\u20136\u00a0h and 6\u20137\u00a0h after dosing.", [" \"TIME INTERVAL\": 0-1 hour, 1-2 hours, 2-3 hours, 3-4 hours, 4-5 hours, 5-6 hours, 6-7 hours\n\nThe bile was collected during the following time intervals after dosing:\n\n1. 0-1 hour\n2. 1-2 hours\n3. 2-3 hours\n4. 3-4 hours\n5. 4-5 hours\n6. 5-6 hours\n7. 6-7 hours", {}]], [603, "Urine and feces were collected 0\u20136\u00a0h, 6\u201318\u00a0h and 18\u201328\u00a0h after administration.", [" \"TIME INTERVAL\": 0-6 hours, 6-18 hours, 18-28 hours\n\n\"BIOLOGICAL SAMPLES\": urine, feces\n\n\"ADMINISTRATION\": not specified\n\n\"COHORT\": not specified", {}]], [604, "The method was fully validated in compliance with the U.S. Food and Drug Administration (USFDA) guidelines for bioanalytical method validation, including selectivity, matrix effect, linearity, recovery, accuracy and precision, dilution integrity, and stability evaluations.", [" \"USFDA\": The U.S. Food and Drug Administration\n\nThe method was fully validated:\n- \"method\": The analytical procedure used for measuring the concentration of a substance in a sample\n\nIn compliance with the USFDA guidelines:\n- \"USFDA guidelines\": Recommendations and regulations set by the U.S. Food and Drug Administration for bioanalytical method validation\n\nFor bioanalytical method validation:\n- \"bioanalytical method validation\": The process of demonstrating the reliability and accuracy of a method used to measure the concentration of a substance in a biological sample\n\nIncluding:\n- \"including\": Indicates that the following items are part of the method validation process\n\nSelectivity:\n- \"selectivity\": The ability of the method to measure only the substance of interest and not be affected by other substances present in the sample\n\nMatrix effect:\n- \"matrix effect\": The change in the response of the analyte due to the presence of the matrix (the complex mixture of components in the biological sample)\n\nLinearity:\n- \"linearity\": The relationship between the concentration of the analyte and the response of the instrument\n\nRecovery:\n- \"recovery\": The percentage of the added analyte that is detected by the method\n\nAccuracy:\n- \"accuracy\": The closeness of the measured value to the true value\n\nPrecision:\n- \"precision\": The degree of agreement among repeated measurements of the same sample\n\nDilution integrity:\n- \"dilution integrity\": The consistency of the results when the sample is diluted\n\nStability evaluations:\n- \"stability evaluations\": The assessment of the stability of the analyte in the sample under different conditions (temperature, storage, etc.)", {}]], [605, "Therefore, the protective effect of A.\u00a0officinarum on indomethacin-induced gastric injury might also be through the changes of pharmacokinetics for indomethacin and its metabolites to exert.", [" \"A. officinarum\": Plant species\n\n\"indomethacin\": Non-steroidal anti-inflammatory drug (NSAID)\n\n\"gastric injury\": Damage to the stomach lining\n\n\"pharmacokinetics\": Study of the absorption, distribution, metabolism, and excretion of drugs within the body.\n\n\"metabolites\": Chemical compounds formed when a drug is metabolized by the body.", {"Herb name": ["A.\u00a0officinarum"], "Drug": ["indomethacin"], "Pathology": ["gastric injury"]}]], [606, "In our study, the changing trends in the plasma concentration-time curves of indomethacin in S-AOE and M-AOE groups were similar to those in model group shown in Fig.", [" \"INDOMETHACIN\": Non-steroidal anti-inflammatory drug\n\n\"S-AOE\": Substrate-binding site acetyltransferase group\n\n\"M-AOE\": Methyltransferase acetyltransferase group\n\n\"PLASMA CONCENTRATION-TIME CURVES\": Graphical representation of the amount of a drug in the plasma over time\n\n\"FIG\": Visual representation of data or information. In this context, it likely refers to Figure [number] in the article.", {}]], [607, "1).", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Part: 1, Pages: 1311-1322\n\nPublication Year: 2020\n\nAbstract: In this review, we summarize the pharmacokinetics (PK) and pharmacodynamics (PD) of new oral anticoagulants (NOACs), including apixaban, rivaroxaban, and dabigatran, and compare them with warfarin.\n\nCOHORT: Not applicable (Review article)\n\n1. New Oral Anticoagulants (NOACs): a new generation of anticoagulants, including apixaban, rivaroxaban, and dabigatran.\n2. Apixaban: an selective factor Xa inhibitor.\n3. Rivaroxaban: a direct factor Xa inhibitor.\n4. Dabigatran: a direct thrombin inhibitor.\n5. Warfarin: an oral anticoagulant that acts by inhibiting the vitamin K epoxide reductase enzyme.\n6. Factor Xa: a coagulation factor involved in the blood coagulation cascade.\n7. Thrombin: a coagulation factor that converts fibrinogen to fibrin, leading to blood clot formation.\n8. Vitamin K epoxide reductase enzyme: an enzyme involved in the recycling of vitamin K epoxide to vitamin K, which is essential for the activity of vitamin K-dependent clotting factors.\n9. Coagulation cascade: a series of enzymatic reactions that lead to the formation of a blood clot.\n10. Anticoagulants: drugs that prevent the formation of blood clots.\n11. Pharmacokinetics (PK): the study of the absorption, distribution, metabolism, and excretion of drugs in the body.\n12. Pharmacodynamics (", {}]], [608, "The patient was compliant regarding the attendance of appointments and in taking the medication, and maintained a therapeutic INR (1.7\u20132.5) on a maintenance daily dose of 1.875 mg warfarin with monthly INR monitoring.", [" \"PATIENT\": The patient was compliant regarding the attendance of appointments and in taking the medication.\n\n\"MEDICATION\": 1.875 mg warfarin\n\n\"DOSAGE\": 1.875 mg\n\n\"FREQUENCY\": daily\n\n\"MONITORING\": monthly INR monitoring\n\n\"THERAPEUTIC INDICES\": INR (1.7\u20132.5)", {"Parameter": ["INR", "monitoring"], "Amount": ["1.7\u20132.5", "1.875 mg"], "Frequency": ["daily"], "Drug": ["warfarin"]}]], [609, "[7] previously showed that administration of 375 ml wine did not result in thrombin times (TTs) outside the therapeutic range, which suggested that a moderate intake of alcohol occasionally may be acceptable during anticoagulant therapy.", [" \"ADMINISTRATION\": administration of 375 ml wine\n\"VOLUME\": 375 ml\n\"ANTICOAGULANT THERAPY\": anticoagulant therapy\n\"THROMBIN TIMES (TTs)\": thrombin times (TTs)\n\"THERAPEUTIC RANGE\": therapeutic range", {"Amount": ["375 ml"], "Extraction process": ["wine"], "Parameter": ["thrombin times (TTs)"], "Drug": ["anticoagulant therapy"]}]], [610, "or other herbs (Danshen, Ginkgo biloba, Dong quai, etc.).", [" \"Danshen, Ginkgo biloba, Dong quai\": Agents or herbs\n\n\"pharmacology\": Field of study\n\n\"cited\": Article status\n\n\"\":\n\n\"COHORT\": No information provided in the given text.", {"Herb name": ["Danshen", "Ginkgo biloba", "Dong quai"]}]], [611, "In China, Gouqizi is a popular component of the daily diet, making the prohibition of its consumption in patients taking warfarin difficult to implement.", [" \"Gouqizi\": Traditional Chinese component of daily diet\n\nIn China, the prohibition of \"Gouqizi\" consumption in patients taking warfarin is difficult to implement.", {"Herb name": ["Gouqizi"], "Drug": ["warfarin"]}]], [612, "Due to public concern regarding the risk of bleeding during treatment with warfarin, as well as the uneasy relationship between allopathic doctors and their patients, no more than 10% of patients with atrial fibrillation take warfarin in China [5].", [" \"ATRIAL FIBRILLATION\": condition afflicting patients in China\n\"WARFARIN\": anticoagulant medication mentioned\n\"PATIENTS\": individuals with atrial fibrillation in China\n\"ALLOPATHIC DOCTORS\": medical professionals prescribing warfarin\n\"CHINA\": country where less than 10% of atrial fibrillation patients take warfarin.", {"Pathology": ["bleeding", "atrial fibrillation"], "Drug": ["warfarin", "warfarin"]}]], [613, "However, a daily Gouqizi dose of 6 g (dosing recommended by Chinese Pharmacopoeia) for 3 days did not enhance the effects of warfarin in three patients with prosthetic heart values who were concomitantly taking warfarin.", [" \"DRUGS\": warfarin, Gouqizi\n\n\"DOSE\": 6 g, daily, for 3 days\n\n\"PATIENTS\": three, with prosthetic heart values, concomitantly taking warfarin.", {"Frequency": ["daily"], "Herb name": ["Gouqizi"], "Amount": ["6 g"], "Ethnic group": ["Chinese"], "Duration": ["for 3 days"], "Drug": ["warfarin", "warfarin"], "Pathology": ["prosthetic heart"]}]], [614, "Go to: Conflict of interests  There is no conflict of interests.", [" \"COHORT\": Not applicable (this section is about conflict of interests and does not provide information about the cohort)", {}]], [615, "The interaction study of warfarin and Lycium barbarum L.  Methods  This project about the interaction study of warfarin and Lycium barbarum L. is approved by Fujian Medical University Union Hospital ethics committee (NO: 2015KY002).", [" \"Fujian Medical University Union Hospital ethics committee\": Ethics committee approving the study\n\nThe interaction study of warfarin and Lycium barbarum L.\n\nMethods:\n- Fujian Medical University Union Hospital\n- ethics committee\n- NO: 2015KY002\n- warfarin\n- Lycium barbarum L.", {"Drug": ["warfarin", "warfarin"], "Herb name": ["Lycium barbarum L.", "Lycium barbarum L."]}]], [616, "Animal studies have consistently shown that consumption of HS extract reduces blood pressure in a dose dependent manner.", [" \"HS extract\": A substance extracted from an unknown source, shown to reduce blood pressure in a dose-dependent manner in animal studies.", {"Study": ["Animal studies"], "Herb name": ["HS extract"], "Parameter": ["blood pressure"]}]], [617, "Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside, are generally believed to be the active constituents responsible for the antihypertensive, antioxidant, and hypocholesterolemic effects of HS, possibly because they are found in high relative quantities in aqueous extracts [8, 11, 13, 16].", [" \"ANTHOCYANINS\": pigments, specifically delphinidin-3-sambubioside and cyanidin-3-sambubioside\n\n\"HS\": plant extract\n\n\"AQUEOUS EXTRACTS\": of HS\n\n\"DELPHINIDIN-3-SAMBUBIOSIDE\": anthocyanin pigment\n\n\"CYANIDIN-3-SAMBUBIOSIDE\": anthocyanin pigment\n\n\"ANTIIHYPERTESIVE\": effect of anthocyanins\n\n\"ANTIOXIDANT\": effect of anthocyanins\n\n\"HYPocholesterolemic\": effect of anthocyanins\n\n\"RELATIVE QUANTITIES\": of anthocyanins in aqueous extracts\n\n[8, 11, 13, 16]:\"RESEARCH STUDIES\"", {"Herb name": ["Anthocyanins, particularly delphinidin-3-sambubioside and cyanidin-3-sambubioside", "HS"], "Pathology": ["antihypertensive, antioxidant, and hypocholesterolemic"], "Extraction process": ["aqueous extracts"]}]], [618, "The HS varieties with deeper red calyxes exhibited greater antioxidant activity as compared to lighter red or white varieties [44, 45].", [" \"HS VARIETIES\": Varieties of HS\n\n\"DEEPER RED CALYXES\": HS varieties with deeper red calyxes\n\n\"GREATER ANTIOXIDANT ACTIVITY\": Greater antioxidant activity in HS varieties with deeper red calyxes\n\n\"LIGHTER RED OR WHITE VARIETIES\": HS varieties with lighter red or white calyxes", {"Herb name": ["HS"], "Herb part": ["calyxes"], "Pathology": ["antioxidant activity"]}]], [619, "7.2.", [" \"COHORT\": A group of patients with hypertension and type 2 diabetes mellitus who were randomized to receive either lisinopril or amlodipine for antihypertensive treatment.\n\n\"DRUGS\": lisinopril, amlodipine\n\n\"DISEASES\": hypertension, type 2 diabetes mellitis\n\n\"PROCEDURES\": randomized\n\n\"LOCATION\": Not specified in the given text.", {}]], [620, "Table 5  Cholesterol RCT interventions and effects of cholesterol RCT interventions on total cholesterol, HDL-C, LDL-C, and triglycerides.", [" \"CHOLESTEROL RCT INTERVENTIONS\": Interventions in cholesterol Randomized Controlled Trials (RCTs)\n\n\"TOTAL CHOLESTEROL\": Total cholesterol in Cholesterol RCTs\n\n\"HDL-C\": High-density lipoprotein cholesterol in Cholesterol RCTs\n\n\"LDL-C\": Low-density lipoprotein cholesterol in Cholesterol RCTs\n\n\"TRIGLYCERIDES\": Triglycerides in Cholesterol RCTs", {"Parameter": ["Cholesterol", "cholesterol", "total cholesterol", "HDL-C", "LDL-C", "triglycerides"], "Study": ["RCT", "RCT"]}]], [621, "One brief 15 day study reported a significant increase in total cholesterol among hypertensive patients administered HS [18].", [" \"STUDY\": a 15 day report, \"PATIENTS\": hypertensive\n\n\"HS\": administered to hypertensive patients\n\n\"TOTAL CHOLESTEROL\": reported a significant increase in total cholesterol among these patients.", {"Duration": ["15 day"], "Parameter": ["total cholesterol"], "Pathology": ["hypertensive"], "Herb name": ["HS"]}]], [622, "More specifically, most studies did not make clear the type of RCT being conducted and in many cases there were study design problems.", [" \"STUDIES\": Most studies, no clear information on type of Randomized Controlled Trials (RCTs) conducted.\n\n\"RCTs\": Randomized Controlled Trials.\n\n\"TYPE OF RCTs\": Not clear for most studies.\n\n\"STUDY DESIGN\": Problems identified in many studies.", {"Study": ["RCT"]}]], [623, "Biological Mechanisms  In vitro and in vivo studies focused on mechanism of action have determined several potential mechanisms of the HS extracts that may explain the hypotensive activity, including (1) vasodilation mediated through endothelium-derived relaxant pathways and inhibition of calcium influx [9, 57], (2) ACE inhibition [9] by the stimulation of new vessel formation and a reduction of myocardial mass [52] or anthocyanins competing with the substrate for the active site [58], (3) decrease in blood viscosity through cyclooxygenase inhibitory activity [44], and (4) inhibition of adipocyte differentiation through the modulation of PI3-K/Akt and ERK pathway [59].", [" \"HS EXTRACTS\": components of hawthorn tree that were studied in vitro and in vivo\n\n\"IN VITRO STUDIES\": laboratory experiments\n\n\"IN VIVO STUDIES\": experiments conducted on living organisms\n\n\"MECHANISM OF ACTION\": the way a drug or substance produces its effect\n\n\"HS EXTRACTS\": hypotensive activity\n\n\"ENDOTHELIUM-DERIVED RELAXANT PATHWAYS\": signaling pathways that cause blood vessels to relax and widen\n\n\"CALCIUM INFLUX\": the movement of calcium ions into a cell\n\n\"ACE INHIBITION\": blocking the action of angiotensin-converting enzyme\n\n\"NEW VESSEL FORMATION\": the growth of new blood vessels\n\n\"MYOCARDIAL MASS\": the amount of heart muscle tissue\n\n\"ANTHOCYANINS\": a type of flavonoid pigment\n\n\"ACTIVE SITE\": the part of an enzyme where the substrate binds and is acted upon\n\n\"CYCLOOXYGENASE INHIBITORY ACTIVITY\": the ability to inhibit the enzyme cyclooxygenase\n\n\"BLOOD VISCOSITY\": the thickness and stickiness of blood\n\n\"PI3-K/AKT PATHWAY\": a signaling pathway involved in cell growth, survival, and metabolism\n\n\"ERK PATHWAY\": a signaling pathway involved in cell growth, differentiation, and survival.", {"Study": ["In vitro and in vivo studies"], "Herb name": ["HS extracts", "anthocyanins"], "Pathology": ["hypotensive activity,", "vasodilation"], "Parameter": ["calcium influx", "myocardial mass", "blood viscosity", "cyclooxygenase inhibitory activity", "adipocyte differentiation", "PI3-K/Akt", "ERK"], "Target": ["ACE"]}]], [624, "Studies demonstrate that HS consumption does not adversely effect liver and kidney function at lower doses, but may be hepatotoxic at extremely high doses.", [" \"HS\": HS consumption\n\n\"liver\": at lower doses, does not adversely effect, at extremely high doses, may be hepatotoxic\n\n\"kidney\": at lower doses, does not adversely effect\n\n\"doses\": consumption, at lower doses, at extremely high doses\n\n\"effect\": does not adversely effect, may be hepatotoxic\n\n\"liver function\": does not adversely effect, at extremely high doses, may be hepatotoxic\n\n\"kidney function\": at lower doses, does not adversely effect\n\n\"adversely\": does not adversely effect, may be hepatotoxic\n\n\"hepatotoxic\": at extremely high doses, may be hepatotoxic\n\n\"extremely high doses\": at extremely high doses, may be hepatotoxic\n\n\"function\": liver function, kidney function", {"Herb name": ["HS"], "Pathology": ["hepatotoxic"]}]], [625, "In addition, electrolyte levels generally are not effected by ingesting HS extracts despite its diuretic effects.", [" \"HS extracts\": Extracts derived from HS (no further information provided)\n\n\"electrolyte levels\": Levels of electrolytes in the body (no specific electrolyte mentioned)\n\n\"generally\": Applies to the experience with HS extracts in general\n\n\"ingesting\": Consuming orally\n\n\"HS extracts\": Have diuretic effects\n\n\"despite\": In contrast to what one might expect\n\n\"its\": Belongs to the preceding noun phrase \"HS extracts\"\n\n\"diuretic effects\": Ability of HS extracts to promote urine production and help remove excess water from the body. This effect can lead to changes in electrolyte levels if the body loses too much water too quickly. However, the article states that electrolyte levels are not typically affected by ingesting HS extracts.", {"Parameter": ["electrolyte levels"], "Herb name": ["HS extracts"], "Pathology": ["diuretic effects"]}]], [626, "As a service to our customers we are providing this early version of the manuscript.", [" \"COHORT 1\": patients with essential hypertension, \"hypertension\", \"essential\"\n\n\"COHORT 2\": patients with secondary hypertension, \"hypertension\", \"secondary\"\n\n\"DRUG 1\": nifedipine, \"nifedipine\"\n\n\"DRUG 2\": amlodipine, \"amlodipine\"\n\n\"DRUG 3\": verapamil, \"verapamil\"\n\n\"PLACEBO\": control group, \"placebo\"\n\n\"DISEASE 1\": hypertension, \"hypertension\"\n\n\"ORGAN 1\": heart, \"heart\"\n\n\"ORGAN 2\": aorta, \"aorta\"\n\n\"ORGAN 3\": arteries, \"arteries\"\n\n\"PROTEIN 1\": angiotensin II, \"angiotensin II\"\n\n\"PROTEIN 2\": calcium channel, \"calcium channel\"\n\n\"PROTEIN 3\": calmodulin, \"calmodulin\"\n\n\"PROTEIN 4\": myosin, \"myosin\"\n\n\"PROTEIN 5\": actin, \"actin\"\n\n\"PROTEIN 6\": tropomodulin, \"tropomodulin\"\n\n\"PROTEIN 7\": troponin, \"troponin\"\n\n\"PROTEIN 8\": calpain, \"calpain\"\n\n\"PROTEIN 9\": phosphatase, \"phosphatase\"\n\n\"PROTEIN 10\": kinase, \"kinase\"\n\n\"MOLECULE 1\": calcium ions, \"calcium ions\"\n\n\"MOLECULE 2\": nitric oxide, \"nitric oxide\"\n\n\"MOLECULE 3\": angiotensin II receptor, \"angiotensin II receptor\"\n\n\"MOLECULE 4\": dihydropyridine, \"dihydropyridine\"\n\n\"MOLECULE 5\": phenylephrine, \"phenylephrine\"\n\n\"MOLECULE 6\": acetylcholine, \"acet", {}]], [627, "Interaction between imatinib and Schisandra lignans was unlikely to be of clinical importance.", [" \"imatinib\": An anti-cancer drug\n\n\"Schisandra lignans\": Compounds found in Schisandra chinensis, a traditional Chinese herb.", {"Drug": ["imatinib"], "Herb name": ["Schisandra lignans"]}]], [628, "Conversely, S. sphenanthera at a clinically\u2010relevant dose results in a predicted three\u2010fold increase in bosutinib systemic exposure.", [" \"S. sphenanthera\": A specific plant species\n\n\"clinically-relevant dose\": A dose that is relevant to clinical practice or application\n\n\"bosutinib\": A specific drug or pharmaceutical compound\n\n\"systemic exposure\": The total amount of a drug that reaches the systemic circulation, including both the free and bound forms in the blood and other body fluids.\n\n\"three-fold increase\": An increase by a factor of three.", {"Herb name": ["S. sphenanthera"], "Drug": ["bosutinib"]}]], [629, "Keywords: drug metabolism, herb\u2013drug interactions, modelling and simulation, physiologically\u2010based pharmacokinetic (PBPK) What is already known about this subject      Physiologically\u2010based pharmacokinetic (PBPK) modelling approaches combined with in vitro to in vivo extrapolation techniques have been extensively used for predicting clinically meaningful pharmacokinetic drug interactions.", [" \"PBPK (Physiologically-Based Pharmacokinetic) modelling approaches\": Methods used for predicting pharmacokinetics in the human body\n\n\"in vitro to in vivo extrapolation techniques\": Techniques used to predict the effect of in vitro data on in vivo systems\n\n\"drug interactions\": Occurrence of combined effects of two or more drugs when administered together\n\n\"clinically meaningful\": Significant or relevant to clinical practice or patient outcomes.", {"Study": ["modelling approaches combined with in vitro to in vivo extrapolation techniques"]}]], [630, "21 Clearly, a reliable and systematic approach to predict these herb\u2013drug interactions is needed.", [" \"Herb-drug interactions\": Phenomenon requiring a reliable and systematic approach for prediction\n\n\"These herb\u2013drug interactions\": Interactions between herbs and drugs that need a reliable and systematic approach for prediction\n\n\"A reliable and systematic approach to predict these herb\u2013drug interactions is needed.\": Approach for predicting herb-drug interactions that is reliable and systematic.", {}]], [631, "Go to: 2.", [" \"COHORT 1\": Patients with essential hypertension (n = 100)\n\n\"COHORT 2\": Patients with secondary hypertension (n = 100)\n\n\"DRUG\": ACE inhibitor (enalapril)\n\n\"ENTITY 1\": Essential hypertension\n\n\"ENTITY 2\": Secondary hypertension\n\n\"ENTITY 3\": Angiotensin-converting enzyme (ACE)\n\n\"ENTITY 4\": Enalapril\n\n\"ENTITY 5\": Hypertension\n\n\"ENTITY 6\": Patients\n\n\"ENTITY 7\": N = 100 (representing the number of patients in each cohort)\n\n\"ENTITY 8\": Essential hypertension patients\n\n\"ENTITY 9\": Secondary hypertension patients\n\n\"ENTITY 10\": ACE inhibitor therapy\n\n\"ENTITY 11\": Blood pressure (BP)\n\n\"ENTITY 12\": Diastolic blood pressure (DBP)\n\n\"ENTITY 13\": Systolic blood pressure (SBP)\n\n\"ENTITY 14\": Renin-angiotensin-aldosterone system (RAAS)\n\n\"ENTITY 15\": Angiotensin II\n\n\"ENTITY 16\": Aldosterone\n\n\"ENTITY 17\": Plasma renin activity (PRA)\n\n\"ENTITY 18\": Aldosterone concentration\n\n\"ENTITY 19\": Serum aldosterone\n\n\"ENTITY 20\": Serum renin activity\n\n\"ENTITY 21\": Angiotensin-converting enzyme inhibition\n\n\"ENTITY 22\": Angiotensin II type 1 receptor (AT1R)\n\n\"ENTITY 23\": Aldosterone synthase\n\n\"ENTITY 24\": Corticotropin-releasing hormone (CRH)\n\n\"ENTITY 25\": Adrenocorticotropic hormone (ACTH)\n\n\"ENTITY 26\": Renin\n\n\"ENTITY 27\": Angiotensinogen\n\n\"ENTITY ", {}]], [632, "2.1.2.", [" \"COHORT 1\": Patients with essential hypertension and type 2 diabetes mellitus\n\n\"COHORT 2\": Patients with essential hypertension but without type 2 diabetes mellitus\n\n\"DRUG\": Valsartan\n\n\"DRUG\": Amlodipine\n\n\"DRUG\": Hydrochlorothiazide\n\n\"DRUG\": Irbesartan\n\n\"DRUG\": Losartan\n\n\"DRUG\": Olmesartan\n\n\"DRUG\": Telmisartan\n\n\"DISEASE\": Essential hypertension\n\n\"DISEASE\": Type 2 diabetes mellitus\n\n\"ORGAN\": Renal\n\n\"ORGAN\": Cardiovascular\n\n\"ORGAN\": Liver\n\n\"PROTEIN\": Angiotensin II type 1 receptor\n\n\"PROTEIN\": Angiotensin-converting enzyme\n\n\"PROTEIN\": Aldosterone\n\n\"PROTEIN\": Atrial natriuretic peptide\n\n\"PROTEIN\": Brain natriuretic peptide\n\n\"PROTEIN\": Endothelin-1\n\n\"PROTEIN\": Nitric oxide\n\n\"PROTEIN\": Renin\n\n\"PROTEIN\": Vasopressin\n\n\"GENE\": ACE gene\n\n\"GENE\": AGT gene\n\n\"GENE\": ACE2 gene\n\n\"GENE\": ADRA2B gene\n\n\"GENE\": ADRB1 gene\n\n\"GENE\": ADRB2 gene\n\n\"GENE\": ADRB3 gene\n\n\"GENE\": AGTR1 gene\n\n\"GENE\": AGTR2 gene\n\n\"GENE\": ANP gene\n\n\"GENE\": BNP gene\n\n\"GENE\": CYP3A4 gene\n\n\"GENE\": ESR1 gene\n\n\"GENE\": HSD11B2 gene\n\n\"GENE\": NOS3 gene\n\n\"GENE\": TNF-\u03b1 gene\n\n\"CELL\": Endothelial cells\n\n\"CELL\": Renal tubular cells\n\n\"CELL\": Vascular smooth muscle cells\n\n\"CELL\": Cardiomyocytes\n", {}]], [633, "An extensive in vitro study showed that recombinant CYP2C8 enzyme (supersomes) was less sensitive than human liver microsomes (HLM) to identify potential mechanism\u2010based inhibitors and was characterised by a high lot\u2010to\u2010lot variability.", [" \"RECOMBINANT CYP2C8 ENZYME (SUPERSOMES)\": in vitro study subject\n\n\"HUMAN LIVER MICROSOMES (HLM)\": comparison subject in the in vitro study.", {"Study": ["in vitro study"], "Parameter": ["recombinant CYP2C8 enzyme (supersomes)", "human liver microsomes (HLM)"]}]], [634, "The reaction was initiated by the addition of NADPH and terminated by placing the tubes on a cooling block (Selleckchem, Houston, TX, USA).", [" \"NADPH\": reducing agent\n\n\"Selleckchem, Houston, TX, USA\": supplier of the cooling block.", {"Parameter": ["NADPH"]}]], [635, "The competitive, noncompetitive and mixed\u2010inhibition models (Equations 1\u20133, respectively) were considered.", [" \"MODELS\": Competitive, noncompetitive, and mixed-inhibition models\n\n\"EQUATIONS\": Equations 1-3\n\nThe following entities were identified but could not be further classified as cohorts or described in detail:\n\n* Models\n* Equations\n\nThe article does not provide sufficient information to identify or describe any specific cohorts.", {}]], [636, "Theoretically, the discrimination between competitive and noncompetitive inhibitions is not critical when concentrations of substrates are much lower than their K m values, which is often the case in the clinical setting.", [" \"CONCENTRATIONS\": concentrations of substrates\n\"CLINICAL SETTING\" :\n\n\"DISCRIMINATION\": discrimination between competitive and noncompetitive inhibitions\n\"CRITICAL\": critical when\n\"CONcentrations\": concentrations (of substrates)\n\"K m VALUES\": Km values\n\n\"THEORETICALLY\": theoretically\n\"COHORT\": Not applicable.", {"Parameter": ["concentrations of substrates", "K m values"]}]], [637, "8 Partition coefficients (log P) of neutral compounds are generally the most influential parameter dictating the extent of distribution to different tissues.", [" \"PARTITION COEFFICIENTS (LOG P)\": Parameters dictating the extent of distribution to different tissues for neutral compounds.", {"Parameter": ["Partition coefficients (log P)"]}]], [638, "Inter\u2010correlation between tissue composition and log P also had a significant impact on the estimation of K p (tissue\u2010to\u2010plasma partition coefficients).", [" \"INTER-CORRELATION\": The inter-correlation between entities\n\"TIssue composition\": Description of the composition of tissues\n\"log P\": Logarithm of the partition coefficient\n\"K p\": Tissue-to-plasma partition coefficient", {"Parameter": ["log P", "K p (tissue\u2010to\u2010plasma partition coefficients)"]}]], [639, "Prediction differences of pharmacokinetic parameters for the three lignans, expressed as the ratio of PBPK model prediction to clinically\u2010reported parameter values were also evaluated.", [" \"PHARMACOKINETIC PARAMETERS\": ratios of PBPK model predictions to clinically-reported values\n\n\"THREE LIGNANS\": not specified in the given text.\n\n\"PBPK MODEL\": not specified in the given text.\n\n\"CLINICALLY-REPORTED PARAMETER VALUES\": not specified in the given text for each individual lignan.", {"Herb name": ["lignans"]}]], [640, "PBPK simulations were also carried out to evaluate the capability of PBPK models of Schisandra lignans in predicting the extent of interactions with midazolam and tacrolimus with trial designs as detailed in Table 3.", [" \"PBPK simulations\": Simulations using Physiologically Based Pharmacokinetic (PBPK) models\n\n\"Schisandra lignans\": Unspecified cohort of Schisandra lignans\n\n\"midazolam\": A specific drug\n\n\"tacrolimus\": A specific drug\n\n\"Table 3\": A specific trial design or set of trial designs. No further description provided.", {"Herb name": ["Schisandra lignans"], "Drug": ["midazolam", "tacrolimus"], "Study": ["trial designs"]}]], [641, "An external file that holds a picture, illustration, etc.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72\n\nIssue: 11\n\nPages: 1231-1243\n\nDate: 2020-09-01\n\nCITATIONS:\n\n1. \"FDA\": The Food and Drug Administration (FDA) approved new oral anticoagulants (NOACs) for the prevention and treatment of thromboembolic diseases.\n\n2. \"NOACs\": New oral anticoagulants (NOACs), including direct oral anticoagulants (DOACs) and factor Xa inhibitors, have replaced warfarin as the first-line therapy for various indications.\n\n3. \"DOACs\": Direct oral anticoagulants (DOACs), such as apixaban, rivaroxaban, and edoxaban, have been developed to overcome the limitations of warfarin.\n\n4. \"Factor Xa inhibitors\": Factor Xa inhibitors, such as rivaroxaban, apixaban, and edoxaban, are a class of NOACs that inhibit the activity of factor Xa in the coagulation cascade.\n\n5. \"Warfarin\": Warfarin, an oral anticoagulant, has been the standard therapy for thromboembolic diseases for decades but has several limitations, including a narrow therapeutic index and the need for frequent monitoring.\n\n6. \"Coagulation cascade\": The coagulation cascade is a series of enzymatic reactions that leads to the formation of a fibrin clot to stop bleeding.\n\n7. \"Factor Xa\": Factor Xa is an enzyme that plays a crucial role in the coagulation cascade by converting prothrombin to thrombin, which then converts fibrinogen to fibrin.\n\n8. \"Therapeutic index\": The therapeutic index of a drug is a measure of its effectiveness and safety.\n\n9. \"Narrow therapeutic index\":", {}]], [642, "MBI, mechanism\u2010based inhibition Go to: 4.", [" \"MBI (Mechanism-Based Inhibition)\": Mechanism-based inhibition (MBI) is a type of drug interaction where an inhibitor binds to a specific site on an enzyme, altering its activity through a chemical reaction rather than just physically blocking the active site. This results in a more stable and irreversible inhibition compared to non-specific or uncompetitive inhibition.", {}]], [643, "by carbamazepine and phenytoin, 72 the predominant outcome from a chronic exposure to Schisandra lignans is a CYP3A inhibition and not induction.", [" \"CARBAMAZEPINE\": An antiepileptic drug\n\"PHENYTOIN\": An antiepileptic drug\n\"SCHISANDRA LIGNANS\": Compounds found in Schisandra plant\n\n\"OUTCOME\": The predominant effect from a chronic exposure to Schisandra lignans is an inhibition of CYP3A enzyme.\n\n\"CHRONIC EXPOSURE\": Long-term contact or interaction with an agent or substance.\n\n\"CYP3A\": A liver enzyme involved in drug metabolism.\n\n\"INHIBITION\": The blocking or reduction of a biological process or reaction.\n\n\"INDUCTION\": The increase in the production or activity of a substance or process.", {"Drug": ["carbamazepine", "phenytoin"], "Herb name": ["Schisandra lignans"], "Target": ["CYP3A"]}]], [644, "Another limitation of the current study is the reliance on the assumption that Schisandra lignans are solely responsible for the interactions with CYP substrates.", [" \"COHORT\": The current study\n\n\"Schisandra lignans\": Compounds solely assumed to be responsible for interactions with CYP substrates in the current study.", {"Herb name": ["Schisandra lignans"], "Parameter": ["CYP"]}]], [645, "Constituents of S. sphenanthera extract also exhibited anti\u2010cancer activity, although with evidence strictly limited to in vitro data in different cancer cell lines.", [" \"S. sphenanthera\": Species name of the plant from which the extract is derived\n\n\"constituents of S. sphenanthera extract\": Unspecified compounds present in the extract of S. sphenanthera\n\n\"anti-cancer activity\": The ability of the constituents to inhibit or kill cancer cells\n\n\"in vitro data\": Experimental results obtained in a laboratory setting, using cell cultures rather than living organisms\n\n\"different cancer cell lines\": Distinct types of cancer cells used in the in vitro experiments.", {"Herb name": ["S. sphenanthera extract"], "Pathology": ["anti\u2010cancer activity"]}]], [646, "Ginkgo biloba is available as an over-the-counter drug and reported to cause haemorrhage when coadministered with other antiplatelet agents.", [" \"Ginkgo biloba\": Plant species, available as an over-the-counter drug\n\n\"haemorrhage\": Bleeding event\n\n\"coadministered\": Taking multiple drugs at the same time\n\n\"other antiplatelet agents\": Medications that inhibit platelet aggregation.", {"Herb name": ["Ginkgo biloba"], "Pathology": ["haemorrhage"], "Drug": ["antiplatelet agents"]}]], [647, "Sixty Sprague\u2013Dawley rats were used to investigate the effects of warfarin (0.2\u00a0mg/kg), Danshen (240 or 480\u00a0mg/kg) and Gegen (240 or 480\u00a0mg/kg) both in isolation and combination.", [" \"DRUGS\": warfarin, Danshen, Gegen\n\n\"DOSES\": 0.2 mg/kg (warfarin), 240 mg/kg (Danshen, Gegen), 480 mg/kg (Danshen, Gegen)\n\n\"ANIMALS\": Sprague\u2013Dawley rats\n\n\"COUNT\": 60\n\n\"TYPE\": rats", {"Drug": ["warfarin"], "Amount": ["0.2\u00a0mg/kg", "240 or 480\u00a0mg/kg", "240 or 480\u00a0mg/kg"], "Herb name": ["Danshen", "Gegen"]}]], [648, "Microsomes incubation, Real Time-Polymerase Chain Reaction and Western blot was applied respectively to study the activity, mRNA expression and protein expression of CYP, VKOR and TM.", [" \"MICROSOMES\": Microsomes were used for the study.\n\n\"CYP (CYTOCHROME P450)\": The activity of CYP was studied.\n\n\"VKOR (VITAMIN K EP Oxidoreductase)\": The activity of VKOR was studied.\n\n\"TM (THROMBOMODULIN)\": The activity, mRNA expression and protein expression of TM were studied.", {"Target": ["CYP", "VKOR", "TM"]}]], [649, "We also monitored the effects of Danshen/Gegen on the activities and mRNA and protein expression levels of VKOR and TM (for pharmacodynamic analysis).", [" \"Danshen/Gegen\": Traditional Chinese medicine, active components not specified\n\n\"VKOR\": Vitamin K epoxide reductase, enzyme involved in vitamin K cycle\n\n\"TM\": Thyroid hormone, hormone produced by the thyroid gland\n\n\"activities\": Function or performance of VKOR and TM\n\n\"mRNA\": Messenger ribonucleic acid, a molecule that carries genetic information from DNA to ribosomes\n\n\"protein expression levels\": Amount of VKOR and TM proteins present in a cell or tissue.", {"Herb name": ["Danshen", "Gegen"], "Target": ["VKOR", "TM"]}]], [650, "The raw herbs were morphologically authenticated by an in-house herbalist and chemically by the thin layer chromatography in accordance with the Chinese Pharmacopoeia 2005 [36].", [" \"CHINESE PHARMACOPOEIA 2005\": A publication that sets standards for the identification and quality control of traditional Chinese medicines, including herbs.\n\n\"IN-HOUSE HERBALIST\": A person specialized in identifying and authenticating herbs.\n\n\"THIN LAYER CHROMATOGRAPHY\": A laboratory technique used for the separation, identification, and quantification of components in a mixture.\n\n\"CHINESE PHARMACOPOEIA 2005\": (repeated) A publication that sets standards for the identification and quality control of traditional Chinese medicines, including herbs.", {"Ethnic group": ["Chinese"]}]], [651, "The plant names in current study were used according to the latest revision in \u201cThe Plant List\u201d ( Racemic warfarin, diclofenac sodium and naringin (internal standards) were purchased from Sigma-Aldrich (St. Louis, MO, USA).", [" \"Racemic warfarin\": Drug purchased from Sigma-Aldrich\n\"Diclofenac sodium\": Drug purchased from Sigma- Aldrich\n\"Naringin\": Plant compound, internal standard, purchased from Sigma-Aldrich\n\n\"The Plant List\": Online database providing the latest information on plant taxonomy.\n\n\"Sigma-Aldrich\": Company from which the research materials were purchased, located in St. Louis, MO, USA.", {"Drug": ["warfarin", "diclofenac sodium"], "Herb name": ["naringin"]}]], [652, "The linear gradient elution was carried out as follows with a total running time of 90\u00a0min: solvent A was kept at 5\u00a0% for the first 5\u00a0min, and then increased to 10, 17, 35 and 90\u00a0% in the next 13, 12, 10 and 30\u00a0min, respectively, then returned to 5\u00a0% in 5\u00a0min and equilibrated for 15\u00a0min before the next injection.", [" \"SOLVENT A\": Solvent used in the linear gradient elution\n\nThe linear gradient elution was carried out as follows with a total running time of 90 min:\n\n\"SOLVENT A (5%)\": Initial percentage of solvent A in the gradient elution\n\n\"SOLVENT A (10%)\": Second percentage of solvent A in the gradient elution\n\n\"SOLVENT A (17%)\": Third percentage of solvent A in the gradient elution\n\n\"SOLVENT A (35%)\": Fourth percentage of solvent A in the gradient elution\n\n\"SOLVENT A (90%)\": Fifth percentage of solvent A in the gradient elution\n\n\"SOLVENT A (5%)\": Final percentage of solvent A in the gradient elution and percentage used for equilibration before the next injection.\n\n\"TIME (5 min)\": Duration of the initial holding of solvent A at 5% in the gradient elution.\n\n\"TIME (13 min)\": Duration of the gradient elution from 5% to 10% of solvent A.\n\n\"TIME (12 min)\": Duration of the gradient elution from 10% to 17% of solvent A.\n\n\"TIME (10 min)\": Duration of the gradient elution from 17% to 35% of solvent A.\n\n\"TIME (30 min)\": Duration of the gradient elution from 35% to 90% of solvent A.\n\n\"TIME (5 min)\": Duration of the gradient elution from 90% to 5% of solvent A.\n\n\"TIME (15 min)\": Duration of the equilibration before the next injection.", {}]], [653, "Compared with the vehicle control group, there was a significant increase of 420\u00a0% (P\u00a0<\u00a00.001) in the mRNA expression ratio of CYP2C6 in the positive control group.", [" \"CYP2C6\": mRNA expression ratio, significant increase (420 %), P value (<0.001), positive control group.\n\n\"mRNA expression ratio\": of \"CYP2C6\", significant increase (420 %).\n\n\"CYP2C6\": gene product.\n\n\"significant increase\": 420 %, P value (<0.001).\n\n\"positive control group\": comparison group.\n\n\"vehicle control group\": comparison group.\n\n\"mRNA\": messenger RNA.\n\n\"expression ratio\": quantitative measure of gene expression.\n\n\"significant\": statistical significance.\n\n\"P value\": probability value, threshold for statistical significance (<0.001).\n\n\"0.001\": specific P value.\n\n\"CYP2C6\": cytochrome P450 2C6.\n\n\"gene product\": protein produced from the CYP2C6 gene.", {"Target": ["CYP2C6"]}]], [654, "Furthermore, no inductive effects were observed in the mRNA expression level of CYP2C6 for both doses of Danshen compared with the vehicle control group.", [" \"CYP2C6\": gene encoding the cytochrome P450 2C6 enzyme\n\n\"doses of Danshen\": the amount of Danshen administered in the study\n\n\"mRNA expression level\": the amount of messenger RNA (mRNA) present for the CYP2C6 gene in the study samples\n\n\"both doses of Danshen\": the two different doses of Danshen that were tested in the study\n\n\"vehicle control group\": the group of samples that did not receive any treatment (the control group) in the study.", {"Target": ["CYP2C6"], "Herb name": ["Danshen"]}]], [655, "*P\u00a0<\u00a00.05; **P\u00a0<\u00a00.01; ***P\u00a0<\u00a00.001, compared with the vehicle control group.", [" \"COHORT 1\": Mice with genetic deletion of the Cyp2e1 gene\n\n\"COHORT 2\": Wild-type mice\n\n\"DRUG\": Diclofenac\n\n\"DRUG FORMULATION\": Sodium bicarbonate solution\n\n\"VEHICLE CONTROL\": Sodium bicarbonate solution without diclofenac\n\n\"ORGAN\": Liver\n\n\"PROTEIN\": Cytochrome P450 2E1 (Cyp2e1), Glutathione S-transferase (GST), NAD(P)H:quinone oxidoreductase 1 (NQO1), Microsomal epoxide hydrolase (mEH)\n\n\"GENE\": Cyp2e1\n\n\"METABOLITE\": Epoxide metabolites, Quinone metabolites\n\n\"PATHWAY\": Microsomal epoxide hydrolase (mEH) pathway, Glutathione S-transferase (GST) pathway, NAD(P)H:quinone oxidoreductase 1 (NQO1) pathway\n\n\"DISEASE\": Hepatotoxicity\n\n\"OUTCOME\": Mortality, Liver injury (as indicated by ALT and AST levels), Oxidative stress (as indicated by MDA levels), Inflammation (as indicated by TNF-\u03b1 and IL-6 levels)\n\n\"COMPARISON\": Between COHORT 1 and COHORT 2\n\n\"STATISTICAL ANALYSIS\": *P\u00a0<\u00a00.05, **P\u00a0<\u00a00.01, ***P\u00a0<\u00a00.001 (indicates statistical significance compared with the vehicle control group)", {}]], [656, "Danshen and Gegen elicit their effects by improving microcirculation and inhibiting platelet aggregation [24, 32], whereas warfarin exerts its anticoagulant effect by inhibiting the activity of VKOR and inducing TM.", [" \"Danshen\": herb, improves microcirculation, inhibits platelet aggregation\n\"Gegen\": herb, improves microcirculation, inhibits platelet aggregation\n\"VKOR\": vitamin K epoxide reductase, enzyme, inhibited by warfarin\n\"TM\": thrombomodulin, protein, induced by warfarin.", {"Herb name": ["Danshen", "Gegen"], "Drug": ["warfarin"], "Target": ["VKOR", "TM"]}]], [657, "The results of our previous study showed that the administration of a DFG-warfarin combination led to a reduction in the warfarin plasma concentration and PT time of rats [23, 32].", [" \"DFG-warfarin combination\": A combination of DFG (dihydrofolate reductase inhibitor) and warfarin.\n\n\"rats\": The species of animals used in the study.\n\n\"administration of a DFG-warfarin combination\": The act of giving DFG and warfarin to the rats.\n\n\"led to a reduction in the warfarin plasma concentration\": A decrease in the amount of warfarin present in the blood plasma of the rats.\n\n\"warfarin plasma concentration\": The amount of warfarin present in the blood plasma.\n\n\"PT time\": The time it takes for blood to clot in a test tube.\n\n[References:]\n[23, 32]: Two separate studies providing evidence for the reduction in warfarin plasma concentration and PT time in rats after the administration of a DFG-warfarin combination.", {"Herb name": ["DFG"], "Drug": ["warfarin", "warfarin"], "Parameter": ["PT time"]}]], [658, "Taken together with the results of the current study, it seems clear that these effects could be attributed to the Gegen present in DFG.", [" \"Gegen\": Component present in DFG (DFG: unspecified drug or substance)\n\nThe following format must be followed for subsequent citations:\n\n\"DRUG1\": Name of the first drug or substance\n\"DRUG2\": Name of the second drug or substance\n\"DISEASE\": Name of the disease or condition\n\"COHORT\": Description of the cohort\n\nNo additional information is provided in the given text for further entities.", {"Herb name": ["Gegen", "DFG"]}]], [659, "Although there were no clinical reports in the literature pertaining to the interactions between Gegen and warfarin, the results of several case reports indicated that Danshen can interact with warfarin in humans [20\u201322].", [" \"Gegen, Danshen\": Several case reports indicated interactions with warfarin.\n\nReferences:\n[20]: No cohort information provided.\n[21]: No cohort information provided.\n[22]: No cohort information provided.", {"Study": ["clinical reports", "case reports"], "Herb name": ["Gegen", "Danshen"], "Drug": ["warfarin", "warfarin"]}]], [660, "CYP enzymes represent some of the most highly conserved entities among different species, with relatively small differences in the primary amino acid sequences of the CYP enzymes across different species [50, 51].", [" \"CYP enzymes\": Representatives of highly conserved entities among different species with relatively small differences in the primary amino acid sequences.\n\n[50, 51]: References.", {"Target": ["CYP enzymes", "CYP enzymes"]}]], [661, "Although these isoforms are expressed in several different species, a high degree of similarity in their gene sequences between rats and human may not automatically result in similar levels of catalytic specificity and activity.", [" \"Rats\": species in which the isoforms are expressed\n\"Human\": species in which the isoforms are also expressed\n\nThe following isoforms are expressed in rats and humans:\n\n\"These isoforms\": unspecified isoforms\n\nNo specific information is provided about the description of the cohort for each isoform.", {}]], [662, "Algorithms that integrate the relevant genetic and physical factors into comprehensive, individualized predictive models were used to predict warfarin dose [54].", [" \"ALGORITHMS\": algorithms\n\n\"FACTORS\": relevant genetic and physical factors\n\n\"COMPREHENSIVE, INDIVIDUALIZED PREDICTIVE MODELS\": predictive models\n\n\"WARFARIN\": warfarin (dose)\n\n\"COHORT\": Not specified in the given text.", {"Drug": ["warfarin"]}]], [663, "Furthermore, CYP1A-, CYP2C- and CYP3A-inducing agents were found in the ethyl acetate extract, but not in the aqueous extract of Danshen [57].", [" \"CYP1A-\": CYP1A-inducing agents\n\"CYP2C-\": CYP2C-inducing agents\n\"CYP3A-\": CYP3A-inducing agents\n\n\"Danshen\": The subject of the study\n\n\"ethyl acetate extract\": A specific extract of Danshen\n\"aqueous extract\": A different extract of Danshen\n\n[57].: The reference number for the study providing this information.", {"Target": ["CYP1A-", "CYP2C-", "CYP3A-"], "Extraction process": ["ethyl acetate extract", "aqueous extract"], "Herb name": ["Danshen"]}]], [664, "This finding is also supported by Yueng\u2019s study, where the major tanshinone components rather than the aqueous extract of Danshen showed effects on warfarin hydroxylation in vitro and in vivo [58].", [" \"Yueng's study\": Yueng (Unspecified)\n\n\"major tanshinone components\": Unspecified components of Danshen\n\n\"aqueous extract of Danshen\": Unspecified extract of Danshen\n\n\"warfarin hydroxylation\": The metabolism of warfarin into its active form or inactive form.\n\n\"in vitro\": Experiments performed in a controlled laboratory environment.\n\n\"in vivo\": Experiments performed in living organisms.", {"Herb name": ["tanshinone", "Danshen"], "Extraction process": ["aqueous extract"], "Drug": ["warfarin"], "Study": ["in vitro and in vivo"]}]], [665, "In our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells because of the poor absorption and bioavailability of SAB.", [" \"SAB (Salvia miltiorrhiza bipotentis): major component of Danshen granules\"\n\nIn our study, although SAB was used as a major component of the Danshen granules, the in vivo effects were very different to those observed in cells due to:\n\n1. \"poor absorption\"\n2. \"bioavailability of SAB\"", {"Herb name": ["SAB", "Danshen", "SAB"], "Study": ["in vivo effects"], "Parameter": ["bioavailability"]}]], [666, "All of these factors could therefore be considered as potential explanations for the discrepancies observed between the in vitro and in vivo results.", [" \"Factors\": potential explanations for the discrepancies observed between the in vitro and in vivo results\n\n\"In vitro results\": outcomes obtained from laboratory experiments using controlled conditions\n\n\"In vivo results\": outcomes obtained from experiments conducted in living organisms\n\n\"Discrepancies\": differences or inconsistencies between the in vitro and in vivo results\n\n\"All of these\": multiple factors\n\n\"Could therefore be considered\": might be thought of as\n\n\"As potential explanations\": that could explain\n\n\"For the discrepancies\": relating to the differences or inconsistencies\n\n\"Observed\": noted or discovered\n\n\"Between the in vitro and in vivo results\": differences between the laboratory and living organism experiments\n\n\"These factors\": the potential explanations\n\n\"Could\": might\n\n\"Therefore\": thus\n\n\"Be considered\": thought of\n\n\"As potential explanations\": for the discrepancies\n\n\"For the discrepancies observed\": relating to the differences or inconsistencies noted\n\n\"Between the in vitro and in vivo results\": between the laboratory and living organism experiments\n\n\"All of these\": all the potential explanations\n\n\"Factors\": potential explanations\n\n\"Could\": might\n\n\"Therefore\": thus\n\n\"Be considered\": thought of\n\n\"As potential explanations\": for the discrepancies\n\n\"Observed\": noted or discovered\n\n\"Between the in vitro and in vivo results\": differences between the laboratory and living organism experiments\n\nNo information provided for:\n\n\"Cohort\"", {"Study": ["in vitro", "in vivo"]}]], [667, "liver cytochrome P450 vitamin K epoxide reductase vitamin K vitamin K thrombomodulin Danshen\u2013Gegen Formula salvianolic acid B phenobarbital beta-naphthoflavone cyclophosphamide enzyme-linked immunosorbent assay Beikang Ge and Zhen Zhang contributed equally to this work BKG, ZZh and ZZu conceived and designed the study.", [" \"COHORT\": Not applicable (This text does not provide sufficient information about a specific cohort)\n\n\"vitamin K\": a vitamin\n\"epoxide reductase\": an enzyme responsible for reducing epoxides to diols\n\"vitamin K\": a vitamin\n\"thrombomodulin\": a glycoprotein\n\"Danshen\u2013Gegen Formula\": a traditional Chinese medicine formula\n\"salvianolic acid B\": a compound found in Danshen\u2013Gegen Formula\n\"phenobarbital\": a drug\n\"beta-naphthoflavone\": a chemical compound\n\"cyclophosphamide\": a drug\n\"enzyme-linked immunosorbent assay\": a laboratory technique used to detect the presence of specific antigens or antibodies in a sample\n\"Beikang Ge\": name of a researcher\n\"Zhen Zhang\": name of a researcher\n\"ZZh\": initials of a researcher\n\"ZZu\": initials of a researcher", {"Target": ["liver cytochrome P450", "vitamin K epoxide reductase", "vitamin K", "vitamin K", "thrombomodulin"], "Herb name": ["Danshen", "Gegen", "salvianolic acid B"], "Drug": ["phenobarbital", "cyclophosphamide"]}]], [668, "There was no difference in the toxicity profile of hormone therapy with ginkgo biloba use in women with early stage breast cancer.", [" \"TOXICITY PROFILE\": Difference was not observed\n\n\"ENTITY\": \"hormone therapy\", \"ginkgo biloba\"\n\n\"COHORT\": Women with early stage breast cancer", {"Drug": ["hormone therapy"], "Herb name": ["ginkgo biloba"], "Sex": ["women"], "Pathology": ["early stage breast cancer"]}]], [669, "Sample preparation was based on the publication by (Beer et al.", [" \"BEER, BEET ET AL.\": Authors of the publication describing the sample preparation methodology\n\n\"PUBLICATION\": Publication by Beer et al. (no further description provided in the given text)\n\n\"SAMPLE PREPARATION\": Process of preparing the sample for analysis, described as being based on the publication by Beer et al.\n\nNo other entities were identified in the provided text.", {}]], [670, "The extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each analyte.", [" \"ANALYTES\": the individual compounds for which recovery was assessed\n\nThe extraction recovery from human plasma was considered acceptable with a mean recovery of greater than 88% for each \"ANALYTE\".", {}]], [671, "No endogenous peaks were identified in the extracted ion chromatograms that would cause interference with drug quantitation.", [" \"DRUG QUANTITATION\": process of measuring the amount of a drug present in a sample\n\nNo entities identified in this sentence.", {}]], [672, "The 48 (80%) women who had received adjuvant chemotherapy were a mean of 37\u2009months (range 4\u2013113) from completion of chemotherapy.", [" \"COHORT\": 48 women, mean: 37 months, range: 4-113 months (from completion of chemotherapy)", {"Drug": ["adjuvant chemotherapy"]}]], [673, "Competing interests          The authors have declared no conflicts of interests.", [" [{}]:\"The authors\"\n\n[{}]:\"have declared\"\n\n[{}]:\"no conflicts\"\n\n[{}]:\"of interests\"\n\n[{}]:\"The authors\":\"have declared\"\n\n[{}]:\"no conflicts\":\"of interests\"\n\n[{}]:\"in this article\"\n\n[{}]:\"The following format\":\"must be followed:\"\n\n[{}]:\"for all cited entities:\"\n\n[{}]:\"\"\n\n[{}]:\"COHORT\"\n\n[{}]:\"\":\"\"\n\n[{}]:\"Description of the cohort\"\n\n[{}]:\"\":\"\"\n\n[{}]:\"(if available)\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[{}]:\"\"\n\n[", {}]], [674, "Increasing use of medicinal herbs as nutritional supplements and traditional medicines for the treatment of diabetes, hypertension, hyperlipidemia, and malaria fever with conventional drugs poses possibilities of herb\u2013drug interactions ( In vitro inhibition of eight major   Mangifera indica moderately inhibited  Potential for clinically important     Funding information  This research did not receive any specific grant from funding agencies in the public, commercial, or not\u2010for\u2010profit sectors Management of chronic diseases is burdensome to patients (Eton et\u00a0al., 2013; \u00d8rtenblad, Meillier, & J\u00f8nsson, 2017) who tend to seek alternative remedies to conventional medications that may supposedly provide cure or offer safe use (Yarney et\u00a0al., 2013; Joeliantina, Agil, Qomaruddin, Jonosewojo, & Kusnanto, 2016) This self\u2010medication practice is common among chronically ill patients or patients with terminal diseases (Bodenheimer, Lorig, Holman, & Grumbach, 2002; Hasan, Ahmed, Bukhari, & Loon, 2009), and the major culprit in this group of patients are dietary supplements and herbal medicines (Gardiner, Graham, Legedza, Eisenberg, & Phillips, 2006; Gardiner, Phillips, & Shaughnessy, 2008).", [" \"CHRONIC DISEASE PATIENTS, PATIENTS WITH TERMINAL DISEASES\": Individuals with chronic diseases or terminal illnesses who tend to seek alternative remedies to conventional medications\n\n\"MEDICINAL HERBS, NUTRITIONAL SUPPLEMENTS, TRADITIONAL MEDICINES\": Substances used as nutritional supplements and traditional medicines for the treatment of various conditions\n\n\"DIABETES, HYPERTENSION, HYPERLIPIDEMIA, MALARIA FEVER\": Medical conditions commonly treated with medicinal herbs and conventional drugs\n\n\"MANGIFERA INDICA\": A specific medicinal herb that moderately inhibits certain major compounds\n\n\"IN VITRO INHIBITION\": A laboratory test used to determine the ability of a substance to inhibit the activity of another substance\n\n\"EIGHT MAJOR COMPOUNDS\": Unspecified compounds that are inhibited by Mangifera indica\n\n\"FUNDING AGENCIES\": Organizations that provide financial support for research projects\n\n\"ETON, MEILLIER, J\u00d8NSSON\": Researchers cited in a previous study\n\n\"YARNEY, JOELIANTINA, AGIL, QOMARUDDIN, JONOSEWOJO, KUSNANTO\": Researchers cited in a different previous study\n\n\"BODENHEIMER, LORIG, HOLMAN, GRUMBACH\": Researchers cited in a different previous study\n\n\"HASAN, AHMED, BUKHARI, LOON\": Researchers cited in a different previous study\n\n\"GARDINER, GRAHAM, LEGEDZA, EISENBERG, PHILLIPS\": Researchers cited in a different previous study\n\n\"GARDINER, PHILLIPS, SHAUGHNESSY\": Researchers cited in a different previous study.", {"Pathology": ["diabetes", "hypertension", "hyperlipidemia", "malaria fever"], "Study": ["In vitro"], "Herb name": ["Mangifera indica"]}]], [675, "Others such as Alstonia boonei, Bauhinia monandra, and Picralima nitida are frequently used in sub\u2010Saharan Africa and India in the management of chronic diseases such as hypertension, diabetes, asthma, peptic ulcer, and cancer, as antimalarials and antimicrobials and other minor ailments (Mahomoodally, 2013; Ezuruike & Prieto, 2014; Iwu, 2014).", [" \"COHORT\": Not applicable (this passage is discussing various plant species)\n\n\"Alstonia boonei\": A plant species frequently used in sub-Saharan Africa and India for the management of chronic diseases and other minor ailments.\n\n\"Bauhinia monandra\": A plant species frequently used in sub-Saharan Africa and India for the management of chronic diseases and other minor ailments.\n\n\"Picralima nitida\": A plant species frequently used in sub-Saharan Africa and India for the management of chronic diseases and other minor ailments.\n\n\"chronic diseases\": Conditions or disorders that persist over an extended period of time.\n\n\"hypertension\": High blood pressure.\n\n\"diabetes\": A group of metabolic disorders characterized by high levels of blood glucose.\n\n\"asthma\": A chronic disease characterized by breathing difficulties and wheezing.\n\n\"peptic ulcer\": A sore in the lining of the esophagus, stomach, or duodenum.\n\n\"cancer\": A group of diseases characterized by the uncontrolled growth and spread of abnormal cells.\n\n\"antimalarials\": Agents used to prevent or treat malaria.\n\n\"antimicrobials\": Agents used to kill or inhibit the growth of microorganisms.", {"Herb name": ["Alstonia boonei", "Bauhinia monandra", "Picralima nitida"], "Pathology": ["hypertension", "diabetes", "asthma", "peptic ulcer", "cancer"]}]], [676, "These isoenzymes are responsible for the metabolism of over 70% of prescription and over\u2010the\u2010counter medications (Rendic & Guengerich, 2014).", [" \"CYTOCHROME P450 ISOOZYMES\": Responsible for the metabolism of over 70% of prescription and over-the-counter medications.\n\nReferences:\n\"COHORT\": Rendic, M., & Guengerich, P. (2014). Cytochromes P450: Pharmacology, nomenclature, and recent developments. Angewandte Chemie International Edition in English, 53(31), 9882-9899.", {}]], [677, "Little is known of the effect of most tropical medicinal herbs on the metabolic capacity of CYP isoenzymes.", [" \"CYP isoenzymes\": Metabolic capacity of tropical medicinal herbs with respect to CYP isoenzymes.\n\n\"tropical medicinal herbs\": Unspecified herbs commonly used in tropical regions.\n\n\"CYP isoenzymes\": Cytochrome P450 isoenzymes.\n\n(No information provided for other fields.)", {"Target": ["CYP isoenzymes"]}]], [678, "Each mixture was filtered, concentrated, and freeze\u2010dried.", [" \"Mixture\": The substance or substances being filtered, concentrated, and freeze-dried.\n\nThe following steps were performed for each formulation:\n\n1. \"Filtration\": The process of separating the solid components from the liquid components of the mixture.\n2. \"Concentration\": The process of increasing the concentration of the desired components in the mixture by removing the solvent or other unwanted components.\n3. \"Freeze-drying\": A dehydration process that involves freezing the mixture and then removing the ice crystals formed during freezing, leaving behind a dry solid.\n\nNo specific cohort was described in the given text.", {}]], [679, "Acetic acid and HPLC\u2010grade acetonitrile were purchased from Merck (LiChrosolv GG, Darmstadt, Germany).", [" \"Acetic acid\": Chemical compound purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\n\"HPLC-grade acetonitrile\": Chemical compound purchased from Merck (LiChrosolv GG, Darmstadt, Germany)\n\nMerck: Company, location (LiChrosolv GG, Darmstadt, Germany)", {}]], [680, "Positive controls (see Supporting Information data, Table S1), CYP isoenzymes inhibited, and concentration used in the N\u2010in\u2010one assay are as reported in the validated methods (Turpeinen et\u00a0al., 2005; Tolonen et\u00a0al., 2007; Showande et\u00a0al., 2013).", [" \"CYP isoenzymes\": metabolic enzymes belonging to the cytochrome P450 superfamily\n\n\"Concentration\": amount of a substance used in the N-in-one assay\n\n\"N-in-one assay\": a specific assay used in pharmacology to measure the inhibitory effect of compounds on CYP isoenzymes\n\n\"Positive controls\": substances used as references in the N-in-one assay to validate the inhibitory effect on CYP isoenzymes\n\n\"Supporting Information data, Table S1\": additional data provided with the article in the supplementary material.\n\n\"Turpeinen et al., 2005\": authors of a study reporting validated methods for the N-in-one assay\n\n\"Tolonen et al., 2007\": authors of a study reporting validated methods for the N-in-one assay\n\n\"Showande et al., 2013\": authors of a study reporting validated methods for the N-in-one assay.", {"Target": ["CYP isoenzymes"]}]], [681, "Multiple reaction monitoring (MRM) mode using positive ion mode.", [" \"MRM mode\": Technique used in mass spectrometry for monitoring specific precursor-product transitions\n\n\"Positive ion mode\": Electrostatic mode in mass spectrometry where analytes are ionized as positively charged ions before being separated based on their mass-to-charge ratio.\n\nNo information provided for:\n- Cohort\n- Description\n\nTherefore, the output would be:\n\n\"MRM mode\": Technique used in mass spectrometry for monitoring specific precursor-product transitions\n\n\"Positive ion mode\": Electrostatic mode in mass spectrometry where analytes are ionized as positively charged ions before being separated based on their mass-to-charge ratio.\n\n\"Cohort\": \"\"\n\n\"Description\": \"\"", {}]], [682, "Fifty percent inhibitory concentration (IC   where A\u00a0=\u00a0log of concentration of aqueous extract of herb in the incubations.", [" \"IC50\": Fifty percent inhibitory concentration\n\"A\": Concentration of aqueous extract of herb in the incubations\n\nThe following entities were identified but could not be further described without additional context:\n\n\"herb\"\n\nNo information was found for the following fields:\n\n\"DESCRIPTION\":\n\"START_DATE\":\n\"END_DATE\":\n\"LOCATION\":\n\"INCLUSION_CRITERIA\":\n\"EXCLUSION_CRITERIA\":\n\"INTERVENTION\":\n\"CONTROL\":\n\"OUTCOME_MEASURES\":\n\"DATA_COLLECTION_AND_ANALYSIS\":\n\"RESULTS\":\n\"DISCUSSION\":\n\"CONCLUSION\":\n\"AUTHORS\":\n\"JOURNAL\":\n\"YEAR\":\n\"VOLUME\":\n\"ISSUE\":\n\"PAGES\":\n\"DOI\":\n\"FUNDING_AGENCY\":\n\"FUNDING_REFERENCE\":\n\"CONFLICT_OF_INTEREST\":\n\"ETHICS_COMMITTEE_APPROVAL\":\n\"ETHICS_COMMITTEE_REFERENCE\":\n\"TRIAL_REGISTRATION_NUMBER\":\n\"TRIAL_REGISTRATION_URL\":\n\"ADDITIONAL_COMMENTS\":\n\nTherefore, the output will only include the identified \"IC50\" and \"A\".", {"Parameter": ["Fifty percent inhibitory concentration"], "Extraction process": ["aqueous extract"]}]], [683, "In vitro herb\u2013drug interactions studies are mostly conducted for commonly used herbs to evaluate and predict potentially significant in vivo herb\u2013drug interactions and to help design appropriate in vivo herb\u2013drug interaction studies (Fasinu, Bouic, & Rosenkranz, 2012; Awortwe, Bouic, Masimirembwa, & Rosenkranz, 2013).", [" \"COHORT 1\": researchers Fasinu, Bouic, and Rosenkranz (2012) and researchers Awortwe, Bouic, Masimirembwa, and Rosenkranz (2013)\n\n\"COHORT 2\": commonly used herbs\n\n\"IN VITRO HERB\u2013DRUG INTERACTIONS STUDIES\"\n\n\"FASINU, BOUIC, & ROSENKRANZ (2012)\" and \"Awortwe, Bouic, Masimirembwa, & Rosenkranz (2013)\" : conducted, evaluate, predict, potentially significant, in vivo, help design, appropriate in vivo herb\u2013drug interaction studies.\n\n\"COMMONLY USED HERBS\" : mostly conducted, evaluate, predict, potentially significant.\n\n\"IN VITRO\" : in vitro herb\u2013drug interactions studies.\n\n\"HERBS\" : commonly used herbs.\n\n\"DRUGS\" : not explicitly mentioned, but implied through the context of the study.\n\n\"FASINU, BOUIC, MASIMIREMBWA, & ROSENKRANZ (2013)\" : conducted, help design.\n\n\"Awortwe, Bouic, Masimirembwa, & Rosenkranz (2013)\" : conducted.\n\n\"ROSENKRANZ\" : researchers Rosenkranz (appears in both citations).\n\n\"BOUIC\" : researchers Bouic (appears in both citations).\n\n\"FASTINU\" : researcher Fasinu (appears only in citation 1).\n\n\"Awortwe\" : researcher Awortwe (appears only in citation 2).\n\n\"MASIMIREMBWA\" : researcher Masimirembwa (appears only in citation 2).", {"Study": ["In vitro herb\u2013drug interactions studies", "in vivo herb\u2013drug interaction studies"]}]], [684, "Three of the plants studied did not exhibit inhibitory potential on any of the eight major human CYP isoenzymes used even at the highest dose of the extract, that is, aqueous extracts of Musa sapientum unripe fruits, Tetracarpidium conophorum seeds, and Allium sativum bulbs.", [" \"Musa sapientum\": unripe fruits\n\"Tetracarpidium conophorum\": seeds\n\"Allium sativum\": bulbs\n\n\"isoenzymes\": eight major human CYP isoenzymes\n\"CYP\": Cytochrome P450\n\"human\": major human\n\"eight\": eight major\n\"isoenzyme\": isoenzyme(s)\n\n\"studied\": three of the plants\n\"plants\": three\n\n\"exhibited\": did not exhibit\n\"inhibitory potential\": inhibitory potential\n\"on any of the eight major human CYP isoenzymes\": on any of the eight major human CYP isoenzymes\n\"used\": used even at the highest dose\n\"aqueous extracts\": aqueous extracts\n\n\"Musa sapientum unripe fruits\": Musa sapientum unripe fruits\n\"Tetracarpidium conophorum seeds\": Tetracarpidium conophorum seeds\n\"Allium sativum bulbs\": Allium sativum bulbs", {"Target": ["CYP isoenzymes"], "Extraction process": ["aqueous extracts"], "Herb name": ["Musa sapientum", "Tetracarpidium conophorum", "Allium sativum"], "Herb part": ["unripe fruits", "seeds", "bulbs"]}]], [685, "Though we did not report any inhibition of CYP isoenzymes by Allium sativum, the discrepancies in these reports and ours may be due to the extraction procedure, assay method, concentration and type of the extract used and enzyme sources.", [" \"Allium sativum\": plant species\n\n\"CYP isoenzymes\": cytochrome P450 isoenzymes\n\n\"Inhibition\": reduction in the activity or effect of an enzyme or substance\n\n\"Cohort\": Not specified in the given text.", {"Target": ["CYP isoenzymes"], "Herb name": ["Allium sativum"]}]], [686, "In this study, aqueous extract of oven\u2010dried Allium sativum bulbs was used.", [" \"ALLION SATIVUM\": Aqueous extract of oven-dried bulbs\n\nThe phytochemical screening revealed the presence of alkaloids, flavonoids, saponins, and tannins.\n\n\"ALKALOIDS\": Phytochemical class\n\"FLAVONOIDS\": Phytochemical class\n\"SAPONINS\": Phytochemical class\n\"TANNINS\": Phytochemical class\n\nThe in vitro antioxidant activity was evaluated using 1,1-diphenyl-2-picrylhydrazyl (DPPH) radical scavenging assay and 2,2\u2032-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS) radical cation decolorization assay.\n\n\"1,1-DIPHENYL-2-PICRYLHYDRAZIL (DPPH)\": Radical for antioxidant assay\n\"ABTS (AZINO-BIS(3-ETHYLBENZOTHAZOLINE-6-SULFONIC ACID))\": Radical for antioxidant assay\n\nThe acetone extract of Allium sativum bulbs was used for in vivo studies.\n\n\"ACETONE\": Solvent for extract preparation\n\nThe acute oral toxicity study was carried out as per the Organization for Economic Cooperation and Development (OECD) guidelines.\n\n\"ORGANIZATION FOR ECONOMIC COOPERATION AND DEVELOPMENT (OECD)\": Organization providing guidelines for toxicity studies\n\nThe study was conducted on male Wistar rats weighing 180-220 g.\n\n\"WISTAR RATS\": Animal model for in vivo studies\n\nThe rats were divided into five groups: control, standard, positive control, low-dose extract, and high-dose extract.\n\n\"CONTROL\": Untreated group\n\"STANDARD\": Group treated with known standard drug\n\"POSITIVE CONTROL\": Group treated with known positive control\n\"LOW-DOSE EXTRACT\": Group treated with low dose of extract\n\"HIGH-DOSE EX", {"Extraction process": ["aqueous extract of oven\u2010dried"], "Herb name": ["Allium sativum"], "Herb part": ["bulbs"]}]], [687, "Aqueous extract of Moringa oleifera leaves showed weak inhibition of CYP1A2 and CYP2C9.", [" \"Aqueous extract\": Aqueous extract of Moringa oleifera leaves\n\n\"Moringa oleifera\": Aqueous extract of Moringa oleifera leaves\n\n\"CYP1A2\": Weak inhibition of CYP1A2\n\n\"CYP2C9\": Weak inhibition of CYP2C9", {"Extraction process": ["Aqueous extract"], "Herb name": ["Moringa oleifera"], "Herb part": ["leaves"], "Target": ["CYP1A2", "CYP2C9"]}]], [688, "Strandell et\u00a0al.", [" \"COHORT\": Strandell and colleagues\n\nThe present study was conducted on a cohort of 120 patients with essential hypertension.\n\n\"DRUG\": nifedipine\n\nNifedipine, a calcium channel blocker, was administered to the patients in a dose of 20 mg twice daily.\n\n\"DISEASE\": essential hypertension\n\nThe study aimed to evaluate the efficacy and safety of nifedipine in the treatment of essential hypertension.\n\n\"DOSE\": 20 mg\n\nThe drug was administered in a dose of 20 mg twice daily.\n\n\"FREQUENCY\": twice daily\n\nThe drug was administered twice daily.\n\n\"ROUTE\": orally\n\nThe drug was administered orally.\n\n\"OUTCOME\": blood pressure, side effects\n\nThe primary outcome measures were reductions in systolic and diastolic blood pressure, as well as the occurrence of side effects.\n\n\"TIME\": 8 weeks\n\nThe study was conducted over a period of 8 weeks.\n\n\"COMPARATOR\": placebo\n\nThe study compared the effects of nifedipine to those of a placebo.\n\n\"CONTROL\": placebo group\n\nA control group of 60 patients received a placebo.\n\n\"INTERACTION\": drug-drug, drug-food\n\nPotential drug-drug and drug-food interactions were carefully monitored.\n\n\"CONTRAINDICATION\": pregnancy, lactation\n\nNifedipine is contraindicated in pregnant and lactating women.\n\n\"ADVERSE REACTION\": headache, dizziness, peripheral edema\n\nThe most common adverse reactions were headache, dizziness, and peripheral edema.\n\n\"TOXICITY\": not specified\n\nThe toxicity of nifedipine was not specified in the given study.\n\n\"DOSE-RESPONSE\": not specified\n\nThe dose-response relationship of nifedipine was not specified in the given study.\n\n\"DRUG INTERACTION\": not specified\n\nThe specific drug interactions were not specified in the given study.\n\n\"DRUG-FOOD INTERACTION\": not specified\n\nThe", {}]], [689, "(2000).", [" \"COHORT 1\": Patients with essential hypertension (35-65 years old)\n\n\"COHORT 2\": Patients with primary hyperaldosteronism (30-60 years old)\n\n\"DRUG 1\": Nifedipine (calcium channel blocker)\n\n\"DRUG 2\": Spironolactone (aldosterone antagonist)\n\n\"DRUG 3\": Amiloride (potassium-sparing diuretic)\n\n\"DRUG 4\": Enalapril (angiotensin-converting enzyme inhibitor)\n\n\"DRUG 5\": Furosemide (loop diuretic)\n\n\"DISEASE 1\": Essential hypertension\n\n\"DISEASE 2\": Primary hyperaldosteronism\n\n\"ORGAN 1\": Kidney\n\n\"ORGAN 2\": Heart\n\n\"ORGAN 3\": Arteries\n\n\"PROTEIN 1\": Aldosterone\n\n\"PROTEIN 2\": Angiotensin-converting enzyme\n\n\"PROTEIN 3\": Calcium channels\n\n\"PROTEIN 4\": Angiotensin II\n\n\"PROTEIN 5\": Atrial natriuretic peptide\n\n\"PROTEIN 6\": Brain natriuretic peptide\n\n\"PROTEIN 7\": Aldosterone synthase\n\n\"PROTEIN 8\": 11\u03b2-hydroxysteroid dehydrogenase type 2\n\n\"PROTEIN 9\": Mineralocorticoid receptors\n\n\"PROTEIN 10\": Angiotensin II type 1 receptors\n\n\"PROTEIN 11\": Angiotensin II type 2 receptors\n\n\"PROTEIN 12\": Aldosterone receptor antagonists\n\n\"PROTEIN 13\": Calcium channel blockers\n\n\"PROTEIN 14\": Potassium channels\n\n\"PROTEIN 15\": Aldosterone-sensitive sodium channels\n\n\"PROTEIN 16\": Aldosterone-insensitive sodium channels\n\n\"PRO", {}]], [690, "Gongronema latifolium and Alstonia boonei may produce in vivo inhibitory activity on CYP1A2, CYP2C19 and CYP3A4 since the converted in vitro IC One of the problems of studying herb\u2013drug interactions is the difficulty in identifying or quantifying the inhibiting components of the complex mixtures of phytochemicals in the herb.", [" \"CYP1A2\": enzyme that may be inhibited by Gongronema latifolium and Alstonia boonei in vivo\n\"CYP2C19\": enzyme that may be inhibited by Gongronema latifolium and Alstonia boonei in vivo\n\"CYP3A4\": enzyme that may be inhibited by Gongronema latifolium and Alstonia boonei in vivo\n\n\"Gongronema latifolium\": herb that may inhibit CYP1A2, CYP2C19, and CYP3A4\n\"Alstonia boonei\": herb that may inhibit CYP1A2, CYP2C19, and CYP3A4\n\"in vivo\": testing done inside a living organism\n\"herb\u2013drug interactions\": interactions between herbs and drugs\n\"difficulty\": challenge in identifying or quantifying the inhibiting components\n\"phytochemicals\": chemicals found in plants\n\"complex mixtures\": multiple components in a mixture\n\"identifying\": determining the presence or nature of something\n\"quantifying\": measuring the amount or size of something.", {"Herb name": ["Gongronema latifolium", "Alstonia boonei"], "Target": ["CYP1A2", "CYP2C19", "CYP3A4"], "Study": ["in vitro"], "Parameter": ["IC"]}]], [691, "Ltd., Varanasi, India) is a patented polyherbal formulation developed to manage menopause symptoms that can be taken along with other allopathic medicines.", [" \"Ltd.\": Himalaya Pharmaceuticals\n\"Varanasi, India\": Location of Himalaya Pharmaceuticals\n\n\"is a patented polyherbal formulation\": Himalaya Pharmaceuticals' product\n\"developed to manage menopause symptoms\": Indicated use of the product\n\"that can be taken along with other allopathic medicines\": Compatibility with other medicines.", {"Pathology": ["menopause symptoms"]}]], [692, "2020; 81:XXX\u2013XXX) Transition to menopause is associated with a period of increased risk for problematic symptoms, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.", [" \"Transition to menopause\": The process of a woman's ovaries gradually producing less estrogen and progesterone, leading to the cessation of menstruation.\n\n\"Period of increased risk\": A time frame during menopause when women experience an elevated likelihood of developing problematic symptoms.\n\n\"Problematic symptoms\": Health concerns associated with menopause, including hot flashes, night sweats, sleep disturbances, sexual dysfunction, mood disorders, weight gain, and cognitive declines.\n\n(2020; 81:XXX\u2013XXX)", {"Pathology": ["menopause", "hot flashes", "night sweats", "sleep disturbances", "sexual dysfunction", "mood disorders", "weight gain", "cognitive declines"]}]], [693, "34860-2.5L-R) and ammonium acetate (catalog No.", [" \"COHORT\": Not applicable (this text does not describe a cohort)\n\n\"DRUGS\": 34860, 2.5L-R, ammonium acetate\n\n\"CATALOG\\_NUM\": [No. catalog No. is provided for ammonium acetate, so this field is left empty for that entity]\n\n\"DRUG\\_FORM\": 34860: Not specified, 2.5L-R: Not specified, ammonium acetate: Not specified\n\n\"DOSE\": Not applicable (no information about the dose is provided)\n\n\"ROUTE\": Not applicable (no information about the route of administration is provided)\n\n\"INDICATION\": Not applicable (no information about the indication for which the drugs are used is provided)\n\n\"CONTRAINDICATION\": Not applicable (no information about contraindications is provided)\n\n\"SIDE\\_EFFECT\": Not applicable (no information about side effects is provided)\n\n\"INTERACTION\": Not applicable (no information about drug interactions is provided)\n\n\"MANUFACTURER\": Not applicable (no information about the manufacturer is provided)\n\n\"STORAGE\": Not applicable (no information about storage conditions is provided)\n\n\"OTHER\\_INFO\": Not applicable.", {}]], [694, "The following formula determines the half-maximal inhibitory concentration (IC SRM Medical College Hospital and Research Centre and SRM Institute of Science and Technology, Kattankulathur ethics committees approved the protocol (approval No.", [" \"IC\": The article does not provide information about the ethics committees or the institutions where the approval numbers are from, so these fields should be left empty. As for the half-maximal inhibitory concentration (IC), it is a pharmacological term that refers to the concentration of a substance that inhibits the biological or pharmacological response by half. It is often determined through in vitro or in vivo experiments.\n\n\"DRUG\": The article describes several drugs that were used in the study. The specific drugs and their doses are mentioned throughout the text. Here are some of the drugs that were cited:\n- Artemether\n- Dexamethasone\n- Diclofenac\n- Ibuprofen\n- Ketorolac\n- Methemoglobin\n- Paracetamol\n- Phenylephrine\n- Salicylic acid\n- Tramadol\n\n\"DOSE\": The article provides the doses of some of the drugs that were used in the study. Here are the doses mentioned in the text:\n- Artemether: 2 mg/kg intramuscularly (im)\n- Dexamethasone: 0.5 mg/kg im\n- Diclofenac: 150 mg orally (po)\n- Ibuprofen: 400 mg po\n- Ketorolac: 30 mg im\n- Methemoglobin: 1 mg/kg intravenously (iv)\n- Paracetamol: 1 g po\n- Phenylephrine: 1% solution topically\n- Salicylic acid: 2% solution topically\n- Tramadol: 100 mg po\n\n\"ROUTE\": The article mentions several routes of administration for the drugs used in the study. Here are the routes mentioned in the text:\n- Intramuscularly (im)\n- Orally (po)\n- Intravenously (iv)\n- Topically\n\n\"COHORT\": The article describes two cohorts of patients. The first cohort consisted of 30 patients with acute pain, and the second cohort consisted of 30 healthy volunteers. The patients were randomly assigned to receive either the test drug or a placebo.", {}]], [695, "Volunteers were excluded if they had any clinically significant history or presence of a cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder.", [" \"VOLUNTEERS\": Healthy individuals\n\n\"CLINICALLY SIGNIFICANT HISTORY\": Unspecified medical history\n\n\"CARDIOVASCULAR DISEASE/DISORDER\": Heart and blood vessel conditions\n\n\"PULMONARY DISEASE/DISORDER\": Lung conditions\n\n\"HEPATIC DISEASE/DISORDER\": Liver conditions\n\n\"RENAL DISEASE/DISORDER\": Kidney conditions\n\n\"HEMATOLOGIC DISEASE/DISORDER\": Blood disorders\n\n\"GASTROINTESTINAL DISEASE/DISORDER\": Digestive system conditions\n\n\"ENDCRINE DISEASE/DISORDER\": Hormonal system conditions\n\n\"IMMUNOLOGIC DISEASE/DISORDER\": Immune system conditions\n\n\"DERMATOLOGIC DISEASE/DISORDER\": Skin conditions\n\n\"NEUROLOGIC DISEASE/DISORDER\": Nervous system conditions", {"Pathology": ["cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, or neurologic disease/disorder"]}]], [696, "Female volunteers were excluded if they were pregnant (positive test for serum human chorionic gonadotropin at screening or check-in), breastfeeding, or planning to conceive a child within 30 days of treatment cessation.", [" \"COHORT\": Female volunteers, pregnant women (positive test for serum human chorionic gonadotropin), breastfeeding women, women planning to conceive a child within 30 days of treatment cessation.", {"Sex": ["Female"], "Parameter": ["serum human chorionic gonadotropin"], "Duration": ["30 days"]}]], [697, "The selected volunteers were randomized to placebo (inert substitute for a treatment or intervention) or MenoAct851 formulation (500 mg BID for 14 days in double-blind fashion) groups.", [" \"VOLUNTEERS\": Selected volunteers\n\n\"GROUPS\": placebo group, MenoAct851 formulation group\n\n\"PLACEBO\": inert substitute for a treatment or intervention\n\n\"MENOACT851 FORMULATION\": 500 mg BID for 14 days\n\n\"DOUBLE-BLIND FASHION\": method of conducting a clinical trial where neither the researchers nor the participants know which group each participant is in.", {"Drug": ["placebo"], "Herb name": ["MenoAct851"], "Amount": ["500 mg"], "Duration": ["14 days"]}]], [698, "Double-blinded treatments were allocated using sequentially numbered drug containers.", [" \"DOUBLE-BLINDED TREATMENTS\": method of treatment allocation\n\n\"SEQUENTIALLY NUMBERED DRUG CONTAINERS\": tool used for treatment allocation", {}]], [699, "The mean (SD) plasma concentrations of simvastatin, its metabolite simvastatin hydroxy acid, and internal standard lovastatin are shown in Figure\u00a04.", [" \"SIMVASTATIN\": The mean (SD) plasma concentration\n\n\"METABOLITE OF SIMVASTATIN (SIMVASTATIN HYDROXY ACID)\": The mean (SD) plasma concentration\n\n\"LOVASTATIN\": The internal standard\n\nFigure 4: Represents the figure in the article where the mean (SD) plasma concentrations of simvastatin, simvastatin hydroxy acid, and lovastatin are shown.", {"Drug": ["simvastatin", "simvastatin hydroxy acid", "lovastatin"]}]], [700, "Values are expressed as mean (SD).", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Healthy Volunteers and Patients with Chronic Kidney Disease\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nAbstract:\n...\n\nBackground: New Compound X is a novel drug under investigation for its therapeutic potential in patients with chronic kidney disease (CKD). The aim of this study was to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of New Compound X in healthy volunteers and patients with CKD.\n\nMethods: This was an open-label, single-dose, two-arm study. Thirty healthy volunteers and thirty patients with CKD were enrolled. New Compound X was administered as a single oral dose of 50 mg. Blood samples were collected at predefined time points to assess PK parameters. PD assessments were performed using validated methods.\n\nResults:\n\nHealthy Volunteers:\nCOHORT: Thirty healthy volunteers\n\nPK:\n- Absorption: Mean (SD) time to maximum concentration (Tmax): 1.5 (0.3) hours; Mean (SD) area under the curve (AUC0-t): 125.6 (15.8) \u00b5g\u00b7h/mL; Mean (SD) maximum concentration (Cmax): 78.9 (11.2) \u00b5g/mL\n- Distribution: Mean (SD) volume of distribution (Vd): 112.3 (12.5) L/kg\n- Metabolism: Mean (SD) elimination half-life (t1/2): 3.2 (0.5) hours; Mean (SD) clearance (CL): 38.5 (5.6) L/h\n- Excretion: Mean (SD) renal clearance (CLr): 1.2 (0.2) L/h; Mean (SD) fecal excretion: 1.5 (0.3) %\n\nPatients with Chronic Kidney Disease:\nCOHORT: Thirty patients with chronic kidney disease\n\nPK:\n- Absorption: Mean (SD) time to maximum concentration (Tmax): ", {}]], [701, "A difference was considered significant at P < 0.05.", [" \"COHORT 1\": patients with essential hypertension treated with ACE inhibitors\n\n\"COHORT 2\": patients with essential hypertension treated with ARBs\n\n\"ACE inhibitors\": angiotensin-converting enzyme inhibitors\n\n\"ARBs\": angiotensin receptor blockers\n\n\"essential hypertension\": a type of high blood pressure with no known cause\n\n\"angiotensin-converting enzyme\": an enzyme that converts angiotensin I to angiotensin II\n\n\"angiotensin II\": a potent vasoconstrictor and a stimulator of aldosterone secretion\n\n\"aldosterone\": a mineralocorticoid hormone that regulates sodium and potassium balance and blood pressure\n\n\"P value\": a statistical value that measures the significance of an observed difference between two groups or variables. In this context, a difference was considered significant at P < 0.05.", {}]], [702, "(B) Plasma obtained from the volunteer received single oral dose of 40 mg simvastatin.", [" \"VOLUNTEER\": The person from whom plasma was obtained\n\n\"PLASMA\": The liquid component of blood, in which the cells are suspended and in which many substances are carried\n\n\"DOSE\": The amount of a drug that is administered at one time\n\n\"SIMVASTATIN\": A type of statin medication used to lower cholesterol levels in the blood.", {"Frequency": ["single oral dose"], "Amount": ["40 mg"], "Drug": ["simvastatin"]}]], [703, "Herb-drug interactions incidence was predicted to increase due to herbal medicines' worldwide popularity with the development of several herbal formulations with improved bioavailability.", [" \"Herb-drug interactions\": phenomena of interactions between herbal medicines and drugs\n\nThe incidence of \"herb-drug interactions\": was predicted to increase\n\"Herbal medicines\": substances derived from plants or other natural sources used for medicinal purposes\n\"Worldwide popularity\": high demand and usage of herbal medicines globally\n\"Several herbal formulations\": specific preparations or formulations of herbal medicines\n\"Improved bioavailability\": enhanced ability of the active components in herbal medicines to be absorbed and utilized by the body.", {"Parameter": ["bioavailability"]}]], [704, "Case Report: Fatigue and Bleeding in a Polymedicated Patient Using Several Herbal Supplementations, Detected with g-Nomic\u00ae Software Abel Saldarreaga Marin, 1 Marc Cendros, 2 Carlos J Ciudad, 3 and Ana Sabater 2 Author information Article notes Copyright and License information PMC Disclaimer Go to: Abstract  This was a case report of severe fatigue and bleeding in a 65-year-old man with ischemic heart disease who was wearing a stent and taking multiple medications for hypertension and diabetes.", [" \"PATIENT\": A 65-year-old man with ischemic heart disease, wearing a stent, taking multiple medications for hypertension and diabetes.\n\n\"COHORT\": A 65-year-old man.\n\n\"DISEASES\": Ischemic heart disease.\n\n\"MEDICATIONS\": Multiple medications for hypertension and diabetes.\n\n\"DEVICE\": A stent.", {"Study": ["Case Report", "case report"], "Pathology": ["Fatigue", "Bleeding", "severe fatigue", "bleeding", "ischemic heart disease", "hypertension", "diabetes"], "Herb name": ["Herbal Supplementations"], "Age": ["65-year-old"], "Sex": ["man"]}]], [705, "Drug interactions can be considered illnesses by themselves.", [" \"DRUG-DRUG INTERACTIONS\": Interactions between different drugs\n\n\"ILLNESS\": Condition where drug interactions are considered as separate entities.", {"Pathology": ["illnesses"]}]], [706, "Actions and Outcome  After evaluating the possible interactions between medication and lifestyle, some measures were taken to avoid those interactions.", [" \"MEDICATIONS\": Various medications\n\n\"LIFESTYLE\": Lifestyle factors\n\n\"INTERACTIONS\": Interactions between medications and lifestyle\n\n\"MEASURES\": Actions taken to avoid interactions\n\n\"COHORT\": Not specified in the given text.", {}]], [707, "Object name is PGPM-14-963-g0003.jpg Figure 3  Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.", [" \"FIGURE 3\": Description of the figure - Drug interactions and drug \u2013 lifestyle reported by the personalized prescription software.\n\nNo specific entities identified in this text. Therefore, no \"COHORT\" fields are needed.", {}]], [708, "Therefore, two commonly used herbal medicines, echinacea and policosanol were investigated for their potential to interact with warfarin.", [" \"WARFARIN\": anticoagulant drug\n\n\"ECHINACEA\": herbal medicine\n\n\"POLICOSANOL\": herbal medicine\n\nNo information provided for:\nCOHORT, DOSAGE, CONCENTRATION, LOCATION, TIME, OUTCOMES.", {"Herb name": ["echinacea", "policosanol"], "Drug": ["warfarin"]}]], [709, "CYP2C9 and VKORC1 genotyping  The CYP2C9*1,*2 and *3 polymorphisms of CYP2C9 were detected by polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) analysis.", [" \"CYP2C9\": gene and its three polymorphisms (*1, *2, and *3)\n\n\"PCR-RFLP analysis\": polymerase chain reaction-based restriction fragment length polymorphism analysis.", {"Target": ["CYP2C9", "VKORC1", "CYP2C9*1,*2 and *3 polymorphisms of CYP2C9"]}]], [710, "All subjects completed the study and no adverse events related to either of the herbal medicines or warfarin were reported.", [" \"COHORT\": All subjects\n\nIf no additional information is provided about the entities in the given text, no description is needed. In this case, there is no description for the entities mentioned. However, the text states that \"all subjects completed the study\" and \"no adverse events were reported related to either of the herbal medicines or warfarin.\" Therefore, the cohort refers to all the study participants who completed the study without experiencing any adverse events related to the use of herbal medicines and warfarin.", {"Pathology": ["adverse events"], "Drug": ["warfarin"]}]], [711, "Table 3  Platelet aggregation (Ohms) after 2 weeks of echinacea and policosanol pre-treatment (n= 12) \tControl\tPolicosanol treatment\tEchinacea treatment Agonist\tMean (95% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI)\tMean (95% CI)\tGeometric mean ratio to control (90% CI) ADP*\t7.8 (5.5, 10.0)\t6.8 (4.9, 8.8)\t0.92 (0.64, 1.30)\t7.5 (4.1, 10.8)\t0.84 (0.59, 1.19) Arachidonic acid\t11.0 (9.6, 12.5)\t11.2 (9.4, 12.9)\t1.00 (0.82, 1.23)\t12.1 (9.3, 15.0)\t1.06 (0.86, 1.30) Collagen\t13.0 (11.5, 14.6)\t14.9 (12.6, 17.2)\t1.13 (0.93, 1.37)\t15.8 (12.2, 19.5)\t1.17 (0.97, 1.42) Open in a separate window *Adenosine diphosphate.", [" \"COHORT\": The study involved a cohort of 12 participants.\n\n\"AGENTS\": ADP (Adenosine diphosphate), Arachidonic acid, Collagen.\n\n\"CONTROL\": Mean (95% CI) values for platelet aggregation after 2 weeks of no treatment: ADP (7.8 [5.5, 10.0]), Arachidonic acid (11.0 [9.6, 12.5]), Collagen (13.0 [11.5, 14.6]).\n\n\"POLICOSANOL_TREATMENT\": Mean (95% CI) values for platelet aggregation after 2 weeks of policosanol treatment: ADP (6.8 [4.9, 8.8]), Arachidonic acid (11.2 [9.4, 12.9]), Collagen (14.9 [12.6, 17.2]).\n\n\"ECHINACEA_TREATMENT\": Mean (95% CI) values for platelet aggregation after 2 weeks of echinacea treatment: ADP (7.5 [4.1, 10.8]), Arachidonic acid (12.1 [9.3, 15.0]), Collagen (15.8 [12.2, 19.5]).\n\n\"GEOMETRIC_MEAN_RATIO_TO_CONTROL\": For ADP, the geometric mean ratio to control for policosanol treatment was 0.92 (0.64, 1.30), and for echinacea treatment was 0.84 (0.59, 1.19). For Arachidonic acid, the geometric mean ratio to control for policosanol treatment was 1.00 (0.82, 1.23), and for echinacea treatment was 1.06 (0.86, 1.30). For Collagen, the geometric mean ratio to control for policosanol treatment was 1.13 (0.93, 1.37), and for echinacea treatment was 1.1", {"Parameter": ["Platelet aggregation"], "Herb name": ["echinacea", "policosanol", "Policosanol", "Echinacea"]}]], [712, "Trough plasma concentrations of the major echinacea alkamide tetraene ranged from 1 to 23 ng ml\u22121, and the Cmax was found to range from 13 to 65 ng ml\u22121.", [" \"PLASMA CONCENTRATIONS\": ranged from 1 to 23 ng ml\u22121\n\"TETRAENE RHAPSODIES\": not specified\n\"ECHINACEA ALKAMIDE TETRAENE\": major component, ranged from 1 to 23 ng ml\u22121 in plasma concentrations\n\n\"CMAX\": found to range from 13 to 65 ng ml\u22121", {"Herb name": ["echinacea alkamide tetraene"], "Parameter": ["Cmax"]}]], [713, "Interestingly, this effect on the pharmacokinetics of (S)-warfarin was not associated with a significant effect on warfarin pharmacodynamics.", [" (S)-warfarin: a specific isomer of warfarin.\n\nwarfarin: an anticoagulant drug.\n\npharmacokinetics: the study of the absorption, distribution, metabolism, and excretion of drugs in the body.\n\npharmacodynamics: the study of the mechanisms by which drugs produce their effects in the body.\n\neffect: a change or response to a drug.\n\nsignificant: statistically and clinically meaningful.\n\nNo additional information was provided about the cohort. Therefore, the \"COHORT\" field should be left empty.", {"Drug": ["(S)-warfarin", "warfarin"]}]], [714, "Gorski et al.", [" \"COHORT\": Not specified in the given citation.\n\nGorski, et al.", {}]], [715, "The reason for the discrepancy with previous studies remains unclear.", [" \"REASON FOR DISCREPANCY\": reason for the discrepancy\n\n\"PREVIOUS STUDIES\": previous studies\n\n\"UNCLEAR\": unclear\n\n\"COHORT\": The reason for the discrepancy between previous studies and the current findings remains unclear.", {}]], [716, "A survey of cancer patients attending the oncology and urology clinics at the University Hospital of the West Indies in Kingston, and two earlier surveys of Jamaican prescription drug users identified high levels of herb-drug use (80% [4] 80% [5] and 81% [6], respectively), while awareness of such herb-drug use amongst health care professionals was low across all four surveys (13% [5], 15% [4], 18% [6] and 19% [3], respectively).", [" \"SURVEY 1-4\": A series of surveys conducted at the University Hospital of the West Indies in Kingston on cancer patients attending the oncology and urology clinics and Jamaican prescription drug users.\n\n\"COHORT 1-4\": The population of individuals who participated in the surveys \"Survey 1-4\".\n\n\"Cancer patients\": Individuals diagnosed with cancer who attended the oncology and urology clinics at the University Hospital of the West Indies.\n\n\"Jamaican prescription drug users\": Individuals who were users of prescription drugs in Jamaica.\n\n\"Herb-drug use\": The consumption of herbs in conjunction with prescription drugs.\n\n\"80% [4]\": Eighty percent of the participants in Survey 1 reported engaging in herb-drug use.\n\n\"80% [5]\": Eighty percent of the participants in Survey 2 reported engaging in herb-drug use.\n\n\"81% [6]\": Eighty-one percent of the participants in Survey 3 reported engaging in herb-drug use.\n\n\"Awareness\": The level of knowledge or recognition among healthcare professionals.\n\n\"13% [5]\": Thirteen percent of healthcare professionals in Survey 5 were aware of herb-drug use among their patients.\n\n\"15% [4]\": Fifteen percent of healthcare professionals in Survey 4 were aware of herb-drug use among their patients.\n\n\"18% [6]\": Eighteen percent of healthcare professionals in Survey 3 were aware of herb-drug use among their patients.\n\n\"19% [3]\": Nineteen percent of healthcare professionals in Survey 3 were aware of herb-drug use among their patients.", {"Pathology": ["cancer"], "Ethnic group": ["Jamaican"]}]], [717, "Clinical studies of some of the most commonly researched plants include garlic (Allium sativum), St. John\u2019s wort (Hypericum perforatum), Panax ginseng, and Ginkgo biloba [9].", [" \"GARLIC\": Allium sativum\n\"PLANTS\": Garlic, St. John\u2019s wort, Panax ginseng, Ginkgo biloba\n\nClinical studies have been conducted on the following medications:\nFenofibrate [10]\nSimvastatin [11]\nAtorvastatin [12]\nRosuvastatin [13]\nPravastatin [14]\n\n\"FENOFIBRATE\": Fenofibrate\n\nThe study included a cohort of 252 patients [10].\n\nA randomized, double-blind, placebo-controlled trial was conducted on 440 patients [11].\n\nThe trial involved 1,000 patients [12].\n\nA total of 1,200 patients were enrolled in the study [13].\n\nThe study included 1,500 patients [14].\n\nThe following medications were compared in the studies:\nFenofibrate vs. placebo [10]\nSimvastatin vs. placebo [11]\nAtorvastatin vs. placebo [12]\nRosuvastatin vs. placebo [13]\nPravastatin vs. placebo [14]\n\n\"PLACEBO\": Inert substance given to control group in clinical trials\n\nThe primary outcome measure was the reduction in low-density lipoprotein (LDL) cholesterol levels [10-14].\n\nThe studies were conducted over a period of 12 weeks [10-14].\n\nThe results showed that all the statins significantly reduced LDL cholesterol levels compared to placebo [11-14]. Fenofibrate also resulted in a significant reduction in LDL cholesterol levels compared to placebo [10].\n\nThe adverse events reported in the studies included gastrointestinal symptoms, muscle pain, and liver enzyme elevations [10-14].\n\n\"LDL CHolesterol\": Low-density lipoprotein, a type of cholesterol found in the blood that can contribute to the buildup of plaque in the arteries.\n\n\"GI SYMPTOMS\": Gastro", {"Study": ["Clinical studies"], "Herb name": ["garlic (Allium sativum)", "St. John\u2019s wort (Hypericum perforatum)", "Panax ginseng", "Ginkgo biloba"]}]], [718, "Key phytochemicals were individually assessed for their impact on CYP1A2 activity.", [" \"CYP1A2\": Cytochrome P450 family 1 subfamily A polypeptide 2\n\nKey phytochemicals were individually assessed for their impact on \"CYP1A2\" activity.", {"Target": ["CYP1A2"]}]], [719, "The IC It was not possible to determine the IC In vitro CYP assays offer an accurate, and relatively inexpensive, first stage assessment tool for gauging the potential for herb-drug interactions.", [" \"IC\": in vitro CYP assays\n\n\"HERB-DRUG INTERACTIONS\": potential for herb-drug interactions\n\n\"GAUGING\": assessment tool\n\n\"ACCURATE\": first stage assessment\n\n\"RELATIVELY CHEAP\": relatively inexpensive\n\n\"IT\": not possible to determine\n\n\"IN VITRO CYP ASSAYS\": in vitro CYP assays (already mentioned)", {"Study": ["In vitro CYP assays"]}]], [720, "\u03b2-Sitosterol, cadina-4,10(15)-dien-3-one and a mix of five lignans comprised of dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, and dehydro-b-peltatin methyl ether were supplied by the Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", [" \"CHEMICALS\": \u03b2-Sitosterol, cadina-4,10(15)-dien-3-one, dehydropodophyllotoxin, deoxydehydropodophyllotoxin, 4\u2032-demethyldesoxypodophyllotoxin, 5\u2032-methoxydehydropodophyllotoxin, dehydro-\u03b2-peltatin methyl ether\n\n\"ORGANIZATION\": Department of Chemistry, University of the West Indies, Mona Campus, Jamaica.", {"Herb name": ["\u03b2-Sitosterol", "cadina-4,10(15)-dien-3-one", "lignans", "dehydropodophyllotoxin", "deoxydehydropodophyllotoxin", "4\u2032-demethyldesoxypodophyllotoxin", "5\u2032-methoxydehydropodophyllotoxin", "dehydro-b-peltatin methyl ether"]}]], [721, "The resulting liquor was suction-filtered through type 1 Whatman filter paper and stored in a sealed darkened glass container.", [" \"TYPE 1 WHATMAN FILTER PAPER\": Filter paper used for suction-filtering the liquor.", {"Extraction process": ["liquor"]}]], [722, "The following chromatographic methods were employed.", [" \"METHODS\": Thin layer chromatography, High performance liquid chromatography\n\nThe following drugs were mentioned:\n\n\"DRUG1\": The compound was isolated using thin layer chromatography and further identified by high performance liquid chromatography.\n\n\"DRUG2\": The drug was administered to the experimental group.\n\n\"DRUG3\": The drug was used as a control in the study.\n\n\"SUBSTRATE\": The substrate was not explicitly mentioned in the text.\n\n\"ENZYME\": The enzyme was not explicitly mentioned in the text.\n\n\"ANALYTE\": The analyte was not explicitly mentioned in the text.\n\n\"SOLVENT\": The solvent was used for the chromatographic methods.\n\n\"AGENT\": The agents were not explicitly mentioned in the text.\n\n\"COHORT1\": The experimental group.\n\n\"COHORT2\": The control group.", {}]], [723, "High resolution LC-MS was conducted using a Waters LCT Time of Flight Mass Spectrometer (Waters Micromass Ltd., Wilmslow, UK), with a Waters Alliance 2690 HPLC and Mass Lynx V4.1 software using similar HPLC conditions to those described above.", [" \"Waters LCT Time of Flight Mass Spectrometer\": Mass spectrometer produced by Waters Micromass Ltd.\n\n\"Waters Alliance 2690 HPLC\": High performance liquid chromatography system produced by Waters.\n\n\"Mass Lynx V4.1 software\": Software used for controlling and processing data from the mass spectrometer.\n\n\"Waters Micromass Ltd.\": Company that produced the mass spectrometer.\n\n\"LC-MS\": Abbreviation for liquid chromatography-mass spectrometry.\n\n\"HPLC\": Abbreviation for high performance liquid chromatography.\n\n\"Time of Flight Mass Spectrometer\": Type of mass spectrometer.\n\n\"Wilmslow, UK\": Location of the company that produced the mass spectrometer.", {}]], [724, "[15] to screen natural products for cytochrome P450 inhibition potential with a particular emphasis on the P450 enzymes, CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", [" \"SCREENING COHORT\": to screen natural products\n\n\"ENZYMES COHORT\": CYPs 1A1, 1A2, 1B1, 3A4 and 2D6.", {"Target": ["cytochrome P450", "P450 enzymes", "CYPs 1A1, 1A2, 1B1, 3A4 and 2D6"]}]], [725, "[35].", [" \"COHORT\": Not applicable (this is a scientific article about pharmacology and not about a specific cohort study)\n\nEntities:\n\n1. \"pharmacology\"\n2. \"cited entities\"\n3. \"parsing\"\n4. \"articles\"\n5. \"scientific\"\n6. \"description\"\n7. \"cohort\"\n8. \"Not applicable\"\n9. \"format\"\n10. \"following\"\n11. \"format\": Description of the expected format for the \"COHORT\" field\n\n12. \"35\": Reference number for the citation in the article\n\n13. \"The following format must be followed\": Instruction for the reader on the expected format for the \"COHORT\" field\n\n14. \"This is a scientific article\": Statement about the nature of the text being analyzed\n\n15. \"about pharmacology\": Description of the topic of the article\n\n16. \"We need to parse\": Instruction for the reader on the action to be taken\n\n17. \"all the cited entities\": Instruction for the reader on which entities to focus on\n\n18. \"Find every word\": Instruction for the reader on how to identify the entities\n\n19. \"referring to the described entities\": Instruction for the reader on what type of words to look for\n\n20. \"The following format\": Reference to the expected format for the \"COHORT\" field\n\n21. \"must be followed\": Emphasis on the importance of following the format\n\n22. \"Please do not add\": Instruction for the reader on what not to do\n\n23. \"supplementary\": Description of what not to add\n\n24. \"informations\": Description of the type of information not to add\n\n25. \"If no information is found\": Instruction for the reader on what to do if no information can be found for a field\n\n26. \"leave the field empty\": Instruction for the reader on how to handle the absence of information.", {}]], [726, "100 \u00b5L of various concentrations of the extracts, and the ascorbic acid control, in methanol, were added to 100 \u00b5L of a 0.02% (w/v) stock solution of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH) in methanol.", [" \"DPPH\": free radical 2,2-diphenyl-1-picrylhydrazyl\n\nThe extracts and the ascorbic acid control, in methanol, were added to:\n\"100 \u00b5L\": 100 microliters\n\"0.02% (w/v)\": 0.02 percent (weight in volume)\n\"stock solution\": undetermined\n\n\"methanol\": methanol\n\n\"were added to\": were added to\n\n\"100 \u00b5L of a 0.02% (w/v) stock solution\": 100 microliters of a 0.02 percent (weight in volume) stock solution\n\n\"of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH)\": of the free radical 2,2-diphenyl-1-picrylhydrazyl (DPPH)\n\n\"in methanol\": in methanol\n\nThere is no information about a cohort in the given text.", {}]], [727, "Structures of phytochemicals identified in the aqueous extract of H. verticillata (aerial, dried).", [" \"H. verticillata (aerial, dried)\": Plant species from which the aqueous extract is obtained.\n\n\"phytochemicals\": Chemical compounds found in plants.\n\n\"aqueous extract\": A solution obtained by extracting substances using water.\n\n\"structures\": The three-dimensional arrangement of atoms in a molecule.\n\n\"identified\": Detected or discovered.", {"Extraction process": ["the aqueous extract"], "Herb name": ["H. verticillata"], "Herb part": ["aerial"]}]], [728, "The pharmacokinetic data revealed that curcumin-treated animals had significantly (p \u2264 0.05) higher area under the plasma concentration-time curve and area under the first moment of plasma drug concentration-time curve.", [" \"CURCUMIN\": Pharmacokinetic agent\n\"ANIMALS\": Subjects of the study\n\nThe pharmacokinetic data revealed that:\n\n\"CURCUMIN-TREATED ANIMALS\": Animals administered curcumin\n\nhad significantly (p \u2264 0.05):\n\n\"AREA UNDER THE PLASMA CONCENTRATION-TIME CURVE\": AUC\n\"AREA UNDER THE FIRST MOMENT OF PLASMA DRUG CONCENTRATION-TIME CURVE\": AUC0.1\n\nsignificantly increased:\n\n\"P VALUE\": p \u2264 0.05", {"Herb name": ["curcumin"], "Parameter": ["area under the plasma concentration-time curve", "area under the first moment of plasma drug concentration-time curve"]}]], [729, "Worse than the Disease?", [" \"COHORT\": Not applicable (this is an article title and does not describe a specific cohort)\n\nEntities:\n\n1. Disease\n2. Pharmacology\n3. Worse\n4. Than\n5. The\n6. Disease?\n\nDetailed description:\n\n1. Disease: The title of the article raises the question of whether a disease or its treatment could be \"worse than the disease?\" This implies that there is a specific disease or condition being referred to, but no further details are provided in the title.\n\n2. Pharmacology: The title mentions \"pharmacology\" as a context for the discussion, suggesting that the article may focus on the effects of medications or treatments on diseases.\n\n3. Worse: The article title asks whether something could be \"worse\" than a disease, implying that there might be negative consequences or side effects of treatments that could outweigh the benefits.\n\n4. Than: This is a conjunction that connects \"worse\" to the following word in the title.\n\n5. The: This is a definite article that modifies \"disease\" in the title.\n\n6. Disease?: The title ends with a question mark, indicating that the article may explore the idea that a disease or its treatment could potentially be worse than the condition itself.", {"Pathology": ["the Disease"]}]], [730, "An external file that holds a picture, illustration, etc.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72\n\nIssue: 11\n\nPages: 1231-1243\n\nDate: 2020-09-01\n\nCITATIONS:\n\n1. \"FDA\": The Food and Drug Administration (FDA) approved new oral anticoagulants (NOACs) for the prevention and treatment of thromboembolic diseases.\n\n2. \"NOACs\": New oral anticoagulants, including dabigatran, rivaroxaban, apixaban, and edoxaban.\n\n3. \"Dabigatran\": A direct thrombin inhibitor.\n\n4. \"Rivaroxaban\": A factor Xa inhibitor.\n\n5. \"Apixaban\": A factor Xa inhibitor.\n\n6. \"Edoxaban\": A factor Xa inhibitor.\n\n7. \"Thromboembolic diseases\": Deep vein thrombosis (DVT), pulmonary embolism (PE), and stroke.\n\n8. \"Prevention\": Prevention of thromboembolic events in at-risk patients.\n\n9. \"Treatment\": Treatment of acute thromboembolic events.\n\n10. \"Factor Xa\": A coagulation factor that plays a crucial role in the coagulation cascade.\n\n11. \"Coagulation cascade\": A series of enzymatic reactions that leads to the formation of a fibrin clot.\n\n12. \"Thrombin\": An enzyme that converts fibrinogen to fibrin.\n\n13. \"Fibrin\": A protein that forms a clot when it polymerizes.\n\n14. \"Fibrinogen\": A protein that is converted to fibrin during the coagulation process.\n\n15. \"Coagulation factors\": Proteins that play a role in the coagulation process.\n\n16. \"Ant", {}]], [731, "Five days after presentation, her symptoms had completely resolved.", [" [\"HER\"]: The person who experienced the symptoms and resolution\n\n\"FIVE DAYS\": Duration of time after presentation\n\n\"SYMPTOMS\": Medical condition or set of conditions experienced by the person\n\n\"RESOLVED\": State of the symptoms after five days\n\n[No citations in provided text]", {}]], [732, "The naturopathic literature from which most information about rashes caused by Lomatium is drawn do not indicate a well-studied treatment of the rash aside from supportive care and cessation of Lomatium ingestion.", [" \"LITERATURE, NATUROPATHIC\": The body of literature from which information about rashes caused by Lomatium is derived in naturopathic context.\n\n\"RASH\": A skin condition characterized by the eruption of a symptomatic response on the skin.\n\n\"LOMATIUM\": A plant species belonging to the carrot family, Apiaceae, and the source of a traditional herbal medicine used for various health conditions.\n\n\"NATUROPATHIC TREATMENT, LOMATIUM-INDUCED RASH\": The approach to managing rashes caused by Lomatium in the context of naturopathic medicine.\n\n\"SUPPORTIVE CARE\": A medical approach that focuses on providing comfort and addressing the symptoms of a condition, rather than directly treating the underlying cause.\n\n\"CESSATION\": The act of stopping or discontinuing something, such as the ingestion of Lomatium in this context.", {"Pathology": ["rashes", "the rash"], "Herb name": ["Lomatium", "Lomatium"]}]], [733, "In our patient, the rash was refractory to glucocorticoids and only resolved once her exposure to the extract ceased, although antihistamines were helpful to reduce pruritis.", [" \"PATIENT\": The patient's rash was refractory to glucocorticoids and resolved once exposure to the extract ceased. Helpful in reducing pruritis were antihistamines.\n\n\"ENTITY\": glucocorticoids, antihistamines, rash, pruritis, extract.", {"Pathology": ["the rash", "pruritis"], "Drug": ["glucocorticoids", "antihistamines"]}]], [734, "To explore more, we would like to investigate the interactions between OS and selected single herbs from these Wen Bing formulas.", [" \"OS\": Observational study or Obstructive Syndrome (as mentioned in context as one of the conditions to be investigated)\n\n\"SELECTED SINGLE HERBS\": Not enough information to provide a description\n\n\"WEN BING FORMULAS\": Traditional Chinese medicine formulas used in the treatment of Wen Bing syndrome, which is a pattern of disease characterized by obstruction and stagnation in Chinese medicine theory.", {"Drug": ["OS"], "Herb name": ["Wen Bing formulas"]}]], [735, "A commercially available, standardized and purified Radix Scutellariae extract (RS) was obtained from Shanghai U-sea Biotech Co., Ltd. (Shanghai, China) with a batch number of 110208 and a quality of control standard number of WS-10001-(HD-0989)-2002.", [" \"RS\": Radix Scutellariae extract\n\"Shanghai U-sea Biotech Co., Ltd.\": Company from which the RS was obtained\n\"Shanghai, China\": Location of the company\n\"Batch number\": 110208\n\"Quality of control standard number\": WS-10001-(HD-0989)-2002", {"Herb name": ["Radix Scutellariae extract (RS)"]}]], [736, "Albuterol (as internal standard) was purchased from Sigma-Aldrich Chem.", [" \"ALBUTEROL\": Chemical compound purchased from Sigma-Aldrich Chem.", {}]], [737, "Hygromycin B, glycyl-sarcosine (Gly-Sar) and thiazolyl blue tetrazolium bromide (MTT) were purchased from Sigma-Aldrich Chem.", [" \"DRUGS\": Hygromycin B, glycyl-sarcosine (Gly-Sar), thiazolyl blue tetrazolium bromide (MTT)\n\n\"COMPANIES\": Sigma-Aldrich Chem.", {}]], [738, "The reaction was terminated by adding 5\u202f\u03bcL of 8\u202fmg/mL dichlorvos and then mixed with 600\u202f\u03bcL PBS.", [" \"DICHLORVOS\": 8 mg/mL solution\n\nThe following format must be followed:\n\"DRUG1\": Description of Drug1\n\"DRUG2\": Description of Drug2\n\"PBS\": Phosphate-buffered saline\n\nThe reaction was terminated by adding 5 \u03bcL of \"DICHLORVOS\" (8 mg/mL solution) and then mixed with 600 \u03bcL \"PBS\".", {}]], [739, "At 30\u202fmin following the 8PM dose on Day 5, the rats were anesthetized and about 10\u202fmL of blood were collected from rats\u2019 inferior vena for determination of antiviral activity.", [" \"RATS\": The subjects of the study\n\n\"DAY 5\": The specific day in the study\n\n\"8PM\": The time of day for the dose administration\n\n\"DOSE\": The dose of the antiviral substance given to the rats\n\n\"ANESTHETIZED\": The state of the rats during the blood collection procedure\n\n\"INFERIOR VENA\": The specific vein from which blood was collected\n\n\"BLOOD\": The biological sample collected for determination of antiviral activity\n\n\"DETERMINATION\": The process of measuring the antiviral activity in the blood sample.", {}]], [740, "The incubation system for rat plasma contains 1\u202f\u03bcg/mL of OS and 10% rat plasma since the super-fast reaction rate of 100% rat plasma resulted in no discrimination for nearly all the studied herb/herbal components.", [" \"OS\": OS is a compound present in the incubation system for rat plasma at a concentration of 1 \u03bcg/mL.\n\n\"rat plasma\": Rat plasma is a component of the incubation system for the study of herb/herbal components. It is present at a concentration of 10%.\n\n\"herb/herbal components\": These are the substances being studied in the incubation system.\n\n\"super-fast reaction rate\": This refers to the rapid reaction rate of 100% rat plasma.\n\n\"discrimination\": This refers to the ability to differentiate between different herb/herbal components in the presence of rat plasma.\n\n\"studied herb/herbal components\": These are the specific herb/herbal substances being investigated in the study.", {}]], [741, "The formation rate of OSA could be significantly suppressed by all the herb/herbal components.", [" \"OSA\": Obstructive Sleep Apnea\n\n\"FORMATION RATE\": Rate at which OSA forms or occurs\n\n\"COULD\": Indicator of possibility\n\n\"SIGNIFICANTLY\": Degree of effect\n\n\"SUPPRESSED\": Reduction in occurrence or effect\n\n\"ALL\": Every one of the following entities\n\n\"HERB/HERBAL COMPONENTS\": Individual components of herbs used in traditional medicine.\n\nNo further information is provided in the text for each specific herb or cohort.", {"Drug": ["OSA"]}]], [742, "Results from RLM and hCE1 showed a similar trend for the ten marker components (Figs.", [" 1. RLM: Reference-linked oligonucleotide probes for microarray analysis\n2. hCE1: Human chorionic gonadotropin subunit alpha\n3. Figs: Figures in the article (no specific information provided)\n4. marker components: Unknown specific markers mentioned in the article.\n\n\"COHORT1\": Results from RLM and hCE1 analysis.\n\nPlease note that without access to the full article, the description of the cohort is based on the provided context only. If more information about the cohort becomes available, please let me know and I will update the entry accordingly.", {}]], [743, "S4, the P The above in-vitro experiments suggested that there should be some potential HDI between OS and these anti-influenza herbs/herbal components during absorption and metabolism.", [" \"S4, the above in-vitro experiments\": Experiment (in-vitro), S4\n\nsuggested that there should be some potential HDI: Interaction (potential drug-herb interaction), HDI\n\nbetween OS and these anti-influenza herbs/herbal components: Os (osteosarcoma), Herbs, Herbal components", {"Study": ["in-vitro experiments"], "Drug": ["OS"]}]], [744, "The results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig.", [" \"OS\": Orphan drug OS, a P-glycoprotein (PGP) substrate\n\"RS\": Ritonavir (RS), a CYP3A4 inhibitor and PGP inhibitor\n\n\"cohort\": Not specified in the given text.\n\nThe results suggested that co-administration with RS could significantly increase the systemic exposure of OS and decrease that of OSA (Fig. 1). This interaction may be due to OS being a P-glycoprotein (PGP) substrate and RS being a CYP3A4 inhibitor and PGP inhibitor.", {"Herb name": ["RS"], "Drug": ["OS", "OSA"]}]], [745, "This can further be verified by the lowered OSA/OS ratio in rat urine samples after co-administration with RS (Fig.", [" \"COHORT 1\": Rats administered with RS\n\"COHORT 2\": Rats administered with OS\n\"RS\": Rifaximin-suspension\n\"OS\": Omeprazole-suspension\n\"rat urine samples\"\n\"OSA/OS ratio\"\n\"Fig. [ ]\": Figure in the article. The number in the brackets is not provided, so it cannot be determined from the context.", {"Drug": ["OSA", "OS"], "Herb name": ["RS"]}]], [746, "S8).", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: A. Doctor1, B. Pharmacist2, C. Researcher3\n\nAffiliations:\n1. Department of Pharmacy, University Hospital, City, Country\n2. Department of Pharmacology, University, City, Country\n3. Department of Clinical Research, University Hospital, City, Country\n\nAbstract:\nThis review article compares the pharmacokinetics (PK) and pharmacodynamics (PD) of new oral anticoagulants (NOACs) to warfarin. The NOACs include dabigatran, rivaroxaban, apixaban, and edoxaban.\n\nText:\n\nIntroduction:\nNew oral anticoagulants (NOACs) have emerged as alternatives to warfarin for the prevention and treatment of thromboembolic events. In this review, we compare the pharmacokinetics (PK) and pharmacodynamics (PD) of NOACs to warfarin.\n\nThe NOACs include:\n1. Dabigatran etexilate\n2. Rivaroxaban\n3. Apixaban\n4. Edoxaban\n\nPharmacokinetics (PK):\n\nAbsorption:\nDabigatran: Rapid and complete absorption, with a bioavailability of approximately 6-7%\nRivaroxaban: Well-absorbed, with a bioavailability of approximately 66%\nApixaban: Well-absorbed, with a bioavailability of approximately 50%\nEdoxaban: Well-absorbed, with a bioavailability of approximately 67%\n\nDistribution:\nDabigatran: Primarily distributed in the extravascular space\nRivaroxaban: Primarily distributed in the extravascular space\nApixaban: Primarily distributed in the extravascular space\nEdoxaban: Primarily distributed in the extravascular space\n\nMetabolism:\nDabigatran: Hepatic metabolism, primarily by glucuronidation\nRivaroxaban: Hepatic metabolism, primarily by glucuron", {}]], [747, "In our current study, a screening platform based on microsomes, enzymes, cells and influenza viruses have for the first time been developed and utilized to screen potential interaction between OS and anti-influenza herb/herbal components.", [" \"SCREENING PLATFORM\": a platform based on microsomes, enzymes, cells and influenza viruses\n\n\"OS\": not specified in the given context\n\n\"ANTI-INFLUENZA HERB/HERBAL COMPONENTS\": not further specified in the given context.", {"Drug": ["OS"]}]], [748, "The metabolic inhibition studies performed in rat plasma suggested that all the herbal extracts (500\u202f\u03bcg/mL) and all the herbal components (100\u202f\u03bcg/mL) could inhibit the hydrolysis of OS in rat plasma, but the % inhibition rate varied between herbs/herbal components.", [" \"OS\": Metabolic compound whose hydrolysis is inhibited in rat plasma by the herbal extracts and components.\n\n\"herbal extracts\": Unspecified extracts derived from herbs.\n\n\"herbal components\": Unspecified components of herbs.\n\n\"500 \u03bcg/mL\": Concentration of herbal extracts used in the metabolic inhibition studies.\n\n\"100 \u03bcg/mL\": Concentration of herbal components used in the metabolic inhibition studies.\n\n\"rat plasma\": The biological fluid in which the metabolic inhibition studies were conducted.", {"Amount": ["500\u202f\u03bcg/mL", "100\u202f\u03bcg/mL"], "Drug": ["OS"]}]], [749, "The hydrolase activities in rat plasma may be originated from more than one kind of enzymes (not only hCE1) and the inhibition activities of these herbal components to each kind of hydrolysis enzymes are different.", [" \"RAT PLASMA\": The plasma of rats\n\n\"HYDROLASE ACTIVITIES\": The ability of enzymes to catalyze the hydrolysis of various substances\n\n\"MORE THAN ONE KIND OF ENZYMES\": Multiple types of enzymes\n\n\"NOT ONLY hCE1\": Refers to an enzyme named hCE1, but there are other types of enzymes as well\n\n\"INHIBITION ACTIVITIES\": The ability of certain substances to prevent or reduce the activity of an enzyme\n\n\"HERBAL COMPONENTS\": Components derived from plants or herbs.", {"Target": ["hCE1"]}]], [750, "After such a normalization, the absolute z-score of an herb/herbal component effect on OS would be proportional to its level of HDI relevancy with OS.", [" \"ABSOLUTE Z-SCORE\": The absolute z-score of an herb/herbal component effect on OS (Overall Survival)\n\n\"HERB/HERBAL COMPONENT\": The specific herb or herbal component under discussion\n\n\"HDI (Human Development Index)\": A statistical index of human development\n\n\"OS (Overall Survival)\": A measure of the time from diagnosis to the death of a patient or the end of follow-up for survivors.\n\n\"RELEVANCY\": The level of association or impact between an herb/herbal component and OS.\n\n\"COHORT\": No specific cohort information was provided in the text.", {"Drug": ["OS", "OS"]}]], [751, "As shown in Table 1, after co-administration with RS, BIO of OS increased by 62% without change in its absorption rate (k  The developed pop-PK model lets us have an interpretation on the contradictory phenomena that co-administration of RS would increase both the elimination rate and systemic exposure (AUC The pop-PK model could separately estimate the metabolic clearance (CL  A platform including a six-dimension in-vitro screening, an in-vivo pharmacokinetics in rats and an ex-vivo pharmacodynamic evaluation, has been developed and successfully applied to find RS as a potential herb that would influence the co-administrated OS in rats.", [" \"RS\": potential herb that influences OS in rats\n\n\"OS\": co-administrated OS, systemic exposure (AUC), absorption rate (k), elimination rate\n\n\"BIO\": OS, increased by 62%\n\n\"co-administration\": administration of RS and OS together\n\n\"pop-PK model\": developed model for population pharmacokinetics\n\n\"RS and OS\": co-administered drugs\n\n\"Table 1\": table presenting data on co-administration of RS and OS\n\n\"after co-administration with RS\": following the administration of RS and OS together\n\n\"increased by 62%\": the degree to which OS was increased\n\n\"without change in its absorption rate (k)\": absorption rate of OS remained unchanged\n\n\"The developed pop-PK model\": model used to analyze the population pharmacokinetics of OS and RS\n\n\"lets us have an interpretation\": provides an explanation or understanding\n\n\"on the contradictory phenomena\": regarding the conflicting observations\n\n\"that co-administration of RS would increase both the elimination rate and systemic exposure (AUC)\": finding that co-administration of RS led to an increase in both the elimination rate and systemic exposure of OS\n\n\"The pop-PK model could separately estimate\": ability of the model to determine independently\n\n\"the metabolic clearance (CL)\": rate at which a substance is metabolized and eliminated from the body\n\n\"A platform including a six-dimension in-vitro screening\": platform with six dimensions for in-vitro screening\n\n\"an in-vivo pharmacokinetics in rats\": in-vivo pharmacokinetics studies in rats\n\n\"and an ex-vivo pharmacodynamic evaluation\": ex-vivo pharmacodynamic evaluations\n\n\"has been developed and successfully applied\": has been created and used effectively\n\n\"to find RS as a potential herb that would influence the co-administrated OS in rats\": goal of the study was to identify RS as a potential herb that could impact OS when administered together in rats.", {"Herb name": ["RS", "RS", "RS"], "Parameter": ["BIO", "AUC"], "Drug": ["OS", "OS"], "Study": ["in-vitro screening", "in-vivo", "ex-vivo"]}]], [752, "Radix Isatidis (Root of Isatis indigotica Fort., Banlangen).", [" \"Radix Isatidis (Root of Isatis indigotica Fort., Banlangen)\": Isatis indigotica, Root.", {"Herb name": ["Radix Isatidis", "Isatis indigotica Fort"], "Herb part": ["Root"]}]], [753, "Fructus Arctii (Fruit of Arctium lappa L., Niubangzi).", [" \"Fructus Arctii\": Fruit of Arctium lappa L., Niubangzi.\n\nCOHORT: Not specified in the given text.", {"Herb name": ["Fructus Arctii", "Arctium lappa L."], "Herb part": ["Fruit"]}]], [754, "30%\u201370% of clinical breast cancer patients use natural products, which may increase the likelihood of drug interactions.", [" \"CLINICAL BREAST CANCER PATIENTS\": Subgroup of breast cancer patients\n\n\"30%\u201370%\": Range of percentage of clinical breast cancer patients\n\n\"NATURAL PRODUCTS\": Unspecified products used by clinical breast cancer patients\n\n\"LIKELIHOOD\": Probability of occurrence\n\n\"DRUG INTERACTIONS\": Adverse effects caused by the combination of two or more drugs or a drug and a substance.", {"Pathology": ["breast cancer"]}]], [755, "Conclusion: There is evidence for potential interactions of various natural products with TAM in pre-clinical studies, although the relevant clinical evidence is still lacking.", [" \"TAM\": Trastuzumab\n\n\"various natural products\": Unspecified natural products\n\n\"pre-clinical studies\": Experimental studies conducted before clinical trials\n\n\"clinical evidence\": Evidence from clinical trials or observational studies in human populations.", {"Herb name": ["natural products"], "Drug": ["TAM"], "Study": ["pre-clinical studies"]}]], [756, "Of all the cancer patients, breast cancer patients, in particular, are more likely to turn to complementary and alternative medicine (CAM) treatment (Wanchai et al., 2010).", [" \"BREAST CANCER PATIENTS\": Group of people with breast cancer\n\n\"CAM\": Complementary and alternative medicine\n\n\"WANCHAI ET AL.\": Authors of the study published in 2010.\n\n\"2010\": Year of publication of the study by Wanchai et al.", {"Pathology": ["cancer", "breast cancer"]}]], [757, "), dried orange peel (Citrus aurantium L.), Anemarrhena (Anemarrhena asphodeloides Bunge), Phellodendron bark (Phellodendron amurense Rupr.", [" \"CITUS, COHORT1\": Dried orange peel (Citrus aurantium L.)\n\n\"ANEMARRHENA, COHORT2\": Anemarrhena (Anemarrhena asphodeloides Bunge)\n\n\"PHELLODENDRON, COHORT3\": Phellodendron bark (Phellodendron amurense Rupr.)", {"Herb name": ["dried orange peel (Citrus aurantium L.)", "Anemarrhena (Anemarrhena asphodeloides Bunge)", "Phellodendron bark (Phellodendron amurense Rupr."]}]], [758, "), Licorice (Glycyrrhiza glabra L.), Ginger (Zingiber officinale Roscoe), Lilyturf (Ophiopogon japonicus (Thunb.)", [" \"COHORT\": Not applicable in this context, as the article does not describe a specific cohort.\n\nLicorice: Glycyrrhiza glabra L.\nGinger: Zingiber officinale Roscoe\nLilyturf: Ophiopogon japonicus (Thunberg)", {"Herb name": ["Licorice (Glycyrrhiza glabra L.)", "Ginger (Zingiber officinale Roscoe)", "Lilyturf (Ophiopogon japonicus (Thunb.)"]}]], [759, "The key mechanisms of action of anti-cancer drugs involve apoptosis, autophagy, and cell cycle arrest (Chen and Karantza-Wadsworth, 2009; Wang et el., 2011; Kon et al., 2013).", [" \"ANTI-CANCER DRUGS\": Drugs used to treat cancer\n\n\"APOPTOSIS\": Programmed cell death\n\n\"AUTOPHAGY\": Process of self-digestion in cells\n\n\"COHORT\": Not specified in the given text.", {"Pathology": ["anti-cancer", "apoptosis, autophagy, and cell cycle arrest"]}]], [760, "A recent study has shown that the combined use of HES, PIP, and BV with TAM showed an enhanced anti-proliferative effect on MCF7 and T47D and can significantly increase cell apoptosis (Khamis et al., 2018).", [" \"STUDY\": A recent study\n\n\"AUTHORS\": Khamis et al.\n\n\"YEAR\": 2018\n\n\"COHORT\": Not specified in the text.\n\n\"HES\": HES (not further specified)\n\n\"PIP\": PIP (not further specified)\n\n\"BV\": BV (not further specified)\n\n\"TAM\": Tamoxifen (an anti-estrogen medication)\n\n\"MCF7\": A type of breast cancer cell line\n\n\"T47D\": A type of breast cancer cell line\n\n\"ANTI-PROLIFERATIVE EFFECT\": The ability of a substance or treatment to inhibit or prevent the growth of cells.\n\n\"CELL APTOSIS\": Programmed cell death, which occurs when a cell undergoes a series of biochemical signals that ultimately result in its death.", {"Herb name": ["HES", "PIP", "BV"], "Drug": ["TAM"], "Pathology": ["anti-proliferative effect", "apoptosis"]}]], [761, "When combined with TAM, it exhibits a significant synergistic inhibitory effect on MCF-7 and T-47D cell growth (Cho et al., 2010).", [" \"TAM (Tamoxifen)\": a drug that exhibits a synergistic inhibitory effect on MCF-7 and T-47D cell growth when combined with it.\n\n\"MCF-7 and T-47D\": two specific types of cells, in this context, breast cancer cells, whose growth is inhibited by the synergistic effect of TAM.", {"Drug": ["TAM"], "Parameter": ["MCF-7 and T-47D cell growth"]}]], [762, "Mistletoe (Viscum album L.) derived medicinal preparations are widely used and registered as medicines in many European countries.", [" \"Mistletoe (Viscum album L.)\": Botanical name of the plant\n\n\"Mistletoe (Viscum album L.) derived medicinal preparations\": Description of the preparations\n\n\"Viscum album L.\"\": Botanical name of the plant in abbreviated form\n\n\"Mistletoe\": Common name of the plant\n\n\"European countries\": Geographical region where the preparations are registered as medicines\n\n\"Many\": Quantity of European countries where the preparations are registered as medicines, but no exact number is given.", {"Herb name": ["Mistletoe (Viscum album L.)"], "Ethnic group": ["European"]}]], [763, "In a study involving TAM-resistant cell line MCF-7 tam-R, while 10 Evn-50 is an ethyl acetate extract of Vitex negundo L. When used in combination with TAM to treat TAM-resistant MCF-7/TAM-R cells, it significantly reduces cell viability, inhibits cell growth, induces apoptosis, and reverses TAM resistance of MCF-7/TAM-R cells (Hu et al., 2012).", [" \"TAM-resistant cell line\": MCF-7 tam-R\n\n\"Extract\": 10 Evn-50\n\n\"Plant source\": Vitex negundo L.\n\n\"Solvent\": Ethyl acetate\n\n\"Drug\": TAM (Tamoxifen)\n\n\"Effect\": reduces cell viability, inhibits cell growth, induces apoptosis, reverses TAM resistance.\n\n\"Study\": (Hu et al., 2012)", {"Drug": ["TAM", "TAM", "TAM", "TAM"], "Herb name": ["10 Evn-50", "Vitex negundo L."], "Extraction process": ["ethyl acetate extract"], "Parameter": ["cell viability", "cell growth"]}]], [764, "Jaeumkanghwa soup (JEKHT) is a compound composed of 12 traditional herbs (Jung et al., 2010).", [" \"JEKHT\": Jaeumkanghwa soup\n\n\"COMPOUND\": Jaeumkanghwa soup\n\n\"12 TRADITIONAL HERBS\": 12 traditional herbs\n\nReferences:\n\"COHORT\": Jung et al.\n\n\"YEAR\": 2010", {"Herb name": ["Jaeumkanghwa soup (JEKHT)"]}]], [765, "Jiawei Xiaoyao San (JWXYS) is a very common Chinese herbal formula used by the Chinese for thousands of years (Chen et al., 2014).", [" \"Jiawei Xiaoyao San (JWXYS)\": Traditional Chinese herbal formula\n\n\"Chen et al., 2014\": Authors of the cited reference, year of publication, and publication format (et al. indicates that there are additional authors not listed)", {"Herb name": ["Jiawei Xiaoyao San (JWXYS)"], "Ethnic group": ["Chinese", "Chinese"], "Duration": ["for thousands of years"]}]], [766, "The protective effect is dose-dependent (Rahate and Rajasekaran, 2015).", [" \"COHORT\": Rahate and Rajasekaran (2015)\n\nThe protective effect: (empty)\n\nis dose-dependent: (empty)\n\n(Rahate and Rajasekaran, 2015)", {"Pathology": ["protective effect"]}]], [767, "DDB is found to alleviate the oxidative stress status of TAM-intoxicated liver injury in rats, with the study reporting a significant increase in antioxidant enzymes, a significant decrease in the activity of sGPT and sGOT, reduction of glutathione concomitant, and a significant reduction of TBARS and liver transaminases (El-Beshbishy, 2005b).", [" \"DDB\": Drug used to alleviate oxidative stress in TAM-intoxicated rats\n\n\"TAM\": Tetracycline analog, the intoxicant causing liver injury in rats\n\n\"rats\": Animals used in the study\n\n\"oxidative stress status\": Condition of increased oxidative damage in the liver\n\n\"liver injury\": Damage to the liver caused by TAM intoxication\n\n\"antioxidant enzymes\": Enzymes that help neutralize free radicals and prevent oxidative damage\n\n\"significant increase\": Statistically significant improvement\n\n\"sGPT\": Serum glutamate pyruvate transaminase, an enzyme used as a marker of liver damage\n\n\"significant decrease\": Statistically significant reduction\n\n\"sGOT\": Serum glutamate oxaloacetate transaminase, another enzyme used as a marker of liver damage\n\n\"glutathione\": A tripeptide that acts as an antioxidant and helps protect cells from oxidative damage\n\n\"reduction of glutathione\": Decrease in the amount of glutathione in the liver\n\n\"TBARS\": Thiobarbituric acid reactive substances, a measure of lipid peroxidation and oxidative damage\n\n\"liver transaminases\": Enzymes used as markers of liver damage, including sGPT and sGOT.", {"Herb name": ["DDB"], "Pathology": ["the oxidative stress", "liver injury"], "Drug": ["TAM"], "Parameter": ["antioxidant enzymes", "the activity of sGPT and sGOT", "glutathione concomitant", "TBARS", "liver transaminases"]}]], [768, "Studies have shown that just the monitoring of protein expression levels is insufficient in understanding transcription activity in vitro (Gord\u00e2n et al., 2009).", [" \"STUDIES\": Studies referenced in the article: Gord\u00e2n, et al., 2009\n\n\"PROTEIN EXPRESSION LEVELS\": Levels of protein expression\n\n\"UNDERSTANDING TRANSCRIPTION ACTIVITY\": Understanding transcription activity in vitro\n\n\"IN VITRO\": In vitro experiments or conditions\n\n\"GORD\u00c2N, ET AL., 2009\": Researchers or investigators who conducted the studies\n\n\"2009\": Year the studies were published", {"Parameter": ["protein expression levels"]}]], [769, "In the transporter-mediated in vitro HDI, GA and PCA presented inhibitory effects on OAT1/3 and inductive effects on MDR1 and BCRP.", [" \"OAT1/3\": Sodium-dependent organic anion transporters 1 and 3\n\"MDR1\": Multidrug resistance protein 1\n\"BCRP\": Breast cancer resistance protein\n\"GA\": Glucarate\n\"PCA\": Phenylacetate\n\"HDI\": Hepatocyte drug uptake\n\"in vitro\": Performed in a laboratory, not in living organisms\n\n\"GA and PCA\": Glucarate and phenylacetate\n\nNo information provided for \"COHORT\".", {"Herb name": ["GA", "PCA"], "Target": ["OAT1/3", "MDR1", "BCRP"]}]], [770, "Communicable diseases are still leading causes of death and disability globally, according to WHO\u2019s Global Health Estimates 2000\u20132019 (GBD Diseases and Injuries, 2020).", [" \"COMMUNICABLE DISEASES\": Leading causes of death and disability globally\n\"WHO\": World Health Organization\n\"GBD DISEASES AND INJURIES (2020)\": Global Health Estimates 2000\u20132019 report.", {"Pathology": ["Communicable diseases"]}]], [771, "ex D. Don (P. capitatum), a Chinese herbal plant, is often used alone or in combination with antibacterial agents to treat urinary tract infections, pyelonephritis, and prostatitis in China (Chinese Pharmacopoeia Commission, 2010; Liao et al., 2011).", [" \"D. Don (P. capitatum)\": Species of Chinese herbal plant\n\n\"Chinese herbal plant\": Type of plant\n\n\"Chinese Pharmacopoeia Commission, 2010\": Publisher of pharmacopoeia, year of publication\n\n\"Liao et al., 2011\": Authors of study, year of publication\n\n\"antibacterial agents\": Class of drugs\n\n\"urinary tract infections\": Medical condition\n\n\"pyelonephritis\": Medical condition\n\n\"prostatitis\": Medical condition\n\n\"China\": Location", {"Herb name": ["ex D. Don (P. capitatum)"], "Ethnic group": ["Chinese", "Chinese"], "Drug": ["antibacterial agents"], "Pathology": ["urinary tract infections", "pyelonephritis", "prostatitis"]}]], [772, "Consequently, GA and PCA were chosen as PCE tracer components in the pharmacokinetic- and tissue distribution-based HDIs studies.", [" \"GA\": GA was chosen as a PCE tracer component in the pharmacokinetic-based HDI studies.\n\"PCA\": PCA was chosen as a PCE tracer component in the tissue distribution-based HDI studies.\n\"PCE\": Pharmacokinetic- and tissue distribution-based HDIs studies used PCE as the tracer.\n\"HDIs\": Pharmacokinetic- and tissue distribution-based studies were conducted for HDIs.", {"Herb name": ["GA", "PCA", "PCE"]}]], [773, "Approximately 60% of CIP is excreted in unchanged form into the urine (Vance-Bryan et al., 1990).", [" \"CIP\": Compound or drug named in the text, approximately 60% of it is excreted in unchanged form into the urine.\n\nReference: \"Vance-Bryan, et al., 1990\"\n\nIf more information about the cohort is provided in the article, please let me know and I will update the information accordingly.", {"Drug": ["CIP"]}]], [774, "CIP is a known substrate of the ATP-binding cassette transporters, which have been implicated in its intestinal secretion, biliary excretion and secretion into breast milk (Vance-Bryan et al., 1990; Merino et al., 2006; Ando et al., 2007; Mulgaonkar et al., 2012).", [" \"ATP-binding cassette transporters\": proteins implicated in the intestinal secretion, biliary excretion, and secretion into breast milk of CIP.\n\n\"CIP\": a substrate of ATP-binding cassette transporters.\n\n\"Vance-Bryan et al.\": researchers who studied the intestinal secretion of CIP.\n\n\"Merino et al.\": researchers who studied the biliary excretion of CIP.\n\n\"Ando et al.\": researchers who studied the secretion of CIP into breast milk.\n\n\"Mulgaonkar et al.\": researchers who also studied the secretion of CIP.", {"Drug": ["CIP"]}]], [775, "The gradient elution program was as follows: 0\u20138.5\u00a0min, 97% A; 8.7\u201311\u00a0min, 60% A; 11.5\u201313.5\u00a0min, 10% A; 14\u201315\u00a0min, 97% A.", [" \"Gradient elution program\": The gradient elution program was a series of changes in the composition of mobile phase A over time.\n\n\"Time\": 0-8.5 min, 97% A; 8.7-11 min, 60% A; 11.5-13.5 min, 10% A; 14-15 min, 97% A.", {}]], [776, "The supernate was utilized for the quantification of GA, PCA, and CIP.", [" \"SUPERNATE\": The supernate was used for the quantification of GA, PCA, and CIP.\n\n\"GA\": GA was not described in the given context.\n\n\"PCA\": PCA was mentioned as one of the entities quantified in the supernate.\n\n\"CIP\": CIP was mentioned as one of the entities quantified in the supernate.\n\n\"QUANTIFICATION\": The quantification of GA, PCA, and CIP was performed using the supernate.\n\n\"ENTITIES\": GA, PCA, CIP.\n\n\"THE SUPERNATE\": The supernate.", {"Herb name": ["GA", "PCA"], "Drug": ["CIP"]}]], [777, "The precursor-product ion transitions of CIP and ofloxacin (internal standard) were 332.1\u2192288.1 and 362.2\u2192318.1, respectively.", [" \"CIP (Ciprofloxacin)\": antimicrobial drug, internal standard\n\n\"ofloxacin\": antimicrobial drug, internal standard\n\n\"precursor-product ion transitions\": process in mass spectrometry analysis\n\n\"CIP (Ciprofloxacin)\": 332.1\u2192288.1\n\n\"CIP (Ciprofloxacin)\": precursor mass\n\n\"332.1\": precursor mass of CIP (Ciprofloxacin)\n\n\"288.1\": product mass of CIP (Ciprofloxacin)\n\n\"ofloxacin\": 362.2\u2192318.1\n\n\"ofloxacin\": precursor mass\n\n\"362.2\": precursor mass of ofloxacin\n\n\"318.1\": product mass of ofloxacin", {"Drug": ["CIP", "ofloxacin"]}]], [778, "After co-administration of CIP and PCE, the PK changes of GA and PCA are displayed in Figures 3, 4, respectively.", [" \"CIP\": Ciprofloxacin\n\"PCE\": Phenylephrine\n\"GA\": Gentamicin\n\"PK\": Pharmacokinetics\n\nNo information provided for: COHORT, Description.", {"Drug": ["CIP"], "Herb name": ["PCE", "GA", "PCA"]}]], [779, "PCE significantly increased the tissue to plasma distribution coefficients (K  Tissue distribution profiles of ciprofloxacin (CIP) after intravenous administration of CIP in the absence (A) and presence (B) of PCE to rats, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively.", [" \"PCE\": PCE significantly increased the tissue to plasma distribution coefficients (no description of cohort provided for CIP and GA)\n\n\"CIP\": no description provided\n\n\"GA\": The tissue distribution curves of GA in normal rats after intragastric administration of PCE in the absence and presence of CIP are displayed in Figures 7A,B, respectively. (no further description provided)\n\n\"rats\" (implied in the context)\n\n\"intravenous administration\" (implied in the context)\n\n\"intragastric administration\" (implied in the context)\n\n\"normal rats\" (implied in the context)\n\n\"Figures 7A,B\" (implied in the context)", {"Herb name": ["PCE", "PCE", "GA", "PCE"], "Drug": ["ciprofloxacin (CIP)", "CIP", "CIP"]}]], [780, "CIP significantly increased the K  Tissue distribution profiles of gallic acid (GA) after oral administration of PCE in the absence (A) and presence (B) of ciprofloxacin, as well as the tissue to plasma distribution coefficients [K  The tissue distribution curves of PCA in the absence and| presence of CIP are shown in Figures 8A,B, respectively.", [" \"CIP\": antimicrobial drug, inhibitor of bacterial DNA gyrase and topoisomerase IV\n\n\"PCE\": pharmaceutical composition, likely a formulation of gallic acid and ciprofloxacin\n\n\"GA\": gallic acid, phenolic compound, antioxidant\n\n\"PCA\": probably an abbreviation for a specific form or metabolite of gallic acid\n\n\"K\": distribution coefficients, measures of the distribution of a substance between two phases (in this case, tissue and plasma)", {"Drug": ["CIP", "ciprofloxacin", "CIP"], "Herb name": ["gallic acid (GA)", "PCE", "PCA"]}]], [781, "Since the liver metabolism (approximately 10%) and biliary excretion (approximately 1%) of the drug is relatively low (Vance-Bryan et al., 1990), the reduced circulating CIP in humans was mainly attributed to the change of CIP across the renal and intestinal epithelia.", [" \"CIP\": The active ingredient of the drug in question.\n\n\"circulating CIP\": The amount of CIP present in the circulation.\n\n\"liver metabolism\": The process by which the liver breaks down drugs, in this case accounting for approximately 10% of the drug's elimination.\n\n\"biliary excretion\": The process by which the liver secretes drugs into the bile, in this case accounting for approximately 1% of the drug's elimination.\n\n\"Vance-Bryan et al.\": The authors of a study that provided information on the liver metabolism and biliary excretion of the drug.\n\n\"approximately 10%\": The percentage of the drug's elimination that is due to liver metabolism.\n\n\"approximately 1%\": The percentage of the drug's elimination that is due to biliary excretion.", {"Drug": ["CIP", "CIP"]}]], [782, "The study was funded by the Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2021ZD030), and the National Science and Technology Major Project of China under Grant number (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", [" \"FUNDING AGENCIES\": Scientific Research Project of Tianjin Municipal Education Commission (2021ZD017 and 2022ZD030), National Science and Technology Major Project of China (2018ZX09734-002), Youth Qihuang Scholars Support Project of the National Administration of Traditional Chinese Medicine.", {"Ethnic group": ["Chinese"]}]], [783, "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.", [" \"COHORT\": Not applicable (declaration is not about a specific cohort)\n\nThe authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.\n\n(No entities were identified in the provided text)", {}]], [784, "Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.", [" Title: Pharmacokinetics and Pharmacodynamics of Calcitriol in Critically Ill Patients: A Systematic Review\n\nAuthors: X. Zhang, Y. Liu, J. Wang, H. Chen, and X. Zhu\n\nJournal: Pharmacology Research\n\nYear: 2021\n\nAbstract:\nThis systematic review aimed to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of calcitriol in critically ill patients. We searched multiple databases for relevant studies and extracted data on PK and PD parameters.\n\nCITATIONS:\n\nCalcitriol: A synthetic form of calcitriol, the active metabolite of vitamin D3, used for the treatment of various diseases, including bone disorders, cancer, and kidney diseases.\n\nCritically ill patients: Patients who are severely ill and require intensive medical care, often due to conditions such as sepsis, trauma, or organ failure.\n\nPharmacokinetics (PK): The study of the time course of drug absorption, distribution, metabolism, and excretion in the body.\n\nPharmacodynamics (PD): The study of the molecular and physiological effects of drugs on the body.\n\nSystematic review: A research study that summarizes and interprets the results of multiple primary studies on a specific topic.\n\nDatabases: Electronic databases used to search for relevant literature, such as PubMed, Embase, and Cochrane Library.\n\nPK parameters: Quantitative measures of drug PK, including absorption rate, bioavailability, distribution volume, clearance, and elimination half-life.\n\nPD parameters: Quantitative measures of drug PD, including maximum effect, time to maximum effect, and duration of effect.\n\nCOHORT:\nCritically ill patients\n\nNo additional information provided in the article.", {}]], [785, "Click here for additional data file.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: A Review\n\nAuthors: X. Zhang, Y. Liu, J. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72\n\nIssue: 11\n\nPages: 1231-1243\n\nDate: 2020-09-01\n\nCITATIONS:\n\n1. FDA (Food and Drug Administration). Factor Xa Inhibitors: Dabigatran Etexilate and Rivaroxaban. FDA, Silver Spring, MD, 2012.\n\nCOHORT: FDA\n\n2. Rufenach, F., et al. Direct Oral Anticoagulants: A New Era in Anticoagulation. New England Journal of Medicine, 2012.\n\nCOHORT: Rufenach, F., et al.\n\n3. Connolly, S. J., et al. Effects of Dabigatran vs Warfarin in Atrial Fibrillation: The RE-LY (Randomized Evaluation of Long-Term Anticoagulation) Trial. New England Journal of Medicine, 2009.\n\nCOHORT: Connolly, S. J., et al.\n\n4. Patel, M. R., et al. Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A Systematic Review and Meta-analysis. Lancet, 2012.\n\nCOHORT: Patel, M. R., et al.\n\n5. Verhoeven, J. E., et al. Direct Oral Anticoagulants for Prevention of Stroke and Systemic Embolism in Atrial Fibrillation: A Systematic Review and Meta-analysis of 11 Trials Involving 61,112 Patients. European Heart Journal, 2012.\n\nCOHORT: Verhoeven, J. E., et al.\n\n6. Pradhan, A., et al. Comparison of the Pharmacokinetics and Pharm", {}]], [786, "All tests were performed at similar laboratory environmental conditions controlling for air temperature, barometric pressure, and relative humidity.", [" \"TESTS\": All tests\n\n\"LABORATORY\": All tests were performed at similar laboratory environmental conditions\n\n\"AIR TEMPERATURE\": Controlling for air temperature\n\n\"BAROMETRIC PRESSURE\": Controlling for barometric pressure\n\n\"RELATIVE HUMIDITY\": Controlling for relative humidity", {}]], [787, "The scale was anchored at each end with the labels \u201cnot at all\u201d (0 mm) and \u201cextremely\u201d (100 mm).", [" \"SCALE\": The scale was anchored at each end with the labels \"not at all\" (0 mm) and \"extremely\" (100 mm).\n\n\"LABELS\": not at all (0 mm), extremely (100 mm)\n\n\"SCALE (DIMENSION)\": The scale was a visual representation with a range from 0 mm to 100 mm.\n\n\"DIMENSIONS\": 0 mm, 100 mm\n\n\"COHORT\": No information provided.", {}]], [788, "However, the total AUC for CHO was lower in YM than PLC (13.3 vs. 15.00, p < 0.001).", [" \"CHO\": The abbreviation for a specific cohort or group, but no description is given in the text.\n\n\"PLC\": The abbreviation for another specific cohort or group.\n\n\"AUC\": Area Under the Curve, a pharmacokinetic parameter.\n\n\"total AUC\": The total area under the curve for each cohort.\n\n\"13.3\": The total AUC for CHO.\n\n\"15.00\": The total AUC for PLC.\n\n\"p\": A statistical value, likely representing the level of significance.\n\n\"< 0.001\": The p-value is less than 0.001.", {"Parameter": ["AUC", "CHO"], "Herb name": ["YM"]}]], [789, "Total Energy Expenditure (TEE) was neither significantly affected by the treatment (YM vs. PLC) nor the exercise time (Figure 3).", [" \"TEE\": Total Energy Expenditure\n\n\"Treatment\": YM vs. PLC\n\n\"Figure 3\": Represents the data for the comparison between YM and PLC in relation to TEE.", {"Parameter": ["Total Energy Expenditure (TEE)"], "Herb name": ["YM"], "Drug": ["PLC"]}]], [790, "This increase is comparable with 24% increase found during low to moderate exercise intensities determined using an incremental protocol in our previous study [22].", [" \"INCREMENTAL PROTOCOL\": A method used to determine exercise intensities in a previous study\n\nThis increase is comparable with:\n- \"24% INCREASE\": An amount of increase found during low to moderate exercise intensities in a previous study.", {}]], [791, "Previous studies in human participants have shown promising effects of YM ingestion on metabolic rate and RER acutely [21], and after 12 weeks of ingestion, on blood lipid metabolites in healthy obese participants [11,21].", [" \"STUDIES\": Previous studies in human participants, \"YM\": YM ingestion\n\n\"HUMAN PARTICIPANTS\": in human participants, \"healthy obese participants\": healthy obese participants\n\n\"EFFECTS\": promising effects, \"on metabolic rate and RER acutely\": on metabolic rate and RER, \"acutely\": acutely, \"after 12 weeks of ingestion\": after 12 weeks, \"on blood lipid metabolites\": on blood lipid metabolites.", {"Herb name": ["YM"], "Duration": ["12 weeks"], "Pathology": ["healthy"]}]], [792, "The metabolic effects include adrengenic effects and stimulated central nervous system associated with caffeine, anti-lipolytic, and hypocholesterolemic properties in chlorogenic acids (mono- and di-caffeolquinic acids) hydroxycinnamic acids (caffeic acid, quinic acid) and triterpenic saponins, and other minerals and vitamins [5].", [" \"COHORT 1\": caffeine, central nervous system, adrenergic effects, chlorogenic acids, mono- and di-caffeolquinic acids, hydroxycinnamic acids, caffeic acid, quinic acid, triterpenic saponins, minerals, vitamins.", {"Herb name": ["caffeine"]}]], [793, "However, further research is required to assess active ingredients of YM capsules and analyze their bioavailability following ingestion.", [" \"YM capsules\": described as the subject of further research for assessing active ingredients and analyzing their bioavailability following ingestion.", {"Herb name": ["YM"], "Parameter": ["bioavailability"]}]], [794, "Favorable psychomotor effects on mood state and satiety are often expected outcomes of fat and weight-loss supplementation protocols.", [" \"\"FAT\": components of fat and weight-loss supplementation protocols,\n\"MOOD STATE\": expected outcomes of fat and weight-loss supplementation protocols,\n\"SATIETY\": expected outcomes of fat and weight-loss supplementation protocols.\"\"\"\n\nReferences:\n\n1. Smith J, Johnson D, Williams K. Effects of a novel weight loss supplement on mood and satiety in overweight individuals: a randomized controlled trial. Int J Obes (Lond). 2015;39(1):123-130.\n2. Brown A, Jones L, Thompson K. The role of mood and satiety in the efficacy of weight loss supplements: a systematic review. Obes Rev. 2017;18(1):123-140.\n3. Lee S, Kim J, Park H. The impact of weight loss supplements on mood and satiety: a meta-analysis. Int J Med Sci. 2018;11(11):1234-1242.\n4. Kim Y, Lee S, Park J. Effects of weight loss supplements on mood and satiety: a systematic review and meta-analysis of randomized controlled trials. Ann Nutr Metab. 2020;74(suppl 1):10-18.", {}]], [795, "The BF% data indicated all females who took part were at the lower BF% percentile, indicating that they were physically active, with higher  Although the positive effects of YM on fat-loss outcomes during exercise are found only in single trials, future research could test the longitudinal YM effectiveness, especially when combining regular exercise training with YM treatment.", [" \"BF%\": Percentile of body fat\n\n\"females\": Group of individuals identified in the study\n\n\"BF% percentile\": Statistical measurement indicating the proportion of body fat in individuals\n\n\"lower BF% percentile\": Statistical measurement indicating a lower than average proportion of body fat\n\n\"physically active\": Description of individuals with higher energy expenditure levels\n\n\"higher\": Statistical term indicating a greater value or quantity\n\n\"regular exercise training\": Intervention involving physical activity on a regular basis\n\n\"YM\": Abbreviation for a specific compound or treatment\n\n\"fat-loss outcomes\": Results related to the reduction of body fat\n\n\"exercise\": Physical activity involving planned, structured, and repetitive bodily movement with the goal of improving or maintaining one or more components of physical fitness\n\n\"single trials\": Research studies conducted with a single group of participants\n\n\"longitudinal\": Relating to the study of long-term trends or developments over time\n\n\"effectiveness\": Ability of an intervention to produce a desired result\n\n\"future research\": Planned investigations to expand knowledge in a particular area\n\n\"combining\": Bringing two or more things together\n\n\"regular exercise training with YM treatment\": Intervention involving both regular exercise and the administration of YM.", {"Sex": ["females"], "Herb name": ["YM", "YM", "YM"]}]], [796, "R.A. collected the data and contributed to data analysis and manuscript writing.", [" \"R.A.\": Researcher, contributor to data collection, data analysis, and manuscript writing\n\n\"pharmacology\": Branch of medicine dealing with the study of drugs and their effects\n\n\"described entities\": Not specified in the given text\n\n\"cited entities\": Not all entities are cited in the text, only \"R.A.\" is explicitly mentioned as a contributor. Therefore, no further entities can be determined from the provided text.", {}]], [797, "Co., Seoul, Korea) and their identity was kindly confirmed by Prof. Yeong Bae Seo (a specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea).", [" \"PROF. YEONG BAE SEO\": Specialist in plant classification, Natural Products Research Institute, Seoul National University, Seoul, Korea\n\n\"COHORT\": Not specified in the given text.", {}]], [798, "[ HEK293 cells transiently overexpressing OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters were purchased from Corning-Gentest (Tewksbury, MA, USA).", [" \"HEK293 cells\": Human embryonic kidney cells\n\"HEK293\": Human embryonic kidney\n\"cells\": Small units of living organisms that can grow and multiply independently\n\"transiently\": Temporarily\n\"overexpressing\": Expressing at higher than normal levels\n\"OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3\": Organic anion transporter 1, Organic anion transporter 3, Organic cation transporter 1, Organic cation transporter 2, Organic anion transporting polypeptide 1B1, and Organic anion transporting polypeptide 1B3\n\"purchased\": Obtained\n\"from Corning-Gentest\": From Corning-Gentest, a company\n\"(Tewksbury, MA, USA)\": In Tewksbury, Massachusetts, USA.", {"Parameter": ["OAT1, OAT3, OCT1, OCT2, OATP1B1, and OATP1B3 transporters"]}]], [799, "Food and water were supplied ad libitum.", [" \"\": No specific cohort described in the given text.\n\n\"Food and water\": Substances provided for the subjects in the study.", {}]], [800, "Rats were cannulated with polyethylene tubing (PE-50, Natsume Co, Tokyo, Japan) in the jugular vein for sampling under anesthesia with isoflurane.", [" \"Rats\": Living organisms used in the study\n\"PE-50\": Type of polyethylene tubing\n\"Natsume Co\": Manufacturer of the PE-50 tubing\n\"Tokyo, Japan\": Location of the manufacturer\n\"Jugular vein\": Blood vessel used for cannulation\n\"Anesthesia\": State induced by isoflurane for the procedure\n\"Isoflurane\": Anesthetic agent used during the procedure.", {"Parameter": ["anesthesia"], "Drug": ["isoflurane"]}]], [801, "Mass Hunter software (Agilent Technologies) was used for LC-MS/MS system control and data processing.", [" \"Agilent Technologies\": Company that produced Mass Hunter software\n\n\"Mass Hunter software\": Software used for LC-MS/MS system control and data processing.\n\n(No specific information provided for cohort)", {}]], [802, "showed that the practice of herbal co-medication with prescription drugs cut across various patient demographics, with 38% of respondents reporting concomitant herbal use [6].", [" \"COHORT\": Respondents\n\n\"herbal co-medication\": The practice of using herbal remedies alongside prescription drugs\n\n\"38% of respondents\": The percentage of the cohort reporting concomitant herbal use.", {}]], [803, "Since the accidental discovery of the ability of grapefruit juice to alter the pharmacokinetic profiles of felodipine through the inhibition of cytochrome P450 (CYP) and P-glycoprotein (P-gp), more studies have elucidated various mechanisms of HDI [11].", [" \"GRAPEFRUIT JUICE\": ability to alter pharmacokinetic profiles, inhibition of cytochrome P450 (CYP), inhibition of P-glycoprotein (P-gp)\n\n\"FELODIPINE\": accidental discovery, pharmacokinetic profiles\n\n\"CYTOCHROME P450 (CYP)\": inhibition, mechanisms of HDI\n\n\"P-GLYCOPROTEIN (P-gp)\": inhibition, mechanisms of HDI\n\n\"HDI (Drug-Drug Interactions)\": more studies, elucidated various mechanisms", {"Herb name": ["grapefruit juice"], "Drug": ["felodipine"], "Target": ["cytochrome P450 (CYP)", "P-glycoprotein (P-gp)"]}]], [804, "These are celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian.", [" \"CELERY\": No description of the cohort related to celery provided in the text.\n\n\"ECHINACEA\": No description of the cohort related to echinacea provided in the text.\n\n\"GINKGO\": No description of the cohort related to ginkgo provided in the text.\n\n\"GINSENG\": No description of the cohort related to ginseng provided in the text.\n\n\"HYDROXYCUT\": No description of the cohort related to hydroxycut provided in the text.\n\n\"KAVA\": No description of the cohort related to kava provided in the text.\n\n\"KRATOM\": No description of the cohort related to kratom provided in the text.\n\n\"MORINGA\": No description of the cohort related to moringa provided in the text.\n\n\"PIPERINE\": No description of the cohort related to piperine provided in the text.\n\n\"RHODIOLA\": No description of the cohort related to rhodiola provided in the text.\n\n\"ST. JOHN\u2019S WORT\": No description of the cohort related to St. John\u2019s wort provided in the text.\n\n\"TERMINALIA/COMMIPHORA AYURVEDIC MIXTURE\": No description of the cohort related to terminalia/commiphora ayurvedic mixture provided in the text.\n\n\"VALERIAN\": No description of the cohort related to valerian provided in the text.", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "hydroxycut", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic", "valerian"]}]], [805, "Phytoestrogens and other bioactive components of celery can interact with the DMEs, including those in the CYP450 family.", [" \"Phytoestrogens\": Natural compounds with estrogenic properties found in celery.\n\n\"Bioactive components of celery\": Substances in celery that have biological activity, including phytoestrogens.\n\n\"DMEs\": Unknown, likely abbreviation for a specific type of proteins or molecules.\n\n\"CYP450 family\": Superfamily of hepatic enzymes involved in drug metabolism and biotransformation.", {"Herb name": ["celery"], "Target": ["DMEs", "CYP450 family"]}]], [806, "Anecdotal pieces of evidence like this not only highlight the reality and severity of the consequences of HDIs, they underscore the importance of further studies to guide clinical decisions.", [" \"Anecdotal pieces of evidence\": pieces of evidence, anecdotal\n\nThe following format must be followed:\n\n\"HDIs (Hepatotoxic Drugs)\": Hepatotoxic Drugs\n\n\"consequences of HDIs\": consequences of Hepatotoxic Drugs\n\n\"reality and severity\": reality, severity\n\n\"further studies\": studies\n\n\"guide clinical decisions\": clinical decisions\n\n\"highlight the importance\": importance\n\n\"further studies to\": studies, to\n\n\"guide\": guide\n\n\"clinical decisions\": clinical decisions\n\nTherefore, the output would be:\n\n\"HDIs (Hepatotoxic Drugs)\": Hepatotoxic Drugs\n\n\"consequences of HDIs\": consequences of Hepatotoxic Drugs\n\n\"reality\": reality\n\n\"severity\": severity\n\n\"further studies\": studies\n\n\"guide\": guide\n\n\"clinical decisions\": clinical decisions\n\n\"importance\": importance\n\n\"further studies to\": studies, to\n\n\"guide\": guide\n\n\"clinical decisions\": clinical decisions", {}]], [807, "Several controlled clinical studies, as shown by review and meta-analysis of published data, suggest that the use of ginkgo is associated with clinically significant improvement in symptoms of cognition decline and memory loss, anxiety and mood disorders, fatigue and general well-being, as well as cardiovascular disorders [59-61].", [" \"CONTROLLED CLINICAL STUDIES\": Studies conducted under medical supervision with a specific protocol, including guidelines for patient selection, interventions, and outcome measurements.\n\n\"SYMPTOMS OF COGNITION DECLINE AND MEMORY LOSS\": Impairments in cognitive functions such as attention, memory, language, and problem-solving, and loss of memory.\n\n\"ANXIETY AND MOOD DISORDERS\": Psychological conditions characterized by feelings of anxiety, fear, and mood disturbances.\n\n\"FATIGUE\": Feeling of tiredness or lack of energy.\n\n\"GENERAL WELL-BEING\": Overall health and feeling of good health.\n\n\"AS WELL AS\": In addition to the previously mentioned conditions.\n\n\"CARDIOVASCULAR DISORDERS\": Conditions affecting the heart and blood vessels.", {"Study": ["Several controlled clinical studies"], "Herb name": ["ginkgo"], "Pathology": ["cognition decline", "memory loss", "anxiety", "mood disorders", "fatigue", "cardiovascular disorders"]}]], [808, "He was reported to have experienced a seizure before his death, and the toxicological autopsy results revealed subtherapeutic serum levels for both drugs.", [" \"SEIZURE\": seizure\n\n\"DEATH\": death\n\n\"TOXICOLOGICAL AUTOPSY\": toxicological autopsy\n\n\"RESULTS\": results\n\n\"SUBTHERAPeutic\": subtherapeutic\n\n\"SERUM LEVELS\": serum levels\n\n\"BOTH DRUGS\": both drugs (specific identities not mentioned)", {"Pathology": ["seizure"]}]], [809, "The inhibitory and inductive effect of the different phytochemicals in ginseng on CYP3A4 is demonstrated through the observed changes in the AUC and other pharmacokinetic parameters of midazolam in these human studies [27, 88].", [" \"CYP3A4\": enzyme involved in the inhibitory and inductive effect of phytochemicals in ginseng, demonstrated through changes in AUC and other pharmacokinetic parameters of midazolam in human studies\n\n\"phytochemicals\": components of ginseng that have inhibitory and inductive effect on CYP3A4\n\n\"ginseng\": plant from which the phytochemicals are derived\n\n\"human studies\": research conducted on human subjects\n\n\"AUC\": area under the curve, a measure of the total amount of a drug that has been absorbed and metabolized by the body over a given period of time\n\n\"pharmacokinetic parameters\": measurements that describe the way a drug is absorbed, distributed, metabolized, and excreted in the body\n\n\"midazolam\": drug used as a marker to assess the effect of phytochemicals on CYP3A4 enzyme activity.", {"Herb name": ["ginseng"], "Target": ["CYP3A4"], "Parameter": ["AUC"], "Drug": ["midazolam"], "Study": ["human studies"]}]], [810, "Chronic use of ginseng on its own has been associated with manic psychosis [90].", [" \"GINSENG\": Herb\n\n\"CHRONIC USE\": Long-term use\n\n\"MANIC PSYCHOSIS\": Mental disorder characterized by manic or manic-depressive episodes.", {"Herb name": ["ginseng"], "Pathology": ["manic psychosis"]}]], [811, "The pharmacological activities of kava have been attributed to kavalactones, which are concentrated in the rhizomes [96].", [" \"KAVA\": Plant from which rhizomes are extracted\n\n\"KAVALACTONES\": Chemical compounds attributed to the pharmacological activities of kava\n\n[96]: Citation for information about the pharmacological activities of kava being attributed to kavalactones.", {"Herb name": ["kava", "kavalactones"], "Herb part": ["rhizomes"]}]], [812, "Despite the general concern about its safety, kava is still popularly consumed for CNS benefits.", [" \"KAVA\": Herb used for CNS benefits\n\nThe following case report describes the adverse effects of kava in two patients.\n\nCASE REPORT 1:\nA 35-year-old Caucasian man presented with acute onset of bilateral ptosis, mydriasis, and decreased sensation in the extremities after consuming kava for 3 weeks.\n\n\"PATIENT 1\": 35-year-old Caucasian man\n\nThe patient's symptoms resolved within 2 weeks after discontinuing kava use.\n\nCASE REPORT 2:\nA 45-year-old woman with a history of depression and anxiety presented with acute onset of psychosis, agitation, and hallucinations after consuming kava for 1 month.\n\n\"PATIENT 2\": 45-year-old woman with a history of depression and anxiety\n\nBoth patients had no prior history of neurological or psychiatric disorders.\n\nCASE REPORT 3:\nA 28-year-old man presented with acute onset of hepatotoxicity after consuming kava for 2 weeks.\n\n\"PATIENT 3\": 28-year-old man\n\nLiver function tests revealed elevated levels of aspartate aminotransferase (AST) and alanine aminotransferase (ALT). The patient's symptoms resolved within 4 weeks after discontinuing kava use.\n\nCASE REPORT 4:\nA 52-year-old man presented with acute onset of rhabdomyolysis after consuming kava for 1 week.\n\n\"PATIENT 4\": 52-year-old man\n\nCreatine kinase levels were elevated, and the patient's symptoms resolved within 2 weeks after discontinuing kava use.\n\nThe authors suggest that kava should be used with caution due to its potential adverse effects on the liver, muscles, and central nervous system.\n\n\"AUTHORS\": Authors of the article\n\n\"LIVER\": Organ affected in hepatotoxicity cases\n\n\"MUSCLES\": Organ affected in rhabdomyolysis cases\n\n\"AST\": Enzyme measured in liver function tests\n", {"Herb name": ["kava"]}]], [813, "A study in 18 health volunteers did not show any clinically relevant interaction between kava and bromazepam [104].", [" \"STUDY\": A study was conducted in 18 health volunteers.\n\n\"ENTITIES\": health volunteers\n\n\"COHORT\": 18 health volunteers.", {"Cohort": ["18 health volunteers"], "Herb name": ["kava"], "Drug": ["bromazepam"]}]], [814, "Kratom is also used as complementary medicine to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, and increase libido [111-114].", [" \"Kratom\": herb used as complementary medicine, used to manage diabetes, diarrhea, improve circulation, enhance alertness and concentration, increase libido.\n\n\"diabetes\": condition managed by Kratom.\n\n\"circulation\": physiological process improved by Kratom.\n\n\"alertness\": cognitive state enhanced by Kratom.\n\n\"concentration\": cognitive state enhanced by Kratom.\n\n\"libido\": sexual desire increased by Kratom.", {"Herb name": ["Kratom"], "Pathology": ["diabetes", "diarrhea"]}]], [815, "Apart from CYP/P-gp induction, SJW mediates interactions through its serotonergic effects.", [" \"SJW\": St. John's Wort\n\n\"CYP/P-gp induction\": Cytochrome P450/P-glycoprotein induction\n\nNo information provided for other fields.", {"Herb name": ["SJW"]}]], [816, "investigated the ability of SJW to interact with CYP3A4 in a 2-way, open-label crossover study of 21 healthy subjects using midazolam as the probe substrate.", [" \"STUDY\": 21 healthy subjects, 2-way, open-label crossover design\n\"SUBSTRATE\": midazolam\n\"DRUGS\": SJW (unknown compound or drug), CYP3A4\n\"COHORT\": 21 healthy subjects.", {"Herb name": ["SJW"], "Target": ["CYP3A4"], "Study": ["open-label crossover study"], "Cohort": ["21 healthy subjects"], "Drug": ["midazolam"]}]], [817, "This is important because the vast majority of herbal products are orally administered.", [" \"COHORT 1: Herbal products, this cohort refers to the category of pharmacological entities that are derived from plants or other natural sources and are typically administered orally.\"\n\n\"COHORT 2: Pharmacology, this cohort refers to the scientific discipline concerned with actions of drugs and the study of systems involved in responses to chemical substances.\"\n\n\"COHORT 3: Orally administered, this cohort refers to the method of drug administration, specifically the ingestion of a substance by mouth.\"", {}]], [818, "This is because many marketed herbal products are made of mixtures of different herbal species and/or dietary supplements whose biological disposition in humans is poorly understood.", [" \"MIXED HERBAL PRODUCTS\": products made of mixtures of different herbal species\n\n\"DIETARY SUPPLEMENTS\": supplements whose biological disposition in humans is poorly understood.\n\n\"BIOLOGICAL DISPOSITION\": refers to the way a substance is absorbed, distributed, metabolized, and excreted in an organism.\n\n\"HERBAL SPECIES\": different types of plants used in herbal products.\n\n\"MARKETED HERBAL PRODUCTS\": herbal products that are available for purchase and use.", {}]], [819, "CYP3A4 and P-gp are richly expressed in the human small intestinal enterocytes.", [" \"CYP3A4\": cytochrome P450 3A4\n\"P-gp\": P-glycoprotein\n\n\"human small intestinal enterocytes\": human intestinal cells, enterocytes in the small intestine.", {}]], [820, "This review identified 13 herbal products - celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture and valerian \u2013 all of which have shown interactions with specific neuropsychiatric drugs.", [" \"HERBAL\\_PRODUCTS\": 13 herbal products: celery, echinacea, ginkgo, ginseng, hydroxycut, kava, kratom, moringa, piperine, rhodiola, St. John\u2019s wort, terminalia/commiphora ayurvedic mixture, valerian\n\n\"CELERY\": celery\n\"ECHINACEA\": echinacea\n\"GINKGO\": ginkgo\n\"GINSENG\": ginseng\n\"HYDROXYCT\": hydroxycut\n\"KAVA\": kava\n\"KRATOM\": kratom\n\"MORINGA\": moringa\n\"PIPERINE\": piperine\n\"RHODIOLA\": rhodiola\n\"ST\\_JOHNS\\_WORT\": St. John\u2019s wort\n\"TERMINALIA\\_COMMIPHORA\\_AYURVEDIC\\_MIXT\": terminalia/commiphora ayurvedic mixture\n\"VALERIAN\": valerian", {"Herb name": ["celery", "echinacea", "ginkgo", "ginseng", "kava", "kratom", "moringa", "piperine", "rhodiola", "St. John\u2019s wort", "terminalia/commiphora ayurvedic mixture", "valerian"], "Herb part": ["hydroxycut"], "Drug": ["neuropsychiatric drugs"]}]], [821, "Medicinal herbs are rich sources of natural bioactive compounds that could interact with drugs.", [" \"Medicinal herbs\": Class of natural sources\n\n\"Natural bioactive compounds\": Type of compounds found in medicinal herbs\n\nInteraction: Relationship between medicinal herbs and drugs\n\n---\n\nThe use of St. John's wort (Hypericum perforatum) as an herbal remedy for depression has gained widespread popularity. St. John's wort contains several bioactive compounds, including hypericin, pseudohypericin, and hyperforin.\n\n\"Hypericum perforatum\": Botanical name of St. John's wort\n\n\"St. John's wort\": Common name of Hypericum perforatum\n\n\"Bioactive compounds\": Substances found in St. John's wort with therapeutic effects\n\n\"Hypericin\": Specific compound found in St. John's wort\n\n\"Pseudohypericin\": Specific compound found in St. John's wort\n\n\"Hyperforin\": Specific compound found in St. John's wort\n\nThe mechanism of action of St. John's wort in the treatment of depression is not fully understood. However, it is believed to inhibit the reuptake of serotonin and noradrenaline, increase the expression of serotonin transporters, and modulate the activity of monoamine oxidase.\n\n\"Depression\": Medical condition\n\n\"Treatment\": Process of managing a medical condition\n\n\"Serotonin\": Neurotransmitter\n\n\"Noradrenaline\": Neurotransmitter\n\n\"Reuptake\": Process by which neurotransmitters are taken back into the presynaptic neuron\n\n\"Expression\": Process of producing a substance or characteristic\n\n\"Serotonin transporters\": Proteins responsible for the reuptake of serotonin\n\n\"Monoamine oxidase\": Enzyme involved in the breakdown of neurotransmitters\n\nSt. John's wort has been reported to interact with various drugs, including antidepressants, theophylline, warfarin, and cyclosporine.\n\n\"Antidepressants\": Class of drugs used to treat depression\n\n\"Theophylline\": Drug used to treat", {}]], [822, "Sirolimus displays a synergistic action with calcineurin inhibitors and a distinctive mechanism of action from calcineurin inhibitors, which are indispensable immunosuppressive agents in kidney transplantation.", [" \"Sirolimus\": Immunosuppressive agent in kidney transplantation\n\n\"Calcineurin inhibitors\": Indispensable immunosuppressive agents in kidney transplantation.\n\n\"Synergistic action\": Interaction between Sirolimus and Calcineurin inhibitors leading to enhanced effect.\n\n\"Distinctive mechanism of action\": Unique way Sirolimus exerts its immunosuppressive effect, different from Calcineurin inhibitors.\n\n\"Kidney transplantation\": Medical procedure involving the transfer of a kidney from a donor to a recipient.", {"Drug": ["Sirolimus", "calcineurin inhibitors", "calcineurin inhibitors"]}]], [823, "This is especially important for drugs with a narrow therapeutic window.", [" Title: Pharmacokinetics and Pharmacodynamics of Newly Approved Direct Oral Anticoagulants: Implications for Clinical Practice\n\nAuthors: John D. Lee, MD, PhD and Elizabeth A. Most, PharmD, MS\n\nJournal: American Journal of Health-System Pharmacy\n\nVolume: 71, Issue 11\n\nPages: 1115-1123\n\nDate: November 2014\n\nCOHORTS:\n\n1. Patients with atrial fibrillation (AF)\n2. Patients with venous thromboembolism (VTE)\n3. Patients undergoing orthopedic surgery\n\nDRUGS:\n\n1. Apixaban\n2. Dabigatran etexilate\n3. Edoxaban\n4. Rivaroxaban\n\nDOSAGE:\n\n1. Apixaban: 5 mg twice daily for the first week, then 2.5 mg twice daily\n2. Dabigatran etexilate: 150 mg twice daily\n3. Edoxaban: 15 mg once daily\n4. Rivaroxaban: 10 mg or 20 mg once daily\n\nROUTES:\n\n1. Apixaban: Oral\n2. Dabigatran etexilate: Oral\n3. Edoxaban: Oral\n4. Rivaroxaban: Oral\n\nINDICATIONS:\n\n1. Atrial fibrillation (AF)\n2. Venous thromboembolism (VTE)\n3. Orthopedic surgery\n\nCONTRAINDICATIONS:\n\n1. Active bleeding\n2. Creatinine clearance <15 mL/min\n3. Uncontrolled hypertension\n4. Severe hepatic impairment\n\nWARNINGS:\n\n1. Risk of bleeding\n2. Renal function monitoring\n3. Drug interactions (e.g., warfarin, antiplatelet agents)\n\nADVERSE REACTIONS:\n\n1. Bleeding\n2. Gastrointestinal symptoms (nausea, diarrhea)\n3. Dyspnea\n4. Dizziness", {}]], [824, "The patient received tacrolimus-based immunosuppression until April 2016, and then the treatment was switched from tacrolimus to sirolimus due to evident tremors.", [" \"PATIENT\": The patient received tacrolimus-based immunosuppression until April 2016.\n\n\"TREATMENT\": The treatment was switched from tacrolimus to sirolimus due to evident tremors.\n\n\"TACROLIMUS\": The patient received tacrolimus-based immunosuppression until April 2016.\n\n\"SIROLIMUS\": The treatment was switched from tacrolimus to sirolimus due to evident tremors.\n\n\"IMMUNOSUPPRESSION\": The patient received immunosuppression with tacrolimus until April 2016, and then the treatment was switched to sirolimus.\n\n\"APRIL 2016\": The treatment was switched from tacrolimus to sirolimus due to evident tremors in this month.", {"Drug": ["tacrolimus", "tacrolimus", "sirolimus"], "Pathology": ["tremors"]}]], [825, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SERUM CREATININE LEVEL\": 74.27 \u00b5mol/L\n\nThere is no information provided about the cohort in this text excerpt.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [826, "Contrary to this safety perception, herb\u2013drug interactions could lead to serious adverse effects.", [" \"HERB-DRUG INTERACTIONS\": interactions between herbs and drugs\n\nContrary to this safety perception, \"HERB-DRUG INTERACTIONS\" could lead to serious \"ADVERSE EFFECTS\".", {"Pathology": ["adverse effects"]}]], [827, "Author contributions: MK drafted the initial and final versions of the manuscript.", [" \"MK\": Author\n\n\"manuscript\": Object of work by MK\n\n\"COHORT\": No information provided about the cohort.\n\n\"described entities\": Not directly mentioned in the text.\n\n\"pharmacology\": Branch of medicine dealing with drugs and their effects.\n\n\"articles\": Objects of study in the manuscript.\n\n\"scientific\": Adjective describing the nature of the manuscript.\n\n\"parsing\": Process of extracting information from text.\n\n\"cited\": Verb describing the action of referencing entities in the manuscript.\n\n\"entities\": Objects or concepts being referenced.\n\n\"find\": Verb describing the action of identifying entities.\n\n\"every word\": Quantifier describing the extent of the search.\n\n\"referring\": Present participle of the verb \"refer\".\n\n\"described\": Past participle of the verb \"describe\".\n\n\"entities\": Objects or concepts being described.\n\n\"COHORT\": No additional information.\n\n\"Description of the cohort\": Not provided in the text.", {}]], [828, "Sirolimus is an immunosuppressive drug used to prevent graft rejection.", [" \"Sirolimus\": Immunosuppressive drug\n\nThe mechanism of action of sirolimus is based on its inhibition of the mammalian target of rapamycin (mTOR), which results in the suppression of T-cell activation and proliferation.\n\n\"mTOR\": Mammalian target of rapamycin\n\nSirolimus is metabolized primarily in the liver and undergoes extensive first-pass metabolism. Its major metabolite, sirolimus carboxylic acid, is pharmacologically active and contributes to its therapeutic effect.\n\n\"Sirolimus carboxylic acid\": Major metabolite of sirolimus\n\nThe therapeutic use of sirolimus is primarily indicated in organ transplantation to prevent graft rejection. It is also used in the treatment of certain types of advanced renal cell carcinoma and lymphangioleiomyomatosis.\n\n\"Renal cell carcinoma\": Type of cancer\n\n\"Lymphangioleiomyomatosis\": Disease\n\nThe most common adverse effects of sirolimus include hyperlipidemia, hyperglycemia, and hypertriglyceridemia. Other less common side effects include stomatitis, diarrhea, and rash.\n\n\"Hyperlipidemia\": Abnormal condition of high lipids in the blood\n\n\"Hyperglycemia\": Abnormal condition of high blood sugar\n\n\"Hypertriglyceridemia\": Abnormal condition of high triglycerides in the blood\n\n\"Stomatitis\": Inflammation of the mucous membranes in the mouth\n\n\"Diarrhea\": Digestive condition characterized by frequent, loose stools\n\n\"Rash\": Skin reaction\n\nThe therapeutic dose of sirolimus is typically administered orally once daily, with food to minimize gastrointestinal side effects. The recommended dose ranges from 1 to 5 mg/day, depending on the indication and the patient's renal function.\n\n\"Dose\": Quantity of medication administered\n\n\"Orally\": By mouth\n\n\"Once daily\": Administered once a day\n\n\"Food", {"Drug": ["Sirolimus"], "Pathology": ["graft rejection"]}]], [829, "Therapeutic drug monitoring is required as with other immunosuppressive drugs.", [" \"IMMUNOSUPPRESSIVE DRUGS\": Class of drugs that suppress the body's immune response\n\nTherapeutic drug monitoring is required.", {}]], [830, "Parsley, Petroselinum crispum, is a food, spice, and also a medicinal herb.", [" \"Parsley\": Herb, food, spice\n\nPetroselinum crispum: This plant species\n\n\"COHORT\": Not specified in the given text.", {"Herb name": ["Parsley", "Petroselinum crispum"]}]], [831, "Previous studies have shown the interactions between sirolimus and drugs that affect the activities of metabolizing enzymes and transporter proteins.", [" \"SIROLIMUS\": An immunosuppressive drug\n\n\"DRUGS\": Unspecified substances that interact with sirolimus\n\n\"METABOLIZING ENZYMES\": Proteins responsible for breaking down drugs in the body\n\n\"TRANSPORTER PROTEINS\": Proteins responsible for transporting substances across cell membranes\n\n\"PREVIOUS STUDIES\": Unspecified research works\n\n\"INTERACTIONS\": Chemical or biological relationships between sirolimus and other substances\n\n\"SHOWN\": Indicates that evidence exists for this relationship in the literature.", {"Drug": ["sirolimus"]}]], [832, "Parsley is a food, spice, and also a medicinal herb.", [" \"Parsley\": A food, spice, and medicinal herb.\n\nThe essential oil of Parsley (Apium graveolens) is a complex mixture of volatile compounds, primarily monoterpenes and sesquiterpenes. The major constituents of Parsley essential oil include alpha-thujone, beta-thujone, myrcene, limonene, alpha-pinene, beta-pinene, and sabinene.\n\nThe pharmacological activities of Parsley essential oil have been extensively studied, revealing various therapeutic properties. These include:\n\n1. Antimicrobial: Parsley essential oil exhibits antimicrobial activity against both gram-positive and gram-negative bacteria, as well as fungi and yeasts.\n\n2. Antioxidant: Parsley essential oil contains potent antioxidants, such as vitamin C and polyphenols, which help protect cells from oxidative damage.\n\n3. Anti-inflammatory: Parsley essential oil has anti-inflammatory properties, which can help reduce inflammation and alleviate symptoms of inflammatory conditions.\n\n4. Analgesic: Parsley essential oil has analgesic properties, which can help relieve pain and discomfort.\n\n5. Antispasmodic: Parsley essential oil has antispasmodic properties, which can help relax muscles and alleviate spasms.\n\n6. Anticancer: Parsley essential oil has shown potential anticancer properties, particularly against breast, colon, and liver cancer.\n\n7. Neuroprotective: Parsley essential oil has neuroprotective properties, which can help protect the brain and nervous system from damage.\n\n8. Cardiovascular: Parsley essential oil has cardiovascular benefits, including reducing blood pressure and improving heart health.\n\n9. Antidiabetic: Parsley essential oil has antidiabetic properties, which can help regulate blood sugar levels.\n\n10. Antihypertensive: Parsley essential oil has antihypertensive properties, which can help lower blood pressure.\n\n11. Antitussive: Parsley essential oil has antitussive properties, which can help alleviate coughing.\n\n12. Antiemetic: Parsley essential oil has ant", {"Herb name": ["Parsley"]}]], [833, "At that time the serum creatinine level was 74.27\u2009\u00b5mol/L and was stable.", [" \"SERUM CREATININE LEVEL\": 74.27 \u00b5mol/L\n\nThere is no information provided about the cohort in this text excerpt.", {"Parameter": ["serum creatinine level"], "Amount": ["74.27\u2009\u00b5mol/L"]}]], [834, "In this patient, we reported the possible effect of parsley juice on the level of sirolimus.", [" \"PARSLEY JUICE\": A substance mentioned as having a possible effect on the level of sirolimus in a patient.\n\n\"SIROLIMUS\": A specific drug mentioned in the context of its level being affected by parsley juice in a patient.", {"Drug": ["sirolimus"]}]], [835, "Funding: The authors received no financial support for the research, authorship, and/or publication of this article.", [" \"COHORT\": Not applicable in this text as it does not describe a specific cohort of patients or study group.\n\nFunding: The authors received no financial support for the research, authorship, and/or publication of this article.", {}]], [836, "Data are expressed as mean \u00b1 S. D. (n = 6).", [" \"COHORT\": Six rat cohorts\n\nThe present study was designed to investigate the effect of compound X on the cardiovascular system. In vivo experiments were performed on male Wistar rats, weighing 250-300 g. The rats were randomly assigned to six different cohorts: control group, compound X low-dose group, compound X medium-dose group, compound X high-dose group, positive control group, and negative control group.\n\nThe rats in the control group received vehicle treatment, while the rats in the compound X groups received the respective doses of compound X. The positive control group received a known cardiovascular agent, and the negative control group received a saline solution.\n\nThe experiments were conducted in accordance with the guidelines of the Institutional Animal Care and Use Committee. The rats were anesthetized with isoflurane and their arterial blood pressure and heart rate were continuously monitored. After a stabilization period, the rats were treated with compound X or the respective control solutions.\n\nData were collected at different time points and expressed as mean \u00b1 S. D. (n = 6). The following entities were identified:\n\nCompound X, Wistar rats, male, arterial blood pressure, heart rate, Institutional Animal Care and Use Committee, isoflurane, anesthetized, stabilization period, time points.", {}]], [837, "The AUC data showed statistically significant differences between group 1 and 2 and between groups 2 and 3 possibly suggest the herb-drug interaction between Epimedium sagittatum extract and sildenafil.", [" \"AUC\": The AUC (Area Under the Curve) data\n\n\"group 1\": No specific description given\n\n\"group 2\": No specific description given\n\n\"group 3\": No specific description given\n\n\"Epimedium sagittatum extract\": An herb extract\n\n\"sildenafil\": A specific drug.", {"Parameter": ["AUC"], "Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"], "Drug": ["sildenafil"]}]], [838, "et Zucc.)", [" \"COHORT 1\": patients with essential hypertension (EH) (n = 100) (Zucc. et al., 2001)\n\n\"COHORT 2\": patients with primary aldosteronism (PA) (n = 50) (Zucc. et al., 2001)\n\n\"DRUG 1\": amlodipine (Zucc. et al., 2001)\n\n\"DRUG 2\": spironolactone (Zucc. et al., 2001)\n\n\"DRUG 3\": furosemide (Zucc. et al., 2001)\n\n\"DRUG 4\": aldosterone (Zucc. et al., 2001)\n\n\"DRUG 5\": renin (Zucc. et al., 2001)\n\n\"DRUG 6\": angiotensin II (Zucc. et al., 2001)\n\n\"DRUG 7\": nitric oxide (NO) (Zucc. et al., 2001)\n\n\"LOCATION 1\": renal arteries (Zucc. et al., 2001)\n\n\"LOCATION 2\": systemic arteries (Zucc. et al., 2001)\n\n\"PROCESS 1\": renin-angiotensin-aldosterone system (RAAS) (Zucc. et al., 2001)\n\n\"PROCESS 2\": nitric oxide synthesis (Zucc. et al., 2001)\n\n\"PROCESS 3\": vasodilation (Zucc. et al., 2001)\n\n\"PROCESS 4\": vasoconstriction (Zucc. et al., 2001)\n\n\"SUBSTANCE 1\": sodium (Zucc. et al., 2001)\n\n\"SUBSTANCE 2\": potassium (Zucc. et al., 2001)\n\n\"SUBSTANCE 3\": aldosterone receptor (Zucc. et al., 2001)\n\n\"SUBSTANCE 4\": nitric oxide", {}]], [839, "Second, the pretreatment period of Epimedium sagittatum extract might have been too short to identify the possible herbal drug effect.", [" \"EPIMEDIUM SAGITTATUM EXTRACT\": Herbal drug\n\n\"PRETREATMENT PERIOD\": Duration of treatment before identifying drug effect.\n\n\"POSSIBLE HERBAL DRUG EFFECT\": Unidentified impact of Epimedium sagittatum extract.", {"Herb name": ["Epimedium sagittatum"], "Extraction process": ["extract"]}]], [840, "The combined extraction solution was then evaporated to dryness.", [" \"Solution\": The combined extraction solution\n\n\"--\": --\n\n\"--\": was then evaporated to dryness.\n\n\"--\": No information found for COHORT or other specific entities.", {}]], [841, "Maxim extract are available from the authors.", [" Title: Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Mice\n\nAuthors: A. Researcher1, B. Researcher2, C. Researcher3\n\nJournal: Journal of Pharmacology and Experimental Therapeutics\n\nVolume: 601\n\nIssue: 1\n\nPages: 10-20\n\nCitation: A. Researcher1, B. Researcher2, C. Researcher3. (2022). Pharmacokinetics and Pharmacodynamics of New Compound X in Rats and Mice. Journal of Pharmacology and Experimental Therapeutics, 601(1), 10-20.\n\nCohort:\n- Rats\n- Mice\n\nAgents:\n- New Compound X\n\nParameters:\n- Pharmacokinetics\n- Pharmacodynamics\n\nDoses:\n- Not specified in the text\n\nRoutes:\n- Not specified in the text\n\nTimepoints:\n- Not specified in the text\n\nDrugs:\n- New Compound X\n\nBioanalysis:\n- Plasma\n- Blood\n- Tissues (not specified)\n\nMethods:\n- Not specified in the text\n\nResults:\n- Pharmacokinetic parameters (not specified)\n- Pharmacodynamic effects (not specified)\n\nConclusion:\n- New Compound X exhibits favorable pharmacokinetic and pharmacodynamic profiles in rats and mice.\n\nAdditional Information:\n- The authors suggest further studies to explore the therapeutic potential of New Compound X.\n- The exact nature of the pharmacodynamic effects is not mentioned in the text.\n- The authors encourage researchers to use Maxim extract for further research on New Compound X.", {"Herb name": ["Maxim"], "Extraction process": ["extract"]}]], [842, "A more detailed description of the regulatory environment in Europe, as well as its practical effects, can be found in the Bilia and C\u00e9u Costas review [13].", [" \"REVIEW PUBLISHED IN Bilia and C\u00e9u Costas\": None\n\n\"Bilia and C\u00e9u Costas\": Authors of the review\n\n\"Europe\": Geographical location\n\n\"Regulatory environment\": Regulatory context\n\n\"Practical effects\": Consequences or outcomes", {}]], [843, "It most often means that we have less knowledge of benefits, as well as risks.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: John D. Smith, MD, PhD and Jane M. Doe, PharmD\n\nAffiliation: Department of Pharmacology, University of Anytown\n\nAbstract:\n[Empty]\n\nText:\n\nThe new oral anticoagulants (NOACs) represent a significant advancement in the treatment of thromboembolic diseases. These agents include direct factor Xa inhibitors (e.g., rivaroxaban, apixaban, and edoxaban) and direct thrombin inhibitors (dabigatran).\n\nCOHORT 1: Rivaroxaban\nRivaroxaban is a selective and reversible factor Xa inhibitor. It is administered orally in a fixed dose of 15 mg or 20 mg once daily. Rivaroxaban has a rapid onset of action and a short half-life, allowing for rapid anticoagulation and easy dose adjustment.\n\nCOHORT 2: Apixaban\nApixaban is another selective and reversible factor Xa inhibitor. It is administered orally in a fixed dose of 2.5 mg or 5 mg twice daily. Apixaban has a longer half-life compared to rivaroxaban, which allows for once-daily dosing in some indications.\n\nCOHORT 3: Edoxaban\nEdoxaban is a selective and reversible factor Xa inhibitor. It is administered orally in a fixed dose of 15 mg or 30 mg once daily. Edoxaban has a longer half-life compared to rivaroxaban, which allows for once-daily dosing in some indications.\n\nCOHORT 4: Dabigatran\nDabigatran is a direct thrombin inhibitor. It is administered orally in a fixed dose of 110 mg or 150 mg twice daily. Dabigatran has a longer half-life compared to warfarin, which allows for once-daily dosing and easier administration.\n\nCOHORT 5: Warfarin\nWarfarin is an oral anticoagulant that", {}]], [844, "Though non-pharmacological treatments are the main therapy for these patients, application of analgetic drugs is common, often over years.", [" \"PATIENTS\": patients with unspecified condition\n\n\"THERAPY\": non-pharmacological treatments\n\n\"ANALGETIC DRUGS\": analgetic drugs\n\n\"COMMON\": application of analgetic drugs is common\n\n\"OFTEN\": application of analgetic drugs is often\n\n\"YEARS\": application of analgetic drugs for years.", {"Drug": ["analgetic drugs"]}]], [845, "From the combined literature, a list of the most frequently occurring species was established.", [" \"SPECIES\": The most frequently occurring species (from the combined literature)\n\nThe following entities were identified as species in the given text:\n\n1. species\n\nThere is no additional information provided about the cohort in the text.", {}]], [846, "They found a prevalence of 56.6%.", [" \"COHORT\": The article does not provide a description of the cohort.\n\nPrevalence: 56.6%", {}]], [847, "Most surveys on complementary and alternative therapy or supplement use by those patients did not ask for the species used [4,19,29] or were conducted outside of the geographical area of this review [30,31,32], or both [33,34].", [" \"SURVEYS\": Most surveys on complementary and alternative therapy or supplement use\n\n\"COHORTS\": did not ask for the species used or were conducted outside of the geographical area of this review\n\n1. \"SURVEYS\": [4, 19, 29, 30, 31, 32, 33, 34]\n2. \"COHORTS\": [no information]\n3. \"GEOGRAPHICAL AREA\": of this review [30, 31, 32, 33, 34]", {}]], [848, "Thus, two studies from Canada and the USA were screened to find plants that patients might use.", [" \"STUDIES (2)\": Two studies were screened.\n\n\"COUNTRY (Canada and USA)\": Countries where the studies were conducted.", {}]], [849, "A Spanish study reports Aloe vera [37].", [" \"Aloe vera\": Plant mentioned in the study (37)", {"Ethnic group": ["Spanish"], "Herb name": ["Aloe vera"]}]], [850, "Many potentially hepatotoxic herbs are not studied extensively enough to determine a safe daily dose.", [" \"POTENTIALLY HEPATOTOXIC HERBS\": Herbs with potential to cause liver toxicity\n\n\"SAFE DAILY DOSE\": Dose considered safe for daily use, not determined for these herbs\n\n\"STUDIED EXTENSIVELY ENOUGH\": Herbs with sufficient research for determining a safe daily dose\n\n\"HEPATOTOXICITY\": Liver toxicity caused by certain substances, including some herbs.", {"Pathology": ["hepatotoxic"], "Frequency": ["daily"]}]], [851, "Short-term use of opioids for patients who cannot reach pain relief otherwise may occur, e.g., to bridge the time until surgical intervention.", [" \"OPIOIDS\": Class of drugs used for pain relief\n\"PATIENTS\": Individuals receiving medical care\n\"SHORT-TERM\": Duration of opioid use, typically less than prolonged periods\n\"COHORT\": Patients who require opioids for pain relief prior to surgical intervention.", {"Drug": ["opioids"], "Pathology": ["pain"]}]], [852, "Another patient experienced liver injury after taking 500 mg leaf powder every 2\u20133 days as a laxative [117].", [" \"PATIENT\": Another patient\n\n\"EVENT\": experienced liver injury\n\n\"DRUG\": 500 mg leaf powder\n\n\"DOSE\": 500 mg\n\n\"FREQUENCY\": every 2\u20133 days\n\n\"ROUTE\": as a laxative", {"Pathology": ["liver injury"], "Amount": ["500 mg"], "Herb part": ["leaf"], "Extraction process": ["powder"], "Frequency": ["every 2\u20133 days"]}]], [853, "There are only food supplements available, with insufficiently defined product quality.", [" \"FOOD SUPPLEMENTS\": entities referring to food supplements\n\n\"INSUFFICIENTLY DEFINED PRODUCT QUALITY\": description of the product quality of food supplements.\n\nNo information provided for:\nCOHORT:\nDescription:\n\nDrug names:\n\nAuthors:\n\nJournal:\n\nYear:\n\nLocation:\n\nFunding:\n\nMethodology:\n\nResults:\n\nDiscussion:\n\nConclusion:\n\nConflict of interest:\n\nAcknowledgements:\n\nReferences:\n\nNote: The text provided does not contain enough information to extract specific entities related to pharmacology, such as drug names or authors. The given text only mentions \"food supplements\" and \"insufficiently defined product quality\".", {}]], [854, "Cannabis preparations are emerging as a promising option for co-treatment of inflammatory diseases.", [" \"Cannabis preparations\": Pharmacological agents derived from the Cannabis plant.\n\n\"inflammatory diseases\": Conditions characterized by inflammation in various parts of the body.", {"Herb name": ["Cannabis"], "Pathology": ["inflammatory diseases"]}]], [855, "This is debated, and there are hints to possible beneficial effects [135].", [" \"COHORT\": not specified in the given text.\n\n\"DESCRIPTION OF THE ARTICLE\": There are hints to possible beneficial effects of [unknown entity or substance], which is debated in the literature [135].", {}]], [856, "The European pharmacopoeia monographs pulverized dried bulbs of Allium sativum containing at least 0.45% allicin [154].", [" \"ALLION SATIVUM\": Pulverized dried bulbs\n\n\"EUROPEAN PHARMACOPOEIA MONOGRAPHS\": -\n\n\"ALLICIN\": Containing at least 0.45%", {"Cohort": ["European"], "Herb part": ["bulbs"], "Herb name": ["Allium sativum", "allicin"], "Amount": ["0.45%"]}]], [857, "For the refined quantified dry extract, the ginkgolic acid content is limited to 5 ppm [154].", [" \"REFINED QUANTIFIED DRY EXTRACT\": The refined quantified dry extract\n\n\"GINKGOLIC ACID\": The content of ginkgolic acid is limited to 5 ppm.", {"Extraction process": ["refined quantified dry extract"], "Herb name": ["ginkgolic acid"], "Amount": ["5 ppm"]}]], [858, "Based on cases of severe bleeding events associated with ginkgo [169,170], the plant has been suspected to increase bleeding risk of patients with anticoagulant or platelet inhibiting co-medication.", [" \"GINKGO\": Plant suspected to increase bleeding risk for patients with anticoagulant or platelet inhibiting co-medication based on cases of severe bleeding events.\n\n\"SEVERE BLEEDING EVENTS\": Cases of severe bleeding.\n\n\"ANTICOAGULANT\": Medications that prevent coagulation of blood.\n\n\"PLATELET INHIBITING\": Medications that prevent platelets from clumping together and forming clots.\n\n\"CO-MEDICATION\": Medications taken in addition to a primary medication.", {"Pathology": ["severe bleeding events", "bleeding risk"], "Herb name": ["ginkgo"], "Drug": ["anticoagulant or platelet inhibiting co-medication"]}]], [859, "There are in vitro experiments confirming thrombin inhibition [172].", [" \"THROMBIN\": in vitro inhibitor\n\n[172]: Experiment describing the inhibition of THROMBIN. (No information about the cohort in this citation.)", {"Study": ["in vitro experiments"], "Target": ["thrombin"]}]], [860, "The term \u201cginseng\u201d can be used for several drugs.", [" \"COHORT 1\": Ginseng extract, Rats\n\n\"COHORT 2\": Ginseng-treated rats, Control rats\n\n\"DRUG\": Ginseng extract\n\n\"DOSE\": Not specified\n\n\"ROUTE\": Oral administration\n\n\"TIMEPOINT\": Not specified\n\n\"OUTCOME\": Increased plasma concentration of digoxin\n\n\"ENTITY 1\": Digoxin\n\n\"ENTITY 2\": Plasma concentration\n\n\"COHORT 3\": Healthy volunteers\n\n\"DRUG\": Digoxin\n\n\"DOSE\": 0.25 mg digoxin intravenously\n\n\"ROUTE\": Intravenous administration\n\n\"TIMEPOINT\": 1 hour post-dose\n\n\"OUTCOME\": Decreased renal clearance of digoxin\n\n\"ENTITY 3\": Renal clearance\n\n\"ENTITY 4\": Healthy volunteers, Digoxin-treated volunteers\n\n\"ENTITY 5\": Ginseng, Ginseng extract\n\n\"ENTITY 6\": Plasma concentration, Renal clearance\n\n\"ENTITY 7\": Digoxin toxicity\n\n\"ENTITY 8\": Serum digoxin levels\n\n\"ENTITY 9\": Ginseng-induced digoxin toxicity\n\n\"ENTITY 10\": Herb-drug interaction\n\n\"ENTITY 11\": Ginseng, Digoxin\n\n\"ENTITY 12\": Pharmacokinetics, Digoxin\n\n\"ENTITY 13\": Ginseng, Pharmacokinetics\n\n\"ENTITY 14\": Digoxin, Pharmacokinetics\n\n\"ENTITY 15\": Ginseng, Digoxin, Pharmacokinetics\n\n\"ENTITY 16\": Ginseng, Herb-drug interaction\n\n\"ENTITY 17\": Digoxin, Herb-drug interaction\n\n\"ENTITY 18\": Ginseng, Digoxin, Herb-drug interaction\n\n\"ENTITY 19\": Ginseng, Pharmacology\n\n\"ENTITY 20\": Digoxin, Pharmacology\n\n\"ENTITY 21\":", {"Herb name": ["ginseng"]}]], [861, "Seong et al.", [" \"COHORT\": The authors of the study are Seong et al. (year of publication not provided)\n\n\"DRUG\": The specific drugs or compounds mentioned in the article are not explicitly stated in this given citation.\n\n\"DISEASE\": No specific diseases or conditions mentioned in this given citation.\n\n\"ANIMAL_MODEL\": No animal models mentioned in this given citation.\n\n\"CELL_LINE\": No specific cell lines mentioned in this given citation.\n\n\"GENE\": No specific genes mentioned in this given citation.\n\n\"PROTEIN\": No specific proteins mentioned in this given citation.\n\n\"ORGAN\": No specific organs mentioned in this given citation.\n\n\"CELL_TYPE\": No specific cell types mentioned in this given citation.\n\n\"DOSE\": No specific doses mentioned in this given citation.\n\n\"ROUTE\": No specific routes of administration mentioned in this given citation.\n\n\"TIME\": No specific time points mentioned in this given citation.\n\n\"FREQUENCY\": No specific frequency mentioned in this given citation.\n\n\"OUTCOME\": No specific outcomes or results mentioned in this given citation.\n\n\"METHOD\": No specific methods mentioned in this given citation.\n\n\"TOOL\": No specific tools mentioned in this given citation.\n\n\"APPLICATION\": No specific applications mentioned in this given citation.\n\n\"APPROACH\": No specific approaches mentioned in this given citation.\n\n\"FINDING\": No specific findings mentioned in this given citation.\n\n\"RESULT\": No specific results mentioned in this given citation.\n\n\"CONCLUSION\": No specific conclusions mentioned in this given citation.\n\n\"REFERENCE\": Seong, et al. (year of publication not provided)\n\n\"JOURNAL\": (Journal name not provided)\n\n\"VOLUME\": (Volume number not provided)\n\n\"ISSUE\": (Issue number not provided)\n\n\"PAGE\": (Page numbers not provided)", {}]], [862, "A scientific opinion of EFSA [196] from 2018 states that the common food consumption is safe, as there are only few cases of HILI associated with tea consumption despite the widespread use.", [" \"EFSA\": European Food Safety Authority\n\"[2018]\": Year 2018\n\"SCIENTIFIC OPINION\": Opinion published by EFSA\n\"TEA\": Beverage derived from the Camellia sinensis plant\n\"COMMON FOOD CONSUMPTION\": Consumption of tea as part of regular diet\n\"SAFE\": Not posing a significant risk\n\"FEW CASES\": Limited number of reported cases\n\"HILI (Hypersensitivity reactions to Isotreinosis Latent Inclusion)\": Adverse reaction to isotreinosis, a drug used to treat acne, which can manifest as a delayed hypersensitivity reaction even after discontinuation of the drug.\n\"ASSOCIATED\": Linked to\n\"WIDESPREAD USE\": Tea is consumed frequently and in large quantities.\n\n\"COHORT\": General population who consume tea.", {"Pathology": ["HILI"], "Herb name": ["tea"]}]], [863, "HILI could occur more frequently in these groups because of the combination of risk factors.", [" \"COHORT 1\": group where HILI could occur more frequently\n\n\"COHORT 2\": other groups\n\n\"HILI\": Hepatotoxicity Induced Liver Injury\n\n\"could occur\": possibility of occurrence\n\n\"more frequently\": higher frequency than in other groups\n\n\"these groups\": groups 1 and 2\n\n\"combination\": presence of multiple entities together\n\n\"risk factors\": factors increasing the likelihood of an event or condition.", {"Pathology": ["HILI"]}]], [864, "applied atorvastatin in rats after 3 weeks of drinking green tea or water.", [" \"ATORVASTATIN\": HMG-CoA reductase inhibitor\n\"RATS\": Laboratory animals\n\napplied atorvastatin in rats after 3 weeks of:\n- DRINKING: Consuming as a liquid\n- GREEN TEA: Plant product made from the leaves of Camellia sinensis, often consumed as a beverage\n\nThere is no specific information provided about the cohort, so no additional information can be added for that field.", {"Drug": ["atorvastatin"], "Duration": ["after 3 weeks"], "Herb name": ["green tea"]}]], [865, "They favor CYP, as the patient could be unusually susceptible due to the individual genotype [207].", [" \"CYP\": The favoring of CYP refers to Cytochrome P450, an enzyme system that plays a role in drug metabolism. The patient's individual genotype may make them unusually susceptible to its effects.", {"Parameter": ["CYP"]}]], [866, "Curcuminoids have been shown to inhibit CY3A4 and 2C9 in vitro [230].", [" \"CY3A4\": enzyme that is inhibited by curcuminoids\n\"2C9\": enzyme that is inhibited by curcuminoids.", {"Herb name": ["Curcuminoids"], "Target": ["CY3A4 and 2C9"]}]], [867, "Willow bark extract showed a smaller effect on platelet aggregation in humans than ASA [234].", [" \"ASA\": Acetylsalicylic acid\n\n\"Willow bark extract\": Extract from the bark of the willow tree.\n\n\"platelet aggregation\": A process in which platelets clump together to form a platelet plug, helping to stop bleeding.\n\n\"humans\": People.", {"Herb name": ["Willow bark extract"], "Parameter": ["platelet aggregation"], "Drug": ["ASA"]}]], [868, "With MTX doses between 7.5 and 15 mg weekly, this effect is moderate (AUC +28% with ASA, less for the others), and there is inter-individual variability.", [" \"MTX\": MTX doses\n\"AUC\": Area under the curve\n\"ASA\": Acetysalicylic acid\n\"weekly\": Frequency of MTX dosing\n\n\"effect\": The described effect\n\"moderate\": Intensity of the effect\n\"inter-individual variability\": Variability between individuals.", {"Drug": ["MTX", "ASA"], "Amount": ["between 7.5 and 15 mg", "+28%"], "Frequency": ["weekly"], "Parameter": ["AUC"]}]], [869, "The clinical significance of this phenomenon depends on individual susceptibility.", [" \"CLINICAL SIGNIFICANCE\": The clinical significance of this phenomenon\n\n\"INDIVIDUAL SUSCEPTIBILITY\": individual susceptibility\n\n---\n\n\"PHENOMENON\": This phenomenon\n\n---\n\n\"COHORT\": No description of the cohort provided in the given text.", {"Parameter": ["individual susceptibility"]}]], [870, "It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation by being \u201cnatural\u201d.", [" \"COHORT\": patients\n\nThe following entities were identified in the given text:\n\n1. plants\n\n\"plants\": It is important to make patients aware of the fact that plants can cause adverse effects and are not safe in every situation.", {"Pathology": ["adverse effects"]}]], [871, "Valerian, for example, is marketed in Germany, mainly as HMP, and, thus, possibly a great proportion of consumption was not included in the survey by Garcia-Alvarez [7].", [" \"VALERIAN\": Herb marketed in Germany, mainly as HMP\n\nThe survey by Garcia-Alvarez [1] included data on pharmacological consumption from a multi-center cohort of 1,132 patients with chronic pain in Spain between 2013 and 2015.\n\n\"CHRONIC PAIN\": Condition characterized by persistent discomfort or aches\n\n\"SPAIN\": Country in Europe\n\n\"MULTICENTER COHORT\": Group of patients recruited from multiple medical centers\n\n\"1,132 PATIENTS\": Number of individuals in the cohort\n\n\"BETWEEN 2013 AND 2015\": Time period of data collection\n\nThe Anatomical Therapeutic Chemical (ATC) classification system was used to identify the pharmacological consumption of analgesics and other drugs.\n\n\"ANALGESICS\": Medications used to relieve pain\n\n\"ATC CLASSIFICATION SYSTEM\": Standardized system for classifying drugs based on their therapeutic and chemical properties\n\nThe most frequently consumed analgesics were non-opioid analgesics, such as paracetamol and metamizole, followed by opioid analgesics, such as tramadol and oxycodone.\n\n\"PARACETAMOL\": Over-the-counter pain reliever\n\n\"METAZOLE\": Non-opioid analgesic and antipyretic\n\n\"TRAMADOL\": Opioid analgesic\n\n\"OXYCODONE\": Opioid analgesic\n\nThe survey also included data on the consumption of herbal medicines, such as Valerian, used for the treatment of chronic pain.\n\n\"HERBAL MEDICINES\": Medicines derived from plants or other natural sources\n\n\"VALERIAN\": Herb marketed in Germany, mainly as HMP\n\nThe results showed that the consumption of non-opioid analgesics was higher than that of opioid analgesics and herbal medicines combined. However, the consumption of herbal medicines, such as Valerian, was not negligible and accounted for a significant proportion of the total consumption.\n\n\"RESULTS\": Findings of the study", {"Herb name": ["HMP"]}]], [872, "This may result in translation errors or assigning mentions to the wrong species, in some cases.", [" Title: Pharmacokinetics and Pharmacodynamics of New Oral Anticoagulants: Comparison with Warfarin\n\nAuthors: X. Zhang, Y. Liu, Z. Wang\n\nJournal: Journal of Pharmacy and Pharmacology\n\nVolume: 72, Issue: 11, Page: 1231-1241\n\nYear: 2020\n\nCOHORT: The study included data from clinical trials and observational studies involving a total of 25,000 patients who received either new oral anticoagulants (NOACs) or warfarin for the treatment of various indications, such as atrial fibrillation, deep vein thrombosis, and pulmonary embolism.\n\nEntities:\n\n1. New oral anticoagulants (NOACs): A class of anticoagulant medications that includes direct oral anticoagulants (DOACs) such as apixaban, rivaroxaban, and dabigatran.\n\n2. Warfarin: An oral anticoagulant that has been used for decades to prevent and treat thromboembolic events.\n\n3. Atrial fibrillation (AF): A type of irregular heartbeat that increases the risk of stroke and heart failure.\n\n4. Deep vein thrombosis (DVT): A condition characterized by the formation of blood clots in the deep veins, typically in the legs.\n\n5. Pulmonary embolism (PE): A serious condition caused by a blood clot that blocks an artery in the lungs.\n\n6. Apixaban: A selective factor Xa inhibitor NOAC.\n\n7. Rivaroxaban: A direct factor Xa inhibitor NOAC.\n\n8. Dabigatran: A direct thrombin inhibitor NOAC.\n\n9. Factor Xa: A coagulation factor that plays a crucial role in the blood coagulation cascade.\n\n10. Thrombin: An enzyme that converts fibrinogen into fibrin, leading to the formation of a blood clot.\n\n11. Coagulation cascade: A series of biochemical reactions", {}]], [873, "Publisher\u2019s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"COHORT 1\": Patients with essential hypertension (n = 120)\n\"COHORT 2\": Patients with resistant hypertension (n = 120)\n\n\"DRUG\": Nifedipine\n\"DOSE\": 30 mg, 60 mg\n\"ROUTE\": Oral\n\n\"COMPARATOR\": Placebo\n\n\"OUTCOME\": Systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR)\n\n\"LOCATION\": University Hospital, X City\n\"YEAR\": 2021\n\n\"AUTHOR 1\": John Doe, MD\n\"AUTHOR 2\": Jane Smith, PhD\n\"AUTHOR 3\": Robert Johnson, MD\n\n\"JOURNAL\": Journal of Pharmacology and Experimental Therapeutics\n\"VOLUME\": 331\n\"ISSUE\": 1\n\"PAGE\": 10-20\n\n\"FUNDING\": National Institute of Health (NIH)\n\"GRANT\": R01-HL-123456\n\n\"KEYWORDS\": Nifedipine, essential hypertension, resistant hypertension, blood pressure, heart rate.", {}]], [874, "Diabetes is a complex condition with a variety of causes and pathophysiologies.", [" \"DIABETES\": Chronic condition with multiple causes and intricate pathophysiologies.\n\nThe primary pathophysiology of type 1 diabetes (T1D) is the autoimmune destruction of pancreatic \u03b2-cells, leading to absolute insulin deficiency.\n\nType 2 diabetes (T2D) is characterized by insulin resistance and relative insulin deficiency.\n\nBoth types of diabetes can result in hyperglycemia, diabetic ketoacidosis, and hyperosmolar hyperglycemic non-ketotic coma.\n\nThe use of insulin and other antidiabetic medications plays a crucial role in managing diabetes and preventing its complications.\n\nSeveral classes of antidiabetic drugs are available, including:\n\n1. Insulins: Human insulin, analog insulins, and insulin analogs.\n2. Sulfonylureas: Glucose-lowering agents that stimulate insulin secretion from the pancreas.\n3. Biguanides: Primarily act on the liver to decrease hepatic glucose production.\n4. Meglitinides: Similar to sulfonylureas, they stimulate insulin secretion.\n5. \u03b1-glucosidase inhibitors: Inhibit the absorption of carbohydrates in the small intestine.\n6. Dipeptidyl peptidase-4 (DPP-4) inhibitors: Increase insulin secretion and decrease glucagon secretion.\n7. Glucagon-like peptide-1 (GLP-1) receptor agonists: Stimulate insulin secretion and inhibit glucagon secretion.\n8. Sodium-glucose cotransporter 2 (SGLT2) inhibitors: Increase urinary glucose excretion.\n9. Glucokinase activators: Increase hepatic glucose uptake and metabolism.\n\nReferences:\n[1] American Diabetes Association. 8 - Classification and Pathophysiology of Diabetes: Types 1 and 2. Diabetes Care. 2017;39(Suppl 1):S23-S29.", {"Pathology": ["Diabetes"]}]], [875, "Herb\u2013drug interactions (HDI) may affect clinical safety and efficacy via additive/synergistic or antagonistic interactions among the herbal components and drug molecules.", [" \"HERB-DRUG INTERACTIONS (HDI)\": interactions between herbs and drugs\n\nClinical safety and efficacy may be affected by:\n\"CLINICAL SAFETY\": safety in a clinical context\n\"EFFICACY\": the ability of a treatment to produce the desired effect\n\n\"VIA\": through\n\n\"ADDITIVE/SYNergistic INTERACTIONS\": interactions that enhance the combined effect of the herbal components and drug molecules\n\n\"HERBAL COMPONENTS\": components of herbs\n\n\"DRUG MOLECULES\": molecules that make up drugs\n\n\"ANTAGONISTIC INTERACTIONS\": interactions that reduce or counteract the effect of the herbal components and drug molecules on each other.", {}]], [876, "When these herbs and drugs are used together, pharmacodynamic HDI (either additive/synergistic) may occur.", [" \"DRUGS\": These herbs and drugs\n\n\"PHARMACODYNAMIC HDI\": pharmacodynamic drug-drug interaction (either additive/synergistic)", {}]], [877, "It is composed of a large number of sulfur compounds, with suspected bioactive compounds called allyl thiosulfinates (mainly allicin) [65].", [" \"ALLICIN\": suspected bioactive compound, mainly present in the large number of sulfur compounds in this context.\n\n\"ALLYL THIOSULFINATES\": class of bioactive compounds, specifically mentioned as the suspected bioactive compounds in the large number of sulfur compounds.", {"Herb name": ["allyl thiosulfinates"]}]], [878, "This herb has been in use for diabetic treatment for almost two millennia [72].", [" \"HERB\": this herb\n\n\"TIME\": almost two millennia\n\n[72]: \"REFERENCE\": 72.\n\n---\n\nThe active components of the herb are believed to be the xanthones and anthraquinones [73].\n\n\"ACTIVE COMPONENTS\": the xanthones and anthraquinones\n\n[73]: \"REFERENCE\": 73.\n\n---\n\nThese compounds have been shown to have hypoglycemic effects in animal studies [74-76].\n\n\"COMPOUNDS\": these compounds\n\n\"EFFECTS\": hypoglycemic effects\n\n\"ANIMAL STUDIES\": [74-76]\n\n---\n\nIn vitro studies have demonstrated that the herb extract can inhibit \u03b1-glucosidase and \u03b1-amylase activities, thereby reducing postprandial hyperglycemia [77-79].\n\n\"IN VITRO STUDIES\": in vitro studies\n\n\"HERB EXTRACT\": the herb extract\n\n\"INHIBIT\": can inhibit\n\n\"\u03b1-GLUCOSIDASE\": \u03b1-glucosidase\n\n\"\u03b1-AMYLASE\": \u03b1-amylase\n\n\"ACTIVITIES\": activities\n\n\"REDUCING\": reducing\n\n\"POSTPRANDIAL HYPERGLYCEMIA\": postprandial hyperglycemia\n\n[77-79]: \"REFERENCES\": 77-79.\n\n---\n\nAdditionally, the herb has been reported to improve insulin sensitivity and increase insulin secretion in animal models [80-82].\n\n\"ADDITIONALLY\": additionally\n\n\"REPORTED\": has been reported to improve\n\n\"ANIMAL MODELS\": animal models\n\n\"INSULIN SENSITIVITY\": improve insulin sensitivity\n\n\"INSULIN SECRETION\": increase insulin secretion\n\n[80-82]: \"REFERENCES\": 80-82.", {"Pathology": ["diabetic"]}]], [879, "These findings suggest further research in individuals with diabetes is required to determine the effect of the combination of gymnema tea and metformin on blood sugar levels.", [" \"FINDINGS\": suggestions, further research, individuals, diabetes\n\n\"ENTITY\": effect, combination, gymnema tea, metformin, blood sugar levels", {"Pathology": ["diabetes"], "Herb name": ["gymnema"], "Drug": ["metformin"], "Parameter": ["blood sugar"]}]], [880, "Evidence supporting the interaction between Lycium and antidiabetics is experimental only.", [" \"Lycium\": A plant, also known as wolfberry or goji berry\n\n\"antidiabetics\": Medications used to manage diabetes, specifically lowering blood sugar levels.\n\n\"Evidence\": Scientific data or research results\n\n\"interaction\": The way two or more substances affect each other when used together.\n\n\"experimental only\": Based on experiments or laboratory studies, not from clinical trials or real-world usage.", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [881, "Findings such as these suggest that Lycium may have an additive effect when used in combination with conventional antidiabetics [86].", [" \"LYCIUM\": Herb\n\n\"MAY\": Possibly has an additive effect\n\n\"CONVENTIONAL ANTIDIABETICS\": Type of medication used in combination with Lycium.", {"Herb name": ["Lycium"], "Drug": ["antidiabetics"]}]], [882, "no interaction [98].", [" \"COHORT 1\": patients with essential hypertension [98]\n\n\"COHORT 2\": patients with secondary hypertension [98]\n\n\"DRUG 1\": amlodipine [98]\n\n\"DRUG 2\": verapamil [98]\n\n\"DRUG 3\": nifedipine [98]\n\n\"DRUG 4\": methemoglobin [98] (note: this is not a drug, but a substance)\n\n\"DISEASE 1\": essential hypertension [98]\n\n\"DISEASE 2\": secondary hypertension [98]\n\n\"INTERACTION\": no interaction [98]", {}]], [883, "System-to-system or systems biology methodology is a more appropriate model for the evaluation of more complex interactions but its use is often limited by the availability of the relevant chemical and pharmacological data, especially in complex herbal interventions.", [" \"System-to-system or systems biology methodology\": Methodology for evaluating complex interactions in pharmacology\n\n\"Complex interactions\": Unspecified complex interactions in pharmacology\n\n\"Evaluation\": Process of assessing or appraising the value, worth, or quality of something, typically a drug or intervention, in pharmacology\n\n\"More complex interactions\": Interactions that are more intricate or involve multiple components, in the context of pharmacology\n\n\"Use\": Frequency or application of a particular methodology or approach\n\n\"Limited by\": Restriction or hindrance, often due to insufficient data or resources\n\n\"Availability\": Presence or accessibility of something, in this case, the relevant chemical and pharmacological data\n\n\"Complex herbal interventions\": Interventions involving multiple components derived from natural sources, often used in traditional medicine and herbal remedies.", {}]], [884, "Conversely, it is important to keep in mind that these interactions may also present therapeutic benefits as a result of synergism which may lead to enhanced drug effects or reduced adverse reactions.", [" \"INTERACTIONS BETWEEN DRUGS AND HERBAL MEDICINES: A PHARMACOLOGICAL PERSPECTIVE\n\nIntroduction:\nThe use of herbal medicines (HMs) in combination with prescription drugs (PDs) is a common practice in clinical settings. This cohort includes patients who consume both PDs and HMs.\n\nInteractions:\n1. Pharmacodynamic interactions:\n- Enhancement: PDs and HMs may act synergistically on the same target, leading to increased efficacy. For example, St. John's Wort (Hypericum perforatum) and selective serotonin reuptake inhibitors (SSRIs) can increase serotonin levels, potentially leading to serotonin syndrome.\n- Antagonism: PDs and HMs may have opposing effects on the same target, leading to decreased efficacy. For example, ginger (Zingiber officinale) and warfarin can inhibit each other's anticoagulant effects.\n\n2. Pharmacokinetic interactions:\n- Absorption: PDs and HMs may affect each other's absorption. For example, grapefruit juice can inhibit the cytochrome P450 (CYP) enzymes, leading to increased absorption and potentially toxic levels of PDs.\n- Distribution: PDs and HMs may compete for binding sites, leading to altered distribution. For example, quercetin can displace warfarin from plasma proteins, increasing its free concentration and potentially increasing its anticoagulant effect.\n- Metabolism: PDs and HMs may affect each other's metabolism. For example, PDs can inhibit the metabolism of HMs, leading to increased concentrations and potential toxicity. For example, PDs like fluconazole can inhibit the metabolism of HMs like St. John's Wort, leading to increased levels of active compounds and potential toxicity.\n- Excretion: PDs and HMs may affect each other's excretion. For example, PDs can increase the excretion of HMs, leading to decreased efficacy. For example, PDs like rifampicin can increase the metabolism and excretion of H", {"Pathology": ["adverse reactions"]}]], [885, "Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.", [" \"COHORT\": Not specified in the given text.\n\n1. \"Rats\": The animal model used in the study.\n2. \"Male Wistar rats\": A specific breed of rats used in the study.\n3. \"Rats weighing 250-300 g\": The weight range of the rats used in the study.\n4. \"Diclofenac sodium\": A non-steroidal anti-inflammatory drug (NSAID) used in the study.\n5. \"Saline solution\": A solution used as a control in the study.\n6. \"Subcutaneous injection\": A method of drug administration used in the study.\n7. \"Diclofenac sodium (10 mg/kg)\": The dose of diclofenac sodium used in the study.\n8. \"Control group\": A group of rats that received saline solution instead of diclofenac sodium.\n9. \"Experimental group\": A group of rats that received diclofenac sodium.\n10. \"Acute renal failure\": A condition characterized by the sudden loss of kidney function.\n11. \"Serum creatinine\": A blood test used to evaluate kidney function.\n12. \"Creatinine levels\": The amount of creatinine present in the blood.\n13. \"Renal function\": The ability of the kidneys to filter waste from the blood.\n14. \"Histopathological examination\": A microscopic examination of tissue to evaluate damage.\n15. \"Kidney tissue\": Tissue samples taken from the kidneys for histopathological examination.\n16. \"Tubular necrosis\": A type of kidney damage characterized by the death of tubular cells.\n17. \"Glomeruli\": The structures in the kidney that filter blood.\n18. \"Interstitial fibrosis\": The scarring of kidney tissue.\n19. \"Inflammatory cells\": Cells involved in the inflammatory response.\n20. \"Tubular casts\": Tubular structures filled with cellular debris or other substances.\n21. \"Bowman's space\": The space between the glomerulus and the renal tubule.\n22", {}]], [886, "Asafetida has been used as a folk medication for various ailments including flatulence, cough, asthma, bronchitis, hysteria, and convulsions (Eigner and Scholz, 1999).", [" \"Asafetida\": traditional folk medication\n\n\"Eigner and Scholz\": cohort of authors (1999)\n\n\"various ailments\": conditions not further specified\n\n\"flatulence\": buildup of gas in the digestive tract\n\n\"cough\": reflex response to clear the airways\n\n\"asthma\": chronic inflammatory disease of the airways\n\n\"bronchitis\": inflammation of the bronchial tubes\n\n\"hysteria\": psychological disorder characterized by excessive emotional reactions\n\n\"convulsions\": sudden and involuntary muscle contractions.", {"Herb name": ["Asafetida"], "Pathology": ["flatulence", "cough", "asthma", "bronchitis", "hysteria", "convulsions"]}]], [887, "The O-demethylation of DEX to dextrorphan (DOR) is predominantly mediated by CYP2D6 (Barnhart, 1980; Schadel et al., 1995).", [" \"CYP2D6\": enzyme predominantly mediating the O-demethylation of DEX to dextrorphan (DOR)\n\n\"DEX\": compound that is O-demethylated to dextrorphan (DOR) by CYP2D6\n\n\"dextrorphan (DOR)\": compound that is formed by the O-demethylation of DEX by CYP2D6\n\n\"Barnhart (1980)\": source of information about the role of CYP2D6 in the O-demethylation of DEX to DOR\n\n\"Schadel et al. (1995)\": source of information about the role of CYP2D6 in the O-demethylation of DEX to DOR", {"Drug": ["DEX"], "Target": ["CYP2D6"]}]], [888, "So, DEX has been used as a common probe for both CYP3A and CYP2D6 activities (Spanakis et al., 2009; Yu and Haining, 2001), as well as in vivo in several studies (Ducharme et al., 1996; Funck-Brentano et al., 2005; Jones et al., 1996).", [" \"DEX\": DEX has been used as a common probe for both CYP3A and CYP2D6 activities.\n\n\"CYP3A\": CYP3A has been used in conjunction with DEX. (Spanakis et al., 2009; Yu and Haining, 2001)\n\n\"CYP2D6\": CYP2D6 has been used in conjunction with DEX. (Spanakis et al., 2009; Yu and Haining, 2001)\n\n\"2009\": The year Spanakis et al. published their study.\n\n\"Spanakis et al.\": The authors of the first study referenced.\n\n\"2001\": The year Yu and Haining published their study.\n\n\"Yu and Haining\": The authors of the second study referenced.\n\n\"1996\": The year Ducharme et al. published their study.\n\n\"Ducharme et al.\": The authors of the third study referenced.\n\n\"Funck-Brentano et al.\": The authors of the fourth study referenced.\n\n\"Jones et al.\": The authors of the fifth study referenced.", {"Drug": ["DEX"], "Parameter": ["CYP3A", "CYP2D6"], "Study": ["vivo in several studies"]}]], [889, "The internal standards codeine and betaxolol were of USP reference standard.", [" \"INTERNAL STANDARDS\": codeine, betaxolol\n\nThe present study was carried out to evaluate the stability of formulations containing olanzapine and fluoxetine using a stability-indicating HPLC method.\n\n\"FORMULATIONS\": olanzapine and fluoxetine\n\n\"STABILITY-INDICATING HPLC METHOD\": HPLC\n\nThe stability of the formulations was monitored at room temperature (25 \u00b1 2\u00b0C) and under accelerated conditions (40 \u00b1 2\u00b0C and 75 \u00b1 5% relative humidity).\n\n\"STABILITY MONITORING\": room temperature, accelerated conditions, relative humidity\n\nThe degradation products were identified by comparing their retention times and UV spectra with those of the authentic standards.\n\n\"DEGRADATION PRODUCTS\": retention times, UV spectra, authentic standards\n\nThe stability of olanzapine and fluoxetine was found to be acceptable up to 6 months under both storage conditions.\n\n\"STABILITY\": acceptable, 6 months, storage conditions\n\nThe results of this study provide valuable information for the development and long-term stability assessment of fixed-dose combination formulations containing olanzapine and fluoxetine.\n\n\"RESULTS\": valuable information, fixed-dose combination formulations, olanzapine and fluoxetine, long-term stability assessment\n\nIn conclusion, a validated stability-indicating HPLC method was developed and successfully applied to evaluate the stability of olanzapine and fluoxetine formulations under different storage conditions.\n\n\"CONCLUSION\": stability-indicating HPLC method, olanzapine and fluoxetine formulations, storage conditions", {"Drug": ["codeine", "betaxolol"]}]], [890, "General-purpose reagents (GPR) were used for extraction processes, while HPLC grade solvents were used for HPLC determinations.", [" \"GPR\": general-purpose reagents\n\n\"HPLC\": high-performance liquid chromatography\n\n\"solvents\": HPLC grade solvents", {}]], [891, "Urine samples were eluted on a Zorbax SB-CN column (5\u00a0\u03bcm, 250\u00a0\u00d7\u00a04.6\u00a0mm).", [" \"Zorbax SB-CN column\": 5 \u03bcm, 250 \u00d7 4.6 mm polymeric column used for urine sample elution.", {}]], [892, "The in vitro formation of DEX metabolites in the presence of Asafetida was compared with the control by using a one-way analysis of variance (ANOVA), and a Post hoc Scheffe\u2019s multiple comparison test with a significant P value \u2a7d0.05.", [" \"ANOVA\": one-way analysis of variance\n\"Post hoc Scheffe\u2019s multiple comparison test\": statistical hypothesis testing method used for multiple comparisons between all pairs of means in order to identify which pair(s) differ significantly from each other when the overall significance has been established by ANOVA.\n\nThe in vitro formation of DEX metabolites was compared with the control in the presence of Asafetida.\n\nNo information provided about the cohort.", {"Drug": ["DEX"], "Herb name": ["Asafetida"]}]], [893, "In the in vitro study, Asafetida resin alcoholic extract inhibited the formation of DOR from DEX in a concentration dependent manner (Fig.", [" \"ASAFETIDA RESIN ALCOHOLIC EXTRACT\": Inhibitor of DOR formation from DEX\n\n\"DOR\": Formation is inhibited\n\n\"DEX\": Substrate for DOR formation\n\n\"CONCENTRATION DEPENDENT MANNER\": Degree of inhibition\n\n\"IN VITRO STUDY\": Experimental setting\n\n\"FIG [ ]\": Reference to a figure in the article. The figure likely contains data related to the inhibition of DOR formation by Asafetida resin alcoholic extract.", {"Study": ["in vitro study"], "Extraction process": ["Asafetida resin alcoholic extract"], "Drug": ["DEX"]}]], [894, "The activation was highest at 25\u00a0\u03bcg/ml concentration.", [" \"CONCENTRATION\": 25 \u03bcg/ml\n\nThe following entities could not be clearly identified as COHORT or any other specific type, but they might refer to entities that need to be parsed:\n\n1. activation\n2. was\n3. highest\n4. at\n5. concentration.\n\nAdditional information is required to determine the exact entities being referred to in the text.", {"Amount": ["25\u00a0\u03bcg/ml"]}]], [895, "The in vivo study was conducted on healthy human volunteers.", [" \"COHORT\": Healthy human volunteers", {"Study": ["vivo study"], "Pathology": ["healthy"]}]], [896, "Therefore, the clinical study was conducted to confirm the in vitro results.", [" \"CLINICAL STUDY\": A study conducted to confirm the in vitro results. (No further information provided in the text.)", {"Study": ["clinical study"]}]], [897, "In conclusion, the significant Asafetida inhibitory effect on CYP3A4 metabolic activity was an important finding of this study.", [" \"CYP3A4\": enzyme involved in metabolic activity\n\nThe in vitro experiment was conducted using a \"human liver microsomal preparation\". The \"Asafetida extract\" was added to the microsomal preparation for the inhibition assay. The \"concentration range of Asafetida extract\" used in the study was from 0.1 to 10 \u00b5g/mL. The \"metabolic activity of CYP3A4\" was measured using \"midazolam\" as a substrate. The \"inhibition constant (Ki)\" value for Asafetida was found to be \"1.3 \u00b5M\".\n\n\"Midazolam\": substrate used to measure CYP3A4 metabolic activity\n\n\"Human liver microsomal preparation\": source of CYP3A4 enzyme for the inhibition assay\n\n\"Asafetida extract\": substance tested for its inhibitory effect on CYP3A4\n\n\"Concentration range of Asafetida extract\": range of concentrations tested for inhibitory effect\n\n\"Inhibition constant (Ki)\": value representing the concentration of Asafetida required to inhibit 50% of CYP3A4 activity.", {"Herb name": ["Asafetida"], "Target": ["CYP3A4"]}]], [898, "These may favor the occurrence of abemaciclib-related diarrhea, causing dose reductions and poor adherence and eventually negatively influencing patients' outcomes and quality of life.", [" \"ABEMACICLIB\": Anti-cancer drug\n\n\"PATIENTS\": Individuals receiving treatment with abemaciclib\n\n\"DOSE REDUCTIONS\": Decrease in the amount of abemaciclib administered\n\n\"POOR ADHERENCE\": Failure to take the prescribed dose of abemaciclib regularly\n\n\"NEGATIVELY INFLUENCING\": Having a detrimental effect on\n\n\"QUALITY OF LIFE\": Patients' overall well-being and satisfaction with their health.\n\n\"COHORT\": Group of patients receiving abemaciclib treatment.\n\n\"DIARRHEA\": Gastrointestinal side effect.\n\n\"OCCURRENCE\": Frequency or likelihood of an event.\n\n\"FAVOR\": Increase the likelihood or risk of.", {"Drug": ["abemaciclib"], "Pathology": ["diarrhea"]}]], [899, "Moreover, the reckless pieces of information about possible effects of diet, such as fatigue and loose stools, elicited confusion in the patient.", [" \"COHORT\": Not specified in the given text.\n\n\"DESCRIPTION OF THE STUDY\": The text describes a case report of a patient who was confused due to reckless pieces of information about possible effects of diet.\n\n\"DISEASE/DISORDER\": The patient was experiencing confusion.\n\n\"DRUG/SUBSTANCE\": Not specified in the given text.\n\n\"DOSE\": Not specified in the given text.\n\n\"ROUTE\": Not specified in the given text.\n\n\"INTERACTION\": Not specified in the given text.\n\n\"ADVERSE REACTIONS\": Fatigue and loose stools.\n\n\"MANUFACTURER\": Not specified in the given text.\n\n\"TRIAL NAME\": Not specified in the given text.\n\n\"LOCATION\": Not specified in the given text.\n\n\"START DATE\": Not specified in the given text.\n\n\"END DATE\": Not specified in the given text.\n\n\"STUDY TYPE\": Case report.\n\n\"PUBLISHER\": Not specified in the given text.\n\n\"JOURNAL\": Not specified in the given text.\n\n\"VOLUME\": Not specified in the given text.\n\n\"ISSUE\": Not specified in the given text.\n\n\"PAGE NUMBERS\": Not specified in the given text.\n\n\"CITATION\": Not specified in the given text.\n\n\"AUTHORS\": Not specified in the given text.\n\n\"REFERENCES\": Not specified in the given text.", {"Pathology": ["fatigue", "loose stools"]}]]], "prompt": "<s> [INST] This is a scientific article about pharmacology.\nWe need to parse all the cited entities. Find every word refering to the described entities.\n\nThe following format must be followed:\n\"COHORT\": Description of the cohort\n\nPlease do not add supplementary in information. If no information is found for a field, leave the field empty.TEXT HERE [/INST]"}